As filed with the Securities and Exchange Commission on July 10, 2015

April 20, 2021

Registration Statement No. 333- 204599

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Amendment No. 1 to




FORM S-1

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

VAPOR CORP.




HEALTHIER CHOICES MANAGEMENT CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
Delaware
210084-1070932

(State or other jurisdiction of


incorporation or organization)

organization)

2100
(Primary Standard Industrial

Classification Code Number)

84-1070932
(I.R.S. Employer

Identification Number)

3001 Griffin Road

Dania Beach, Florida 33312

(888) 766-5351

3800 North 28th Way
Hollywood, FL 33020
(305) 600-5004

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Jeffrey Holman

Chief Executive Officer
3800 North 28th Way
Hollywood, FL 33020
(305) 600-5004

Vapor Corp.

3001 Griffin Road

Dania Beach, Florida 33312

(888) 766-5351


(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Brian
Martin, T. Schrier, Esq.
Christopher J. Bellini, Esq.
Cozen O’Connor
200 S. BernsteinBiscayne Boulevard
30th Floor
Miami, FL 33133
Tel: 305-704-5954
Ralph V. De Martino
Michael D. HarrisCavas S. Pavri
Nason, Yeager, Gerson, White
Barry I. Grossman, Esq.
Sarah E. Williams, Esq.
Matthew Bernstein, Esq.
Ellenoff Grossman & Lioce, P.A.
Schiff HardinSchole LLP
1645 Palm Beach Lakes Blvd., Suite 1200901 K Street, NW Suite 700
West Palm Beach, Florida 33401Washington, DC 20001
(561) 686-3307(202) 778–6400
1345 Avenue of the Americas
New York, New York 10105
(212) 370-1300

Approximate date of commencement of proposed sale to the public:  As soon as practicable after the effective date of this registration statement.

Registration Statement is declared effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: [X]

box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [  ]

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [  ]

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [  ]




Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”filer,” “smaller reporting company” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer [  ] Accelerated filer [  ] ☐
Non-accelerated filer [  ] (Do not check if a smaller reporting company)
 Smaller reporting company [X] ☒
Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.



CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities to be Registered
Proposed Maximum
Aggregate Offering Price(1)
Amount of Registration Fee
Non-transferable Rights to purchase Shares(2)
Shares issuable upon exercise of Non-transferable Rights                                                          $100,000,000$10,910
Total            $100,000,000$10,910
(1) Aggregate offering prices are estimated solely for purposes of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933. Pursuant to Rule 416 under the Securities Act of 1933, the securities being registered hereunder include such indeterminate number of additional securities as may be issuable to prevent dilution resulting from stock splits, stock dividends or similar transactions.
(2) Non-transferable Rights are being issued without consideration.



The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to saidsuch Section 8(a), may determine.

 

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we areis not soliciting an offer to buy these securities in any statejurisdiction where the offer or sale is not permitted.permitted

PRELIMINARY PROSPECTUSSUBJECT TO COMPLETIONDATED JULY 10, 2015

VAPOR CORP.

.


SUBJECT TO COMPLETION, DATED APRIL 20, 2021
PRELIMINARY PROSPECTUS

Subscription Rights to Purchase
Up to            3,800,000 Units Consisting of

Shares of Series A Convertible PreferredCommon Stock and

Series A Warrants


We are offering by this prospectus up to 3,800,000 units, with each unit consisting of one-fourth of a share of our Series A Convertible Preferred Stock convertible into five sharesdistributing, at no charge, non-transferable Subscription Rights entitling holders of common stock and 10 Series A Warrants each exercisable intoas of the record date of 5:00 p.m. (Eastern time) on                 , 2021, one Subscription Right to purchase one share of common stock (the “Units”). The Units are being offered at a price of $[_____] per Unit. The Units, the Series A Convertible Preferred Stock and the Series A Warrants will not be certificated.

Thefor every four shares of Series A Convertible Preferred Stock andcommon stock owned. The per share exercise price (the “Actual Subscription Price”) of the Series A WarrantsSubscription Right will automatically separate six months after the date of this prospectus. However, the shares of Series A Convertible Preferred Stock and the Series A Warrants will separate priorbe a 25% discount to the expirationvolume-weighted average of the six-month period if at any time after 30 days from the date of this prospectus either (i) the closing pricetrading prices (“VWAP”) of our common stock is greater than $[_____] per shareon the OTC Pink Sheets for 10the five consecutive trading days (a “Trading Separation Trigger”), (ii)ending on the Series A Warrants are exercised for cash (solely with respect to the Units that included the exercised Series A Warrants) (a “Cash Warrant Exercise Trigger”) or (iii) the Units are delisted (a “Delisting Trigger”) from the Nasdaq Capital Market for any reason (such earlierexpiration date the “Separation Trigger Date”). We refer to this separation prior to the six-month period as an Early Separation. The Units will become separable: (i) 15 days after the Trading Separation Trigger date or (ii) immediately after the Series A Warrants are exercised for cash (solely with respect to the Units that included the exercised Series A Warrants) or a Delisting Trigger. In the event of an Early Separation, the Preferred Stock will become convertible into common stock: (i) immediately upon the separation of the Unit if a Trading Separation Trigger or a Delisting Trigger occurs, or (ii) on the six month anniversaryoffering. If calculated as of the date of this prospectus, (unless an earlier Trading Separation Trigger or Delisting Trigger occurs)this subscription price would be $_____ (the “Estimated Subscription Price”).


The holders of our Series D convertible preferred stock will also receive Subscription Rights based on the occurrencenumber of a Cash Warrant Exercise Trigger.

Each one-fourth of a share of Series A Convertible Preferred Stock will be convertible at the option of the holder into five shares of common stock that would be received upon conversion in full of such preferred stock. The maximum aggregate amount of subscriptions that will be accepted by the separationCompany will be $100 million (“Maximum Offering Amount”).


Pursuant to your Subscription Rights, you will have the right, which we refer to as your basic right, to purchase a number of the Units , provided that upon a Cash Warrant Exercise Trigger the Series A Convertible Preferred Stock will not be convertible until six-months after the date of this prospectus (unless an Early Separation occurs due to a Trading Separation Trigger or Delisting Trigger). The Series A Warrants have an exercise price of $[_____]. The Series A Warrants will expireshares based on the fifth anniversarynumber of the date of this prospectus. This prospectus also covers the shares of common stock issuable from timeyou held as of the record date. If you exercise your basic right in full, you will also have the right, or over-subscription privilege, to time uponpurchase additional shares for which other rights holders do not subscribe. If you wish to exercise your over-subscription privilege, you may request to purchase any number of shares of common stock. These requests for the exercise of the Series A Warrants orover-subscription privilege, however, will be subject to a pro-rata reduction in the conversion ofevent that the Series A Convertible Preferred Stock. This prospectus also coversMaximum Offering Amount is reached, in which case you will only pay for the Unitsshares that you are able to purchase and underlying securities issuable upon exercise of the unit purchase option toa refund will be issued to you for the underwriters.

unapplied subscription payment. Once made, all exercises of Subscription Rights are irrevocable.


Your basic rights and over-subscription privilege will expire if not exercised by 5:00 p.m. (Eastern time) on                , 2021 (the “Expiration Date”), unless we extend or terminate this offering. We may extend this offering for one or more additional periods in our sole discretion. We will announce any extension in a press release issued no later than 9 a.m. (Eastern time) on the business day after the most recently announced Expiration Date.

There is no minimum number of shares that we must sell in order to complete the rights offering. Stockholders who subscribe for their full basic right will not be diluted as they will continue to own at least the same percentage of the total shares of common stock outstanding. Stockholders who do not participate in the rights offering will continue to own the same number of shares, but will own a smaller percentage of the total shares outstanding to the extent that other stockholders participate in the rights offering. One way a rights offering differs from a reverse stock split is that a stockholder’s actual number of shares owned are not reduced in a rights offering. Subscription Rights that are not exercised by the Expiration Date will expire and have no value. The Subscription Rights are not transferable.

The purpose of this rights offering is to raise equity capital in a cost-effective and potentially non-dilutive manner that provides all of our existing stockholders the opportunity to participate and purchase up to approximately an additional 20% of the Company’s common stock. The net proceeds will be used for general working capital purposes, including the protection of our intellectual property rights through litigation and other methods, funding future research and development for both our intellectual property suite and products, and funding for growth initiatives for both our grocery and vape segments.

Our common stock is listedtraded on the Nasdaq Capital MarketOTC Pink Sheets under the symbol “VPCO.“HCMC.”  On July 9, 2015, theThe last reported salessale price of ourthe common stock on the Nasdaq Capital Market_______, 2021 was $1.39$[•] per share. On July 8, 2015, the Company effectuated a one-for-five reverse stock split of its common stock. There is no market for our Units. We have applied for the listing of the Units on the Nasdaq Capital Market under the trading symbol “VPCOU”. If this offering is completed, trading of the Units will not commence until the closing of the offering, which we expect to occur on [_____], 2015. We do not intend to list the Series A Convertible Preferred Stock or the Series A Warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system.

Before investing


Investing in our Units, preferred stock and warrants exercisable for common stock, you should carefully read the discussion ofsecurities involves risks. See “Risk Factors” beginning on page 5. Any investment in___ of this prospectus. We and our company is highly speculative and could result inboard of directors are not making any recommendation regarding the lossexercise of your entire investment. rights.

We have engaged Maxim Group LLC, or Maxim, to act as dealer-manager for this offering.

Our offering is being conducted on a best-efforts basis, and we do not need to receive any minimum amount of proceeds in order to complete the offering. We have not entered into any standby purchase agreement, backstop commitment or similar arrangement in connection with this offering.

Broadridge Corporate Issuer Solutions, Inc. will serve as the subscription agent for this offering and will hold in escrow funds received from subscribers until we complete or terminate the offering.

Per ShareTotal(1)
Estimated subscription price$$_____________
Dealer-manager fees and expenses(2)$$_____________
Proceeds to us, before expenses$$_____________
(1)Assumes sale of all offered shares.
(2)Represents maximum amount payable. We have agreed to pay Maxim, as dealer-manager, a cash fee equal to 7.0% of the proceeds to us.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined ifpassed upon the accuracy or adequacy of this prospectus is truthful or complete.prospectus. Any representation to the contrary is a criminal offense.

Per UnitTotal
Public offering price
Underwriting commissions (1)
Offering proceeds to us, before expenses

(1)

Does not include other compensation payable to Dawson James Securities, Inc., the representative of the underwriters. See “Underwriting.”

The underwriters are selling the Units


It is anticipated that delivery of shares purchased in this offering will be made on a “best efforts” basis. The underwriters are not required to sell any specific number or dollar amount of Units, but will use their best efforts to sell the securities offered. Because this is a best efforts offering, the underwriters do not have an obligation to purchase any securities, and, as a result, there is a possibility that we may not receive any proceeds from the offering.

The underwriters expect to deliver the securities to investors upon payment approximately three business days following acceptance of an order.

This offering shall terminate upon the earlier of [_____________]about                  , 2015 or the receipt of a notice of termination from the underwriters.

Dawson James Securities, Inc.

2021.


Dealer-Manager

Maxim Group LLC

The date of this prospectus is                    [_____], 2015.

i
2021.






TABLE OF CONTENTS


  Page
 
 2
 3
 5
 22
 23
 23
 24
 24
 26
 27
 32
 43
 46
 50
 51
54
Shares Eligible for Future Sale59
Underwriting60
Legal Matters64
Experts64
Where you Can Find More Information64
Index to Financial StatementsF-1





ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the “SEC”). The exhibits to the registration statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. Since these summaries may not contain all the information that you may find important in deciding whether to purchase our securities, you should review the full text of these documents. The registration statement and the exhibits can be obtained from the SEC as indicated under the sections entitled “Where You Can Find Additional Information” and “Incorporation by Reference.”

You should rely only on the information contained in this prospectus and any free writing prospectus we may authorize to be delivered to you. We have not, and Maxim has not, authorized anyone to provide anyyou with information different from, or in addition to, make any representations other than thosethat contained in this prospectus or inand any related free writing prospectus prepared by or on behalf of us or to which we have referred you.prospectus. We and Maxim take no responsibility for, and can provide no assuranceassurances as to the reliability of, any other information that others may give you. This prospectus is not an offer to you.sell, nor is it seeking an offer to buy, these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is only accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus orand any sale of our common stock.

shares.


Any reference in this prospectus to information that is “contained,” “referred to” or “included” in this prospectus, or any similar expression, includes not only the information expressly set forth in this prospectus but also the information incorporated by reference in this prospectus.

Unless the context requires otherwise, references in this prospectus to “Vapor”, the “Company,“HCMC,” “our company,” “we,” “our” “us” or “our”and similar terms refer to VaporHealthier Choices Management Corp., a Delaware corporation. When we refer to “Smoke Anywhere” we are referring to Smoke Anywhere USA, Inc., our wholly-owned subsidiary. When we refer to Vaporin, we are referring to Vaporin, Inc., a company we merged with in March 2015. All warrant, option, common stockcorporation, and per share of common stockits subsidiaries, unless the context otherwise requires.

PROSPECTUS SUMMARY

The following summary highlights selected information contained in this prospectus gives effect toprospectus. Because the 1-for-5 reverse split of our common stock effectuated on July 8, 2015.

ii

PROSPECTUS SUMMARY

The following information is only a summary, of the prospectus and it does not contain all of the information you should consider before investing in our securities. YouBefore making an investment decision, you should carefully read all of the entireinformation contained in this prospectus, carefully, including the risks described under “Risk Factors” section and our consolidated financial statements and the related notes relating to the financial statements,incorporated by reference from our 2020 Form 10-K, before making an investment decision.


Our Business

Healthier Choices Management Corp. is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. The Company

We operate nine Florida-based currently operates eight retail vape stores (and expects to open two more in the next three weeks)Southeast region of the United States, through which it offers e-liquids, vaporizers and are focusingrelated products. The Company also operates Ada’s Natural Market, a natural and organic grocery store, through its wholly owned subsidiary Healthy Choice Markets, Inc. and Paradise Health and Nutrition, stores that offer fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items through its wholly owned subsidiary-Healthy Choice Markets 2, LLC. The Company also sells vitamins and supplements on expandingits website TheVitaminStore.com and on Amazon.com marketplace through its wholly-owned subsidiary Healthy U Wholesale, Inc.


Through its wholly owned subsidiary, HCMC Intellectual Property Holdings, LLC, the number of Company operated stores as well as launching a franchise program. Wemanages and intends to expand on its intellectual property portfolio. The Company also design, market, and distribute vaporizers, e-liquids, electronic cigarettes and accessoriesmarkets its Q-Cup™ technology under the emagine vaporTM, Krave®vape segment. This patented technology is based on a small, quartz cup called the Q-Cup™, Fifty-One® (also known as Smoke 51)which a customer can purchase already filled by a third party in some regions, or can partially fill themselves with either cannabis or CBD concentrate (approximately 50 mg), Vapor X®also purchased from a third party. The Q-Cup™ can then be inserted into the patented Q-Unit™, Hookah Stix®which heats the cup from the outside without coming in direct contact with the solid concentrate. This Q-Cup™ and Alternacig® brands. WeQ-Unit™ technology provides significantly more efficiency and an “on the go” solution for consumers who prefer to vape concentrates either medicinally or recreationally. The Q-Cup™ can also design and develop private label brands for our distribution customers. Third party manufacturers manufacture our products to meet our design specifications. We market our products as alternatives to traditional tobacco cigarettes and cigars. In 2014,be used in other devices as a response to market product demand changes, Vapor began to shift its primary focus from electronic cigarettes to vaporizers. “Vaporizers” and “electronic cigarettes,” or “e-cigarettes,” are battery-powered products that enable users to inhale nicotine vapor without smoke, tar, ash, or carbon monoxide.

We offer our vaporizers and e-cigarettes and related products through our vape stores , online, to retail channels through our direct sales force, and through third party wholesalers, retailers and value-added resellers. Retailersconvenient micro-dosing system.


For a complete description of our products include small-box discount retailers, big-box retailers, gas stations, drug stores, convenience stores,business, financial condition, results of operations and tobacco shops and kiosk locations in shopping malls throughoutother important information, please read our filings with the United States. Vapor leverages its ability to design, market and develop multiple vaporizer and e-cigarette brands and to bring those brands to market through its multiple distribution channels including the vape stores, online and through retail operations operated by third parties. The Company’s business strategy is currently focused on a multi-pronged approach to diversify our revenue streams to include the Vape Store brick-and-mortar retail locations which Vaporin had successfully deployed.

Our Corporate Information

The Company was originally incorporated under the name Consolidated Mining International, Inc. in 1985. On November 5, 2009, the Company acquired Smoke Anywhere a distributor of electronic cigarettes, in a reverse triangular merger. On January 7, 2010, the Company changed its name to Vapor Corp. The Company reincorporated in the State of Delaware from the State of Nevada effective on December 31, 2013. On March 3, 2015, the Company merged with Vaporin and was the surviving and controlling entity.

Our executive officesSEC that are located at 3001 Griffin Road, Dania Beach, Florida 33312, and our telephone number is (888) 766-5351. Our website is located at www.vapor-corp.com. The information contained on, or that can be accessed through, our website is not incorporated by reference in this prospectus, including our 2020 Form 10-K. For instructions on how to find copies of these documents, please read “Where You Can Find Additional Information.”


This Offering

Subscription Rights

We are distributing, at no charge, non-transferable Subscription Rights (“Subscription Rights”) entitling holders of common stock as of the record date of 5:00 p.m. (Eastern time) on                 , 2021, whom we refer to as rights holders or you, to purchase additional shares of our common stock. Your Subscription Rights will consist of:

your basic right, which will entitle you to purchase one share of common stock for every four shares you held as of the record date; and
your over-subscription privilege, which will be exercisable only if you exercise your basic right in full and will entitle you to purchase additional shares for which other rights holders do not subscribe, subject to a pro rata allocation of those additional shares to participating rights holders based on their percentage ownership in the Company.

1

Subscription Price

All shares are being offered and sold at a subscription price equal to 75% of the volume-weighted average of the trading prices (the “VWAP”) of our common stock on the OTC Pink Sheets for the five consecutive trading days ending on the Expiration Date (the “Actual Subscription Price”). For purposes of completing the Subscription Certificate, the estimated subscription price will be $___________ (“Estimated Subscription Price”), which is equal to 75% of the VWAP for the five consecutive trading days ending on the date of the commencement of this offering, resulting in a 25% discount to the VWAP.  The number of shares purchased will be adjusted for the Actual Subscription Price.

Because the Actual Subscription Price will be determined on the Expiration Date, rights holders will not know the subscription price at the time of exercise. The rights holders, therefore, will be required initially to pay for the shares subscribed for pursuant to their basic rights and any additional shares subscribed for pursuant to the over-subscription privilege at the Estimated Subscription Price of $______ per share.

If, on the Expiration Date, the Actual Subscription Price is lower than the Estimated Subscription Price, any excess subscription amounts paid by a subscriber (the “Excess Subscription Amount”) will be put towards the purchase of additional shares in the rights offering. If, on the Expiration Date, the Actual Subscription Price is higher than the Estimated Subscription Price, the subscriber will receive less shares than subscribed for. For more information, see “Questions and Answers About the Rights Offering” below.

Exercise of Subscription Rights

Subscription Rights, consisting of basic rights and over-subscription privileges, may be exercised at any time during the subscription period, which commences on                         , 2021 and expires at 5:00 p.m. (Eastern time) on                            , 2021, or the Expiration Date, unless we extend or terminate this offering. Once made, all exercises of Subscription Rights are irrevocable.

We may extend this offering for one or more additional periods in our sole discretion. We will announce any extension in a press release issued no later than 9:00 a.m. (Eastern time) on the business day after the most recently announced Expiration Date.

  Subscription Rights may only be exercised in aggregate for at least one whole right. Any fractional Subscription Rights will be rounded up to one Subscription Right.

Transferability

The Subscription Rights are evidenced by a subscription certificate and are non-transferable. Shares of common stock included in the offering will be transferable following their issuance.

Use of Proceeds

Assuming this offering is fully subscribed, we estimate our net proceeds from the offering will total approximately $91.0 million, after deducting fees and expenses of Maxim, as dealer-manager, and our other estimated offering expenses. We intend to use the net proceeds for general working capital purposes, including the protection of our intellectual property rights through litigation and other methods, funding future research and development of our intellectual property and products, and funding for growth initiatives for both our grocery and vape segments. See “Use of Proceeds.”

Issuance of Our Common Stock

If you purchase shares of common stock through the rights offering, we will issue those shares to you in book-entry, or uncertificated, form as soon as practicable after the completion of the rights offering. Stock certificates will not be issued for shares of our common stock purchased in the rights offering.


2

Subscription Information

In order to obtain subscription information, you should contact:

Broadridge Corporate Issuer Solutions, Inc., which will act as the subscription agent and the information agent in connection with this offering, by telephone at (855) 793-5068 or by email at shareholder@broadridge.com; or
your broker-dealer, trust company or other nominee (including any mobile investment platform) where your Subscription Rights are held.

Subscription Procedures

In order to exercise your Subscription Rights, including your over-subscription privilege, you should:

deliver a completed subscription certificate and the required payment to Broadridge Corporate Issuer Solutions, Inc., the subscription agent for this offering, by the Expiration Date, or
if your shares of common stock are held in an account with a broker-dealer, trust company, bank or other nominee (including any mobile investment platform) that qualifies as an Eligible Guarantor Institution under Rule 17Ad-15 under the Exchange Act, have your Eligible Guarantor Institution deliver a notice of guaranteed delivery to the subscription agent by the Expiration Date.

Important Dates

Set forth below are important dates for this offering, which generally are subject to extension:

Record date 
, 2021
Commencement date 
, 2021
Expiration Date 
, 2021
Deadline for delivery of subscription certificates and payment of subscription prices, 2021
Deadline for delivery of notices of guaranteed delivery 
, 2021
Deadline for delivery of subscription certificates and payment of subscription prices pursuant to notices of guaranteed delivery, 2021
Anticipated delivery of shares purchased in this offering 
, 2021

Dealer-manager

Maxim Group LLC will act as the dealer-manager for the rights offering.

3

QUESTIONS AND ANSWERS RELATING TO THIS OFFERING

The following are examples of what we anticipate will be common questions about this offering. The answers are based on selected information included elsewhere in this prospectus. The following questions and answers do not contain all of the information that may be important to you and may not address all of the questions that you may have about this offering. This prospectus, including the documents we incorporate by reference, contains more detailed descriptions of the terms and conditions of this offering and provides additional information about our company and our business, including potential risks related to our business, the Rights Offering and common stock.

What is the Rights Offering?

We are issuing to each holder of common stock and the holders of our Series D convertible preferred stock (“Series D Preferred Stock”) as of the record date, whom we refer to as a rights holder or you, one non-transferable subscription right for every four shares of common stock then owned by the holder as of the Record Date. Each basic right entitles the holder to purchase one share at the Actual Subscription Price. For purposes of submitting subscription payments, the Estimated Subscription Price will be $___________. The Actual Subscription Price is equal to 75% of the VWAP of our common stock on the OTC Pink Sheets for the five consecutive trading days ending on the Expiration Date. In effect, the participants in the rights offering will be purchasing their shares at a 25% discount to such price.

What is the Subscription Price?

The Actual Subscription Price for the shares to be issued pursuant to the offer will equal 75% of the VWAP of our common stock on the OTC Pink Sheets for the five consecutive trading days ending on the Expiration Date. Because the subscription price will be determined on the Expiration Date, rights holders will generally not know the subscription price at the time of exercise and will be required initially to pay for both the shares subscribed for pursuant to their basic Subscription Rights and, if eligible, any additional shares subscribed for pursuant to the over-subscription privilege at the Estimated Subscription Price of $______ per share. The Estimated Subscription Price reflects what the Actual Subscription Price would be if it was calculated using the date the Rights Offering is commenced as the end date for the VWAP. Regardless of the Actual Subscription Price, Stockholders who exercise their rights will have no right to rescind their subscriptions after receipt of their completed subscription certificates together with payment for shares or a notice of guaranteed delivery by the subscription agent.

By way of example, if you wish to purchase 1,000,000 shares at the Estimated Subscription Price of $0.0012, you would be investing $1,200. The amount of shares that you receive for your $1,200 will be adjusted based on the Actual Subscription Price. Using the previous example, if the Actual Subscription Price is $0.0010, you will receive 1,200,000 shares for your same $1,200 investment. Conversely, if the Actual Subscription Price is increased to $0.0014 you will receive 857,143 shares for your $1,200 investment. However, in both cases you will be receiving a 25% discount to the VWAP for the common stock over the five consecutive trading days ending on the Expiration Date.

What are the basic rights?

For each basic right held, each rights holder has the opportunity to purchase one share at the Actual Subscription Price, provided that (1) basic rights must be exercised for a whole share (cannot exercise 0.5 Subscription Rights), and (2) the total subscription price payable upon any exercise of Subscription Rights will be rounded to the nearest whole cent. Any fractional basic rights will be rounded up to one Subscription Right. We have granted to you, as a holder of common stock as of the record date, one basic right for each four shares of common stock you then owned. For example, if you owned 4,000 shares of common stock as of the record date, you would receive 1,000 basic rights and would have the right to purchase, for an aggregate Subscription Price, 1,000 shares of common stock. You may exercise all, a portion or none of your basic rights. If you exercise fewer than all of your basic rights, however, you will not be entitled to purchase any additional shares pursuant to the over-subscription privilege. See “—What is the over-subscription privilege?” below.
4


What is the over-subscription privilege?

If you exercise all of your basic rights, you will have the right, which we refer to as the over‑subscription privilege, to purchase additional shares that remain unsubscribed as a result of any unexercised basic rights. We refer to the basic rights and over-subscription privilege collectively as Subscription Rights. You should indicate on your subscription certificate, or the form provided by your nominee if your shares are held in the name of a nominee, how many additional shares you would like to purchase pursuant to your over-subscription privilege. You are entitled to exercise your over-subscription privilege only if you exercise your basic rights in full. If over-subscription requests exceed the number of shares available, however, we will allocate the available shares pro rata among rights holders who over-subscribe based on their percentage ownership in the Company. See “The Rights Offering—Over-Subscription Privilege.”

May the Subscription Rights that I exercise be reduced for any reason?

Yes. While we are distributing to holders of our common stock and Series D preferred stock one subscription right for every four shares of common stock owned or deemed owned on the Record Date, we are only seeking to raise $100 million dollars in gross proceeds in this offering. As a result, based on (1) [  ] shares of common stock outstanding as of the Record Date and (2) [   ] shares of common stock deemed to be owned by the Series D holders that have a contractual right to participate in this offering and deemed to be outstanding as of the Record Date, we would grant subscription rights to acquire [   ] shares of common stock but will only accept subscriptions for [    ] shares of common stock based on the Estimated Subscription Amount. Accordingly, sufficient shares may not be available to honor your subscription in full. If the Company receives $100 million or less in subscriptions, there will be a sufficient number of shares available for sale to honor your basic rights in full. As a result, unless this offering results in subscription proceeds in excess of $100 million, you will receive shares to the full extent you have properly exercised your basic rights in whole or in part for such shares. In the event the subscription proceeds would exceed $100 million, the Company will reduce the subscriptions pro rata based on current share ownership in relation to the total subscription amounts.

In addition, sufficient shares may not be available to honor your exercise of the over‑subscription privilege. If exercises of over‑subscription privileges exceed the number of shares available, we will allocate the available shares pro rata among rights holders who over-subscribe based on the number of over-subscription shares for which the rights holders have subscribed.

Why are we conducting this offering?

In accordance with our strategic plan, we are conducting this offering primarily to raise funds to facilitate the enforcement of our patent rights through litigation and other methods, research and development of our intellectual property suite and products, to accelerate our growth efforts in the health food, vitamin and vape sectors, to improve our overall liquidity, and for other general corporate purposes. Our board of directors has approved this offering and believes it will allow us to raise equity capital in a cost-effective manner that provides all of our existing stockholders the opportunity to participate in a non-dilutive manner. Based on information available to the board, as well as subsequent analyses of the board, the board believes that this offering is in the best interests of our company and stockholders. Our board is not, however, making any recommendation regarding your exercise of the Subscription Rights.

Our board considered and evaluated a number of factors relating to this offering, including:
the fact that existing stockholders would have the opportunity to purchase additional shares;
our current capital resources and indebtedness, and our future need for additional liquidity and capital;
our need for increased financial flexibility in order to enable us to achieve our business plan;
the size and timing of the offering and alternative securities to be offered;
the potential dilution to our current stockholders if they choose not to participate in the offering;
the non-transferability of the Subscription Rights; and
alternatives available for raising capital.

5

Am I required to exercise the Subscription Rights I receive in this offering?

No. You may exercise any number of your Subscription Rights, or you may choose not to exercise any of your Subscription Rights. If, however, you choose not to exercise your Subscription Rights or you exercise less than your full amount of Subscription Rights and other stockholders fully exercise their Subscription Rights, the percentage of common stock owned by other stockholders will increase relative to your ownership percentage and your voting and other rights in our company will likewise be diluted due to your reduced ownership in HCMC ― see “Description of Securities” for a description of the voting and liquidation rights of our common stock. However, your amount of shares you own will in no instance be reduced.

May I sell, transfer or assign my Subscription Rights?

No. You may not transfer, sell or assign any of the Subscription Rights distributed to you, except that Subscription Rights will be transferable by operation of law (e.g., by death). The Subscription Rights are non-transferable and will not be listed on any securities exchange or included in any automated quotation system. Therefore, there will be no market for the Subscription Rights.

How do I exercise my Subscription Rights if my shares of common stock are held in my name?

If you hold your shares of common stock in your name and you wish to participate in this offering, you must deliver a properly completed and duly executed subscription certificate and all other required subscription documents, together with payment of the full subscription price, to the subscription agent before 5:00 p.m. (Eastern time) on the Expiration Date.

If you send an uncertified check, payment will not be deemed to have been delivered to the subscription agent until the check has cleared. In certain cases, you may be required to provide signature guarantees. If you send an uncertified check, please send it as early as possible to have the best chance of it clearing before the Expiration Date.

Please follow the delivery instructions on the subscription certificate. Please DO NOT deliver documents to HCMC. You are solely responsible for completing delivery of your subscription certificate, all other required subscription documents and subscription payment to the subscription agent. You should allow sufficient time for delivery of your subscription materials to the subscription agent so that the subscription agent receives them by 5:00 p.m. (Eastern time) on the Expiration Date. See “—To whom should I send my forms and payment?” below.

If you send a payment that is insufficient to purchase the shares you requested, or if the number of shares you requested is not specified in the forms, the payment received will be applied to exercise your Subscription Rights to the fullest extent possible based on the amount of the payment received pursuant to your Subscription Rights. Any payment that is received but not so applied will be refunded to you without interest (subject to the rounding of the amount so applied to the nearest whole cent).

What form of payment is required to purchase shares in the offering?

As described in the instructions accompanying the subscription certificate, payments submitted to the subscription agent must be made in U.S. dollars. Checks or bank drafts drawn on U.S. banks should be payable to the order of “Broadridge Corporate Issuer Solutions, Inc., as Subscription Agent for Healthier Choices Management Corp.”  Payments by uncertified check will be deemed to have been received upon clearance. Please note that funds paid by uncertified check may take five or more business days to clear. Accordingly, rights holders who wish to pay the subscription price by means of uncertified check are urged to make payment sufficiently in advance of the expiration time to ensure that such payment is received and clears by such date. If you hold your shares of common stock in the name of a broker, dealer, custodian bank or other nominee (including any mobile investment platform), separate payment instructions may apply. Please contact your nominee, if applicable, for further payment instructions.

6

How do I exercise my Subscription Rights if my shares of common stock are held in the name of a broker, dealer, custodian bank or other nominee?

If you hold shares of common stock in the name of a broker, dealer, custodian bank or other nominee (including any mobile investment platform) that uses the services of Depository Trust Company (DTC), then Depository Trust Company will credit one basic right to your nominee record holder for every four shares of common stock that you beneficially owned as of the record date. If you are not contacted by your nominee (including any mobile investment platform), you should contact your nominee as soon as possible.

How soon must I act to exercise my Subscription Rights?

If your shares of common stock are registered in your name and you elect to exercise any of your Subscription Rights, the subscription agent must receive your properly completed and duly executed subscription certificate, all other required subscription documents and full subscription payment, including final clearance of any uncertified check, before 5:00 p.m. (Eastern time) on the Expiration Date on                   , 2021. If you hold shares in the name of a broker, dealer, custodian bank or other nominee, your nominee (including any mobile investment platform) may establish an earlier deadline before the expiration of this offering by which time you must provide the nominee with your instructions and payment to exercise your Subscription Rights.

Although we will make reasonable attempts to provide this prospectus to our stockholders to whom rights are distributed, this offering and all related Subscription Rights will expire at 5:00 p.m. (Eastern time) on the Expiration Date, whether or not we have been able to locate and deliver this prospectus to you or any other stockholder.

After I exercise my Subscription Rights, can I change my mind?

No. Once made, all exercises of Subscription Rights are irrevocable, even if you later learn information that you consider to be unfavorable to the exercise of your Subscription Right or if the offering is extended by the board of directors. You should not exercise your subscription right unless you are certain that you wish to purchase shares at the Estimated Subscription Price.

What happens if the Actual Subscription Price is less than the Estimated Subscription Price?

If, on the Expiration Date, the Actual Subscription Price is lower than the Estimated Subscription Price paid by the subscriber, any Excess Subscription Amounts paid by a subscriber will be put towards the purchase of additional shares in the rights offering. For example, assume that the Estimated Initial Subscription Price is $0.0012 per share. If you want to exercise your rights to purchase 1,000,000 shares, you will promptly send payment to the subscription agent in the amount of $1,200. If the final subscription price decreases to $0.0010 per share, you will receive 1,200,000 shares rather than 1,000,000 shares and no cash back. Detailed instructions to exercise your rights, including regarding payment of the subscription price, are also included on your rights certificate. For assistance you may contact the subscription agent, Broadridge Corporate Issuer Solutions, Inc., toll free at 1-888-789-8409 or by e-mail at shareholder@broadridge.com.

Does HCMC need to achieve a minimum participation level in order to complete the rights offering?

No. There is no minimum subscription requirement. We may consummate the offering regardless of the amount raised from the exercise of basic and over-subscription rights by the expiration date.

Can this offering be terminated or extended?

Yes. If we terminate this offering, neither we nor the subscription agent will have any obligation with respect to Subscription Rights that have been exercised except to promptly return, without interest or deduction, any subscription payment the subscription agent received from you. If we were to terminate this offering, any money received from subscribing stockholders would be promptly returned, without interest or deduction, and we would not be obligated to issue shares or shares of common stock to rights holders who have exercised their Subscription Rights prior to termination.
7

Is a rights offering similar to a reverse stock split?

No. These are completely different corporate actions. Among other differences between these actions, the numbers of shares owned by a stockholder is reduced in a reverse stock split. No reduction in shares owned by any stockholder will occur as a result of the rights offering.

How was the subscription price determined?

The subscription price was set by our board of directors, considering, among other things, input from its dealer-manager for this offering. The factors considered by our board are discussed in “The Rights Offering—Reasons for this Offering” and “Determination of the Subscription Price.”

Has the board of directors made a recommendation to stockholders regarding the exercise of rights under this offering?

No. Our board of directors has not made, nor will it make, any recommendation to stockholders regarding the exercise of Subscription Rights in this offering. We cannot predict the price at which shares of our outstanding common stock will trade after this offering. You should make an independent investment decision about whether or not to exercise your Subscription Rights. Rights holders who exercise Subscription Rights risk investment loss on new money invested. We cannot assure you that the market price for common stock will remain above the price payable per share of common stock, or that anyone purchasing shares of common stock at the exercise price will be able to sell those shares in the future at the same price or a higher price. If you do not exercise your Subscription Rights, you will lose any value represented by your Subscription Rights, and if you do not exercise your rights in full, your percentage ownership interest and related rights in our company will be diluted due to your reduced ownership in HCMC.

May I participate in this offering if I sell my common stock after the record date?

The record date for this offering is 5:00 p.m. (Eastern time)                  , 2021. If you own common stock as of the record date, you will receive Subscription Rights and may participate in this offering even if you subsequently sell your common stock.

Are there any risks associated with this offering?

Yes. The exercise of your Subscription Rights involves risks. Exercising your Subscription Rights involves the purchase of common stock and should be considered as carefully as you would consider any other equity investment. Among other things, you should carefully consider the risks described under the heading “Risk Factors” in this prospectus and all other information contained in this prospectus.

Will the directors and executive officers participate in this offering?

No. To the extent they hold common stock as of the record date, our directors and executive officers are entitled to participate in this offering on the same terms and conditions applicable to all other stockholders. Our directors and executive officers, however, have agreed with the Company not to participate in this offering, although they are not required to do so.

May stockholders in all jurisdictions participate in the rights offering?

Although we intend to distribute the rights to all stockholders, we reserve the right in some states to require stockholders, if they wish to participate, to state and agree upon exercise of their respective rights that they are acquiring the shares for investment purposes only, and that they have no present intention to resell or transfer any shares acquired. Our securities are not being offered in any jurisdiction where the offer is not permitted under applicable local laws.

8

When will I receive my shares of common stock?

If you purchase shares of common stock through the rights offering, we will issue those shares to you in book-entry, or uncertificated, form. Although we will endeavor to issue the appropriate book-entries as soon as practicable after completion of this offering, there may be some delay between the Expiration Date and the time that we issue the new book-entries. Stock certificates will not be consideredissued for shares of our common stock purchased in the rights offering.

What effects will this offering have on our outstanding common stock?

Based on shares of common stock outstanding as of                       , 2021, if this offering is fully subscribed, we will have                       shares of common stock outstanding, representing an increase of         % in our outstanding shares as of the record date. If you fully exercise your basic rights, your proportional interest in our company will not change. If you exercise only a partportion, or none, of this prospectus.

THE OFFERING

Price per Unit.$[____] per Unit.

Securities we are offering; Separation of the Units

Up to 3,800,000 Units. Each Unit consists of one-fourth of a share of Series A Convertible Preferred Stock, convertible into five shares of common stock and 10 Series A Warrants each exercisable for one share of common stock.

The shares of Series A Convertible Preferred Stock and the Series A Warrants will automatically separate six months after the date of this prospectus. However, the shares of Series A Convertible Preferred Stock and the Series A Warrants will separate prior to the expiration of the six-month period if at any time after 30 days from the date of this prospectus there is an Early Separation. The Units will become separable: (i) 15 days after the Trading Separation Trigger date or (ii) immediately after a Cash Warrant Exercise Trigger (solely with respect to the Units that included the exercised Series A Warrants) or a Delisting Trigger. In the event of an Early Separation, the Preferred Stock will become convertible into common stock: (i) immediately upon a Trading Separation Trigger or a Delisting Trigger, or (ii) on the six month anniversary of the date of this prospectus if the separation occurs due to a Cash Warrant Exercise Trigger (unless an earlier Trading Separation Trigger or Delisting Trigger occurs ). We are also registering the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and the exercise or exchange of the Series A Warrants.

Series A Convertible Preferred Stock we are offering

Each one-fourth of a share of Series A Convertible Preferred Stock will be convertible into five shares of common stock upon the separation of the Units, provided that upon a Cash Warrant Exercise Trigger the Series A Convertible Preferred Stock will not be convertible until six-months after the date of this prospectus (unless an Early Separation occurs due to a Trading Separation Trigger or Delisting Trigger). For additional information, see “Description of Capital Stock—Preferred Stock Included in the Units Offered Hereby” on page 56 of this prospectus.

Series A Warrants we are offeringEach Series A Warrant is exercisable for one share of common stock. The Series A Warrants have an exercise price of $[___] and are exercisable upon the separation of the Units ; provided they may be exercised for cash 30 days from the date of this prospectus, which will cause a Cash Warrant Exercise Trigger. The Series A Warrants will expire on the fifth anniversary of the date of this prospectus. For additional information, see “Description of Capital Stock—Warrants Included in the Units Offered Hereby” on page 56 of this prospectus.
Best EffortsThe underwriters are selling the Units offered in this prospectus on a “best efforts” basis and are not required to sell any specific number or dollar amount of the Units offered by this prospectus, but will use their best efforts to sell the Units.
Common stock outstanding before this offering

7, 600,657 shares

Common stock to be outstanding immediately after this offering7,600,657 , which assumes no conversion of the Series A Convertible Preferred Stock or exercise of the Series A Warrants.
Use of proceeds

Assuming we complete the maximum offering, we estimate that the net proceeds from this offering will be approximately $[_______] million, at a public offering price of $[_______] per Unit, after deducting the underwriting commissions and estimated offering expenses payable by us. Since this is a “best efforts” offering, there is no assurance that any Units will be sold, and therefore no assurance that there will be any proceeds. We intend to use the net proceeds from this offering as follows:

(i)approximately $4.97 million to repay indebtedness;
(ii)approximately $[_______] million to acquire and/or build vape stores;
(iii)

approximately $[_______] million in sales and marketing expenses; and

(iv)the remaining proceeds, if any, will be used for general corporate purposes, including working capital. See “Use of Proceeds” for a more complete description of the intended use of proceeds from this offering.
Risk FactorsInvesting in our securities involves substantial risks. You should read the “Risk Factors” section starting on page 5 for a discussion of factors to consider carefully before deciding to invest in our securities.
NasdaqCapital Market symbol for our common stockVPCO
Proposed Nasdaq Capital Market symbol for our UnitsWe intend to apply for listing of the Units on the Nasdaq Capital Market under the symbol “VPCOU”. No assurance can be given that such listing will be approved or that a trading market will develop.

your basic rights, your interest in our company will be diluted and your proportional interest in our company will decrease.


The number of shares of common stock outstanding listed in each case above assumes that (1) all of the other shares of common stock issued and outstanding on the record date will remain issued and outstanding and owned by the same persons as of the closing of this offering, and (2) we will not issue any shares of common stock in the period between the record date and the closing of this offering.

Can the holders of the Series D Preferred Stock Participate in the Rights Offering?

Yes. The holders of our Series D convertible preferred stock will also receive Subscription Rights based on the number of shares of common stock that would be received upon conversion in full of such preferred stock. Pursuant to our Certificate of Incorporation, the 5,000 shares of the Series D Preferred Stock outstanding may currently convert into 2,083,333,333.33 shares of our common stock outstanding before and afterin the aggregate.

How much will HCMC receive from this offering, and how will its proceeds be used?

If this offering is fully subscribed, we estimate our net proceeds from the offering will total approximately $91.0 million, after deducting fees and expenses of Maxim, as set forthdealer-manager, and our other estimated offering expenses. We intend to use the net proceeds to facilitate the enforcement of our intellectual property rights through litigation and other methods, research and development of our intellectual property suite and products, to accelerate our growth efforts in the table above,health food, vitamin and vape sectors, to improve our overall liquidity, and for other general corporate purposes.

If my exercise of Subscription Rights is based on 6,727,152cutback due to the offering being oversubscribed, is not valid or if this offering is not completed, will my subscription payment be refunded to me?

Yes. The subscription agent will hold all funds it receives in escrow until the completion or termination of this offering. If your exercise of Subscription Rights is deemed not to be valid or this offering is not completed, all subscription payments received by the subscription agent will be promptly returned, without interest or deduction, following the expiration of the offering. If you own shares outstanding as of March 31, 2015 and excludes as of that date:

up to 19,000,000 shares of common stock issuable upon the full conversion of the Series A Convertible Preferred Stock offered hereby and up to 38,000,000 shares of common stock upon the full exercise of the Series A Warrants assuming the warrants are exercised for cash (if the warrants are exercised on a cashless basis as described in “Description of Capital Stock – Warrant Included in the Units Offered Hereby” the number of shares of common stock issuable is indeterminate);

up to 950,000 shares of common stock issuable upon the full conversion of the Series A Convertible Preferred Stock offered hereby and up to 1,900,000 shares of common stock upon the full exercise of the Series A Warrants assuming the warrants are exercised for cash included in the unit purchase option to be issued to the representative of the underwriters in connection with this offering (if the warrants are exercised on a cashless basis as described in “Description of Capital Stock – Warrant Included in the Units Offered Hereby” the number of shares of common stock issuable is indeterminate);

248,567 shares of common stock issuable upon the exercise of outstanding stock options;
841,981 shares of common stock issuable upon the full exercise of previously issued warrantsthrough a nominee (including any mobile investment platform), it may take longer for you to receive your subscription price repayment because the subscription agent will return payments through your nominee.

What fees or charges apply if I purchase shares of common stock;

378,047 shares of common stock issuable upon the delivery of fully vested restricted stock units;

358,682 shares of our common stock underlying outstanding convertible notes; and
38,000,000 shares of common stock issuable upon exercise of the warrants issued to the public in connection with this offering.

Unless otherwise indicated, all information in this prospectus:

assumes 7,600,657 shares of our common stock outstanding immediately prior to the closing of this offering;

● assumes no exercise of the representative’s unit purchase option; and
assumes no exercise of any outstanding options or warrants to purchase common stock.

offering?


We are not charging any fee or sales commission to issue rights to you or, if you exercise any of your Subscription Rights, to issue shares to you. If you exercise your Subscription Rights through a broker, dealer, custodian bank or other nominee (including any mobile investment platform), you are responsible for paying any fees your nominee may charge you.


SUMMARY FINANCIAL DATA9

The summary financial data set forth below


What are the U.S. federal income tax consequences of exercising my Subscription Rights?

For U.S. federal income tax purposes, a rights holder should be readnot recognize income or loss in conjunctionconnection with our financial statements and the related notes, “Selected Financial Data” and “Management’s Discussion and Analysisreceipt or exercise of Financial Condition and Results of Operations” included elsewhererights in this prospectus.

offering. You should consult your tax advisor as to your particular tax consequences resulting from the offering. For a summary of certain U.S. federal income tax consequences of this offering, see “Material U.S. Federal Income Tax Considerations.”


To whom should I send my forms and payment?

If your shares of common stock are held in the name of a broker, dealer, custodian bank or other nominee (including any mobile investment platform), then you should deliver all required subscription documents and subscription payments pursuant to the instructions provided by your nominee. If your shares of common stock are held in your name, then you should send your subscription certificate, all other required subscription documents and your subscription payment by mail to:

Broadridge Corporate Issuer Solutions, Inc.
Attn: BCIS re-Organization Dept.
P.O. Box 1317
Brentwood, NY 11717-0718
or by hand delivery or overnight courier to:

Broadridge Corporate Issuer Solutions, Inc.
Attn: BCIS IWS
51 Mercedes Way
Edgewood, NY 11717

You and, if applicable, your nominee are solely responsible for completing delivery to the subscription agent of your subscription certificate, as well as for completing delivery of all other required subscription documents and your subscription payment. You should allow sufficient time for delivery of your subscription materials to the subscription agent and for clearance of payments before the expiration of this offering. If you hold your common stock through a broker, dealer, custodian bank or other nominee (including any mobile investment platform), your nominee may establish an earlier deadline before the Expiration Date of this offering.

Who is the dealer-manager?

Maxim will act as dealer-manager for this offering. Under the terms and subject to the conditions contained in the dealer-manager agreement, Maxim will act as an advisor for purposes of this offering. We derivedhave agreed to pay Maxim certain fees for acting as dealer-manager and to reimburse it for certain expenses incurred in connection with this offering. Maxim is not underwriting, soliciting or placing any of the statementSubscription Rights or the shares of operations data for the fiscal years ended December 31, 2014 and 2013 and balance sheet data as of December 31, 2014 and 2013 from our audited consolidated financial statements appearing elsewherecommon stock being issued in this prospectus. We derivedoffering and is not making any recommendation with respect to such Subscription Rights (including with respect to the statementexercise or expiration of operations data forsuch Subscription Rights) or shares of common stock.

Whom should I contact if I have other questions?

If you have any questions regarding this offering, completion of the three months ended March 31, 2015 and 2014 and balance sheet data as of March 31, 2015 from our unaudited condensed consolidated financial statements appearing elsewheresubscription certificate or any other subscription documents or submitting payment in this prospectus.

  

Years Ended

December 31,

  

Three Months Ended

March 31,

 
  2014  2013  2015  2014 
        (unaudited) 
    
Statement of Operations Data:                
Sales, Net $15,279,859  $25,990,228  $1,468,621  $4,792,544 
Cost of Goods Sold  14, 497 ,254   16,300,333   1,651,110   3,831,928 
                 
Gross (Loss) Profit  782,605   9,689,895   (182,489)  960,616 
Operating expenses:                
Selling, general and administrative  11,126,759   6,464,969   3,243,189   2,769,726 
Advertising  2,374,329   2,264,807   105,177   367,615 
                 
Total operating expenses  13,501,088   8,729,776   3,348,366   3,137,341 
                 
Operating (loss) income  (12,718,483)  960,119   (3,530,855)  (2,176,725)
                 
Other expense                
Induced conversion expense  -   (299,577)  -   - 
Amortization of deferred financing costs  (17,458)  -   (34,917)  - 
Change in fair value of derivative liabilities  -   -   (37,965)  - 
Interest expense  (348,975)  (383,981)  (378,775)  (28,434)
Interest income  -   -   1,316   - 
                 
Total other expenses  (366,433)  (683,558)  (450,341)  (28,434)
                 
(LOSS) INCOME BEFORE INCOME TAX (EXPENSE) BENEFIT  (13,084,916)  276,561   (3,981,196)  (2,205,159)
Income tax (expense) benefit  (767,333)  524,791   -   752,400 
                 
NET (LOSS) INCOME $(13,852,249) $801,352  $(3,981,196) $(1,452,759 
                 
BASIC (LOSS) EARNINGS PER COMMON SHARE $( 4.22) $0.31  $( 0.89) $( 0.45)
                 
DILUTED (LOSS) EARNINGS PER COMMON SHARE $( 4.22) $0.30  $( 0.89) $( 0.45)
                 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC  3,283,030   2,563,697   4,494,855   3,253,550 
                 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – DILUTED  3,283,030   2,637,273   4,494,855   3,253,550 
  As of December 31,  As of 
  2014  2013  March 31, 2015 
          

(unaudited) 

 
Balance Sheet Data:            
Cash $471,194  $6,570,215  $1,911,199 

Working capital (deficit)

  127,874   11,657,615   (811,970)
Intangibles assets, net of accumulated depreciation  -   -   2,058,423 
Goodwill  -   -   15,654,484 
Total assets  4,928,483   13,962,375   24,052,575 
Senior convertible notes payable – related parties, net of debt discount  156,250   -   468,750 
Convertible notes, net of debt discount  -   -   517,579 
Notes payable – related party  -   -   1,000,000 
Term Loan  750,000   478,847   523,727 
Total stockholders’ equity $811,810  $11,751,584  $17,519,578 

the offering, please contact Broadridge Corporate Issuer Solutions, Inc. by telephone at (855) 793-5068 or by email at shareholder@broadridge.com.

10


RISK FACTORS

An investment


Investing in our securities involves a high degree of risk. Before you invest in our securities, youYou should give careful consideration toconsider and read carefully all of the following risk factors, in addition to therisks and uncertainties described below, as well as other information includedcontained in this prospectus, including our financial statements and related notes, before deciding whethermaking an investment decision with respect to invest in our securities. The occurrence of any of the adverse developments described in the following risk factorsrisks or those incorporated by reference, or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely harmaffect our business, financial condition, results of operations or prospects.cash flows. In thatany such case, the trading price of our common stock, could decline, and you may lose all or part of your investment.

This prospectus also contains forward-looking statements and estimates that involve risks and uncertainties. Our ability to continueactual results could differ materially from those anticipated in the forward-looking statements as a going concern isresult of specific factors, including the risks and uncertainties described below and those incorporated by reference.


RISKS RELATED TO THE RIGHTS OFFERING

This offering may cause the price of common stock to decline, and the price may not recover for a substantial period of time, or at all.

The subscription price of shares in this offering, together with the number of shares of common stock we propose to issue and ultimately will issue in the offering, may result in an immediate decrease in the market value of the common stock. If the market price of common stock falls, you may have irrevocably committed to buy shares of common stock in this offering at an effective price per share greater than the prevailing market price. Further, if a substantial doubt absent obtaining adequate new debtnumber of Subscription Rights are exercised and the exercising rights holders choose to sell some or equity financing, successfulall of the shares purchased directly, the resulting sales could depress the market price of common stock. We cannot assure you that the market price of common stock will not decline prior to the expiration of this offering or that, after shares of common stock are issued upon exercise of Subscription Rights, you will be able to sell shares of common stock purchased in the offering at a price greater than or equal to the effective price paid in the offering.

The subscription price determined for this offering may not be indicative of the fair value of common stock.

The subscription price was set by our board of directors, and you should not consider the subscription price as an indication of the fair value of common stock. The subscription price does not necessarily bear any relationship to the book value of our assets, net worth, past operations, cash flows, earnings/losses, financial condition or any other established criteria for fair value. The market price of common stock could decline during or after this offering, and you may not be able to sell shares of common stock purchased in the offering, at a price equal to or greater than the effective price paid in the offering, or at all.

Your interest in our company may be diluted as a result of this offering.

If you do not fully exercise your basic rights, you will, at the completion of this offering, own a smaller proportional interest in our company on a fully diluted basis than would have been the case if you had fully exercised your basic rights. Based on shares outstanding as of                       , 2021, after giving effect to this offering (assuming the offering is fully subscribed at the Estimated Subscription Price of $_____), we would have                    shares of common stock outstanding, representing an increase in outstanding shares of        %.

The Subscription Rights are non-transferable.

You cannot transfer or generating sufficient revenuesell your Subscription Rights to anyone else. We therefore do not intend to list the Subscription Rights on any securities exchange or include them in any automated quotation system and there will be no market for the Subscription Rights.


11

We may have broad discretion in the use of a significant portion of the net proceeds from operations.

Ourthis offering and may not use those net proceeds effectively.


We intend to use the net proceeds to facilitate enforcement of our intellectual property rights through litigation and other methods, research and development of our intellectual property rights and products to accelerate our growth rate in the health food, vitamin and vape segments to improve our overall liquidity and capital resourcesreduce our indebtedness, and for other general corporate purposes. We cannot specify with any certainty the particular uses of the net proceeds, if any, that we receive from this offering. Our management will have decreased significantlybroad discretion in the application of those additional net proceeds, and we may spend or invest those net proceeds in a way with which stockholders disagree. The failure by management to apply these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds in a manner that does not produce income or that loses value.

Our common stock price may be more volatile as a result of this Rights Offering.

Historically, the market price of our netcommon stock has fluctuated over a wide range for a variety of reasons, including company-specific factors and industry-wide conditions and events. The price of the common stock that will prevail in the market after this Rights Offering may be higher or lower than the Actual Subscription Price depending on many factors, some of which are beyond our control and may not be directly related to our operating losses. Althoughperformance. Financings that may be available to us under current market conditions frequently involve sales at prices below the prices at which our common stock currently trades on the OTC Pink Sheets, as well as the issuance of warrants or convertible equity that require exercise or conversion prices that are calculated in the future at a discount to the then market price of our common stock.

We cannot assure you that the trading price of our common stock will not decline after you exercise your Subscription Rights. If that occurs, you may have bought shares of common stock in the rights offering at a price greater than the prevailing market price and could have an immediate unrealized loss. Moreover, we completedcannot assure you that, following the purchase of common stock in the rights offering, you will be able to sell your common stock at a Private Placementprice equal to or greater than the Actual Subscription Price, and received net proceedsyou may lose all or part of approximately $1.46 millionyour investment in our common stock. Until shares of common stock are delivered upon expiration of the Rights Offering, you will not be able to sell the shares of our common stock that you purchase in the Rights Offering. Shares of our common stock purchased in the rights offering will be issued as of June 22, 2015 and have taken other actions to manage our cash on hand and working capital and to increase cash flows from operating and financing activities, there is no assurance we will have sufficient liquidity and capital resources to fund our business. As of March 31, 2015, we had negative working capital of approximately $(811,970) compared to $127,874 at December 31, 2014, a decrease of approximately $940,000. Our consolidated financial statementssoon as practicable after the rights offering has expired, payment for the year ended December 31, 2014 indicate there is substantial doubt about our ability to continue as a going concern as we require additional equity and/or debt financing to continue our operations. Asshares subscribed for has cleared, and all prorating calculations and reductions contemplated by the terms of the rights offering have been effected. We will not pay you interest on funds delivered to the Subscription Agent pursuant to your exercise of Subscription Rights.

We may amend or modify the terms of the Rights Offering at any time before the expiration of the Rights Offering in a way that could adversely affect your investment.

Our Board of Directors reserves the right to amend or modify the terms of the Rights Offering. The amendments or modifications may be made for any reason and may adversely affect your Subscription Rights. These changes may include, for example, changes to the Subscription Price or other matters that may induce greater participation by our stockholders in the Rights Offering. If we make any fundamental change (such as subscription price or the shares available to purchase pursuant to the basic right) to the terms of the Rights Offering after the date of effectiveness of this prospectus, we believewill file a post-effective amendment to the registration statement in which this prospectus is included and offer subscribers the opportunity to cancel their subscriptions. In such event, we will issue subscription refunds to each stockholder subscribing to purchase shares in the rights offering and recirculate an amended prospectus after the post-effective amendment is declared effective with the Commission. If we extend the Expiration Date in connection with any post-effective amendment, we will allow holders of Subscription Rights a reasonable period of additional time to make new investment decisions on the basis of the new information set forth in the prospectus that will form a part of the post-effective amendment. In such event, we will issue a press release announcing the changes to the rights offering and the new Expiration Date. Even if an amendment does not rise to the level that is fundamental and would thus require us to offer to return your subscription payment, the amendment may nonetheless adversely affect your rights and any prospective return on your investment.


12

You may not be able to immediately resell any shares of our common stock that you purchase upon the exercise of Subscription Rights immediately upon expiration of the Rights Offering.
If you exercise your Subscription Rights, you may not be able to resell the common stock you purchase by exercising your Subscription Rights until you (or your broker or other nominee) have enough cashreceived a book-entry representing those shares. Although we will endeavor to issue the appropriate book-entries as soon as practicable after completion of this offering, there may be some delay between the Expiration Date and the time that we issue the new book-entries. Until shares of common stock are delivered upon expiration of the Rights Offering, you will not be able to sell or transfer the common stock that you purchase in the Rights Offering. The price of our common stock as quoted on handthe OTC Pink Sheets may decrease in the time period between the Expiration Date when you purchase your shares and the date you access to such shares and may have the ability to sell them.

You may not revoke your exercise of rights.

Once you exercise your subscription rights, you may not revoke or change the exercise unless we are required by law to permit revocation. Accordingly, if you exercise your subscription rights and the market price of our common stock falls below the Actual Subscription Price or you later learn information about us or the rights offering that you consider unfavorable to the exercise of your subscription rights, you will be committed to buying shares and may not revoke or change your exercise. 

We do not know how many stockholders will participate in the Rights Offering.

We have no other agreements or understandings with any persons or entities with respect to their exercise of rights or their participation as an underwriter, broker or dealer in the rights offering. We therefore do not know how many other stockholders, if any, will participate in our rights offering. If the rights offering is not otherwise fully subscribed, we will not have the capital necessary to fund our operationscontemplated uses of the net proceeds of the rights offering and might need to look to other sources of funding for three months.

The underwriters are offering the Units on a “best efforts” basis. The underwriters are not required to sell any specific number or dollar amount of Units, but will use their best efforts to sell the Units. As a “best efforts” offering, there can bethese contemplated uses. There is no assurance that these alternative sources will be available and at what cost.


Exercising the Subscription Rights limits your ability to engage in certain hedging transactions that could provide you with financial benefits.

By exercising the Subscription Rights, you are representing to us that you have not entered into any short sale or similar transaction with respect to our common stock since the Record Date for the rights offering. This requirement prevents you from pursuing certain investment strategies that could provide you greater financial benefits than you might have realized if the Subscription Rights did not contain these requirements.

If we terminate this offering, contemplated herebyneither we, nor the subscription agent will ultimatelyhave any obligation to you except to promptly return your subscription payments.

We may terminate this offering at any time. If we do, neither we, nor the subscription agent will have any obligation to you with respect to Subscription Rights that you have exercised, other than to promptly return, without interest or deduction, the subscription payment you delivered to the subscription agent.

If you do not act on a timely basis and follow subscription instructions, your exercise of Subscription Rights may be consummatedrejected.

Holders of common stock who desire to purchase shares in this offering must act on a timely basis to ensure that all required forms and payments are actually received by the subscription agent prior to 5:00 p.m. (Eastern Time) on the Expiration Date, unless extended. If you are a beneficial owner of shares of common stock and you wish to exercise your Subscription Rights, you must act promptly to ensure that your broker, custodian bank or other nominee (including any mobile investment platform) acts for you and that all required forms and payments are actually received by your broker, custodian bank or other nominee (including any mobile investment platform) in sufficient time to deliver such forms and payments to the subscription agent in order to exercise your Subscription Rights by 5:00 p.m. (Eastern time) on the Expiration Date, unless extended. We will resultnot be responsible if your broker, custodian or nominee (including any mobile investment platform) fails to ensure that all required forms and payments are actually received by the subscription agent in a timely manner.

13

If you fail to complete and sign the required subscription forms, send an incorrect payment amount, or otherwise fail to follow the subscription procedures that apply to your exercise of rights, the subscription agent may, depending on the circumstances, reject your subscription or accept it only to the extent of the payment received. Neither we, nor the subscription agent undertakes to contact you concerning an incomplete or incorrect subscription form or payment, nor are we or the subscription agent under any proceeds being madeobligation to us.correct such forms or payment. We have the sole discretion to determine whether a subscription exercise properly follows the subscription procedures.

If you pay the subscription price by uncertified check, your check may not clear in sufficient time to enable you to exercise your Subscription Rights.

Any uncertified check used to pay for the subscription price in this offering must clear prior to the Expiration Date of this offering. The successclearing process may require five or more business days. If you choose to pay the subscription price, in whole or in part, by uncertified check and your check does not clear prior to the Expiration Date of this offering, you will not have satisfied the conditions to exercise your rights and you will not receive the shares you wish to purchase.

You may not receive all of the shares for which you subscribe under the over-subscription privilege.

Rights holders who fully exercise their basic rights will have the right, pursuant to their over-subscription privileges, to purchase additional shares to the extent other rights holders do not exercise their basic rights in full. Over-subscription privileges will be allocated pro rata among rights holders who over-subscribe, based on the number of over-subscription shares for which the rights holders have subscribed. We cannot guarantee that you will receive all, or a significant portion, of the shares for which you subscribe pursuant to your over-subscription privilege.

If the number of shares allocated to you is less than your subscription request, the excess funds held by the subscription agent on your behalf will be promptly returned to you, without interest or deduction, after this offering has expired, and we will have no further obligations to you.

This offering may cause the market price of our common stock to decrease.

The subscription price, together with the number of shares of common stock we propose to issue and ultimately will issue in the rights offering, may result in an immediate decrease in the market price of our common stock. This decrease may continue throughout and after the completion of the rights offering. If that occurs, you may have committed to buy common stock in the rights offering at a price greater than the prevailing market price of our common stock. Further, if a substantial number of subscription rights are exercised and the subscribing holders choose to sell some or all of the shares of common stock received upon exercise of those rights, the resulting sales could depress the market price of our common stock. There is no assurance that following the rights offering you will be able to sell your shares of common stock purchased in the rights offering at a price equal to or greater than the subscription price.

Because no minimum subscription is required and because we do not have formal commitments from our stockholders for the entire amount we seek to raise pursuant to the rights offering, we cannot assure you of the amount of proceeds that we will receive from the rights offering.

No minimum subscription is required for consummation of the rights offering. We do not have formal commitments from our stockholders for the amount we seek to raise pursuant to the Rights Offering, and it is possible that no other rights will be exercised in connection with the Rights Offering. As a result, we cannot assure you of the amount of proceeds that we will receive in the Rights Offering. Therefore, if you exercise all or any portion of your subscription rights, but other stockholders do not, we may not raise the desired amount of capital in the Rights Offering, the market price of our common stock could be adversely impacted and we may find it necessary to pursue alternative means of financing, which may be dilutive to your investment.

14

Your receipt of Subscription Rights may be treated as a taxable dividend to you.

The distribution of Subscription Rights in this offering should be a non-taxable stock dividend under Section 305(a) of the Internal Revenue Code of 1986. This position is not binding on the Internal Revenue Service or the courts, however. If this offering is part of a “disproportionate distribution” under Section 305 of the Internal Revenue Code, your receipt of Subscription Rights may be treated as the receipt of a distribution equal to the fair market value of the rights. Any such distribution treated as a disproportionate distribution would be treated as dividend income to the extent of our current and accumulated earnings and profits, with any excess being treated as a return of basis to the extent thereof and then as capital gain. See “Material U.S. Federal Income Tax Considerations.”

Maxim, as dealer-manager, is not acting as an underwriter or placement agent of the Subscription Rights or the securities underlying the Subscription Rights.

Maxim will act as dealer-manager for this offering and, in that capacity, will provide marketing assistance in connection with the offering. Maxim is not underwriting, soliciting or placing any of the Subscription Rights or the shares (or the common stock comprising the shares) and is not making any recommendation with respect to such Subscription Rights (including with respect to the exercise or expiration of such Subscription Rights) or shares. Maxim will not be subject to any liability to us in rendering services to us except for an act involving bad faith, willful misconduct or gross negligence.

Because we do not have a standby purchase agreement, backstop commitment or similar arrangement in connection with this offering, the net proceeds we receive from the offering may be less than we intend.

We have currently not entered into any standby purchase agreement, backstop commitment or similar arrangement in connection with this offering. We therefore cannot assure you that any of our stockholders will exercise all or any part of their Subscription Rights. We do not have arrangements under which Maxim or any other investment bank, financial advisor or other entity will be obligated to sell securities not purchased in this offering. If rights holders subscribe for fewer shares than anticipated, the net proceeds we receive from this offering could be significantly reduced. Regardless of whether this offering is fully subscribed.

We have not paid dividends and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.

We have not paid cash dividends on our common stock and do not anticipate doing so in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.

The Rights Offering May Result in the Reduction of the Conversion Price of the Series D Preferred Stock and Dilution to Existing Shareholders.

The conversion price for the Series D Preferred Stock is currently $0.0024. The conversion price will be lesser of $0.0024 and either (1) 85% of the average of the volume weighted average price (VWAP) during the 10 trading days immediately following the effective date and public announcement of the next reverse stock split of HCMC, (2) 80% of the lowest daily VWAP during the 5 trading days immediately preceding the date the conversion shares are either registered for resale or may be sold pursuant to Rule 144 and (3) the per share price at which Company securities are sold in the future. If the Actual Subscription Price is less than $0.0024, the conversion price for the Series D Preferred Stock will be reduced to such price, causing dilution to existing stockholders upon conversion of the Series D Preferred Stock.


15

Risks Related to Our Securities

The market price of our common stock has been and may continue to be volatile.

The market price of our common stock has been volatile, and fluctuates widely in price in response to various factors, which are beyond our control. The price of our common stock is not necessarily indicative of our operating performance or long-term business prospects. In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock. Factors such as the following could cause the market price of our common stock to fluctuate substantially:

our quarterly operating and financial results;
government regulation of our industry;
the introduction of new products by our competitors;
changing conditions in the electronic cigarette and tobacco industries; as well as the grocery business
developments concerning proprietary rights; or
litigation or public concern about the safety of our products.

The stock market in general experiences from time to time extreme price and volume fluctuations. Periodic and/or continuous market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility may be worse if the trading volume of our common stock is low.

Future sales of our common stock may depress our stock price.

As of _______________, 2021, we had approximately ___________ billion shares of our common stock outstanding. Approximately __________ billion of our outstanding shares are eligible for resale without restrictions. If any significant number of these shares are sold, such sales could have a depressive effect on the market price of our stock. The remaining shares are eligible, and some of the shares underlying the restricted stock units options upon issuance, will be eligible to be offered from time to time in the public market pursuant to registration statements we have filed and Rule 144 Securities Act, and any such sale of these shares may have a depressive effect as well. We are unable to predict the effect, if any, that the sale of shares, or the availability of shares for future sale, will have on the market price of the shares prevailing from time to time. Sales of substantial amounts of shares in the public market, or the perception that such sales could occur, could depress prevailing market prices for the shares. Such sales may also make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price, which we deem appropriate.

Costs incurred because we are a public company may affect our profitability.

As a public company, we incur significant legal, accounting, and other expenses, and we are subject to the SEC’s rules and regulations relating to public disclosure that generally involve a substantial expenditure of financial resources. In addition, the Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the SEC, requires changes in corporate governance practices of public companies. We expect that full compliance with such rules and regulations will significantly increase our legal and financial compliance costs and make some activities more time-consuming and costly, which may negatively impact our financial results. To the extent our earnings suffer as a result of the financial impact of our SEC reporting or compliance costs, our ability to finance operations overdevelop an active trading market for our securities could be harmed.


16

We do not expect to pay dividends for the next 12 months. If no Units are soldforeseeable future, and we may never pay dividends.

We currently intend to retain any future earnings to support the development and expansion of our business and do not anticipate paying cash dividends in this offering, or if we sell only a minimum numberthe foreseeable future. Our payment of Units yielding insufficient gross proceeds,any future dividends will be at the discretion of our Board of Directors after taking into account various factors, including but not limited to, our financial condition, operating results, cash needs, growth plans and the terms of any credit agreements that we may be unablea party to successfully fundat the time. In addition, our operations, or executeability to pay dividends on our common stock may be limited by state law. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize certain returns on their investment.

Our common stock may become a “penny stock,” and thereby be subject to additional sale and trading regulations that may make it more difficult to sell.

Our common stock could be considered to be a “penny stock.”  It may not qualify for one of the exemptions from the definition of “penny stock” under Section 3a51-1 of the Exchange Act. The principal result or effect of being designated a “penny stock” is that securities broker-dealers participating in sales of our common stock are subject to the “penny stock” regulations set forth in Rules 15-2 through 15g-9 promulgated under the Securities Exchange Act. For example, Rule 15g-2 requires broker-dealers dealing in penny stocks to provide potential investors with a document disclosing the risks of penny stocks and to obtain a manually signed and dated written receipt of the document at least two business plan.days before effecting any transaction in a penny stock for the investor’s account. Moreover, Rule 15g-9 requires broker-dealers in penny stocks to approve the account of any investor for transactions in such stocks before selling any penny stock to that investor. This wouldprocedure requires the broker-dealer to (i) obtain from the investor information concerning his or her financial situation, investment experience and investment objectives; (ii) reasonably determine, based on that information, that transactions in penny stocks are suitable for the investor and that the investor has sufficient knowledge and experience as to be reasonably capable of evaluating the risks of penny stock transactions; (iii) provide the investor with a written statement setting forth the basis on which the broker-dealer made the determination in (ii) above; and (iv) receive a signed and dated copy of such statement from the investor, confirming that it accurately reflects the investor’s financial situation, investment experience and investment objectives. Compliance with these requirements may make it more difficult and time consuming for holders of our common stock to resell their shares to third parties or to otherwise dispose of them in the market or otherwise.

FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our common shares.

In addition to the “penny stock” rules described above, FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common shares, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.


17

Our Board of Directors’ ability to issue undesignated preferred stock and the existence of anti-takeover provisions may depress the value of our common stock.

Our authorized capital includes 1,000,000 shares of preferred stock. Of this amount, 5,000 of such shares have been designated as Series D Convertible Preferred Stock and all such shares are issued and outstanding. Our Board of Directors has the power to issue any or all of the shares of undesignated preferred stock, including the authority to establish one or more series and to fix the powers, preferences, rights and limitations of such class or series, without seeking stockholder approval. Further, as a Delaware corporation, we are subject to provisions of the Delaware General Corporation Law regarding “business combinations.”  We may, in the future, consider adopting additional anti-takeover measures. The authority of our Board of Directors to issue undesignated stock and the anti-takeover provisions of Delaware law, as well as any future anti-takeover measures adopted by us, may, in certain circumstances, delay, deter or prevent takeover attempts and other changes in control of the company not approved by our Board of Directors. As a result, our stockholders may lose opportunities to dispose of their shares at favorable prices generally available in takeover attempts or that may be available under a merger proposal and the market price, voting and other rights of the holders of common stock may also be affected.

Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.

We also expect that additional capital will be needed in the future to continue our planned operations. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results. As a result, we could become subject to sanctions or investigations by regulatory authorities and/or stockholder litigation, which could harm our business and have an adverse effect on our stock price.

As a public reporting company, we are required to comply with the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC, including periodic reports, disclosures and more complex accounting rules. As directed by Section 404 of Sarbanes-Oxley, the SEC adopted rules requiring public companies to include a report of management on a company’s internal control over financial reporting in their Annual Report on Form 10-K. Based on current rules, we are required to report under Section 404(a) of Sarbanes-Oxley regarding the effectiveness of our internal control over financial reporting. If we were to determine that we have material weaknesses, it may be necessary to make restatements of our consolidated financial statements and investors will not be able to rely on the completeness and accuracy of the financial information contained in our filings with the SEC and this could potentially subject us to sanctions or investigations by the SEC or other regulatory authorities or stockholder litigation.

Our management conducted an evaluation of the effectiveness of our internal control over financial reporting and concluded that our internal control over financial reporting was not effective as of December 31, 2020. If we fail to remediate these issues and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud.


18

Our management conducted an evaluation of the effectiveness of our internal control over financial reporting and concluded that our internal control over financial reporting was not effective as of December 31, 2020 as a result of material weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of our company's financial statements will not be prevented, or detected and corrected on a timely basis.  The primary material weaknesses identified by management related to a lack of accounting personnel and the failure to have properly documented and designed controls and procedures.

We have undertaken initiatives to improve our internal control over financial reporting and disclosure controls.  However, the implementation of these initiatives may not fully address the material weaknesses in our internal control over financial reporting. In addition, the process of designing and implementing an effective financial reporting system is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a financial reporting system that satisfies our reporting obligations. Our failure to remediate the material weaknesses or our failure to discover and address any other material weaknesses or deficiencies may result in inaccuracies in our financial statements, delay in the preparation of our financial statements, and the loss of investor confidence in the reliability of our financial statements, which in turn could negatively influence the trading price of our common stock. Also, as a result, our business, financial condition, results of operations and prospects may be materially and adversely affected.

General Risks

If we fail to retain our key personnel, we may not be able to achieve our anticipated level of growth and our business could suffer.

Our future depends, in part, on our ability to attract and retain key personnel and the continued contributions of our executive officers, each of whom may be difficult to replace. In particular, Jeffrey Holman, our Chief Executive Officer, is important to the management of our business and operations and the development of our strategic direction. The loss of the services of this officer, and the process to replace him would involve significant time and expense and may significantly delay or prevent the achievement of our business objectives.

The COVID-19 Pandemic and related economic repercussions may affect our business.

The COVID-19 pandemic and related economic repercussions have created significant volatility, uncertainty, and turmoil in businesses globally. While these events have not yet had a material adverse effect on our business prospects,and B2C platforms like ours have seen elevated sales levels from consumer shifts to online purchasing, we can offer no assurance that the COVID-19 pandemic will not have an adverse effect in the future, particularly if the pandemic worsens or endures for an extended period of time.

At the onset of the pandemic we implemented several changes to enhance safety and mitigate health risk in our work environment. For our warehouse and manufacturing operations, these included split shifts, temperature scans, additional contactless hand sanitizing stations, protective equipment, social distancing guidelines, and increased cleaning and sanitization. These changes resulted in higher operational costs, and as a result, we instituted cost savings programs to offset these increased costs. We also put a hold on new spending commitments as we cautiously manage through this environment.

The COVID-19 pandemic may adversely impact our results. Our supply chain has remained operational otherwise, but we can offer no assurance that it will not be adversely affected in the future, particularly as the COVID-19 pandemic continues to worsen.  If the impact of the COVID-19 pandemic continues for an extended period of time or worsens, it could have a material adverse effect on our supply chain or workforce, either of which could have a material adverse effect on our business, financial condition and resultsliquidity. In addition, if the impact of the COVID-19 pandemic continues it may heighten the other risks that could affect our business.

19

Reliance on information technology means a significant disruption could affect our communications and operations.


We increasingly rely on information technology systems for our internal communications, controls, reporting and relations with customers and suppliers and information technology is becoming a significantly important tool for our sales staff. In addition, our reliance on information technology exposes us to cyber-security risks, which could have a material adverse effect on our ability to compete. Security and privacy breaches may expose us to liability and cause us to lose customers or may disrupt our relationships and ongoing transactions with other entities with whom we contract throughout our supply chain. The failure of our information systems to function as intended, or the penetration by outside parties’ intent on disrupting business processes, could result in significant costs, loss of revenue, assets or personal or other sensitive data and reputational harm.

Risks Relating to Our Vaporizer Business

We have incurred significant operating losses in the past and cannot assure you that we will achieve and/or maintain profitable operations.

As of March 31, 2015, we had an accumulated deficitoperations or liquidity.


The Company reported a net loss allocable to common stockholders of approximately $19.2 million.$2.799 million and $3.722 million for the years ended December 31, 2019 and 2020. Our accumulated deficit isoperating losses are primarily due to, among other reasons, the establishment ofincreasing competition, in both our business infrastructurevape and operations, stock-based compensation expenses and increases in our marketing expenditures. Additionally, Vapor did not anticipate the shift from e-cigarettes which caused in part the large losses beginning in 2014. For the three months ended March 31, 2015 and 2014, we had net losses of $3,981,196 and $1,452,759, respectively. For the year ended December 31, 2014, we had a net loss of $13,852,249 compared to net income of $801,352 for the year ended December 31, 2013. Unless we raise at least $11 million in this offering, there is no assurance we will have sufficient liquidity and capital resources available to fund our business for the next 12 months. Ourgrocery businesses.

The Company’s liquidity and capital resources have decreased significantly as a result of the net operating losses we incurred during the year ended December 31, 2014.losses. We cannot assure you that we will be able to generate operating profits in the future on a sustainable basis or at all as we continue to expand our infrastructure, open additional retail stores, further develop our marketing efforts and otherwise implement our growth initiatives. WorkingFuture working capital limitations continue tocould impinge on our day-to-day operations, thus contributing to continued operating losses.

Because


If the FDA passed regulations to extend its authority to e-vapor products, including e-cigarettes, vaporizers and e-liquids, necessitating stringent and costly product review requirements, such regulations could curtail or prevent our ability to sell e-vapor products and significantly reduce the number of changes in our industry, it is difficult to accurately predict our future sales and appropriately budget our expenses.

We acquired Smoke Anywhere, a distributor of electronic cigarettes, in November 2009 and Vaporin in March 2015. Smoke Anywhere commenced its business in 2008 and Vaporin commenced its operations in 2013. Because our industry is still evolving, it is difficult to accurately predict our future sales and appropriately budget our expenses. Additionally, our operations will be subject to risks inherent in the establishment of a developing new business as well as a new business model of deploying new vape stores, including, among other things, efficiently deploying our capital, costs or difficulties relatinge-vapor products available for sale to the integrationpublic.


It is anticipated that the FDA’s prospective regulation of e-vapor products, including requiring costly formal product approvals, limiting the merger with Vaporin, developing ourmanufacture and distribution of e-vapor products opening retail stores, developingwill impact availability. Any such regulations and implementing our marketing campaignsapproval process would make product development and strategies and developing brand awareness and acceptance of our products. Our ability to generate future sales will be dependent on a number of factors, many of which are beyond our control, includingmanufacture cost prohibitive for the pricing of competingCompany. A reduction in available e-vapor products overall demandwould diminish the need for our products, changes in consumer preferences, market competition and government regulation. Assuming we are successful in raising funds in this offering, we will expand our vape stores and marketing and advertising campaigns and operational expenditures in anticipation of future sales growth. If our sales do not increase as anticipated, we could incur significant losses due to our higher infrastructure expense levels if we are not able to decrease our advertising and operating expenses in a timely manner to offset any shortfall in future sales.

The potential regulation of vaporizers and electronic cigarettes by the United States Food and Drug Administration may materially adversely affect our business.

On April 24, 2014, the United States Food and Drug Administration, or the FDA,released proposed rules that would extend its regulatory authority to vaporizers, electronic cigarettes and certain other tobacco products under the Family Smoking Prevention and Tobacco Control Act of 2009, or the Tobacco Control Act. Our references to electronic cigarettes in these risk factors are intended to include vaporizers, unless otherwise clear from the context. We note that the proposed rules would require that electronic cigarette manufacturers (i) register with the FDA and report electronic cigarette product and ingredient listings; (ii) market new electronic cigarette products only after FDA review; (iii) only make direct and implied claims of reduced risk if the FDA confirms that scientific evidence supports the claim and that marketing the electronic cigarette product will benefit public health as a whole; (iv) not distribute free samples; (v) implement minimum age and identification restrictions to prevent sales to individuals under age 18; (vi) include a health warning; and (vii) not sell electronic cigarettes in vending machines, unless in a facility that never admits youth.

More recently, on July 1, 2015, the FDA published a document entitled “Advanced Notice of Proposed Rulemaking,” or the Advance. Through the Advance, the FDA solicited public comments on whether it should issue rules with respect to nicotine exposure warning and child-resistant packaging for e-liquids containing nicotine. Following public comment, the FDA may issue proposed rules in furtherance of the purposes outlined in the Advance and ultimately pass the rules as proposed or in modified form.

It is not known how long the regulatory process to finalize and implement any of these rules may take. Accordingly, although we cannot predict the content of any final rules from the proposed rules or the impact they may have, we believe that if the final rules enacted are materially more stringent then the proposed rules they could have a material adverse effect on our business, financial conditions and results of operations.

For a description of risks related to other government regulations, please see “Risks Related to Government Regulation” in this Section.

dedicated retail stores.


The recent development of electronic cigarettes has not allowed the medical profession to study the long-term health effects of electronic cigarette use.


Because electronic cigarettes were recently developed the medical profession has not had a sufficient period of time to study the long-term health effects of electronic cigarette use. Currently, therefore, there is no way of knowing whether or not electronic cigarettes are safe for their intended use. If the medical profession were to determine conclusively that electronic cigarette usage poses long-term health risks, electronic cigarette usage could decline, which could have a material adverse effect on our business, results of operations and financial condition.



20


Our business, results of operations and financial condition could be adversely affected if our products are taxed like other tobacco products or if we are required to collect and remit sales tax on certain of our Internet sales.

products.


Presently the sale of electronic cigarettes and vaporizers is not subject to federal, state and local excise taxes like the sale of conventional cigarettes or other tobacco products, all of which have faced significant increases in the amount of taxes collected on their sales. Should federal, state and local governments and or other taxing authorities impose excise taxes similar to those levied against conventional cigarettes and tobacco products on our products, it may have a material adverse effect on the demand for our products, as consumers may be unwilling to pay the increased costs for our products.

We may be unable to establish the systems and processes needed to track and submit the excise and sales taxes we collect through Internet sales, which would limit our ability to market our products through our websites which would have a material adverse effect on our business, results of operations and financial condition. A number of states including New York, North Carolina, Texas and California have begun collecting sales taxes on Internet sales where companies have used independent contractors in those states to solicit sales from residents of that state. The requirement to collect, track and remit sales taxes based on independent affiliate sales may require us to increase our prices, which may affect demand for our products or conversely reduce our net profit margin, either of which would have a material adverse effect on our business, results of operations and financial condition.

The market for electronic cigarettes is a niche market, subject to a great deal of uncertainty and is still evolving.

Vaporizers and electronic cigarettes, having recently been introduced to market, are at an early stage of development, represent a niche market and are evolving rapidly and are characterized by an increasing number of market entrants. Our future sales and any future profits are substantially dependent upon the widespread acceptance and use of electronic cigarettes. Rapid growth in the use of, and interest in, electronic cigarettes is recent, and may not continue on a lasting basis. The demand and market acceptance for these products is subject to a high level of uncertainty. Therefore, we are subject to all of the business risks associated with a new enterprise in a niche market, including risks of unforeseen capital requirements, failure of widespread market acceptance of electronic cigarettes, in general or, specifically our products, failure to establish business relationships and competitive disadvantages as against larger and more established competitors.


Because we face intense competition from big tobacco companies and other competitors, our failure to compete effectively could have a material adverse effect on our business, results of operations and financial condition.


Competition in the electronic cigarette and vaporizer industry is intense. The nature of our competitors is varied as the market is highly fragmented and the barriers to entry into the business are low.


We compete primarily on the basis of product quality, brand recognition, brand loyalty, service, marketing, advertising and price. We are subject to highly competitive conditions in all aspects of our business. The competitive environment and our competitive position can be significantly influenced by weak economic conditions, erosion of consumer confidence, competitors’ introduction of low-priced products or innovative products, cigarette excise taxes, higher absolute prices and larger gaps between price categories, and product regulation that diminishes the ability to differentiate tobacco products.


Our principal competitors are “big tobacco”,tobacco,” U.S. cigarette manufacturers of both conventional tobacco cigarettes and electronic cigarettes like Altria Group, Inc., Lorillard, Inc. and Reynolds American Inc. We compete against “big tobacco” which offers not only conventional tobacco cigarettes and electronic cigarettes but also smokeless tobacco products such as “snus” (a form of moist ground smokeless tobacco that is usually sold in sachet form that resembles small tea bags), chewing tobacco and snuff.snuff, and now so called “heat not burn” (HNB) products such as “IQOS”. Furthermore, we believe that “big tobacco” will devote more attention and resources to developing and offering electronic cigarettes (including vaporizers)vaporizers and HNB) as the market grows. Because of their well-established sales and distribution channels, marketing expertise and significant financial and marketing resources, “big tobacco” is better positioned than small competitors like us to capture a larger share of the electronic cigarette market. We also compete against numerous other smaller manufacturers or importers of cigarettes. There can be no assurance that we will be able to compete successfully against any of our competitors, some of whom have far greater resources, capital, experience, market penetration, sales and distribution channels than us. If our major competitors were, for example, to significantly increase the level of price discounts offered to consumers, we could respond by offering price discounts, which could have a materially adverse effect on our business, results of operations and financial condition.


Sales of conventional tobacco cigarettes have been declining, which could have a material adverse effect on our business.


The overall U.S. market for conventional tobacco cigarettes has generally been declining in terms of volume of sales, as a result of restrictions on advertising and promotions, funding of smoking prevention campaigns, increases in regulation and excise taxes, a decline in the social acceptability of smoking, and other factors, and such sales are expected to continue to decline. In September 2014, CVS, a leading national drug store chain ceased selling tobacco products. If other national drug store chains also decide to cease selling tobacco products, cigarette sales could decline further. While the sales of vaporizers have been increasing over the last several years, the vaporizer and electronic cigarettes market is only developing and is a fraction of the size of the conventional tobacco cigarette market. A continual decline in cigarette sales may adversely affect the growth of the vaporizer and electronic cigarette market, which could have a material adverse effect on our business, results of operations and financial condition.



21

If we are subject to further intellectual property litigation, or if the present suit becomes actively litigated, we may incur substantial additional costs which will adversely affect our results of operations.


The cost to prosecute infringements of our intellectual property or the cost to defend our products against patent infringement or other intellectual property litigation by others could be substantial. We cannot assure you that:

pending and future patent applications will result in issued patents;
patents we own or which are licensed by us will not be challenged by competitors;
the patents will be found to be valid or sufficiently broad to protect our technology or provide us with a competitive advantage; and
we will be successful in defending against current and future patent infringement claims asserted against our products as described in the next risk factor.


pending and future patent applications will result in issued patents;
patents we own or which are licensed by us will not be challenged by competitors;
the patents will be found to be valid or sufficiently broad to protect our technology or provide us with a competitive advantage;
we will be successful in defending against patent infringement claims asserted against our products; and
we will be successful in prosecuting patent infringement claims asserted.

Both the patent application process and the process of managing patent disputes can be time consuming and expensive. In addition, changes in the U.S. patent laws could prevent or limit us from filing patent applications or patent claims to protect our products and/or technologies or limit the exclusivity periods that are available to patent holders. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law and includes a number of significant changes to U.S. patent law, including the transaction from a “first-to-invent’ system to a “first-to-file” system and changes to the way issued patents are challenged. These changes may favor larger and more established companies that have more resources than we do to devote to patent application filing and prosecution. The U.S. Patent and Trademark Office issued new Regulations effective March 16, 2013 to administer the Leahy-Smith Act. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries and our ability to enforce or defend our issued patents. However, it is possible that in order to adequately protect our patents under the “first-to-file” system, we will have to allocate significant additional resources to the establishment and maintenance of a new patent application process designed to be more streamlined and competitive in the context of the new “first-to-file” system, which would divert valuable resources from other areas of our business. In addition to pursuing patents on our technology, we have taken steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, and corporate partners. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate.


If a third partythird-party asserts that we are infringing on its intellectual property, whether successful or not, it could subject us to costly and time-consuming litigation or require us to obtain expensive licenses, and our business may be adversely affected.


Although we have filed patent applications, we do not own anyissued patents relating to our vaporizers and electronic cigarettes. Thepatents pending, the vaporizer and electronic cigarette industry is nascent and third parties may claim patent rights over one or more types of vaporizers and electronic cigarettes. For example, Ruyan Investment (Holdings) Limited, which we refer to as “Ruyan”, a Chinese company, has made certain public claims as to their ownership of patents relating to our products and has filed a number of separate lawsuits against us. We and Ruyan settled the first lawsuit, and another lawsuit has been stayed along with other patent infringement lawsuits filed by Ruyan against other defendants pending the results of an inter parties reexamination requested by one of the defendants in the other lawsuits. Additionally, in 2014, Ruyan filed three separate lawsuits against the Company alleging that we infringed on their patents. These three complaints were consolidated and the trial is currently scheduled for November 2015. For a description of Ruyan’s lawsuits against us, please see the section titled “Legal Proceedings” contained in this prospectus. We currently purchase our products from Chinese manufacturers other than Ruyan.

Ruyan’s lawsuits as well as any other thirdThird party lawsuits alleging our infringement of patents, trade secrets or other intellectual property rights could cause us to do one or more of the following:

stop selling products or using technology that contains the allegedly infringing intellectual property;
incur significant legal expenses;
cause our management to divert substantial time to our defenses;
pay substantial damages to the party whose intellectual property rights we may be found to be infringing;
indemnify distributors and customers;
redesign those products that contain the allegedly infringing intellectual property; or
attempt to obtain a license to the relevant intellectual property from third parties, which may not be available to us on reasonable terms or at all.


stop selling products or using technology that contains the allegedly infringing intellectual property;
incur significant legal expenses;
cause our management to divert substantial time to our defenses;
pay substantial damages to the party whose intellectual property rights we may be found to be infringing;
indemnify distributors and customers;
redesign those products that contain the allegedly infringing intellectual property; or
attempt to obtain a license to the relevant intellectual property from third parties, which may not be available to us on reasonable terms or at all.

Third party lawsuits alleging our infringement of patents, trade secrets or other intellectual property rights could have a material adverse effect on our business, results of operations and financial condition.


If we cannot protect our intellectual property rights, we may be unable to compete with competitors developing similar technologies.


We believe that patents, trademarks, trade secrets and other intellectual property we use and are developing are important to sustaining and growing our business. We utilize third party manufacturers to manufacture our products in China, where the validity, enforceability and scope of protection available under intellectual property laws are uncertain and still evolving. Implementation and enforcement of Chinese intellectual property-related laws have historically been deficient, ineffective and hampered by corruption and local protectionism. Accordingly, we may not be able to adequately protect our intellectual property in China, which could have a material adverse effect on our business, results of operations and financial condition. Furthermore, policing unauthorized use of our intellectual property in China and elsewhere is difficult and expensive, and we may need to resort to litigation to enforce or defend our intellectual property or to determine the enforceability, scope and validity of our proprietary rights or those of others. Such litigation and an adverse determination in any such litigation, if any, could result in substantial costs and diversion of resources and management attention, which could harm our business and competitive position.


If vaporizers continue to face intense media attention and public pressure, our operations may be adversely affected.22

Since the introduction of electronic cigarettes and vaporizers, certain members of the media, politicians, government regulators and advocate groups, including independent medical physicians, have called for an outright ban of all electronic cigarettes and vaporizers, pending regulatory review and a demonstration of safety. A partial or outright ban would have a material adverse effect on our business, results of operations and financial condition and we may have to shut down our operations in the locations implemented any such ban.

If we fail to retain our key personnel, we may not be able to achieve our anticipated level of growth and our business could suffer.

Our future depends, in part, on our ability to attract and retain key personnel and the continued contributions of our executive officers, each of whom may be difficult to replace. In particular, Jeffrey Holman, our Chief Executive Officer, Gregory Brauser, our President, and James Martin, our Chief Financial Officer, are important to the management of our business and operations and the development of our strategic direction. The loss of the services of any of these officers and the process to replace any key personnel would involve significant time and expense and may significantly delay or prevent the achievement of our business objectives.


We may experience product liability claims in our business, which could adversely affect our business.


The tobacco industry in general has historically been subject to frequent product liability claims. As a result, we may experience product liability claims from the marketing and sale of electronic cigarettes.cigarettes or vaporizers. Any product liability claim brought against us, with or without merit, could result in:

liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;
an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;
damage to our reputation and the reputation of our products, resulting in lower sales;
regulatory investigations that could require costly recalls or product modifications;
litigation costs; and
the diversion of management’s attention from managing our business.


liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;
an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;
damage to our reputation and the reputation of our products, resulting in lower sales;
regulatory investigations that could require costly recalls or product modifications;
litigation costs; and
the diversion of management’s attention from managing our business.

Any one or more of the foregoing could have a material adverse effect on our business, results of operations and financial condition.


If we experience product recalls, we may incur significant and unexpected costs and our business reputation could be adversely affected.


We may be exposed to product recalls and adverse public relations if our products are alleged to cause illness or injury, or if we are alleged to have violated governmental regulations. A product recall could result in substantial and unexpected expenditures and could harm our reputation, which could have a material adverse effect on our business, results of operations and financial condition. In addition, a product recall may require significant management time and attention and may adversely impact on the value of our brands. Product recalls may lead to greater scrutiny by federal or state regulatory agencies and increased litigation, which could have a material adverse effect on our business, results of operations and financial condition.

If we experience a high amount of product exchanges, returns and warranty claims, our business will be adversely affected.

If we are unable to maintain an acceptable degree of quality control of our products, we will incur costs associated with the exchange and return of our products as well as servicing our customers for warranty claims. In addition, customers may require us to take back unsold products which we may be unable to resell. Any of the foregoing on a significant scale may have a material adverse effect on our business, results of operations and financial condition.


If the economy declines, such decline may adversely affect the demand for our products.


Vaporizers and electronic cigarettes may be regarded by users as a novelty item and expendable as such demand for our products may be extra sensitive to economic conditions. When economic conditions are prosperous, discretionary spending typically increases; conversely, when economic conditions are unfavorable, discretionary spending often declines. Any significant decline in economic conditions that affects consumer spending could have a material adverse effect on our business, results of operations and financial condition.

Generating foreign sales will result in additional costs and expenses and may expose us to a variety of risks.

Generating sales of our products foreign jurisdictions will require us to incur additional costs and expenses. Furthermore, our entry into foreign jurisdictions may expose us to various risks, which differ in each jurisdiction, and any of such risks may have a material adverse effect on our business, financial condition and results of operations. Such risks include the degree of competition, fluctuations in currency exchange rates, difficulty and costs relating to compliance with different commercial, legal, regulatory and tax regimes and political and economic instability.


Our future growth and profitability will depend in large part upon the effectiveness of our marketing and advertising expenditures.


Our future growth and profitability will depend in large part upon our media performance, including our ability to:

● create greater awareness of our products and stores;
identify the most effective and efficient level of spending in each market and specific media vehicle;
determine the appropriate creative message and media mix for advertising, marketing, and promotional expenditures; and
● effectively manage marketing costs (including creative and media).


create greater awareness of our products and stores;
identify the most effective and efficient level of spending in each market and specific media vehicle;
determine the appropriate creative message and media mix for advertising, marketing, and promotional expenditures; and
effectively manage marketing costs (including creative and media).

23

Our planned marketing expenditures may not result in increased revenue. If our media performance is not effective, our future results of operations and financial condition will be adversely affected.


If we areunable to promote and maintain our brands, our results of operations will be adversely affected.


We believe that establishing and maintaining the brand identities of our products is a critical aspect of attracting and expanding a large customer base. Promotion and enhancement of our brands will depend largely on our success in continuing to provide high quality products. If our customers and end users do not perceive our products to be of high quality, or if we introduce new products or enter into new business ventures that are not favorably received by our customers and end users, we will risk diluting our brand identities and decreasing their attractiveness to existing and potential customers.


Moreover, in order to attract and retain customers and to promote and maintain our brand equity in response to competitive pressures, we may have to increase substantially our financial commitment to creating and maintaining a distinct brand loyalty among our customers. If we incur significant expenses in an attempt to promote and maintain our brands, our business, results of operations and financial condition could be adversely affected.

If we cannot manage our vape stores as we grow, we may incur substantial operating losses and adversely affect our financial condition.

Our business model is focusing on expanding the number of vape stores beyond the 10 we presently operate. As we expand the number of vape stores and their location, it will be more difficult to manage them and our promotional costs will increase. None of our senior managers has experience in operating a significant number of retail stores in different locations. If we expand our vape stores beyond our capabilities, we may be materially and adversely affected.

We rely on the efforts of third party agents to generate sales of our products, and loss of any such agents may be time consuming to replace.

We rely on the efforts of independent distributors to purchase and distribute our products to wholesalers and retailers. No single distributor currently accounts for a material percentage of our sales and we believe that should any of these relationships terminate we would be able to find suitable replacements and do so on a timely basis. However, any loss of distributors or our ability to timely replace any given distributor could have a material adverse effect on our business, financial condition and results of operations.

We rely, in part, on the efforts of independent salespersons who sell our products to distributors and major retailers and Internet sales affiliates to generate sales of products. No single independent salesperson or Internet affiliate currently accounts for a material percentage of our sales and we believe that should any of these relationships terminate we would be able to find suitable replacements and do so on a timely basis. However, any loss of independent sales persons or Internet sales affiliates or our ability to timely replace any one of them could have a material adverse effect on our business, financial condition and results of operations.

We may not be able to establish sustainable relationships with large retailers or national chains.

We believe the best way to develop brand and product recognition and increase sales volume is to establish relationships with large retailers and national chains. We currently have established relationships with several large retailers and national chains and in connection therewith we have agreed to pay such retailers and chains fees, known as “slotting fees”, to carry and offer our products for sale based on the number of stores our products will be carried in. These existing relationships are “at-will” meaning that either party may terminate the relationship for any reason or no reason at all. We may not be able to sustain these relationships or establish other relationships with large retailers or national chains or, even if we do so, sustain such other relationships. Our inability to develop and sustain relationships with large retailers and national chains will impede our ability to develop brand and product recognition and increase sales volume and, ultimately, require us to pursue and rely on local and more fragmented sales channels, which will have a material adverse effect on our business, results of operations and financial condition.


If we are unable to adapt to trends in our industry, our results of operations will be adversely affected.


We may not be able to adapt as the vaporizer and electronic cigarette industry and customer demand evolve, , whether attributable to regulatory constraints or requirements, a lack of financial resources or our failure to respond in a timely and/or effective manner to new technologies, customer preferences, changing market conditions or new developments in our industry. Any of the failures to adapt for the reasons cited herein or otherwise could make our products obsolete and would have a material adverse effect on our business, financial condition and results of operations.


If our third partythird-party manufacturers produce unacceptable or defective products or do not provide products in a timely manner, our business will be adversely affected.


We depend on third party manufacturers for our electronic cigarettes, vaporizers and accessories. Our customers associate certain characteristics of our products including the weight, feel, draw, unique flavor, packaging and other attributes of our products to the brands we market, distribute and sell. Any interruption in supply, consistency of our products may adversely impact our ability to deliver our products to our wholesalers, distributors and customers and otherwise harm our relationships and reputation with customers, and have a materially adverse effect on our business, results of operations and financial condition.


Although we believe that several alternative sources for the components, chemical constituents and manufacturing services necessary for the production of our products are available, any failure to obtain any of the foregoing would have a material adverse effect on our business, results of operations and financial condition.


Because we rely on Chinese manufacturers to produce our products, we are subject to potential adverse safety and other issues.


The majority of our manufacturers are based in China. Certain Chinese factories and the products they export have recently been the source of safety concerns and recalls, which is generally attributed to lax regulatory, quality control and safety standards. Should Chinese factories continue to draw public criticism for exporting unsafe products, whether those products relate to our products or not we may be adversely affected by the stigma associated with Chinese production, which could have a material adverse effect on our business, results of operations and financial condition.



We expect that new products and/or brands we develop will expose us to risks that may be difficult to identify until such products and/or brands are commercially available.24

We are currently developing, and in the future will continue to develop, new products and brands, the risks of which will be difficult to ascertain until these products and/or brands are commercially available. For example, we are developing new formulations, packaging and distribution channels. Any negative events or results that may arise as we develop new products or brands may adversely affect our business, financial condition and results of operations.

If we are unable to manage our anticipated future growth, our business and results of operations could suffer materially.

Our business has grown rapidly during our limited operating history. Our future operating results depend to a large extent on our ability to successfully manage our anticipated growth. To manage our anticipated growth, including that arising from our recent merger with Vaporin, we believe we must effectively, among other things:

hire, train, and manage additional employees;
expand our marketing and distribution capabilities;
increase our product development activities;
add additional qualified finance and accounting personnel; and
implement and improve our administrative, financial and operational systems, procedures and controls.

We are increasing our investment in marketing and distribution channels and other functions to grow our business. We are likely to incur the costs associated with these increased investments earlier than some of the anticipated benefits and the return on these investments, if any, may be lower, may develop more slowly than we expect or may not materialize.

If we are unable to manage our growth effectively, we may not be able to take advantage of market opportunities or develop new products, and we may fail to satisfy product requirements, maintain product quality, execute our business plan or respond to competitive pressures, any of which could have a material adverse effect on our business, results of operations and financial condition.

We face competition from foreign importers who do not comply with government regulation which may result in the loss of customers and result in adverse affect to our results of operations.

We face competition from foreign sellers of electronic cigarettes and vaporizers that may illegally ship their products into the United States for direct delivery to customers. These market participants will not have the added cost and expense of complying with U.S. regulations and taxes and as a result will be able to offer their product at a more competitive price than us and potentially capture market share. Moreover, should we be unable to sell certain of our products during any regulatory approval process we have no assurances that we will be able to recapture those customers that we lost to our foreign domiciled competitors during any “blackout” periods, during which we are not permitted to sell our products. This competitive disadvantage may have a material adverse effect on our business, results of operations and our financial condition.

Information technology system failures or interruptions or breaches of our network security may interrupt our operations, subject us to increased operating costs and expose us to litigation.

At present we generate a portion of our sales through e-commerce sales on our websites. We manage our websites and e-commerce platform internally and as a result any compromise of our security or misappropriation of proprietary information could have a material adverse effect on our business, financial condition and results of operations. We rely on encryption and authentication technology licensed from third parties to provide the security and authentication necessary to effect secure Internet transmission of confidential information, such as credit and other proprietary information. Despite our implementation of security measures, all of our technology systems are vulnerable to damage, disability or failures due to hacking or physical theft, fire, power loss, telecommunications failure or other catastrophic events, as well as from internal and external security breaches, denial of service attacks, viruses, worms and other disruptive problems caused by hackers. If our technology systems were to fail, and we were unable to recover in a timely way, we could experience an interruption in our operations. Furthermore, if unauthorized access to or use of our systems were to occur, data related to our proprietary information and personal information of customers could be compromised. The occurrence of any of these incidents could have a material adverse effect on our business, financial condition and results of operations. To the extent that some of our reporting systems require or rely on manual processes, it could increase the risk of a breach. We may be required to expend significant capital and other resources to protect against security breaches or to minimize problems caused by security breaches. To the extent that our activities or the activities of others involve the storage and transmission of proprietary information, security breaches could damage our reputation and expose us to a risk of loss and/or litigation. Our security measures may not prevent security breaches. Our failure to prevent these security breaches may result in consumer distrust, expose us to litigation either of which would adversely affect our business, results of operations and financial condition.


Our results of operations could be adversely affected by currency exchange rates and currency devaluations.


Our functional currency is the U.S. dollar; substantially all of our purchases and sales are currently generated in U.S. dollars. However, our manufacturers and suppliers of vape products are located in China. The Chinese currency, the renminbi, has appreciated significantly against the U.S. dollar in recent years. Fluctuations in exchange rates between our respective currencies could result in higher production and supply costs to us which would have a material adverse effect on our results of operations if we are not willing or able to pass those costs on to our customers.


Risks Related to Government Regulation


Changes in laws, regulations and other requirements could adversely affect our business, results of operations or financial condition.


In addition to the anticipated regulation of our business by the FDA, our business, results of operations or financial condition could be adversely affected by new or future legal requirements imposed by legislative or regulatory initiatives, including, but not limited to, those relating to health care, public health and welfare and environmental matters. For example, in recent years, states and many local and municipal governments and agencies, as well as private businesses, have adopted legislation, regulations or policies which prohibit, restrict, or discourage smoking; smoking in public buildings and facilities, stores, restaurants and bars; and smoking on airline flights and in the workplace. At present, it is not clear if electronic cigarettes, which omit no smoke or noxious odors, are subject to such restrictions. Furthermore, some states and localities prohibit and others are prohibiting the sales of electronic cigarettes and vaporizers to minors. Other similar laws and regulations are currently under consideration and may be enacted by state and local governments in the future. If electronic cigarettes and vaporizers are subject to restrictions on smoking in public and other places, our business, operating results and financial condition could be materially and adversely affected. New legislation or regulations may result in increased costs directly for our compliance or indirectly to the extent such requirements increase the prices of goods and services because of increased costs or reduced availability. We cannot predict whether such legislative or regulatory initiatives will result in significant changes to existing laws and regulations and/or whether any changes in such laws or regulations will have a material adverse effect on our business, and localities, results of operations or financial condition.

Restrictions on the public use of vaporizers and electronic cigarettes may reduce the attractiveness and demand for our products.

Certain states, cities, businesses, providers of transportation and public venues in the U.S. have already banned the use of vaporizers and electronic cigarettes, while others are considering banning their use. If the use of vaporizers and electronic cigarettes are banned anywhere the use of traditional tobacco burning cigarettes is banned, our products may lose their appeal as an alternative to traditional tobacco burning cigarettes, which may reduce the demand for our products and, thus, have a material adverse effect on our business, results of operations and financial condition.


Limitation by states on sales of vaporizers and electronic cigarettes may have a material adverse effect on our ability to sell our products.

On February 15, 2010, in response to a civil investigative demand from the Office of the Attorney General of the State of Maine, we voluntarily executed an assurance of discontinuance with the State of Maine, which prohibits us from selling electronic cigarettes in the State of Maine until such time as we obtain a retail tobacco license in the state. While suspending sales to residents of Maine is not material to our operations, other electronic cigarette companies have entered into similar agreements with other states, such as the State of Oregon.


If one or more states from which we generate or anticipate generating significant sales bring actions to prevent us from selling our products unless we obtain certain licenses, approvals or permits and if we are not able to obtain the necessary licenses, approvals or permits for financial reasons or otherwise and/or any such license, approval or permit is determined to be overly burdensome to us then we may be required to cease sales and distribution of our products to those states, which would have a material adverse effect on our business, results of operations and financial condition.

The FDA has issued an import alert which has limited our ability to import certain of our products.

As a result of FDA import alert 66-41 (which allows the detention of unapproved drugs promoted in the U.S.), the U.S. Customs has from time to time temporarily and in some instances indefinitely detained products sent to us by our Chinese suppliers. If the FDA modifies the import alert from its current form which allows U.S. Customs discretion to release our products to us, to a mandatory and definitive hold we will no longer be able to ensure a supply of saleable product, which will have a material adverse effect on our business, results of operations and financial condition. We believe this FDA import alert will become less relevant to us as and when the FDA regulates electronic cigarettes and vaporizers under the Tobacco Control Act.


The application of the Prevent All Cigarette Trafficking Act and/or the Federal Cigarette Labeling and Advertising Act to vaporizers and/or electronic cigarettes would have a material adverse affecteffect on our business.

At present, neither the


The Prevent All Cigarette Trafficking Act (which prohibits the use of the U.S. Postal Service to mail most tobacco products and which amends the Jenkins Act, which would require individuals and businesses that make interstate sales of cigarettes or smokeless tobacco to comply with state tax laws) norand the Federal Cigarette Labeling and Advertising Act (which governs how cigarettes can be advertised and marketed) apply to vaporizers and/or electronic cigarettes. The application of either or both of theseThese federal laws to either vaporizers and/or electronic cigarettes could result in additional expenses, could prohibit us from selling products through the Internet and require us to change our advertising and labeling and method of marketing our products, any of which would have a material adverse effect on our business, results of operations and financial condition.

We have been named as defendants in litigation brought under California Proposition 65 which, if resolved adversely to us, could have a material adverse impact on our financial condition.

On June 22, 2015, the Center for Environment Health, as plaintiff, filed suit against a number of defendants including us, our wholly-owned subsidiary, the Vape Store, Inc., Vaporin and another wholly-owned subsidiary, Vaporin Florida, Inc. The lawsuit was filed in the Superior Court of the State of California, County of Alameda. The suit seeks relief under California Proposition 65 which makes it unlawful for businesses to knowingly and intentionally expose individuals in California to chemicals known to cause birth defects or other harm without providing clear and reasonable warnings. All of the defendants are alleged to have sold products containing significant quantities of nicotine in violation of Proposition 65. The plaintiff is seeking a civil penalty against these defendants in the amount of $2,500 per day for each violation of Proposition 65, together with attorneys’ fees and costs.

The Company and its subsidiaries are in the process of hiring counsel and intend to defend the allegations. We believe that all of the e-liquid products derived from nicotine sold by Vapor Corp. have always contained an appropriate warning. We are gathering information on sales by Vaporin and its former subsidiaries. We cannot assure you that we will prevail in this litigation. If the case is resolved adversely to us and we are the subject of substantial civil penalties, it could have a material adverse impact on our financial condition. Even if the litigation is dismissed or ultimately resolved in our favor, the cost of litigating could be substantial and adversely affect our financial condition.


We may face the same governmental actions aimed at conventional cigarettes and other tobacco products.


The tobacco industry expects significant regulatory developments to take place over the next few years, driven principally by the World Health Organization’s Framework Convention on Tobacco Control, or the FCTC. The FCTC is the first international public health treaty on tobacco, and its objective is to establish a global agenda for tobacco regulation with the purpose of reducing initiation of tobacco use and encouraging cessation. Regulatory initiatives that have been proposed, introduced or enacted include:

the levying of substantial and increasing tax and duty charges;
restrictions or bans on advertising, marketing and sponsorship;
the display of larger health warnings, graphic health warnings and other labeling requirements;
restrictions on packaging design, including the use of colors and generic packaging;
restrictions or bans on the display of tobacco product packaging at the point of sale, and restrictions or bans on cigarette vending machines;
requirements regarding testing, disclosure and performance standards for tar, nicotine, carbon monoxide and other smoke constituents levels;
requirements regarding testing, disclosure and use of tobacco product ingredients;
increased restrictions on smoking in public and work places and, in some instances, in private places and outdoors;
elimination of duty free allowances for travelers; and
encouraging litigation against tobacco companies.


the levying of substantial and increasing tax and duty charges;
restrictions or bans on advertising, marketing and sponsorship;
the display of larger health warnings, graphic health warnings and other labeling requirements;
restrictions on packaging design, including the use of colors and generic packaging;
restrictions or bans on the display of tobacco product packaging at the point of sale, and restrictions or bans on cigarette vending machines;
requirements regarding testing, disclosure and performance standards for tar, nicotine, carbon monoxide and other smoke constituent’s levels;
requirements regarding testing, disclosure and use of tobacco product ingredients;
increased restrictions on smoking in public and work places and, in some instances, in private places and outdoors;
elimination of duty free allowances for travelers; and
encouraging litigation against tobacco companies.
If vaporizers and/or electronic cigarettes are subject to one or more significant regulatory initiatesinitiatives enacted under the FCTC, our business, results of operations and financial condition could be materially and adversely affected.


25

Risks Related To Our Natural Grocery Business

We may not be successful in our efforts to grow our grocery business.

Our Securities

The marketgrowth largely depends on our ability to increase sales in our existing natural grocery stores and successfully open and operate new stores on a profitable basis. Our comparable store sales growth could be lower than our historical average for various reasons, including the opening of new competing stores that cannibalize sales in existing stores, increased competition, general economic conditions, regulatory changes, price changes as a result of competitive factors and product pricing and availability.


Delays or failures in opening new stores, or achieving lower than expected sales in new stores, could materially and adversely affect our growth. Our plans for expansion could place increased demands on our financial, managerial, operational and administrative resources. For example, our planned expansion will require us to increase the number of people we employ and may require us to upgrade our management information system and our distribution infrastructure. These increased demands and operating complexities could cause us to operate our business less efficiently, which could materially and adversely affect our operations, financial performance and future growth.

We may not be able to open new stores on schedule or operate them successfully. Our ability to successfully open new stores depends upon a number of factors, including our ability to select suitable sites for our new store locations, to negotiate and execute leases, to coordinate the contracting work on our new stores, to identify and recruit store managers, and other staff, to secure and manage the inventory necessary for the launch and successful operation of our common stock has beennew stores and to effectively promote and market our new stores. If we are ineffective in performing these activities, our efforts to open and operate new stores may be unsuccessful or unprofitable, which could materially and adversely affect our operations, financial performance and future growth.

Our natural grocery stores and any newly acquired stores may negatively impact our financial results in the short-term, and may not achieve expected sales and operating levels on a timely basis or at all.

We will actively pursue new store growth. Our new store openings may not be successful or reach the sales and profitability levels of our existing stores. Although we target particular levels of cash-on-cash returns and capital investment for each of our new stores, new stores may not meet these targets. Any store we open may not be profitable or achieve operating results similar to those of our existing store. New store openings may negatively impact our financial results in the short-term due to the effect of store opening costs and lower sales and contribution to overall profitability during the initial period following opening. New stores build their sales volume and their customer base over time and, as a result, generally have lower margins and higher operating expenses, as a percentage of net sales, than our existing store. New stores may not achieve sustained sales and operating levels consistent with our more mature store base on a timely basis or at all. This may have an adverse effect on our financial condition and operating results.

26

The Company could be adversely affected if consumers lose confidence in the safety and quality of the food supply chain. Adverse publicity about these types of concerns, whether or not valid, could discourage consumers from buying our products. The real or perceived sale of contaminated food products by us could result in a loss of consumer confidence and product liability claims, which could have a material adverse effect on our sales and operations.

Inflation and deflation in the prices of food and other products we sell may affect our sales, gross profit and gross margin. The short-term impact of inflation and deflation is largely dependent on whether or not the effects are passed through to our customers, which is subject to competitive market conditions. Food inflation and deflation is affected by a variety of factors and our determination of whether to pass on the effects of inflation or deflation to our customers is made in conjunction with our overall pricing and marketing strategies. Although we may experience periodic effects on sales, gross profit and gross margins as a result of changing prices, the effect of inflation could have an adverse impact on our future revenues.

In addition, we may not be able to successfully integrate new stores into existing stores and those new stores may not be as profitable as existing stores. Further, we have experienced in the past, and expect to experience in the future, some sales volume transfer from our existing stores to our new stores as some of our existing customers switch to new, closer locations. If our new stores are less profitable than our existing stores, or if we experience sales volume transfer from our existing stores, our financial condition and operating results may be adversely affected.

If we are unable to successfully identify market trends and react to changing consumer preferences in a timely manner, our sales may decrease.

We believe our success depends, in substantial part, on our ability to:
oanticipate, identify and react to natural and organic grocery and dietary supplement trends and changing consumer preferences in a timely manner;
otranslate market trends into appropriate, saleable product and service offerings in our stores before our competitors; and
odevelop and maintain vendor relationships that provide us access to the newest merchandise, and dairy products that satisfy upgraded standards, on reasonable terms.
Consumer preferences often change rapidly and without warning, moving from one trend to another among many product or retail concepts. Our performance is impacted by trends regarding natural and organic products, dietary supplements and at-home meal preparation. Consumer preferences towards dietary supplements or natural and organic food products might shift as a result of, among other things, economic conditions, food safety perceptions, reduced or changed consumer choices and the cost of these products. Our store offerings are comprised of natural and organic products and dietary supplements. A change in consumer preferences away from our offerings, including as a result of, among other things, reductions or changes in our offerings, would have a material adverse effect on our business. Additionally, negative publicity regarding the safety of natural and organic products or dietary supplements, or new or upgraded regulatory standards may adversely affect demand for our products and could result in lower customer traffic, sales and results of operations. In addition, reduced or changed consumer choices may result from, among other things, the implementation of our requirements for dairy products that satisfy our pasture-based, non-confinement standards.

If we are unable to anticipate and satisfy consumer merchandise preferences in the regions where we operate, our net sales may decrease, and we may be forced to increase markdowns of slow-moving merchandise, either of which could have a material adverse effect on our business, financial condition and results of operations.

27

Our comparable store sales and quarterly financial performance may fluctuate for a variety of reasons.

Our comparable store sales and quarterly results of operations have fluctuated in the past, and we expect them to continue to be volatile.

The market pricefluctuate in the future. A variety of other factors affect our common stock has been volatile,comparable store sales and fluctuates widely in price in response to various factors, whichquarterly financial performance, including:

ochanges in our merchandising strategy or product mix;
operformance of our newer and remodeled stores;
othe effectiveness of our inventory management;
othe timing and concentration of new store openings, and the related additional human resource requirements and pre-opening and other start-up costs;
othe cannibalization of existing store sales by new store openings;
olevels of pre-opening expenses associated with new stores;
otiming and effectiveness of our marketing activities;
oseasonal fluctuations due to weather conditions and extreme weather-related disruptions;
oactions by our existing or new competitors, including pricing changes;
oregulatory changes affecting availability and marketability of products;
osupply shortages; and
ogeneral United States economic conditions and, in particular, the retail sales environment.
Accordingly, our results for any one fiscal year or quarter are beyond our control. The price of our common stock is not necessarily indicative of our operating performancethe results to be expected for any other year or long-term business prospects.quarter, and comparable store sales of any particular future period may decrease. In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performanceevent of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock. Factors such as the following could cause the market price of our common stock to fluctuate substantially:

our quarterly operating and financial results;
government regulation of our industry;
the introduction of new products by our competitors;
conditions in the electronic cigarette and tobacco industries;
developments concerning proprietary rights; or
litigation or public concern about the safety of our products.

The stock market in general experiences from time to time extreme price and volume fluctuations. Periodic and/or continuous market fluctuations could result in extreme volatility ina decrease, the price of our common stock would likely decline.


We may be unable to compete effectively in our markets, which are highly competitive.

The markets for natural and organic groceries and dietary supplements are large, fragmented and highly competitive, with few barriers to entry. Our competition varies by market and includes conventional supermarkets, natural, gourmet and specialty food markets, mass and discount retailers, warehouse clubs, independent health food stores, dietary supplement retailers, drug stores, farmers’ markets, food co-ops, mail order and online retailers and multi-level marketers. These businesses compete with us for customers on the basis of price, selection, quality, customer service, shopping experience or any combination of these or other factors. They also compete with us for products and locations. In addition, some of our competitors are expanding to offer a greater range of natural and organic foods. Many of our competitors are larger, more established and have greater financial, marketing and other resources than us, and may be able to adapt to changes in consumer preferences more quickly, devote greater resources to the marketing and sale of their products, or generate greater brand recognition. An inability to compete effectively may cause us to lose market share to our competitors and could have a material adverse effect on our business, financial condition and results of operations.

If we, or our third-party suppliers fail to comply with regulatory requirements, or are unable to provide products that meet our specifications, our business and our reputation could suffer.

If we, or our third-party suppliers, including suppliers of our private label products, fail to comply with applicable regulatory requirements or to meet our quality specifications, we could be required to take costly corrective action and our reputation could suffer. We do not own or operate any manufacturing facilities, except for our bulk food repackaging facility and distribution center discussed below, and therefore depend upon independent third-party vendors to produce our private label branded products, such as vitamins, minerals, dietary supplements, body care products, food products and bottled water. Third-party suppliers of our private label products may not maintain adequate controls with respect to product specifications and quality. Such suppliers may be unable to produce products on a timely basis or in a manner consistent with regulatory requirements. We depend upon our bulk food repackaging facility and distribution center for the majority of our private label bulk food products. We may also be unable to maintain adequate product specification and quality controls at our bulk food repackaging facility and distribution center, or produce products on a timely basis and in a manner consistent with regulatory requirements. In addition, we may be required to find new third-party suppliers of our private label products or to find third-party suppliers to source our bulk foods. There can be no assurance that we would be successful in finding such third-party suppliers that meet our quality guidelines.

28

Disruptions affecting our significant suppliers, or our relationships with such suppliers, could negatively affect our business.

Due to this concentration of purchases from third-party suppliers, the cancellation or non-renewal of our distribution agreement or the disruption, delay or inability of these third party suppliers to deliver product to our stores may materially and adversely affect our operating results and we may be unable to establish alternative distribution channels on reasonable terms or at all.

Certain of our vendors use overseas sourcing to varying degrees to manufacture some or all of their products. Any event causing a sudden disruption of manufacturing or imports from such foreign countries, including the imposition of additional import restrictions, unanticipated political changes, increased customs duties, labor disputes, health epidemics, adverse weather conditions, crop failure, acts of war or terrorism, legal or economic restrictions on overseas suppliers’ ability to produce and deliver products, and natural disasters, could increase our costs and materially harm our business and financial condition and results of operations. Our business is also subject to a variety of other risks generally associated with indirectly sourcing goods from abroad, such as political instability, disruption of imports by labor disputes and local business practices. In addition, requirements imposed by the FSMA compel importers to verify that food products and ingredients produced by a foreign supplier comply with all applicable legal and regulatory requirements enforced by the FDA, which could cause a declineresult in the valuecertain products being deemed inadequate for import.

The current geographic concentration of our common stock. Price volatility may be worse if the trading volume of our common stock is low.

The volatilitystores creates exposure to local economies, regional downturns or severe weather or catastrophic occurrences.


Our existing natural grocery stores are all located in our common stock price may subject us to securities litigation.

The market for our common stock is characterized by significant price volatility when compared to seasoned issuers,Florida in Ft. Myers, Palm Bay and Melbourne and we expect new stores to also be located in Florida. As a result, our business is currently more susceptible to regional conditions than the operations of more geographically diversified competitors, and we are vulnerable to economic downturns in those regions. Any unforeseen events or circumstances that negatively affect these areas could materially adversely affect our share price will continuerevenues and profitability. These factors include, among other things, changes in demographics, population, competition, consumer preferences, new or revised laws or regulations, fires, floods or other natural disasters in these regions.


Consumers or regulatory agencies may challenge certain claims made regarding our products.

Our reputation could also suffer from real or perceived issues involving the labeling or marketing of our products. Products that we sell may carry claims as to be more volatile thantheir origin, ingredients or health benefits, including, by way of example, the use of the term “natural.”  Although the FDA and USDA each has issued statements regarding the appropriate use of the word “natural,” there is no single, United States government regulated definition of the term “natural” for use in the food industry. The resulting uncertainty has led to consumer confusion, distrust and legal challenges. Plaintiffs have commenced legal actions against a seasoned issuernumber of food companies that market “natural” products, asserting false, misleading and deceptive advertising and labeling claims, including claims related to genetically modified ingredients. In limited circumstances, the FDA has taken regulatory action against products labeled “natural” but that nonetheless contain synthetic ingredients or components. Should we become subject to similar claims, consumers may avoid purchasing products from us or seek alternatives, even if the basis for the indefinite future. Inclaim is unfounded. Adverse publicity about these matters may discourage consumers from buying our products. The cost of defending against any such claims could be significant. Any loss of confidence on the past, plaintiffs have often initiated securities class action litigation against a company following periodspart of volatilityconsumers in the market price of its securities. We may, in the future, be the target of similar litigation. Securities litigation could result in substantial costs and liabilities to us and could divert our management’s attention and resources from managing our operations and business.

Future salestruthfulness of our common stocklabeling or ingredient claims would be difficult and costly to overcome and may depresssignificantly reduce our stock price.

As of July 9, 2015, we had approximately 7.6 million shares of our common stock outstanding and restricted stock units, and warrants, and options that are exercisable into approximately 2 million shares of our common stock. Approximately 7.3 million of our outstanding shares are eligible for resale without restrictions. If any significant numberbrand value. Any of these shares are sold, such sales could have a depressive effect on the market price of our stock. The remaining shares are eligible, and some of the shares underlying the restricted stock units, and warrants and options upon issuance, will be eligible to be offered from time to time in the public market pursuant to registration statements we have filed and Rule 144 of the Securities Act of 1933, which we refer to as the “Securities Act”, and any such sale of these shares may have a depressive effect as well. We are unable to predict the effect, if any, that the sale of shares, or the availability of shares for future sale, will have on the market price of the shares prevailing from time to time. Sales of substantial amounts of shares in the public market, or the perception that such sales could occur, could depress prevailing market prices for the shares. Such sales may also make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price, which we deem appropriate.

If our stock price materially declines, the Series A Warrant holders will have the right to a large number of shares of common stock upon cashless exercise which may result in significant dilution.

The Series A Warrants contained in the Units have a feature which is designed to compensate the Series A Warrant holders regardless if the price of our common stock rises or falls. Similar to a typical warrant, the holder benefits when the price of the underlying common stock rises; however, even if our common stock falls below the exercise price, the Series A Warrant holders are provided with value. If our common stock price materially falls following the separation of the Units, unless we elect to pay the Series A Holder a cash payment equal to the Black Scholes Value (see page 57), we may be obligated to issue a large number of shares to holders who cashlessly exercise their Series A Warrants even though the exercise price is more than current fair market value of our common stock. This in turn may materially dilute existing shareholders. The potential for such dilutive exercise of the Series A Warrants may depress the price of common stock regardless of our business performance, and could encourage short selling by market participants, especially if the trading price of our common stock begins to decrease.

If our common stock continues to trade at prices below $1.00, we may not be able to maintain our Nasdaq listing.

On May 19, 2015, Nasdaq notified us that based on the failure to meet a $1 minimum bid price for 30 consecutive business days, we no longer meet the continued listing requirements. Accordingly, we have until November 16, 2015 to have our closing bid price be at least $1 for a minimum of 10 consecutive business days. On July 7, 2015, we filed an amendment to our Certificate of Incorporation to effectuate a one-for-five reverse stock split , effective July 8, 2015. Nasdaq will require us to meet the minimum bid price for at least 10 business days prior to November 16th. However, if our common stock is delisted from Nasdaq, trading in our common stock could be conducted on the OTCQB or in what is commonly referred to as the “pink sheets.” If this occurs, a shareholder will find it more difficult to dispose of our common stock or to obtain accurate quotations as to the price of our common stock. Lack of any active trading market would have an adverse effect on a shareholder’s ability to liquidate an investment in our common stock easily and quickly at a price acceptable to the shareholder. It might also contribute to volatility in the market price of our common stock andevents could adversely affect our ability to raise additional equity or debt financing on acceptable terms or at all.

If Nasdaq were to delistreputation and brand and decrease our common stock from its exchange, your ability to make transactions in our common stock would be limited and may subject us to additional trading restrictions.

Should we fail to satisfy the continued listing requirements of Nasdaq, such as the minimum closing bid price requirement, our common stock may be delisted from Nasdaq. If Nasdaq delists our common stock, it is probable it will delist our Units (assuming that when our listing application is submitted to Nasdaq, such listing application is accepted), which will cause the Units to separate. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we would take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

If the Nasdaq Capital Market does not maintain the listing of our securities for trading on its exchange, we could face significant material adverse consequences, including:

a limited availability of market quotations for our securities;
reduced liquidity with respect to our securities;
our shares of common stock will be a “penny stock”, which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;
a limited amount of news and analyst coverage for our company; and
decreased ability to issue additional securities or obtain additional financing in the future.

Therefore, it may be difficult for investor to sell any shares if they desire or need to sell them.

If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results. As a result, we could become subject to sanctions or investigations by regulatory authorities and/or stockholder litigation, which could harm our business and have an adverse effect on our stock price.

As a public reporting company, we are required to comply with the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC, including periodic reports, disclosures and more complex accounting rules. As directed by Section 404 of Sarbanes-Oxley, the SEC adopted rules requiring public companies to include a report of management on a company’s internal control over financial reporting in their Annual Report on Form 10-K. Based on current rules, we are required to report under Section 404(a) of Sarbanes-Oxley regarding the effectiveness of our internal control over financial reporting. If we determine that we have material weaknesses, it may be necessary to make restatements of our consolidated financial statements and investors will not be able to rely on the completeness and accuracy of the financial information contained in our filings with the SEC and this could potentially subject us to sanctions or investigations by the SEC or other regulatory authorities or stockholder litigation.

Risks Related to the Merger

If we are unable to successfully integrate Vaporin, our future results of operations and financial condition may be materially and adversely affected.

We face a number of risks from our recently completed merger with Vaporin. The success of the merger will depend, in large part, on Vapor’s ability to realize the anticipated benefits from combining the businesses of Vapor and Vaporin by reducing duplicative costs and maintaining customer relationships and not losing sales. To realize the anticipated benefits of the merger, we must successfully integrate the businesses of Vapor and Vaporin and integrate their management teams and employees. This integration will be complex and time-consuming.

Potential difficulties we may encounter include, among others:

unanticipated issues in integrating logistics, information, communications and other systems;
integrating personnel from the two companies while maintaining focus on providing a consistent, high quality level of service;
integrating the systems in a seamless manner that minimizes any adverse impact on, suppliers, customers, employees and others;
performance shortfalls as a result of the diversion of management’s attention from day-to-day operations caused by activities surrounding the completion of the merger and integration of the companies’ operations;
potential unknown liabilities, liabilities that are significantly larger than anticipated, unforeseen expenses or delays associated with the merger and the integration process;
unanticipated changes in applicable laws and regulations;
dealing with different corporate cultures; and
complexities associated with managing the larger, combined business.

Some of these factors are outside of our control.

Vapor has not completed a merger or acquisition comparable in size or scope to the Vaporin merger. Our failure to successfully integrate the operations of Vapor and Vaporin or otherwise to realize any of the anticipated benefits of the merger could cause an interruption of, or a loss of momentum in, the activities of Vapor and could adversely affect its results of operations. The integration process maybe more difficult, costly or time-consuming than anticipated, which could cause Vapor’s stock price to decline.

If we are unable to retain Vaporin’s key employees, our results of operations may be adversely affected.

The merger involves the integration of two companies that have previously operated independently. The difficulties of combining the operations of the two companies include integrating personnel with diverse business backgrounds, combining different corporate cultures and retaining key employees. However, Vapor may not be successful in retaining those employees who have not agreed to work for Vapor for the time period necessary to successfully integrate Vaporin’s operations with those of Vapor. The loss of Vaporin employees could have an adverse effect on the business and results of operation of Vapor following the merger.

Because Vaporin had no working capital and our expenses are higher following the merger, our future results of operations may be adversely affected.

At the time we completed the merger, Vaporin had no working capital and material liabilities. Following the merger, our expenses are higher as a result of the new Vaporin employees who joined Vapor. If our cash resources are inadequate to pay expenses as they become due in the normal course of operations, our ability to continue operating as a going concern could be jeopardized. Furthermore, if we are not able to substantially increase our revenues following the merger, we may report increased operating losses,sales, which would have a material adverse effect on our common stock price.

Asbusiness, financial condition and results of operations.


Perishable food product losses could materially impact our results of operations.

Our stores offer a significant number of perishable products. Our offering of perishable products may result in significant product inventory losses in the event of extended power or other utility outages, natural disasters or other catastrophic occurrences.

29

The decision by certain of our suppliers to distribute their specialty products through other retail distribution channels could negatively impact our revenue from the sale of such products.

Some of the merger,specialty retail products that we have recordedsell in our stores are not generally available through other retail distribution channels such as drug stores, conventional grocery stores or mass merchandisers. In the future, our suppliers could decide to distribute such products through other retail distribution channels, allowing more of our competitors to offer these products, and adversely affecting the desirability of these products to our core customers, which could negatively impact our revenues.

A widespread health epidemic could materially impact our business.

Our business could be severely impacted by a significant amountwidespread regional, national or global health epidemic. A widespread health epidemic may cause customers to avoid public gathering places such as our stores or otherwise change their shopping behaviors. Additionally, a widespread health epidemic could adversely impact our business by disrupting production and delivery of goodwill onproducts to our balance sheet,stores and by impacting our ability to appropriately staff our stores.

Union activity at third-party transportation companies or labor organizing activities among our employees could disrupt our operations and harm our business.

Independent third-party transportation companies deliver the majority of our merchandise to our stores and to our customers. Some of these third parties employ personnel represented by labor unions. Disruptions in the delivery of merchandise or work stoppages by employees of these third parties could delay the timely receipt of merchandise, which could result in significant future impairment chargescancelled sales, a loss of loyalty to our stores and negativelyexcess inventory.

While all of our employees are currently non-union, our employees may attempt to organize and join a union. That effort was unsuccessful. We could face union organizing activities at other locations. The unionization of all or a portion of our workforce could result in work slowdowns, could increase our overall costs and reduce the efficiency of our operations at the affected locations, could adversely affect Vapor’s futureour flexibility to run our business competitively, and could otherwise have a material adverse effect on our business, financial condition and results of operationsoperations.

Our products could suffer from real or perceived quality or food safety concerns and stock price.

Applicable acquisition accounting rules requiremay cause unexpected side effects, illness, injury or death that could result in their discontinuance or expose us to the extent that the purchase price paid by Vaporlawsuits, any of which could result in unexpected costs and damage to our reputation.


We could be materially, adversely affected if consumers lose confidence in the merger exceedssafety and quality of products we sell. There is substantial governmental scrutiny of and public awareness regarding food safety. We believe that many customers hold us to a higher quality standard than other retailers. Many of our products are vitamins, herbs and other ingredients that are classified as foods or dietary supplements and are not subject to pre-market regulatory approval in the net fair valueUnited States. Our products could contain contaminated substances, and some of our products contain ingredients that do not have long histories of human consumption. Previously unknown adverse reactions resulting from human consumption of these ingredients could occur. Unexpected side effects, illness, injury or death caused by our products could result in the discontinuance of sales of our products or prevent us from achieving market acceptance of the Vaporin tangibleaffected products. Such side effects, illnesses, injuries and intangible assets and liabilities, Vapor will record such assets as goodwill on its consolidated balance sheet. Goodwilldeath could also expose us to product liability or negligence lawsuits. Any claims brought against us may exceed our existing or future insurance policy coverage or limits. Any judgment against us that is not amortized, but is tested for impairment at least annually. In testing goodwill for impairment, Vapor’s management willin excess of our policy limits would have to be required to analyze its future estimated operating results andpaid from our cash flows. If the future operating results and cash flows of Vapor do not improve in comparison to its performance in 2014, Vapor may incur significant impairment charges in the future. Any impairment charges will directly be treated as an expense and negatively affect Vapor’s future financial results. Announcement of such impairment charges may also significantlyreserves, which would reduce the price of Vapor’s common stock.

Other Risks Related to this Offering

Our management team will have immediate and broad discretion over the use of the net proceeds from this offering andour capital resources. Further, we may use the net proceeds in ways with which you disagree.

The net proceeds from this offering will be immediately available to our management to use at their discretion. We currently intend to use the net proceeds from this offering for acquiring and/or developing new vape stores , marketing and, general corporate purposes and working capital. See “Use of Proceeds.” You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as partsufficient capital resources to pay a judgment in which case our creditors could levy against our assets. The real or perceived sale of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that thecontaminated or harmful products would cause negative publicity regarding our company, brand or products, including negative publicity in social media, which could in turn harm our reputation and net proceeds will be invested in a way that does not yield a favorable, or any, return for us or our shareholders. The failure of our management to use such funds effectivelysales and could have a material adverse effect on our business, prospects, financial condition and results of operation.

operations, or result in our insolvency.



You will experience immediate30

Increases in the cost of raw materials could hurt our sales and substantial dilutionprofitability.

Costs of the raw agricultural commodities used in our private label products, including our bulk repackaged products could increase. Such commodities are generally subject to availability constraints and price volatility caused by weather, supply conditions, government regulations, energy prices, price inflation and general economic conditions and other unpredictable factors. An increase in the demand for or a reduced supply of raw agricultural commodities could cause our vendors to seek price increases from us, which could cause the retail price we charge for certain products to increase, in turn decreasing our sales of such products. Supply shortages may cause certain items to be unavailable, which could negatively affect our sales. Our profitability may be adversely impacted as a result of this offering and may experience additional dilutionsuch developments through reduced gross margins or a decline in the future.

You will incur immediatenumber and substantial dilutionaverage size of customer transactions. The cost of construction materials we use to build and remodel our stores is also subject to significant price volatility based on market and economic conditions. Higher construction material prices would increase the capital expenditures needed to construct a new store or remodel an existing store and, as a result, could increase the rent payable by the Company under its leases.


Legal proceedings could adversely affect our business, financial condition and results of this offering. After giving effectoperations.

Our operations, which are characterized by transactions involving a high volume of customer traffic and a wide variety of product selections, carry a higher exposure to consumer litigation risk when compared to the sale by usoperations of up to 19,000,000 shares of common stock containedcompanies operating in certain other industries. Consequently, we have been, are, and may in the Units (upon conversionfuture become a party to individual personal injury, product liability and other legal actions in the ordinary course of our business. While these actions are generally routine in nature, incidental to the operation of our business and immaterial in scope, the outcome of litigation is difficult to assess or quantify. Additionally, we could be exposed to industry-wide or class-action claims arising from the products we carry or industry-specific business practices. Further, we have been, are and may in the future become subject to claims for discrimination, harassment, wages and hours and other federal or state employment matters. While we maintain insurance, such coverage may not be adequate or may not cover a specific legal claim. Moreover, the cost to defend against litigation may be significant. As a result, litigation could have a material adverse effect on our business, financial position and results of operations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements within the meaning of Section 27A of the Series A Preferred Stock), at a public offering priceSecurities Act of $[_______] per Unit and after deducting discounts and estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of $[______] per share, at1933 or the public offering price, assuming no exerciseSecurities Act, Section 21E of the warrants contained inSecurities Exchange Act of 1934 or the Units or issued toExchange Act, and the underwriter. To the extent these warrantsPrivate Securities Litigation Reform Act of 1995. Forward-looking statements are ultimately exercised for common stock, you will sustain future dilution.

Holders ofthose that reflect our Series A Convertible Preferred Stock and Series A Warrants will have no rights as common shareholders until such holders convert their preferred stock or exercise their warrants and acquire our common stock.

Until holders of our Series A Convertible Preferred Stock or Series A warrants acquire shares of our common stock upon conversion of the preferred stock or exercise of the warrants, holders of preferred stock and warrants will have no rightscurrent views with respect to the shares of our common stock underlying such preferred stockfuture events and warrants. Upon conversion of the preferred stock or exercise of the warrants, the holders will be entitled to exercise the rights of a common shareholder only as to matters for which the record date occurs after the conversion or exercise date.

There is no public market for the Series A Convertible Preferred Stock or the Series A Warrants to purchase common stock in this offering.

There is no public trading market for the Series A Convertible Preferred Stock or the Series A Warrants being offered in this offering,financial performance, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Series A Convertible Preferred Stock or the Series A Warrants on any securities exchange. Unit holders who exercise their warrants for cash (and receives common stock) prior to the six-month separation date will be required to hold the Series A Preferred Stock until the six month period expires, an earlier Trading Separation Trigger or a Delisting Trigger. Without an active market, the liquidity of the Series A Convertible Preferred Stock and the Series A Warrants will be extremely limited.

CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS

This prospectus includes forward-looking statements including market opportunities for our products, intended listing of the Units on Nasdaq, anticipated expansion of vape stores , liquidity and capital expenditures. Allall statements other than statements of historical factsfact are statements that are, or could be, deemed forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “believe,” “expect,” “seek,” “anticipate,” “intend,” “estimate,” “plan,” “target,” “project,” “forecast,” “envision” or the negative of these terms, and other similar phrases. All statements contained in this prospectus including statementsand any prospectus supplement regarding our future financial position, liquidity, business strategysales, costs, earnings, losses, cash flows, other measures of results of operations, capital expenditures or debt levels and plans, and objectives, of management for future operations,outlook, targets, guidance or goals are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect”


You should not place undue reliance on our forward-looking statements because they are not guarantees of future performance or expectations, and similar expressions, as they relateinvolve risks and uncertainties. Our forward-looking statements are based on the information currently available to us are intended to identifyand speak only as of the date on the cover of this prospectus, the date of any prospectus supplement, or, in the case of forward-looking statements. We have basedstatements incorporated by reference, the date of the filing that includes the statement. Although we believe that the expectations reflected in these forward-looking statements largely on our current expectations and projections aboutare reasonable, these statements relate to future events or our future operational or financial performance, and financial trends that we believe may affect our financial condition, results of operations, business strategyinvolve known and financial needs. These forward-looking statements are subject to a number ofunknown risks, uncertainties and assumptions described in in the section titled “Risk Factors” and elsewhere in this prospectus.

Other sections of this prospectus may include additionalother factors which could adversely affect our business and financial performance. Moreover, our business is competitive and our business model is expected to change. New risk factors emerge from time to time and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any risk factor, or combination of risk factors,that may cause our actual results, performance or achievements to differbe materially different from those contained in any future results, performance or achievements expressed or implied by these forward-looking statements.

Except as otherwise required by applicable laws,law, we undertakeassume no obligation, and disclaim any obligation, to publicly update or revise any forward-looking statements or the risk factors described in this prospectus, whether as a result of new information, future events changed circumstances or any other reason after the date of this prospectus.

PRIVATE PLACEMENT

On June 25, 2015, the Company closed on a Securities Purchase Agreement, dated as of June 22, 2015, with certain purchasers pursuant to which the Company sold, at a 5% original issue discount, a total of $1,750,000 convertible debentures, which we refer to as the “Debentures”. Net proceeds to the Company from sale of the Debentures, after payment of commissions and legal fees of the lead investor, were $1,466,250. otherwise.


The placement agent for this June 2015 offering elected to use $47,500 of the commissions payable to it and acquire a $50,000 Debenture; the placement agent also received a warrant to purchase 70,000 shares of our common stock at $2.525 per share over a five-year period beginning on December 24, 2015. The Debentures mature December 22, 2015, and accrue interest at 10% per year. Amounts of principal and accrued interest under the Debentures are convertible into common stock of the Company at a price per share of $2.50. Principal and accrued interest on the Debentures are payable in three approximately equal installments on September 22, 2015, October 22, 2015 and December 22, 2015, at the election of the holders of the Debentures, (i) in cash for an additional 25% premium, or (ii) in common stock of the Company at a price per share of $2.50. As lead investor under the Securities Purchase Agreement, Redwood Management, LLC received a right of first refusal to purchase up to 100% of the securities offered by the Company in future private placement offerings through December 22, 2015. The Company’s obligations under the Debentures can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company’s obligations, the Company would be required to pay 130% of amounts of principal and interest then outstanding under the Debentures. The Company’s obligations under the Debentures are secured under a Security Agreement, under which Redwood Management, LLC acts as Collateral Agent, by a second lien on substantially all of the Company’s assets, including all of the Company’s interests in its consolidated subsidiaries.

In November 2014 and March 2015, the Company had engaged in two private placements each of which precluded the Company from using capital or otherwise issuing shares of common stock or common stock equivalents below $10.00 and $5.10, respectively. In order to raise further capital in the June 25 private placement, the Company was required to enter into agreements with prior investors modifying these covenants. In consideration for modifying these covenants, the Company issued these prior investors, 647,901 shares of common stock and 595,685 five-year warrants exercisable at $2.525 per share beginning December 20, 2015. Additionally, the Company agreed to issue additional shares of common stock to these investors ranging from 27,959 total shares if effective price per share of common stockforward-looking statements contained in this offering (or a future offering) is $2.65 up to 2,328,598 shares if the effective price per share of common stock is $1.05 per share. Assuming the effective price per share of this offering was the closing price on the date prior to the date of this prospectus we would be obligated to issue approximately 1.4 million shares of common stock to these investors. Any of these future issuances are subject to approval of our shareholdersset forth principally in order to comply with Nasdaq rules.

USE OF PROCEEDS

Assuming the maximum offering is completed, the net proceeds from our issuance“Risk Factors” above, and sale of 3,800,000 Units in this offering will be approximately $[________] million, based on a public offering price of $[________] per Unit, after deducting underwriting commissions and estimated offering expenses payable by us. There can be no assurance that all of the Units or any of the Units will be sold, and therefore there is no assurance that any net proceeds will be received by the Company.

Assuming that we receive net proceeds of at least $11 million, we expect the net proceeds from this offering will allow us to fund our operations for up to 12 months following the closing of the offering. We intend to use the net proceeds from this offering as follows:

(1)to repay $4.97 million of indebtedness;
(2)the acquisition and/or development of vape stores;
(3)marketing; and
(4)the remaining proceeds, if any, will be used for general corporate purposes, including working capital.

This expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including industry and general economic conditions and future revenues. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. We may find it necessary or advisable to use the net proceeds from this offering for other purposes, and we will have broad discretion in the application of net proceeds from this offering. Furthermore, we anticipate that we will need to secure additional funding before we reach profitability.

MARKET PRICE HISTORY

We will be applying for the listing of the Units on the Nasdaq Capital Market under the symbol “VPCOU”. No assurance can be given that such listing will be approved or that a trading market will develop.

Our shares of common stock are currently quoted on the Nasdaq Capital Market under the symbol “VPCO”. The following table sets forth the high and low prices of our common stock, as reported by the Nasdaq Capital Market, for the periods indicated (as adjusted for the one-for-five reverse split effectuated on July 9, 2015):

Year  Quarter Ended  Stock Price 
      High  Low 
      ($)  ($) 
           
2015  March 31   7.80   5.00 
             
2014  December 31   14.05   5.10 
   September 30   25.45   6.65 
   June 30   33.75   19.50 
   March 31   45.25   28.15 
             
2013  December 31   49.00   20.00 
   September 30   29.25   19.00 
   June 30   33.00   9.75 

As of July 9, 2015, there were approximately 1,370 record shareholders. As of July 9, 2015, the closing price of our common stock was $1.39 per share.

DIVIDEND POLICY

We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the discretion of our Board of Directors, which we refer to as the “Board”, and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our Board deems relevant. Our future ability to pay cash dividends on our stock may also be limited by the terms of any future debt or preferred securities or future credit facility. Additionally,dividends under the Delaware General Corporation Law, may only be paid from our net profits or surplus neither of which we currently have.

CAPITALIZATION

The following table sets forth our cash and cash equivalents and our capitalization as of March 31, 2015:

● on an actual basis; and
on an adjusted basis, based upon an assumed offering price of $[_____] per Unit, to give effect to the sale of the Units being offered hereunder, after deducting the estimated underwriting fees and commissions and estimated offering expenses payable by us.

Based on the assumed offering price of $[____] per Unit, we allocated all of the consideration to common stock and additional paid-in capital. You should read this table in conjunction with “Use of Proceeds” above as well as our “Management’s Discussion and Analysis of Financial Condition and Results of Operations”Operations,” “Business” and other sections in our 2020 Form 10-K.  In addition, there may be events in the future that we are not able to predict accurately or control which may cause actual results to differ materially from expectations expressed or implied by forward-looking statements. Please consider our forward-looking statements in light of these risks as you read this prospectus and any prospectus supplement.


31

USE OF PROCEEDS

If this offering is fully subscribed, we estimate our net proceeds from the offering will total approximately $91.0 million, after deducting fees and expenses of Maxim, as dealer-manager, and our other estimated offering expenses. However there is no minimum number of Subscription Rights that must be exercised in order for this offering to close.

We intend to use the net proceeds to facilitate enforcement of our intellectual property rights through litigation and other methods, research development of our intellectual property rights and products to accelerate our growth rate in the health food, vitamin and vape sectors to, improve our overall liquidity and reduce our indebtedness, and for other general corporate purposes. Because we cannot currently specify with any certainty the particular uses of a significant portion of our net proceeds, our management will have broad discretion in the application of those net proceeds.

Pending use of our net proceeds, we may invest the excess net proceeds in short-term, investment-grade, interest-bearing instruments, certificates of deposit, or direct or guaranteed obligation of the U.S. government.

CAPITALIZATION

The table below sets forth our capitalization as of _________, 2021 on an actual basis and on a pro forma basis to reflect our issuance and sale of                              shares of common stock to purchase                shares of common stock in this offering and our receipt of the proceeds from this offering, after deducting fees and expenses of Maxim, as dealer-manager, and our other estimated offering expenses. This table should be read in conjunction with “Use of Proceeds” above and our consolidated audited and unaudited financial statements and the related notes appearing elsewherethereto incorporated by reference in this prospectus.

  March 31, 2015 
  

Actual

  

As

Adjusted

 
  (2)  (2) 
Shareholders’ Equity:        
         

Preferred stock, $0.001 par value, 1,000,000 shares authorized, none issued and outstanding.

 $-  $ 
         
Common stock, $0.001 par value, 150 ,000,000 shares authorized, 6,727,152 shares issued and outstanding (1)  6,727     
         
Additional paid-in capital  36, 725,950     
         
Accumulated deficit  (19,213,099)    
         
Total stockholders’ equity $17,519,578  $ 
         
Total capitalization $24,052,575  $ 


 (1)

As of July 8, 2015, the Company filed an amendment to its Certificate of Incorporation to increase its authorized capital to 150 million shares of common stock and effectuate a one-for-five reverse stock split.

_________, 2021
ActualPro Forma
(in thousands)
Debt – current portion 
$    
Long-term debt 
   
Stockholders’ equity:
(2)The Adjusted amounts give effect to the sale of the Units being sold in this offering. The table above excludes, as of March 31, 2015:

a total of 248,567 shares of common stock issuable upon the exercise of outstanding stock options;
   
a total of 378,047
Series D convertible preferred stock, $1,000 par value per share, 5,000 shares of common stock issuable upon the delivery of fully vested restricted stock units;authorized and 5,000 shares issued and outstanding
Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized and ________ shares issued and outstanding
   
Additional paid-in capital 
a total of 841,981 shares of common stock issuable upon the exercise of warrants;
   
Retained deficit 
total of 358,682 shares of common stock issuable upon the conversion of outstanding convertible notes;
   
Accumulated other comprehensive loss 
up to 19,000,000 shares of common stock issuable upon the full conversion of the Series A Convertible Preferred Stock offered hereby and up to 38,000,000 shares of common stock upon the full exercise of the Series A Warrants assuming the warrants are exercised for cash (if the warrants are exercised on a cashless basis as described in “Description of Capital Stock – Warrant Included in the Units Offered Hereby” the number of shares of common stock issuable is indeterminate); and
   
Total stockholders’ equity 

up to 950,000 shares of common stock issuable upon the full conversion of the Series A Convertible Preferred Stock offered hereby and up to 1,900,000 shares of common stock upon the full exercise of the Series A Warrants assuming the warrants are exercised for cash included in the unit purchase option to be issued to the representative of the underwriters in connection with this offering (if the warrants are exercised on a cashless basis as described in “Description of Capital Stock – Warrant Included in the Units Offered Hereby” the number of shares of common stock issuable is indeterminate).

Total capitalization 

You should read this



The table together with “Management’s Discussionabove excludes:
_________ shares of common stock issuable upon the exercise of outstanding options and Analysisother equity awards; and
_________ shares of Financial Condition and Results of Operations” andcommon stock reserved for issuance under our financial statements and the related notes appearing elsewhere in this prospectus.

equity incentive plan.


32


DILUTION

The


At _____________, 2021, we had a net tangible book value of our common stock on March 31, 2015 was approximately $(193,329),$____ million, or approximately $(0. 029 )$___ per outstanding share based on 6,727,152 shares of our common stock. We calculate net tangible book value per share by calculating the difference between the total assets less intangible assets and total liabilities, and dividing the result by the number of shares of common stock outstandingoutstanding. Pro forma as of March 31, 2015. Netadjusted net tangible book value per share represents the amount of our total tangible assets, less our total liabilities, divided by the total number of shares of our common stock outstanding. Dilution in net tangible book value per share to new investors represents the difference between the amount per share paid by purchasers for Units in this offering and thepro forma net tangible book value per share of our common stock immediately afterwards.

after the completion of the Rights Offering. 


After giving effect to the sale of 3,800,000 Units by us at a public offering price of $[ _______ ] per Unit (with each Unit containing one-fourth of a share of Series A Convertible Preferred Stock convertible into five shares of common stock and 10 Series A Warrants each exercisable for one share of common stock ), less the underwriting commissions and our estimated offering expenses,Rights Offering, our pro forma as adjusted net tangible book value at March 31, 2015as of _____________, 2021, would be $ [____]have been approximately $_____ million or $ [____]$_____ per share. This amount represents an immediate dilution of approximately $____ per share to existing stockholders, and an immediate increase in the as adjusted net tangible book value of $ [____] per share to existing shareholders and an immediate dilution of $[____]approximately $_____ per share to new investors purchasing shares at an assumed public offeringof our common stock in the Rights Offering.

MARKET FOR COMMON STOCK AND DIVIDEND POLICY

Common stock is quoted on the OTC Pink Sheets under the symbol “HCMC.” As of _____________, 2021, the last reported sale price of the common stock as reported on the OTC Pink Sheets was $[____]●] per share.

As of _________ __, 2021, there were approximately _____ holders of record of common stock. The following table illustratesactual number of stockholders is greater than this dilutionnumber of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees (including any mobile investment platform).


We have not paid cash dividends on a per share basis:

Public offering price per Unit$
Conversion price per share of Series A Convertible Preferred Stock contained in a Unit$
Net tangible book value per share as of March 31, 2015$(0.0 29)
Increase in net tangible book value per share attributable to new investors in this offering$
Pro forma net tangible book value per share as of March 31, 2015, after giving effect to this offering
Dilution per share to new investors in this offering

The foregoing illustration does not reflect potential dilution from the conversion of our outstanding convertible preferred stock or the exercise of outstanding stock options or warrants.

The above table is based on 6,727,152 shares outstanding as of March 31, 2015 and excludes, as of that date:

248,567 shares of common stock issuable upon the exercise of options with an average exercise price of approximately $30.85 per share;
378,047 shares underlying restricted stock units; and
841,981 shares of common stock issuable upon the exercise of warrants with an average exercise price of $ 8 .75 per share.

To the extent that any of these securities are exercised, there will be further dilution to new investors.

The following table shows on an adjusted basis at March 31, 2015, assuming [_______] shares of our common stock outstanding after giving effectand do not plan to pay cash dividends in the foreseeable future.


PRICE RANGE OF OUR COMMON STOCK

Our common stock trades on the OTC Pink Sheets under the symbol “HCMC.”  The following table sets forth the range of high and low closing bid prices for our common stock as quoted on OTC Pink Sheets for the periods indicated.

 HighLow
Year Ended December 31, 2019:
 
 
 
  
 
First Quarter
$
0.0001 
$
0.0001 
Second quarter
$0.0001
 
$0.0001
 
Third quarter
$0.0001
 
$0.0001
 
Fourth quarter
$0.0001
 
$0.0001
 
 
  
 
  
 
Year Ended December 31, 2020:  
 
  
 
First quarter
$0.0001
 
$0.0001
 
Second quarter
$0.0001
 
$0.0001
 
Third quarter
$0.0001
 
$0.0001
 
Fourth quarter
$0.0001
 
$0.0001
 
 
  
 
  
 
Year Ending December 31, 2021:  
 
  
 
First quarter
$0.00495
 
$0.0001 
Second quarter (through April 19, 2021)
$0.0016
 
$0.0010
 


The last reported sale price of our common stock on the OTC Pink Sheets on _______, 2021 was $__ per share. Past price performance is not indicative of future price performance.

33


THE RIGHTS OFFERING

Before deciding whether to exercise your Subscription Rights, you should carefully read this prospectus, including the information set forth under the heading “Risk Factors” and the information incorporated by reference into this prospectus.

Reasons for this Offering

In accordance with our strategic plan, we are conducting this offering primarily to accelerate our restructuring efforts, improve our overall liquidity and reduce our indebtedness, and for other general corporate purposes. Our board of directors has approved this offering, and it established the pricing and other financial terms of the securities in the offering. Based on information available to the sale of allboard, as well as subsequent analyses of the Unitsboard, the board believes that this offering is in the best interests of our company and stockholders. Our board is not, however, making any recommendation regarding your exercise of the Subscription Rights.

Our board considered and evaluated a number of factors relating to this offering, including:
the fact that existing stockholders would have the opportunity to purchase additional shares;
our current capital resources and indebtedness, and our future need for additional liquidity and capital;
our need for increased financial flexibility in order to enable us to achieve our business plan;
the size and timing of the offering and alternative securities to be offered;
the potential dilution to our current stockholders if they choose not to participate in the offering;
the non-transferability of the Subscription Rights; and
alternatives available for raising capital.

Terms of this Offering

Share Amount. We are issuing, at no charge, non-transferable Subscription Rights entitling holders of common stock as of the record date, whom we refer to as rights holders or you. Your Subscription Rights will consist of:

your basic right, which will entitle you to purchase one share for every four shares of common stock you held as of the record date; and
your over-subscription privilege, which will be exercisable only if you exercise your basic right in full and will entitle you to purchase additional shares for which other rights holders do not subscribe, subject to the pro rata allocations and ownership limitation described in “—Over-Subscription Privilege.”

For purposes of determining the number of shares a rights holder may acquire in this offering:

  Shares Purchased    Total Consideration   Average Price
Per Share
 
  Number   Percent      Amount   Percent    
Existing shareholders      % $   $ % $ 
New investors participating in this offering          % $  $  $ 
                    
Total      100% $   $100% $ 

The table above doesoffering, broker-dealers, trust companies, banks or others whose shares are held of record by Cede & Co. or by any other depository or nominee will be deemed to be the holders of the Subscription Rights that are issued to Cede & Co. or the other depository or nominee on their behalf. Any fractional Subscription Rights will be rounded up to one Subscription Right.


Subscription Period. Subscription Rights may be exercised at any time during the subscription period, which commences on                    , 2021, and ends at 5:00 p.m. (Eastern time) on                    , 2021, the Expiration Date, unless extended by us.

Subscription Price. All shares are being offered and sold at the Actual Subscription Price. Because the subscription price will be determined on the Expiration Date, stockholders will not include:

248,567 shares of common stock issuable upon the exercise of outstanding options to purchase common stock as of March 31, 2015 under our equity compensation plans, at a weighted-average exercise price of $30.85 per share;
841,981 shares of common stock issuable upon the exercise of outstanding warrants with an average exercise price of $ 8 .75 per share ;

up to 19,000,000 shares of common stock issuable upon the full conversion of the Series A Convertible Preferred Stock offered hereby and up to 38,000,000 shares of common stock upon the full exercise of the Series A Warrants assuming the warrants are exercised for cash (if the warrants are exercised on a cashless basis as described in “Description of Capital Stock – Warrant Included in the Units Offered Hereby” the number of shares of common stock issuable is indeterminate); and

up to 950,000 shares of common stock issuable upon the full conversion of the Series A Convertible Preferred Stock offered hereby and up to 1,900,000 shares of common stock upon the full exercise of the Series A Warrants assuming the warrants are exercised for cash included in the unit purchase option to be issued to the representative of the underwriters in connection with this offering (if the warrants are exercised on a cashless basis as described in “Description of Capital Stock – Warrant Included in the Units Offered Hereby” the number of shares of common stock issuable is indeterminate).

know the actual subscription price at the time of exercise of their Subscription Rights. Stockholders will be required to pay for the shares subscribed for at the Estimated Subscription Price as set forth in the prospectus. If, on the Expiration Date, the Actual Subscription Price is lower than the Estimated Subscription Price, any excess subscription amounts paid by a subscriber (the “Excess Subscription Amount”) will be put towards the purchase of additional shares in the rights offering. For more information, see “Questions and Answers About the Rights Offering” above.


34

No Minimum Offering; Maximum Offering Amount. There is no minimum number of Subscription Rights that must be exercised in order for this offering to close. While we are distributing to holders of our common stock and Series D preferred stock one subscription right for every four shares of common stock owned or deemed owned on the Record Date, we are only seeking to raise $100 million dollars in gross proceeds in this offering. As a result, based on (1) [  ] shares of common stock outstanding as of the Record Date and (2) [   ] shares of common stock deemed to be owned by the Series D holders that have a contractual right to participate in this offering and deemed to be outstanding as of the Record Date, we would grant subscription rights to acquire [   ] shares of common stock but will only accept subscriptions for [    ] shares of common stock based on the Estimated Subscription Amount. Accordingly, sufficient shares may not be available to honor your subscription in full. If the Company receives $100 million or less in subscriptions, there will be a sufficient number of shares available for sale to honor your basic rights in full. As a result, unless this offering results in subscription proceeds in excess of $100 million, you will receive shares to the full extent you have properly exercised your basic rights in whole or in part for such shares. In the event the subscription proceeds exceed $100 million, the Company will reduce the subscriptions pro rata based on current share ownership in relation to the total subscription amounts.

Over-Subscription Privilege

If you exercise your basic rights in full, you may also choose to exercise your over-subscription privilege.

 Allocation of Shares Available for Over-Subscription Privileges

Subject to the ownership limitation described below, we will seek to honor the over‑subscription requests in full if less than $100,000,000 in Subscription Rights are exercised. If over-subscription requests exceed the number of shares available, however, we will allocate the available shares pro rata among the rights holders in proportion to their percentage ownership in the Company. Broadridge Corporate Issuer Solutions, Inc., which will act as the subscription agent in connection with this offering and which we refer to as the subscription agent, will determine the over-subscription allocation based on the formula described above.

To the extent these outstanding options or warrants (and warrants issued subsequentyour aggregate subscription payment for the actual number of unsubscribed shares available to March 31, 2015) are exercised thereyou pursuant to the over-subscription privilege is less than the amount you actually paid in connection with the exercise of the over-subscription privilege, you will be further dilutionallocated only the number of unsubscribed shares available to you, and any excess subscription payment will be promptly returned to you, without interest or deduction, after the new investors.

In addition, we may chooseexpiration of this offering.


We can provide no assurances that you will actually be entitled to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Topurchase the extent that additional capital is raised throughnumber of shares issuable upon the saleexercise of equity or convertible debt securities,your over-subscription privilege in full at the issuanceexpiration of these securities may result in further dilution to our shareholders.

26
this offering.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations and our financial statements and the related notes appearing elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this prospectus.

Company Overview

The Company operates nine Florida-based vape stores (and expects to open two more in the next three weeks) and online where it sells vaporizers, liquids for vaporizers and e-cigarettes. The Company is focusing on expanding

 Ownership Limitation

Each rights holder exercising its Company-owned vape stores and beginning a franchise program. The Company also designs, markets and distributes electronic cigarettes, vaporizers, e-liquids and accessories under the Krave®, Vapor X ®, Hookah Stix®, Alternacig®, Fifty-One® (also known as Smoke 51), EZSMOKER ®, Green Puffer®, Americig®, Vaporin, FumaréTM, and Smoke Star® brands. “Electronic cigarettes” or “e-cigarettes,” are battery-powered products that enable users to inhale nicotine vapor without fire, smoke, tar, ash, or carbon monoxide. We also design and develop private label brands for our distribution customers. Third party manufacturers manufacture our products to meet our design specifications. We market our products as alternatives to traditional tobacco cigarettes and cigars. In 2014, as a response to market product demand changes, Vapor began to shift its primary focus from electronic cigarettes to vaporizers. “Vaporizers” and “electronic cigarettes,” or “e-cigarettes,” are battery-powered products that enable users to inhale nicotine vapor without smoke, tar, ash, or carbon monoxide.

We offer our vaporizers and e-cigarettes and related products through our vape stores , online , customer direct phone center, online stores, to retail channels through our direct sales force, and through third party wholesalers, retailers and value-added resellers. Retailers of our products include small-box discount retailers, big-box retailers, gas stations, drug stores, convenience stores, tobacco shops and kiosk locations in shopping malls throughout the United States. We previously offered our vaporizers and electronic cigarettes and related products through our direct response television marketing efforts.

The Company’s business strategy is currently focused on a multi-pronged approach to diversify our revenue streams to include the Vape Store brick-and-mortar retail locations which Vaporin had successfully deployed. We are seeing that there is a large consumer demand centered on the vaporizer products and the retention “atmosphere” created by the stores. We are also expanding our web presence and customer direct phone center operations that work closely to drive consumer sales. Our distribution sales continue to be a significant part of our operations and we anticipate regrowth as we have adjusted towards vaporizers in addition to our e-cigarette brands.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations set forth below under the headings “Results of Operations” and “Liquidity and Capital Resources” have been prepared in accordance with U.S. GAAP and should be read in conjunction with our consolidated financial statements and notes thereto contained herein. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our critical accounting policies and estimates, including identifiable intangible assets and goodwill, stock-based compensation, derivative liabilities and long-lived assets. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. A more detailed discussion on the application of these and other accounting policies can be found in Note 3 to the consolidated financial statements contained herein. If the Company’s current business strategy is not successful and the expected synergies resulting from the Company’s acquisition of Vaporin are not achieved, the Company mayrights will be required to take a partialrepresent to us in its subscription certificate that, together with any of its affiliates or full impairment charge against its goodwill or other long-lived assets which arose fromassociates, it will not beneficially own more than           % of our recent merger transaction. Actual results may differ from these estimates under different assumptions and conditions.

While all accounting policies impact the financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require management’s most subjective or complex judgments and estimates. Our management believes the policies that fall within this category are the policies on accounting for identifiable intangible assets and goodwill, stock-based compensation, derivative liabilities and long-lived assets.

27

Warrant Derivative Liability

The Series A Warrants contain a cashless exercise provision using a predetermined Black Scholes Value. See page 58 below for a further description. Such provision, if exercised by the holder, would require the Company to settle these warrants, at its option (subject to certain conditions), either by a cash payment or the granting of a variable number ofoutstanding shares of common stock. This provision results in the potential for the Company to either have to net cash settle the warrant or potentially issue an indeterminate numberstock (calculated immediately upon closing of shares. Accordingly, the warrants are accounted for as a derivative liability and are recorded at fair value at inception and subject to re-measurement on each balance sheet date, with any change in fair value recognized as a component of other income (expense) in the statements of operations. The fair value of these warrants will be based on, amongst various factors, at the valuation measurement date of which the estimated market value of the underlying common stock is one of them. Therefore, normally any increase in our stock price will result in an increase of our warrant liability resulting in a non-cash expense and, conversely, normally any decrease in our stock price will result in a decrease of our warrant liability resulting in a non-cash gain.

Results of Operations for the Three Months Ended March 31, 2015 Compared to the Three Months Ended March 31, 2014

Sales, net for the three months ended March 31, 2015 and 2014 were $1,468,621 and $4,792,544, respectively, a decrease of $3,323,923 or approximately 69.4%. The decrease in sales is primarily attributable to decreased sales of our television direct marketing campaign for our Alternacig® brand, a decrease in sales from our on-line stores, distributor inventory build leveling off and continued pipeline load in the e-cigarette category in 2014, and the increasing prevalence of vaporizers, tanks and open system vapor products that are marginalizing the e-cigarette category and increased returns of e-cigarette products. Sales were also negatively impacted by new national competitors’ launches of their own branded products during 2014. Due to low conversion rates of our Alternacig® and Vapor X ® branded direct marketing campaign, we limited the direct marketing campaign, resulting in lower sales of direct marketing products. In addition, sales decreased due to certain wholesale and distribution customers selling off their current inventory of electronic cigarette products so they can switch to e-vapor products. We anticipate that the demand for vaporizer products will continue to increase, as users want products that have more advanced technology with higher performance and longer battery life. As a result, we are in the process of altering our product mix to include more vaporizer products, including premium USA made e-liquids.

Cost of goods sold for the three months ended March 31, 2015 and 2014 were $1,651,110 and $3,831,928, respectively, a decrease of $2,180,818, or approximately 56.9%. The decrease is primarily due to the decrease in sales. During the three months ended March 31, 2015, as compared to the three months ended March 31, 2014, cost of goods sold was higher as a percentage of sales primarily due to consignment inventory write off of $70,657 and from customer returns of e-cigarettes that were resold below cost at liquidation prices.

Selling, general and administrative expenses for the three months ended March 31, 2015 and 2014 were $3,243,189 and $2,769,726, respectively, an increase of $473,463 or approximately 17.0%. Non-cash stock compensation expense was $364,576 and $610,414 for the three months ended March 31, 2015 and 2014, respectively, a decrease of $245,838 relating to the cancellation of a consulting agreement with a former director. Professional fees increased to $394,145 from $385,435 in the three months ended March 31, 2015 and 2014, respectively. In addition, depreciation and amortization expense increased to $85,013 from $3,888 in the three months ended March 31, 2015 and 2014, respectively, an increase of $81,125 primarily due to the increase in depreciable assets as a result of leasehold improvements and the purchase of kiosks. There was also a loss on the disposal of assets from the write off of kiosks that were closed during March and April 2015 in the amount of $289,638 that was recorded at March 31, 2015. Payroll expenses during the three months ended March 31, 2015 and 2014 were $1,242,981 and $822,695, respectively, an increase of $419,820 due primarily to increased headcount for retail store employees and employees transitioned to the Company post-merger.

Advertising expense was approximately $105,177 and $367,615 for the three months ended March 31, 2015 and 2014, respectively, a decrease of $262,438 or approximately 71.4%. The decrease was due to decreases in Internet advertising and television direct marketing campaign for our Alternacig® brand, print advertising programs, and participation at trade shows and other advertising campaigns.

Interest expense was approximately $378,775 and $28,434 for the three months ended March 31, 2015 and 2014, respectively. The interest expense was attributable to the term loan, the $1,250,000 Senior Convertible note, the $567,000 convertible notes to various lenders and other outstanding debts in 2015. The Company recorded an aggregate of $317,702 in non-cash interest expense which is included in interest expense for the three months ended March 31, 2015.

Income tax (benefit) expense for the three months ended March 31, 2015 and 2014 was $2,791 and ($752,400), respectively.

Net (loss) income for the three months ended March 31, 2015 and 2014 was ($3,981,196) and ($1,452,759), respectively,this offering) as a result of the items discussed above.

Resultsexercise of Operationsrights. Any rights holder found to be in violation of such representation will have granted to us in the subscription certificate, with respect to any such excess shares, (1) an irrevocable proxy and (2) a right for a limited period of time to repurchase such excess shares at the Year Ended December 31, 2014 Comparedlesser of the subscription price and market price, as set forth in more detail in the subscription certificate.


Expiration of Offer

This offering will expire at 5:00 p.m. (Eastern time) on                    , 2021, unless extended by us, and Subscription Rights may not be exercised thereafter.

Our board of directors may determine to extend the subscription period, and thereby postpone the Expiration Date, to the Year Ended December 31, 2013

Net sales forextent it determines that doing so is in the year ended December 31, 2014 and 2013 were $15,279,860 and $25,990,227, respectively, a decrease of $10,710,367 or approximately 41.2%. The decrease in sales is primarily attributable to decreased salesbest interest of our television direct marketing campaign for our Alternacig® brand,stockholders.


35

Any extension of this offering will be followed as promptly as practicable by announcement thereof, and in no event later than 9:00 a.m. (Eastern time) on the next business day following the previously scheduled Expiration Date. Without limiting the manner in which we may choose to make such announcement, we will not, unless otherwise required by law, have any obligation to publish, advertise or otherwise communicate any such announcement other than by issuing a decrease in salespress release or such other means of our on-line stores and distributor inventory buildup in the e-cigarette category that existed in 2013 and continued during 2014. This is a resultannouncement as we deem appropriate.

Determination of the increasing prevalenceSubscription Price

The subscription price was set by our board of vaporizers, tanks and open system vapor products that are dramatically marginalizingdirectors considering, among other things, input from its dealer-manager for this offering. In approving the e-cigarette category and increased our customer returnssubscription price, the board of e-cigarette products. We have increased our purchases of vaporizers, tanks and open system vapor products as we shift our inventory mix to align with products in high customer demand. Sales were also negatively impacted by new national competitors’ launches of their own branded products duringdirectors considered, among other things, the second quarter of 2014. Due to low conversion rates of our Alternacig® and Vapor X ® branded direct marketing campaign, we limited following factors:

the direct marketing campaign, resulting in lower sales of direct marketing products. In addition, sales decreased due to certain wholesale and distribution customers selling off their current inventory of electronic cigarette products so they can switch to e-vapor products. During the second half of 2014 we introduced several new e-vapor products under the Vapor X brand, including premium USA manufactured e-liquids. We anticipate that the demand for e-vapor products will continue to increase, as users want products that have more advanced technology with higher performance and longer battery life. During the fourth quarter of 2014 we opened eight new emagine vaporTM retail kiosks to expand our distribution channels for vaporizer and e-cigarette products. In 2015, we have closed eight of our nine retail kiosks. In addition we are altering our product mix to include more e-vapor products e-liquids and vaporizer accessories and transitioning our customer base to these favorable demand products.

Cost of goods sold for the year ended December 31, 2014 and 2013 was $14,497,254 and $16,300,333, respectively, a decrease of $1,803,077, or approximately 11.1%. The decrease is primarily due to the overall decrease in sales, offset by write downs of $1,834,619 for obsolete and slow moving inventory that primarily consisted of e-cigarettes. As customers complete the migration to vaporizers, tanks and open vaporizer systems, our sales incentives should decrease.

Our gross margins decreased to 5.1% from 37.3% primarily due to write downs of $1,834,619 for obsolete and slow moving inventory, increase in sales returns, discounts, incentives and allowances that primarily resulted from the customer demand shift from e-cigarettes to e-vapor products.

Selling, general and administrative expenses for the year ended December 31, 2014 and 2013 were $11,126,759 and $6,464,969, respectively, an increase of $4,661,790 or approximately 72.1%. The increase is primarily attributable to increases in non-cash stock compensation expense of $1,631,340 primarily attributable to the consulting agreement with Knight Global Services, professional fees of $3,281,388 due to implementing the corporate actions we agreed to take in connection with the private placementmarket price of common stock we completed in October 2013, including registeringprior to public announcement of the shares for resale with subscription price;

the SEC, reincorporating infact that the State of Delaware from Subscription Rights will be non-transferable;
the State of Nevada, effecting the 1-for-5 reverse stock splitliquidity of our common stockstock;
the fact that holders of rights will have an over-subscription privilege;
the terms and uplistingexpenses of this offering relative to other alternatives for raising capital, including fees payable to Maxim, and our ability to access capital through such alternatives;
comparable precedent transactions, including the Nasdaq Capital Market, costsrange of $576,138 incurreddiscounts to market value represented by the subscription prices in connection with other rights offerings;
the initiationsize of this offering; and termination
the general condition of the previously contemplated acquisition of International Vapor Group,securities market.

Subscription Agent

Broadridge Corporate Issuer Solutions, Inc.’s online, wholesale, the subscription agent and retail operations, consultinginformation agent, will receive for its administrative, processing, invoicing and recruiting fees of $882,590other services a fee estimated to be approximately $          , plus reimbursement for all out-of-pocket expenses related to the developmentoffering.

A completed subscription certificate, together with full payment of the emagine vaporTM retail kiosk and store distribution channel, and costs incurred in connection with the merger of Vaporin, Inc. We also incurred additional filing and listing fees related to our uplistingsubscription price, must be sent to the Nasdaq Capital Market, business insurance due to the increases in coverage limits and increases in travel due to increased presence at trade shows and conferences, netsubscription agent for all whole numbers of decreased personnel costs attributable to decreased payroll net of the accrued severance related to the resignation of our former Chief Executive Officer, merchant card processing fees due to lower transaction volumes.

Advertising expenseshares subscribed for the years ended December 31, 2014 and 2013 was $2,374,329 and $2,264,807, respectively, an increase of $109,522 or 4.8%. As a percentage of sales advertising expense increased to 15.5% for the year ended December 31, 2014 from 8.7% for the year ended December 31, 2013. During the year ended December 31, 2014, we decreased our Internet advertising and television direct marketing campaign for our Alternacig brand, increased our print advertising programs, participation at trade shows, initiated several new marketing campaigns in which we sponsored several music concerts and we continued various other advertising campaigns.

Other expense for the years ended December 31, 2014 and 2013 was $366,433 and $683,558, respectively, a decrease of $317,125. Included in other expense is interest expense which was $348,975 and $383,981, for the years ended December 31, 2014 and 2013 respectively, a decrease of $35,006 or 9.1%. The decrease was attributable to lower amounts of outstanding debt throughout 2014 compared to 2013. In addition, the Company incurred an induced conversion expense during the year ended December 31, 2013 of $299,577 related to the reduction in the conversion price for the $350,000 Senior Convertible Notes and $75,000 Senior Convertible Notes in order to induce the holders to convert the notes. Such inducement did not reoccur in 2014.

Income tax expense (benefit) for the years ended December 31, 2014 and 2013 was $767,333 and $(524,791), respectively, an increase of $1,292,124 or 246.2%. The Company determined, based on the weight of the available evidence, that a valuation allowance of $5,695,446 (or 100% of the Company’s net deferred tax assets) is required at December 31, 2014, which is the cause of the significant increase in income tax expense compared to the year ended December 31, 2013. At December 31, 2013, the Company had determined that a valuation allowance against its net deferred tax assets was not necessary and recorded an income tax benefit.

Net (loss) income for the years ended December 31, 2014 and 2013 was $(13,852,249) and $801,352, respectively, a decrease of $14,653,601 as a result of the items discussed above.

Liquidity and Capital Resources

The Company had net losses of approximately $3.98 million and $1.45 million for the three month periods ending March 31, 2015 and 2014, respectively, and has experienced cash outflows from operating activities. The Company also has an accumulated deficit of $19.2 million as of March 31, 2015. The Company had $1.91 million of cash at March 31, 2015 and negative working capital of approximately $812,000. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

Our net cash used in operating activities was $2,149,505 and $2,165,114 for the three months ended March 31, 2015 and 2014, respectively, a decrease of $15,609. Our net cash used in operating activities for the three months ended March 31, 2015 resulted from our net loss of $3,981,196 offset by non-cash charges of $1,200,468 and changes in operating assets and liabilities of $631,223.

Our net cash provided by (used in) investing activities was $536,071 and ($4,795) for the three months ended March 31, 2015 and 2014, respectively. The increase of proceeds from investing activities of $540,866 over the three months ended March 31, 2015 and 2014 is primarily due to increases in cash collected from repayment of loans receivable’s and cash acquired from the March 2015 Vaporin merger, partially offset with an increase in purchases of property and equipment.

Our net cash provided by (used in) financing activities was $3,043,439 and ($290,835) for the three months ended March 31, 2015 and 2014, respectively. The increase in cash provided by financing activities over the three months ended March 31, 2015 and 2014 was primarily related to proceeds from the Securities Purchase Agreement, entered into in connection with the March 2015 Vaporin merger, with certain accredited investors providing for the sale of $3,500,960 in shares of the Company’s common stock at a price of $1.02 per share, offset by offering costs of $559,000. The increase was partially offset with payments to the term loan and capital lease obligations.

Our net cash used in operating activities was $6,291,027 and $4,120,152 for the years ended December 31, 2014 and 2013, respectively, an increase of $2,170,875. Our net cash used in operating activities for the year ended December 31, 2014 resulted primarily from our net losses, purchases of new inventories to meet future customer demand, and changes in accounts receivable, prepaid expenses, accounts payable, accrued expenses and due from merchant credit card processor, which are attributable to our efforts to accommodate anticipated future sales growth.

Our net cash used in investing activities was $1,987,505 and $14,779 for the years ended December 31, 2014 and 2013, respectively. Our net cash used in investing activities for the year ended December 31, 2014 resulted primarily from entering into loans receivable with International Vapor Group, Inc. and Vaporin and for purchases of property and equipment utilized in connection with the opening of eight retail kiosks.

Our net cash provided by financing activities was $2,269,481 and $10,528,738 for the years ended December 31, 2014 and 2013, respectively, a decrease of $8,259,256. These financing activities relate to the Company’s sale of $1,250,000 Senior Convertible Notes entered into in November 2014, $1,000,000 Loan Payable to Related Party entered into in December 2014, and the $1,000,000 Term Loan entered into in September 2014 and proceeds fromthrough the exercise of stock options neta basic right and the over-subscription privilege by one of principal repayments under the $750,000methods described below. We will accept only properly completed and $1,000,000 Term Loans and principle repaymentsduly executed subscription certificates actually received at any of capital lease obligations.

In the ordinary course of our business, we enter into purchase orders for components and finished goods, which mayaddresses listed below, at or may not require vendor deposits and may or may not be cancellable by either party. At March 31, 2015 and December 31, 2014, we had $298,320 and $319,563 in vendor deposits, respectively, which are included in prepaid expenses and vendor depositsprior to 5:00 p.m. (Eastern time) on the condensed consolidated balance sheets included elsewhere in this prospectus . At March 31, 2015 and December 31, 2014, we do not have any material financial guarantees or other contractual commitments with these vendors that are reasonably likely to have an adverse effect on liquidity.

Our existing liquidity is not sufficient to fund our operations, anticipated capital expenditures, working capital and other financing requirements for the foreseeable future. AsExpiration Date of June 22, 2015, we sold, at a 5% original issue discount, a total of $1,750,000 of Debentures and received net proceeds of approximately $1,466,000. The Debentures mature on December 22, 2015, and accrue interest at 10% per year. See the section titled “Private Placement” above. Subsequent to the Debenture offering, we still do not have sufficient working capital to sustain our current operations for 12 months and are relying upon this offering or another material financing.

31

BUSINESS

We operate nine Florida-based vape stores (and expect to open two more inby the next three weeks) and are focusing on expanding the numberclose of Company operated stores as well as launching a franchise program. We design, market, and distribute vaporizers, e-liquids, electronic cigarettes and accessories under the emagine vaporTM, Krave®, Fifty-One® (also known as Smoke 51), Vapor X ®, Hookah Stix® and Alternacig® brands. Third party manufacturers manufacture our products to meet our design specifications. We market our products as alternatives to traditional tobacco cigarettes and cigars. In 2014, as a response to market product demand changes, Vapor began to shift its primary focus from electronic cigarettes to vaporizers.

The Company’s business strategy is currently focused on the vape store concept which Vaporin had successfully deployed. We are seeing that there issecond business day after the Expiration Date of the offering following timely receipt of a large consumer demand centerednotice of guaranteed delivery. See “Payment for Securities” below. In this prospectus, close of business means 5:00 p.m. (Eastern Time) on the vaporizer products and the “atmosphere” created by the stores. Vapor leverages its ability to design, market and develop multiple vaporizer and e-cigarette brands and to bring those brands to market through its multiple distribution channels including the vape stores, online and through retail operations operated by their parties.

Vaporizers and Electronic Cigarettes

“Vaporizers” and “electronic cigarettes,” or “e-cigarettes,” are battery-powered products that enable users to inhale nicotine vapor without smoke, tar, ash, or carbon monoxide. Electronic cigarettes look like traditional cigarettes and, regardless of their construction are comprised of three functional components:

relevant date.

Subscription Certificate Delivery Method
a mouthpiece, which is a small plastic cartridge that contains a liquid nicotine solution;Address/Number
By Notice of Guaranteed Delivery:
the heating element that vaporizes the liquid nicotine so that it can be inhaled; and
the electronics, which include: a lithium-ion battery,
Contact an airflow sensor, a microchip controller and an LED, which illuminates to indicate use.

When a user draws air through the electronic cigarette and/or vaporizer, the air flow is detected by a sensor, which activates a heating element that vaporizes the solution stored in the mouthpiece/cartridge, the solution is then vaporized and it is this vapor that is inhaled by the user. The cartridge contains either a nicotine solution or a nicotine free solution, either of which may be flavored.

Our Vaporizers and Electronic Cigarettes

Vaporizers feature a tank or chamber, a heating element and a battery. The vaporizer user fills the tank with e-liquid or the chamber with dry herb or leaf. The vaporizer battery can be recharged and the tank and chamber can be refilled.

We also offer disposable electronic cigarettes in multiple sizes, puff counts, styles, flavors and nicotine strengths; rechargeable electronic cigarettes that use replaceable cartridges (also known as “atomizers or cartomizers”), and rechargeable vaporizers for use with either electronic cigarette solution (“e-liquid”) or dry herbs or leaf. Disposable electronic cigarettes feature a one-piece construction that houses all the components and is utilized until the nicotine or nicotine free solution is depleted. Rechargeable electronic cigarettes feature a rechargeable battery and replaceable cartridge (also known as an “atomizer or cartomizer”). The atomizers or cartomizers are changed when the solution is depleted from use.

Our Brands

We sell our vaporizers, electronic cigarettes and e-liquids under several different brands, including emagine vaporTM, Krave®, Fifty-One® (also known as Smoke 51), Vapor X ®, Stix® and Alternacig® brands. We also design and develop private label brands for our distribution customers. Our in-house engineering and graphic design team’s work to provide aesthetically pleasing, technologically advanced affordable vaporizers and e-cigarette options. We are in the process of preparing to commercialize additional brands which we intend to market to new customers and demographics.

Our Improvements and Product Development

We have developed and trademarked or are preparing to commercialize additional products. We include product development expenses as part of our operating expenses. We currently own no patents which are material to our business. We have a number of patent applications pending in the United States including those described below. There is no assurance that we will be awarded patents for of any of these pending patent applications.

Flavor Profiles

We are developing new flavor profiles that are distinct to our brands. We believe that as the vaporizer and electronic cigarette industry matures, users of vaporizers and electronic cigarettes will develop, if they have not already, preferences for the product based not only on their quality, ability to successfully deliver nicotine, battery capacity, and smoke volume they generate, but on taste and flavor, like smokers do with their preferred brand of conventional tobacco cigarettes.

Soft Tip Filters

We have a patent pending for a soft-tip electronic cigarette filter, which more closely resembles the tactile experience of a conventional tobacco cigarette in a user’s mouth. To date electronic cigarettes have been made of metal and hard plastic and do not offer users the same malleable feel as the cellulose filters of conventional tobacco cigarettes.

Electronic Cigarette Air Flow Sensor Patent

We have a patent pending on a new configuration for the airflow sensors currently used in electronic cigarettes. The new configuration will allow the battery to be sealed to enhance the reliability and performance of the electronic cigarette. There is no assurance that we will be awarded a patent for this configuration.

Vaporizer Biometric Fingerprint Lock Sensor Patent

We have a patent pending for a biometric fingerprint lock sensor that can be used in vaporizers. The biometric fingerprint lock sensor will allow the owner of the vaporizer to keep the device locked and turned off unless the authorized user unlocks the device via fingerprint scan, protecting the device from use by another individual. This technology may be used to protect against minors being able to turn on the device and will also deem the devices unusable in the event the device is lost or stolen. There is no assurance that we will be awarded a patent for this technology.

Our Kits and Accessories

Our vaporizer and electronic cigarettes are available in kits that contain everything a user needs to begin enjoying their “vaping” experience. In addition to kits we sell replacement parts including batteries, refill cartridges or cartomizers that contain the liquid solution, atomizers, tanks and e-liquids. Our refill cartridges and e-liquids are available in various assorted flavors and nicotine levels (including 0.0% nicotine). In addition to our electronic cigarette and vaporizer products we sell an assortment of accessories, including various types of chargers (including USB chargers), carrying cases and lanyards.

The Market for Vaporizers and Electronic Cigarettes

We market our vaporizers and electronic cigarettes as an alternative to traditional tobacco cigarettes and cigars. We offer our products in multiple nicotine strengths, flavors and puff counts. Because vaporizers and electronic cigarettes offer a “smoking” experience without the burning of tobacco leaf, vaporizers and electronic cigarettes offer users the ability to satisfy their nicotine cravings without smoke, tar, ash or carbon monoxide. In many cases vaporizers and electronic cigarettes may be used where tobacco-burning cigarettes may not. Vaporizers and electronic cigarettes may be used in some instances where for regulatory or safety reasons tobacco burning cigarettes may not be used. However, certain states, cities, businesses, providers of transportation and public venues in the U.S. have already banned the use of vaporizers and electronic cigarettes, while others are considering banning the use of vaporizers and electronic cigarettes. We cannot provide any assurances that the use of vaporizers and electronic cigarettes will be permitted in places where traditional tobacco burning cigarette use is banned. See the Risk Factor on page 16.

According to the U.S. Centers for Disease Control and Prevention, in 2012, an estimated 42.1 million people, or 17.4% of adults, in the United States smoke cigarettes. In 2011, about 21% of adults who smoke traditional tobacco cigarettes had used electronic cigarettes, up from about 10% in 2010, according to the U.S. Centers for Disease Control and Prevention. Annual sales of electronic cigarettes in the United States were estimated to increase to $1.7 billion in 2014 from $1 billion in 2013. Annual sales of traditional tobacco cigarettes, according to industry estimates, were $80 billion in 2012.

Advertising

Currently, we advertise our products primarily on the Internet, through trade magazine ads and through point of sale materials and displays at retail locations. We also attempt to build brand awareness through innovative social media marketing activities, price promotions, in-store and on-premise promotions, slotting fees (i.e., fees payable based on the number of stores at which our products are carried and sold), public relations and trade show participation. Our advertising expense as a percentage of sales for the year ended December 31, 2014 and 2013 has been approximately 15.5% and 8.8%, respectively; for the three months ended March 31, 2015, this decreased to 7.2%. Assuming we are successful in this offering, we intend to continue to strategically expand our advertising activities in 2015 and also increase our public relations campaigns to gain editorial coverage for our brands. Some of our competitors promote their brands through print media and television commercials, and through celebrity endorsements, and have substantial resources to devote to such efforts. We believe that our and our competitors’ efforts have helped increase our sales, our product acceptance and general industry awareness.

Distribution and Sales

We offer our vaporizers and electronic cigarettes and related products through our vape stores , our websites, a retail kiosk, retail channels through our direct sales force, and through third party wholesalers, retailers and value-added resellers. Retailers of our products include small-box discount retailers, big-box retailers, gas stations, drug stores, convenience stores, tobacco shops and kiosk locations in shopping malls throughout the United States. We previously offered our vaporizers and electronic cigarettes and related products through our direct response television marketing efforts.

Vapor sells directly to consumers through nine company owned retail vape stores . Vapor acquired eight of these retail vape stores in the March 2015 merger with Vaporin. The Company expects to open two additional stores in the next three weeks. Our management believes that consumers are shifting towards vape shops for an enhanced experience. This enhanced experienced is derived from the greater variety of products at the stores, the knowledgeable staff and the social atmosphere. Vapor anticipates a significant portion of future revenue will come from the retail stores.

We also offer our products online through our websites includingwww.vapor-corp.com. The contents of this website are not incorporated by reference into this prospectus. Our strategy is to increase our online sales by expanding our presence through additional Vapor websites and enhancing the overall online experience for consumers.

When first introduced to the U.S. market, electronic cigarettes were predominantly sold online. In the past year brick and mortar sales of electronic cigarettes and vaporizers have eclipsed the on-line sales volumes in the U.S. market. Tobacco products, most notably cigarettes are currently sold in approximately 400,000 retail locations. We believe that future growth of vaporizers and electronic cigarettes is dependent on either higher volume, lower margin sales channels, like the broad based distribution network through which cigarettes are sold or through Company- owned stores. Thus, we are focusing on growing our retail distribution reach by opening retail stores and entering into distribution agreements with large and established value added resellers. We currently have established relationships with several large retailers and national chains and in connection therewith we have agreed to pay slotting fees based on the number of stores our products will be carried in. These existing relationships are “at-will” meaning that either party may terminate the relationship for any reason or no reason at all. We believe that these higher volume lower margin opportunities are critical towards broadening the reach and appeal of vaporizers and electronic cigarettes and we believe that as vaporizers and electronic cigarettes become more widely known and available, the market for our products will grow. In 2015, we have closed eight of our nine kiosks and are focusing on acquiring and developing the vape stores in Florida. In addition, we are in the process of launching a franchise program, although we cannot assure you this program will be successful.

Distribution of our Products in Canada

Under our private label production and supply agreement with Spike Marks Inc./Casa Cubana, or “Spikes”, we agreed to produce and supply Spikes with such quantities of our electronic cigarettes bearing their trademark and other brand attributes for resale within Canada. For the years ended December 31, 2014 and 2013, we had sales for distribution in Canada of $2,912,525 and $3,847,310, respectively. The last sales order received from Spikes was in February 2015. In April 2015, we received a notice from Spikes that we had breached the agreement and a subsequent notice of termination. Although we refute Spike’s allegations and believe we are owed money by them, there is no assurance that we will not be required to pay them money nor recover any of the amounts we believe we are due in accordance with the agreement. We are currently selling our products to another distributor in Canada under an oral agreement.

Business Strategy

We believe and are seeing in our current stores that there is a large consumer demand centered on the vaporizer products and the “atmosphere” created by the vape stores . Additionally, our business strategy leverages our ability to design market and develop multiple vaporizer and e-cigarette brands and to bring those brands to market through our multiple distribution channels.

We believe we were among the first distributors of vaporizers and electronic cigarettes in the U.S. Thus, we believe that our reputation and our experience in the electronic cigarette industry, both from a development, customer service and production perspective give us an advantage in attracting customers, specifically re-sellers who require ongoing support, reliable and consistent supply chains and mechanisms in place for supporting broad based distributors and big box retailers.

Moreover, we believe that our history with our suppliers, including the volume of products we source, gives us an advantage over other market participants as it relates to favorable pricing, priority as to inventory supply and delivery and first access to new products, including first access to next generation electronic cigarette products and technology.

Our goal is to achieve a position of sustainable leadership in the vaporizer industry. Our strategy consists of the following key elements:

continue to expand the footprint of the vape stores ;
develop new brands and engineer product offerings;
continue to shift our product focus from e-cigarettes to vaporizers;
seek potential franchisees for the vape stores ;
invest in and leverage our new and existing brands through marketing and advertising;
increase our presence in national and regional retailers;

expand our brand awareness and online web presence;
introduce our products to the consumer through increased infomercial broadcasts;
develop continuity programs for our end user customers;
expanding into new potential markets;
scale our distribution through strategic resale partnerships; and
align our product offerings and cost with market demand.

36

Competition

Competition in the electronic cigarette industry, including the vaporizer and e-liquid segments, is intense. We compete with other sellers of electronic cigarettes, most notably Lorillard, Inc., Altria Group, Inc. and Reynolds American, Inc., which are big tobacco companies that have electronic cigarette business segments. The nature of our competitors is varied as the market is highly fragmented and the barriers to entry into the business are low. Our direct competitors sell products that are substantially similar to ours and through the same channels through which we sell our electronic cigarette products. We compete with these direct competitors for sales through distributors, wholesalers and retailers, including but not limited to national chain stores, tobacco shops, gas stations, travel stores, shopping mall kiosks, in addition to direct to public sales through the Internet, mail order and telesales.

As a general matter, we have access to market and sell the similar vaporizers and electronic cigarettes as our competitors and we sell our products at substantially similar prices as our competitors; accordingly, the key competitive factors for our success is the quality of service we offer our customers, the scope and effectiveness of our marketing efforts, including media advertising campaigns and, increasingly, the ability to identify and develop new sources of customers.

Part of our business strategy focuses on the establishment of contractual relationships with distributors. We are aware that e-cigarette competitors in the industry are also seeking to enter into such contractual relationships. In many cases, competitors for such contracts may have greater management, human, and financial resources than we do for entering into such contracts and for attracting distributor relationships. Furthermore, certain of our electronic cigarette and vaporizer competitors may have better control of their supply and distribution, be better established, larger and better financed than our Company.

As discussed above, we compete against “big tobacco”, U.S. cigarette manufacturers of both conventional tobacco cigarettes and electronic cigarettes like Altria Group, Inc., Lorillard, Inc. and Reynolds American, Inc. We compete against “big tobacco” who offers not only conventional tobacco cigarettes and electronic cigarettes but also smokeless tobacco products such as “snus” (a form of moist ground smokeless tobacco that is usually sold in sachet form that resembles small tea bags), chewing tobacco and snuff. “Big tobacco” has nearly limitless resources, global distribution networks in place and a customer base that is fiercely loyal to their brands. Furthermore, we believe that “big tobacco” will devote more attention and resources to developing and offering electronic cigarettes as the market for electronic cigarettes grows. Because of their well-established sales and distribution channels, marketing expertise and significant resources, “big tobacco” is better positioned than small competitors like us to capture a larger share of the electronic cigarette market.

Manufacturing

We have no manufacturing capabilities and do not intend to develop any manufacturing capabilities. Third party manufacturers manufacture our products to meet our design specifications. We depend on third party manufacturers for our vaporizers, electronic cigarettes and accessories. Our customers associate certain characteristics of our products including the weight, feel, draw, unique flavor, packaging and other attributes of our products to the brands we market, distribute and sell. Any interruption in supply and or consistency of our products may harm our relationships and reputation with customers, and have a material adverse effect on our business, results of operations and financial condition. In order to minimize the risk of supply interruption, we currently utilize several third party manufacturers to manufacture our products to our specifications.

We currently utilize approximately 13 different manufacturers, all of which are based in China. We contract with our manufacturers on a purchase order basis. We do not have any output or requirements contracts with any of our manufacturers. Our manufacturers provide us with finished products, which we hold in inventory for distribution, sale and use. Certain Chinese factories and the products they export have recently been the source of safety concerns and recalls, which is generally attributed to lax regulatory, quality control and safety standards. Should Chinese factories continue to draw public criticism for exporting unsafe products, whether those products relate to our products or not, we may be adversely affected by the stigma associated with Chinese production, which could have a material adverse effect on our business, results of operations and financial condition.

Although we believe that several alternative sources for our products are available, any failure to obtain the components, chemical constituents and manufacturing services necessary for the production of our products would have a material adverse effect on our business, results of operations and financial condition.

Source and Availability of Raw Materials

We believe that an adequate supply of product and raw materials will be available to us as needed and from multiple sources and suppliers.

Intellectual Property

We have developed and trademarked or are preparing to commercialize additional products. We include product development expenses as part of our operating expenses. We currently own no patents which are material to our business. We have a number of patent applications pending in the United States including those described below. There is no assurance that we will be awarded patents for of any of these pending patent applications.

Soft Tip Filters

We have a patent pending for a soft-tip electronic cigarette filter, which more closely resembles the tactile experience of a conventional tobacco cigarette in a user’s mouth. To date electronic cigarettes have been made of metal and hard plastic and do not offer users the same malleable feel as the cellulose filters of conventional tobacco cigarettes.

Electronic Cigarette Air Flow Sensor Patent

We have a patent pending on a new configuration for the air flow sensors currently used in electronic cigarettes. The new configuration will allow the battery to be sealed to enhance the reliability and performance of the electronic cigarette.

Vaporizer Biometric Fingerprint Lock Sensor Patent

We have a patent pending for a biometric fingerprint lock sensor that can be used in vaporizers. The biometric fingerprint lock sensor will allow the owner of the vaporizer to keep the device locked and turned off unless the authorized user unlocks the device via fingerprint scan, protecting the device from use by another individual. This technology may be used to protect against minors being able to turn on the device and will also deem the devices unusable in the event the device is lost or stolen.

Trademarks

We own trademarks on certain of our brands, including: Fifty-One®, Krave®, Vapor X®, Alternacig®, EZSMOKER®, Green Puffer®, Americig®, Hookah Stix®and Smoke Star® brands. We have also filed additional trademarks, which have yet to be awarded.

Patent Litigation

We are a defendant in a certain patent lawsuit described in the section titled“Legal Proceedings” in this prospectus.

Such patent lawsuit as well as any other third party lawsuits alleging our infringement of patents, trade secrets or other intellectual property rights could force us to do one or more of the following:

stop selling products or using technology that contains the allegedly infringing intellectual property;
incur significant legal expenses;
pay substantial damages to the party whose intellectual property rights we may be found to be infringing;
redesign those products that contain the allegedly infringing intellectual property; or
attempt to obtain a license to the relevant intellectual property from third parties,Eligible Guarantor Institution, which may not be availableinclude a commercial bank or trust company, a member firm of a domestic stock exchange or a savings bank or credit union, to notify us on reasonable terms or at all.

Third party lawsuits alleging our infringement of patents, trade secrets or other intellectual property rights could have a material adverse effect on our business, results of operations and financial condition.

We may be required to obtain licenses to patents or proprietary rights of others. We cannot assure you that any licenses required under any such patents or proprietary rights would be made available on terms acceptable to us or at all. If we do not obtain such licenses, we could encounter delays in product market introductions while we attempt to design around such patents, or could find that the development, manufacture, or sale of products requiring such licenses could be foreclosed. Litigation may be necessary to defend against claims of infringement asserted against us by others, or assert claims of infringement to enforce patents issued to us or exclusively licensed to us, to protect trade secrets or know-how possessed by us, or to determine the scope and validity of the proprietary rights of others. In addition, we may become involved in oppositions in foreign jurisdictions, reexaminations declared by the United States Patent and Trademark Office, or interference proceedings declared by the United States Patent and Trademark Office to determine the priority of inventions with respect to our patent applications or those of our licensors. Litigation, opposition, reexamination or interference proceedings could result in substantial costs to and diversion of effort by us, and may have a material adverse impact on us. In addition, we cannot assure you that our efforts to maintain or defend our patents will be successful.

Government Regulation

Since a 2010 U.S. Court of Appeals decision, the FDA is permitted to regulate electronic cigarettes as “tobacco products” under the Family Smoking Prevention and the Tobacco Control Act. Under this decision, the FDA is not permitted to regulate electronic cigarettes as “drugs” or “devices” or a “combination product” under the Federal Food, Drug and Cosmetic Act unless they are marketed for therapeutic purposes. This is contrary to anti-smoking devices like nicotine patches, which undergo more extensive FDA regulation. Because Vapor does not market Vapor’s electronic cigarettes for therapeutic purposes, Vapor’s electronic cigarettes are subject to being classified as “tobacco products” under the Tobacco Control Act. The Tobacco Control Act grants the FDA broad authority over the manufacture, sale, marketing and packaging of tobacco products, although the FDA is prohibited from issuing regulations banning all cigarettes or all smokeless tobacco products, or requiring the reduction of nicotine yields of a tobacco product to zero.

On April 24, 2014, the FDA released proposed rules that would extend its regulatory authority to electronic cigarettes and certain other tobacco products under the Tobacco Control Act. The proposed rules would require that electronic cigarette manufacturers (i) register with the FDA and report electronic cigarette product and ingredient listings; (ii) market new electronic cigarette products only after FDA review; (iii) only make direct and implied claims of reduced risk if the FDA confirms that scientific evidence supports the claim and that marketing the electronic cigarette product will benefit public health as a whole; (iv) not distribute free samples; (v) implement minimum age and identification restrictions to prevent sales to individuals under age 18; (vi) include a health warning; and (vii) not sell electronic cigarettes in vending machines, unless in a facility that never admits youth. The proposed rules were subject to a 75-day public comment period, following which the FDA will finalize the proposed rules. It is not known how long this regulatory process to finalize and implement the rules may take. Accordingly, Vapor cannot predict the content of any final rules from the proposed rules or the impact they may have. See the risk factor on page 6 which also discusses possible additional FDA rulemaking.

In this regard, total compliance and related costs are not possible to predict and depend substantially on the future requirements imposed by the FDA under the Tobacco Control Act. Costs, however, could be substantial and could have a material adverse effect on Vapor’s business, results of operations and financial condition. In addition, failure to comply with the Tobacco Control Act and with FDA regulatory requirements could result in significant financial penalties and could have a material adverse effect on Vapor’s business, financial condition and results of operations and ability to market and sell Vapor’s products. At present, it is difficult to predict whether the Tobacco Control Act will impact Vapor to a greater degree than competitors in the industry, thus affecting Vapor’s competitive position.

State and local governments currently legislate and regulate tobacco products, including what is considered a tobacco product, how tobacco taxes are calculated and collected, to whom and by whom tobacco products can be sold and where tobacco products may or may not be smoked. State and local regulation of the e-cigarette market and the usage of e-cigarettes is beginning to accelerate.

As local regulations expand, vaporizers and electronic cigarettes may lose their appeal as an alternative to cigarettes, which may have the effect of reducing the demand for Vapor’s products and as a result have a material adverse effect on Vapor’s business, results of operations and financial condition.

At present, neither the Prevent All Cigarette Trafficking Act (which prohibits the use of the U.S. Postal Service to mail most tobacco products, which would require individuals and businesses that make interstate sales of cigarettes or smokeless tobacco to comply with state tax laws) nor the Federal Cigarette Labeling and Advertising Act (which governs how cigarettes can be advertised and marketed) apply to electronic cigarettes. The application of either or both of these federal laws to vaporizers and electronic cigarettes would have a material adverse effect on Vapor’s business, results of operations and financial condition.

On July 1, 2015, the FDA published a document entitled “Advanced notice of proposed rulemaking” or the Advance. Through the Advance, the FDA solicited public comments on whether it should issue rules with respect to nicotine exposure warning and child-resistant packaging for e-liquids containing nicotine. Following public comment, the FDA may issue proposed rules in furtherance of the purposes outlined in the Advance and ultimately pass the rules as proposed or in modified form. We cannot predict whether if rules are passed it will have a material adverse effect on our future results of operations and financial conditions.

Vapor expects that the tobacco industry will experience significant regulatory developments over the next few years, driven principally by the World Health Organization’s FCTC. The FCTC is the first international public health treaty on tobacco, and its objective is to establish a global agenda for tobacco regulation with the purpose of reducing initiation of tobacco use and encouraging cessation. Regulatory initiatives that have been proposed, introduced or enacted include:

of your intent to exercise the levying of substantial and increasing tax and duty charges;
restrictions or bans on advertising, marketing and sponsorship;
the display of larger health warnings, graphic health warnings and other labelling requirements;
restrictions on packaging design, including the use of colors and generic packaging;
restrictions or bans on the display of tobacco product packaging at the point of sale, and restrictions or bans on cigarette vending machines;
requirements regarding testing, disclosure and performance standards for tar, nicotine, carbon monoxide and other smoke constituents levels;
requirements regarding testing, disclosure and use of tobacco product ingredients;
increased restrictions on smoking in public and work places and, in some instances, in private places and outdoors;
elimination of duty free allowances for travelers; and
encouraging litigation against tobacco companies.

If Vaporizers, electronic cigarettes, or e-liquids, are subject to one or more significant regulatory initiates enacted under the FCTC, Vapor’s business, results of operations and financial condition could be materially and adversely affected.

Employees

As of June 29 , 2015, we had 93 full-time employees and three part-time employees, none of which are represented by a collective bargaining agreement. We believe that our employee relations are good.

Legal Proceedings

On June 22, 2012, Ruyan filed a lawsuit against the Company alleging infringement of U.S. Patent No. 8,156,944, entitled “Aerosol Electronic Cigarette” (the “944 Patent”). Ruyan also filed separate cases for patent infringement against nine other defendants also asserting infringement of the ’944 Patent. Ruyan’s lawsuit against the Company captioned as Ruyan Investment (Holdings) Limited v. Vapor Corp., No. 12-cv-5466, is pending in the United States District Court for the Central District of California. All of these lawsuits have been consolidated for discovery and pre-trial purposes. On February 25, 2013, Ruyan’s patent infringement lawsuit against the Company as well as all of the other consolidated lawsuits were stayed as a result of the Court granting a stay in one of the consolidated lawsuits. The Court granted the motion to stay Ruyan’s lawsuit against the Company and the other defendants based on the filing of a request for inter partes reexamination of the ’944 Patent at the U.S. Patent and Trademark Office. As a result of the stay, all of the consolidated lawsuits involving the ’944 Patent were stayed until the reexamination is completed. As a condition to granting the stay of all the lawsuits, the Court required any other defendant who desires to seek reexamination of the ’944 Patent and potentially seek another stay (or an extension of the existing stay) based on any such reexamination to seek such reexamination no later than July 1, 2013. Two other defendants sought reexamination of the ’944 Patent before expiration of such Court-imposed deadline of July 1, 2013. All reexamination proceedings of the ’944 Patent were stayed by the United States Patent and Trademark Office Patent Trial and Appeal Board pending its approval of one or more of them. On December 24, 2014, the Patent Trial and Appeal Board issued its ruling that all of the challenged claims in the reexamination proceedings of the ’944 patent were invalid except for one claim. To the extent this claim is asserted against the Company, the Company will vigorously defend itself against such allegations. Currently, the case remains stayed.

On March 5, 2014, Fontem Ventures, B.V. and Fontem Holdings 1 B.V. (the successors to Ruyan) filed a complaint against the Company in the U.S. District Court for the Central District of California, captioned Fontem Ventures B.V., et al. v. Vapor Corp., No. 14-cv-1650. The complaint alleges infringement of U.S. Patent No. 8,365,742, entitled “Aerosol Electronic Cigarette”, U.S. Patent No. 8,375,957, entitled “Electronic Cigarette” (the “957 Patent”), U.S. Patent No. 8,393,331, entitled “Aerosol Electronic Cigarette” (the “331 Patent”) and U.S. Patent No. 8,490,628, entitled “Electronic Atomization Cigarette” (the “628 Patent”). On April 8, 2014, plaintiffs amended their complaint to add U.S. Patent No. 8,689,805, entitled “Electronic Cigarette” (the “805 Patent”). The products accused of infringement by plaintiffs are various Krave, Fifty-One and Hookah Stix products and parts. Nine other companies were also sued in separate lawsuits alleging infringement of one or more of the patents listed above. The Company filed its Answer and Counterclaims on May 1, 2014 and believes the claims are without merit. Other defendants have filed petitions for inter partes review of the ’742, ’957, ’331, ’628 and ’805 Patents at the U.S. Patent and Trademark Office. The U.S. Patent and Trademark Office has already instituted the majority of the petitions, with decisions on whether to institute additional petitions expected soon.

On October 21, 2014, Fontem Ventures B.V. and Fontem Holdings 1 B.V. filed a complaint against the Company in the U.S. District Court for the Central District of California, captioned Fontem Ventures B.V., et al. v. Vapor Corp., No. 14-cv-8155. The complaint alleges infringement of United States Patent No. 8,863,752, entitled “Electronic Cigarette” and U.S. Patent No. 8,893,726, entitled “Electronic Cigarette”. The products accused of infringement by plaintiffs are various Krave, Fifty-One, Vapor X and Hookah Stix products and parts. On January 15, 2015, the Company filed its Answer and Counterclaims. The Company will vigorously defend itself against such allegations.

On December 2, 2014, Fontem Ventures B.V. and Fontem Holdings 1 B.V. filed a complaint against the Company in the U.S. District Court for the Central District of California, captioned Fontem Ventures B.V., et al. v. Vapor Corp., No. 14-cv-09267. The complaint alleges infringement of United States Patent No. 8,899,239, entitled “Electronic Cigarette”. The products accused of infringement by plaintiffs are various Krave, Vapor X, Hookah Stix and Fifty-One products and parts. Fontem amended its complaint on December 16, 2014, to allege infringement of United States Patent No. 8,910,641, entitled “Electronic Cigarette” against the same products. On January 15, 2015, the Company filed its Answer and Counterclaims. The Company will vigorously defend itself against such allegations.

All of the above referenced cases filed by Fontem in 2014 have been consolidated and are currently scheduled for trial in November 2015.

On June 22, 2015, the Center for Environment Health, as plaintiff, filed suit against a number of defendants including Vapor Corp., its wholly-owned subsidiary, the Vape Store, Inc., Vaporin and another wholly-owned subsidiary, Vaporin Florida, Inc. The lawsuit was filed in the Superior Court of the State of California, County of Alameda. The suit seeks relief under California Proposition 65 which makes it unlawful for businesses to knowingly and intentionally expose individuals in California to chemicals known to cause birth defects or other harm without providing clear and reasonable warnings. All of the defendants are alleged to have sold products containing significant quantities of nicotine in violation of Proposition 65. The plaintiff is seeking a civil penalty against these defendants in the amount of $2,500 per day for each violation of Proposition 65, together with attorneys’ fees and costs. The Company and its subsidiaries are in the process of hiring counsel and intend to defend the allegations. The Company believes that all of the products sold by Vapor Corp. have always contained an appropriate warning. The Vape Store, Inc., operates vape stores located only in the State of Florida and has not, to the best of its knowledge, sold any products into the State of California.

Properties

We lease approximately 13,323 square feet of office and warehouse facilities located at 3001 and 3091 Griffin Road, Dania Beach Florida, under a 24 month lease agreement terminating in March 2016. In October 2013, we amended this lease to include an additional approximately 2,200 square feet.

The Company has leases on 1 1 vape stores and one kiosk. In April 2015, the Company shut down seven of the eight kiosks that it opened in the fourth quarter of 2014 and is negotiating terminations of these leases. Under these leases, the initial lease terms range from one to five years.

Additionally, we have one lease for a warehouse all located in Cape Coral, Florida.

MANAGEMENT

The following table represents our Board:

NameAgePosition
Jeffrey Holman46Chairman of the Board
Gregory Brauser30Director

William Conway III

31Director
Daniel MacLachlan36Director
Nikhil Raman31Director

Board of Director Biographies

Jeffrey Holman has been our Chairman of the Board and Chief Executive Officer since April 2014. From February 2013 until March 4, 2015, Mr. Holman serviced as our President. Mr. Holman has been a member of our Board since May 2013 and has served as a member of the Board of Directors of our subsidiary Smoke Anywhere since its inception on March 24, 2008. Since 1998, Mr. Holman has been the President of Jeffrey E. Holman & Associates, P.A., a South Florida based law firm. He has also been a Partner in Holman, Cohen & Valencia since 2000. Mr. Holman was selected as a director for his business and legal experience. In addition, as the founder of Smoke Anywhere, Mr. Holman possesses an in-depth understanding of the challenges, risks and characteristics unique to our industry.

Gregory Brauser has served as a director since March 4, 2015. Prior to that, Mr. Brauser served as Chief Operating Officer of Vaporin beginning in January 2014. Mr. Brauser founded Direct Source China in 2009, a sourcing company headquartered in Shanghai, China, that assists mid-size U.S. businesses with their direct manufacturing overseas. Since 2010, Mr. Brauser has served as Vice Chairman and director of Dog-E-Glow, Inc., a manufacturer and distributer of LED lighted dog collars and leashes, which he formed. Mr. Brauser was appointed as a Vaporin designee in connection with the merger with Vaporin, Inc.

William Conway III has been a director since June 2015. Since 2008, Mr. Conway has served in management positions with City Furniture, with the latest being Director of Operations and Customer Service. Mr. Conway was appointed as a director for his business and operating expertise.

Daniel MacLachlan has been a director since April 18, 2015. Mr. MacLachlan served as the Chief Financial Officer of The Best One, Inc., from October 2014 through early February 2015, facilitating its merger with IDI, Inc. (FKA, Tiger Media, Inc.) (NYSE MKT: IDI). Mr. MacLachlan served as Director of Finance and Chief Financial Officer for TransUnion Risk and Alternative Data Solutions, Inc., after it acquired substantially all the assets of TLO, LLC (“TLO”), a leading provider of data fusion technology-driven investigative products and solutions, in December 2013. Mr. MacLachlan was Chief Financial Officer of TLO since its inception in 2009. Mr. MacLachlan was appointed a director for his financial and accounting expertise.

Nikhil Raman was appointed as a director on July 7, 2015. Since November 6, 2014, Mr. Raman has been the Chief Executive Officer of usell.com, Inc. (OTCQB: USEL), a technology based company focused on creating an online marketplace for used cell phones. Mr. Raman has served as a director of usell.com since April 24, 2012. From January 27, 2012 until November 6, 2014, Mr. Raman served as the Chief Operating Officer of usell.com. After graduating from Harvard Business School, Mr. Raman founded and served as Manager of Ft. Knox Recycling, LLC doing business as EcoSquid. Mr. Raman also served as Chief Executive Officer of EcoSquid from its founding through its acquisition by usell.com in April 2012. From 2008 until 2010, Mr. Raman attended Harvard Business School. Mr. Raman was appointed as a director for his management and operations expertise.

Executive Officers

NameAgePosition
Jeffrey Holman46Chief Executive Officer
Gregory Brauser30President
James Martin48Chief Financial Officer
Christopher Santi43Chief Operating Officer

Executive Officer Biographies

See above for Mr. Jeffrey Holman’s and Mr. Gregory Brauser’s biographies.

James Martin has served as Chief Financial Officer since March 4, 2015. Prior to that, Mr. Martin served as Chief Financial Officer of Vaporin, Inc. beginning in April 2014. Prior to his appointment as Chief Financial Officer of Vaporin, Mr. Martin was Chief Financial Officer of Non-Invasive Monitoring Systems, Inc., or “NIMS”, a publicly held medical device company since January 2011. Mr. Martin previously had served as Chief Financial Officer of SafeStitch Medical, Inc., a publicly-held medical device company from January 2011 through October 2013. From January 2011 through December 2011 Mr. Martin also served as Vice President of Finance of Aero Pharmaceuticals, Inc., a privately held pharmaceutical distributor that voluntarily dissolved in December 2011. From July 2010 through January 2011, Mr. Martin served as Controller of each of NIMS, SafeStitch and Aero. Also from May 2008 through July 2010, Mr. Martin served as Controller of AAR Aircraft Services-Miami, a subsidiary of AAR Corp, an aerospace and defense company in which he was responsible for all financial reporting and inventory logistics.

Christopher Santi has been our Chief Operating Officer since December 12, 2012. Prior to that Mr. Santi served as Director of Operations of Vapor beginning in October 2011. Mr. Santi served as the National Sales Manager of Collages.net from November 2007 to October 2011.

There are no family relationships among our directors and executive officers.

Corporate Governance

Board Responsibilities

The Board oversees, counsels, and directs management in the long-term interest of Vapor and its shareholders. The Board’s responsibilities include establishing broad corporate policies and reviewing the overall performance of Vapor. The Board is not, however, involved in the operating details on a day-to-day basis.

Board Committees and Charters

The Board and its Committees meet throughout the year and act by written consent from time-to-time as appropriate. The Board delegates various responsibilities and authority to different Board Committees. Committees regularly report on their activities and actions to the Board.

The Board currently has and appoints the members of: the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. Each of these committees have a written charter which can be found on our corporate website atir.vapor-corp.com/committee-charters.

The following table identifies the independent and non-independent current Board and committee members:

NameIndependentAuditCompensationNominating
andCorporate
Governance
Jeffrey Holman
Gregory Brauser

William Conway III

xxxx
Daniel MacLachlanxxxx
Nikhil Ramanxxxx

Director Independence

Our Board has determined that William Conway III, Nikhil Raman and Daniel MacLachlan are independent in accordance with standards under the Nasdaq Listing Rules. Our Board determined that as a result of being executive officers, Messrs. Jeffrey Holman and Gregory Brauser were not independent under the Nasdaq Listing Rules. Our Board has also determined that William Conway III, Nikhil Raman and Daniel MacLachlan are independent under the Nasdaq Listing Rules independence standards for Audit Committee members.

Committees of the Board

Audit Committee

The Audit Committee, which currently consists of William Conway III, Nikhil Raman and Daniel MacLachlan, reviews Vapor’s financial reporting process on behalf of the Board and administers our engagement of the independent registered public accounting firm.The Audit Committee approves all audit and non-audit services, and reviews the independence of our independent registered public accounting firm.

Audit Committee Financial Expert

Our Board has determined that Daniel MacLachlan and Nikhil Raman both qualified as Audit Committee Financial Experts , as that term is defined by the rules of the SEC and in compliance with the Sarbanes-Oxley Act of 2002.

Compensation Committee

The function of the Compensation Committee is to determine the compensation of our executive officers. The Compensation Committee has the power to set performance targets for determining periodic bonuses payable to executive officers and may review and make recommendations with respect to shareholder proposals related to compensation matters. Additionally, the Compensation Committee is responsible for administering Vapor’s equity compensation plans including the Plan.

The members of the Compensation Committee are all independent directors within the meaning of applicable Nasdaq Listing Rules and all of the members are “non-employee directors” within the meaning of Rule 16b-3 under the Securities Exchange Act of 1934, or the Exchange Act.

Nominating and Corporate Governance Committee

The responsibilities of the Nominating and Corporate Governance Committee include the identification of individuals qualified to become Board members, the selection of nominees to stand for election as directors, the oversight of the selection and composition of committees of the Board, establish procedures for the nomination process including procedures and the oversight of the evaluations of the Board and management. The Nominating and Corporate Governance Committee has not established a policy with regard to the consideration of any candidates recommended by shareholders since no shareholders have made any recommendations. If we receive any shareholder recommended nominations, the Nominating Committee will carefully review the recommendation(s) and consider such recommendation(s) in good faith.

EXECUTIVE AND DIRECTOR COMPENSATION

Non-employee directors are paid a monthly fee of $1,000 per month and $1,000 for each meeting attended. Because we do not pay any compensation to employee directors, Messrs. Holman and Frija are omitted from the following table.

Fiscal 2014 Director Compensation

Name

(a)

 Fees
Earned or
Paid in Cash
($)(b)
  Option
Awards
($)(d)(1)
  All Other
Compensation
($)(g)
  Total
($)(j)
 
Robert J Barrett III (2)  27,000   388,800   0   415,800 
                 
Angela Courtin  21,000   388,800   0   409,800 
                 
Frank E. Jaumot (3)  27,000   388,800   0   415,800 
                 
Ryan Kavanaugh (2)  13,000   498,000   1,540,000(4)  2,051,000 
(1)This represents the fair value of the award as of the grant date in accordance with FASB ASC Topic 718. These amounts represent awards that are paid in shares of common stock or options to purchase shares of our common stock and do not reflect the actual amounts that may be realized by the directors. In April 2014, these directors were granted 12 ,000 stock options exercisable at $32.40 and vesting in three equal annual increments beginning April 25, 2015.Subscription Rights.
  
(2)By Mail:

Messrs. Barrett and Kavanaugh and Ms. Courtin resigned prior to the date of this prospectus.

Broadridge Corporate Issuer Solutions, Inc.
Attn: BCIS re-Organization Dept.
P.O. Box 1317
Brentwood, NY 11717-0718
  
(3)By Hand or Overnight Courier:Did not standfor re-election in connection with the 2015 Annual Meeting.
(4)Represents 40 ,000 shares of common stock issued in connection with consulting services. See footnote (1) above.
Broadridge Corporate Issuer Solutions, Inc.
Attn: BCIS IWS
51 Mercedes Way
Edgewood, NY 11717


Summary Compensation Table36

The following table sets forth information regarding the compensation for services performed during fiscal years 2014 and 2013, awarded


Delivery to paid to or earned by our Named Executive Officers, which include all Chief Executive Officers serving during fiscal 2014 and (iii) our twoan address other most highly compensated executive officers, as determined by reference to total compensation for fiscal year 2014, who were serving as executive officers at the end of fiscal year 2014.

Name and

Principal Position

(a)

 Year
(b)
  Salary
($)(c)
  Bonus
($)(d)(1)
  All Other
Compensation
($)(i)
  Total
($)(j)
 
                
Jeffrey Holman(2)  2014   182,000   0   0   182,000 
Chief Executive Officer  2013   169,400   20,000   0   189,400 
                     
Kevin Frija(2)  2014   53,203   0   

85,615

(3)  138, 818 
Former Chief Executive Officer  2013   150,404   20,000   0   170,404 
                     
Harlan Press  2014   188,339   0   0   188,389 
Former Chief Financial Officer  2013   179,939   20,000   10,442(4)  210,381 
                     
Christopher Santi  2014   162,246   0   0   162,246 
Chief Operating Officer  2013   156,231   20,000   0   176,231 

(1)Represent cash bonuses for 2013 which were paid on February 28, 2014.
(2)

In April 2014, Mr. Holman replaced Mr. Frija as Chief Executive Officer.

(3)

Represents severance payments.

(4) Represents a cash payment for unused accrued vacation for 2013 that was paid on November 15, 2013.

Named Executive Officer Employment Agreements

The chart below summarizes the terms and conditions of employment agreements with our Named Executive Officers.

Executive (1)TermBase Salary
Jeffrey HolmanFebruary 11, 2013 through December 31, 2015 which shall automatically be renewed unless either party is given six months’ notice of non-renewal$182,000
Christopher Santi (2)December 12, 2012 through December 11, 2015 which shall automatically be renewed unless either party is given six months’ notice of non-renewal$156,000 in first year, increasing to $162,000 in second year and $170,000 thereafter. Currently, $170,000

(1)

Mr. Harlan Press, a Named Executive Officer, resigned effective April 10, 2015. He will receive nine-months’ severance and accrued vacation in the amount of approximately $159,000.

(2)In accordance with his Employment Agreement, Mr. Santi received a 10-year option to purchase up to 4,000 shares of the Company’s common stock at an exercise price of $6.25 , vesting monthly at the rate of approximately 111 per month.

The Compensation Committee will have the discretion to award eachthan one of the Named Executive Officers a bonus based upon job performanceaddresses listed above may not constitute valid delivery and, accordingly, may be rejected by us.


Any questions or any other factors determined byrequests for assistance concerning the Compensation Committee.

Termination Provisions

The table below describes the severance payments that our Named Executive Officers are entitled to in connection with a terminationmethod of their employment upon death, disability, dismissal without cause, Change of Controlsubscribing for shares or for Good Reason. Alladditional copies of the termination provisions are intendedthis prospectus or subscription certificates or notices of guaranteed delivery may be directed to comply with Section 409A of the Internal Revenue Code of 1986 and the Regulations thereunder.

HolmanPressSanti
Death or Total DisabilityAny amounts due at time of terminationAny amounts due at time of terminationAny amounts due at time of termination
Dismissal Without Cause or Termination by ExecutiveBroadridge Corporate Issuer Solutions, Inc., by telephone at (855) 793-5068 or by email at shareholder@broadridge.com.

Rights holders may also contact their broker-dealers or nominees for Good Reason or upon a Change of Control (1)
Three months of Base Salary for each year of service, up to 18 months maximumThree months of Base Salary for each year of service, up to 18 months maximumTwo months of Base Salary for each year of service, up to 12 months maximum
(1)Good Reason is generally (with certain exceptions) defined as (i) a relocation of principal place of employment outside a stated area, (ii) a material reduction in Base Salary, (iii) the diminution of the Named Executive Officers’ duties, or (iv) any other action or inaction that constitutes a material failure by Vapor to fulfill its obligations under the Employment Agreements. All of these events are subject to a 30-day cure period.
(2)Change of Control is generally defined as (i) a sale of substantially all of the Company, (ii) any “person” (as such term is defined under the Exchange Act) becomes the beneficial owners of over 50% of the Company’s voting power, (iii) a change in the majority of the composition of the Board or (iv) a transaction that results in over 50% of the Company’s voting power ceasing to hold a majority of the voting power post-transaction.

Risk Assessment Regarding Compensation Policies and Practices as they Relate to Risk Management

Our compensation program for employees does not create incentives for excessive risk taking by our employees or involve risks that are reasonably likely to have a material adverse effect on us. Our compensation has the following risk-limiting characteristics:

Our base pay programs consist of competitive salary rates that represent a reasonable portion of total compensation and provide a reliable level of income on a regular basis, which decreases incentive on the part of our executives to take unnecessary or imprudent risks;
A portion of executive incentive compensation opportunity is tied to long-term incentive compensation that emphasizes sustained performance over time. This reduces any incentive to take risks that might increase short-term compensation at the expense of longer term company results;
Awards are not tied to formulas that could focus executives on specific short-term outcomes;
Equity awards may be recovered by us should a restatement of earnings occur upon which incentive compensation awards were based, or in the event of other wrongdoing by the recipient; and
Equity awards, generally, have multi-year vesting which aligns the long-term interests of our executives with those of our shareholders and, again, discourages the taking of short-term risk at the expense of long-term performance.

Outstanding Equity Awards

Listed below is information with respect to unexercised options,this offering.


Methods for Exercising Subscription Rights

Exercise of the Subscription Right

Subscription Rights are evidenced by subscription certificates that, except as described below under “Foreign Stockholders,” will be mailed to record date stockholders or, if a record date stockholder’s shares are held by a depository or nominee (including any mobile investment platform) on his, her or its behalf, to such depository or nominee. Subscription Rights may be exercised by completing and signing the subscription certificate that accompanies this prospectus and mailing it in the envelope provided, or otherwise delivering the completed and duly executed subscription certificate to the subscription agent, together with payment in full for the shares at the estimated subscription price by the Expiration Date of this offering. Subscription Rights may also be exercised by contacting your broker, trustee or other nominee (including any mobile investment platform), who can arrange, on your behalf, to guarantee delivery of payment and delivery of a properly completed and duly executed subscription certificate pursuant to a notice of guaranteed delivery by the close of business on the second business day after the Expiration Date. A fee may be charged by your broker, trustee or other nominee (including any mobile investment platform) for this service. Completed subscription certificates and related payments must be received by the subscription agent prior to 5:00 p.m. (Eastern time) on or before the Expiration Date (unless payment is effected by means of a notice of guaranteed delivery as described below under “Payment for Securities”) at the offices of the subscription agent at the address set forth above.

Exercise of the Over-Subscription Privilege

Rights holders who fully exercise all of their basic rights may purchase additional shares in accordance with the over-subscription privilege by indicating on their subscription certificate the number of additional shares they are willing to acquire. If sufficient shares are available after all exercises of basic rights, we will seek to honor over-subscriptions requests in full, subject to the pro rata allocations and ownership limitation described in “—Over-Subscription Privilege.”

Record Date Stockholders Whose Shares are Held by a Nominee

Record date stockholders whose shares are held by a nominee, such as a bank, broker-dealer, trustee, depositories or mobile investment platform, must contact that nominee to exercise their Subscription Rights. In that case, the nominee will complete the subscription certificate on behalf of the record date stockholder and arrange for proper payment by one of the methods set forth under “Payment for Securities” below.

Nominees

Nominees, such as brokers, trustees, depositories or mobile investment platforms for securities, who hold shares of common stock that hasfor the account of others, should notify the respective beneficial owners of the shares as soon as possible to ascertain the beneficial owners’ intentions and to obtain instructions with respect to the Subscription Rights. If the beneficial owner so instructs, the nominee should complete the subscription certificate and submit it to the subscription agent with the proper payment as described under “Payment for Securities” below.

37

General

All questions as to the validity, form, eligibility (including times of receipt and matters pertaining to beneficial ownership) and the acceptance of subscription forms and the subscription price will be determined by us, which determinations will be final and binding. No alternative, conditional or contingent subscriptions will be accepted. We reserve the right to reject any or all subscriptions not vested and equity incentive awards for each Named Executive Officerproperly submitted or the acceptance of which would, in the opinion of our counsel, be unlawful.

We reserve the right to reject any exercise of rights if such exercise is not in accordance with the terms of this offering or not in proper form or if the acceptance thereof or the issuance of shares thereto could be deemed unlawful. We reserve the right to waive any deficiency or irregularity with respect to any subscription certificate. Subscriptions will not be deemed to have been received or accepted until all irregularities have been waived or cured within such time as we determine in our sole discretion. We will not be under any duty to give notification of December 31, 2014:

Outstanding Equity Awards At Fiscal Year-End

Name
(a)
  Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable (b)
  Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
(c)
 


Equity

Incentive

Plan Awards:

Number of

Securities

Underlying

Unexercised

or

Unearned

Options

(#)

(d)

  Option
Exercise
Price
($)
(e)
  Option
Expiration
Date
(f)
 
                 
Jeffrey Holman                    
    24,000  0(1)     11 .25   10/1/15
                    
Kevin Frija                   
    36,000  0(1)     11 .25   10/1/15
                    
Harlan Press                   
    7,556  445(2)     5 .00   2/28/22
                    
Christopher Santi                   
    4,000  2,000(3)     5.75   3/29/22
    2,778  1,223(4)     6 .25   12/11/22

(1)This option is fully vested.
(2)These unvested options, at December 31, 2014, were fully vested as of the date of this prospectus.
(3)Of the unvested options, ½ vested on March 30, 2015 and ½ will vest on March 30, 2016.
(4)The unvested options vested, or will vest,any defect or irregularity in 11 equal monthly increments beginning January 11, 2015.

CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS

In connection with the issuancesubmission of $300,000 18% senior convertible notes, which we refersubscription certificates or incur any liability for failure to asgive such notification.


No Revocation or Change

Once you submit the “$300,000 Senior Convertible Notes”, in 2012subscription certificate or have instructed your nominee of your subscription request, you are not allowed to Kevin Frija, Vapor’s then Chief Executive Officer, Harlan Press, Vapor’s then Chief Financial Officer,revoke or change the exercise or request a refund of monies paid. All exercises of Subscription Rights are irrevocable, even if you learn information about us that you consider to be unfavorable. You should not exercise your Subscription Rights unless you are certain that you wish to purchase shares at the Estimated Subscription Price.

Transferability

The Subscription Rights are evidenced by a subscription certificate and Doron Ziv, a greater than 10% shareholder of Vapor, Vapor paid $48,674 of interest to these noteholders in 2013 until these notes were converted in full intoare non-transferable. The Subscription Rights will not be listed for trading or any securities exchange or trading system. The shares of the Company’s common stock on October 29, 2013.included in shares will be transferable following their issuance.

Regulatory Limitations; No Unlawful Subscriptions

We will not mail this prospectus or Subscription Rights Certificates to stockholders or holders of record with addresses that are outside the United States or that have an army post office or foreign post office address. The Company did not pay any principal onSubscription Agent will hold these Subscription Rights Certificates for their account. To exercise Subscription Rights, our foreign stockholders must notify the $300,000 Senior Convertible Notes in 2013Subscription Agent prior to or in connection with their conversion.

In connection with5:00 p.m., Eastern Time, on ______, the issuancethird business day prior to the Expiration Date, of your exercise of Subscription Rights and provide evidence satisfactory to us, such as a $500,000 24% senior note, which we refer to aslegal opinion from local counsel, that the “Senior Note”, in 2012 to Ralph Frija,exercise of such Subscription Rights does not violate the fatherlaws of the Company’s then Chief Executive Officer, Vapor paid approximately $106,800 of interest to this noteholderjurisdiction in 2013 until it was convertedwhich such stockholder resides and provide payment by a U.S. bank in full into sharesU.S. dollars before the expiration of the Company’s common stock on October 29, 2013. The Senior Note wasrights offering. If no notice is received by such time or the evidence presented is not convertible until Vapor and Ralph Frija amendedsatisfactory to us, the NoteSubscription Rights represented thereby will expire.


We will not be required to provide for (i) cash principal and interest payments on a weekly basis, (ii) an extended maturity date for paymentissue to April 22, 2016 and (iii) to make the Senior Note convertible into shares of Vapor’s common stock at a conversion price of $12.85 per share. The Company paid principal of $70,513 on the Senior Note in 2013 prior to its conversion.

On July 9, 2013, the Company entered into Securities Purchase Agreements with, among others, Ralph Frija, and Philip Holman, the father of Jeffrey Holman, Vapor’s then President, pursuant to which (x) Mr. Frija purchased a senior convertible note from Vapor in the principal amount of $200,000 and warrants to purchase 1,927 shares of the Company’s common stock at $28.55 per share and (y) Mr. Holman purchased a senior convertible note from Vapor in the principal amount of $100,000 and warrants to purchase 192 shares of the Company’s common stock with an exercise price of $28.55 per share. These senior convertible notes paid interest at 18% per annum, a maturity date of July 8, 2016, and were convertible into shares of the Company’s common stock at $28.55 per share. The Company paid interest of $16,126 to these noteholders during 2013 until they were converted extinguished on October 29, 2013. The Company did not pay any principal on these senior convertible notes prior to or in connection with their conversion.

On October 29, 2013, Kevin Frija, our then Chief Executive Officer, Jeffrey Holman, our then President and current Chairman of the Board and Chief Executive Officer, Harlan Press, our former Chief Financial Officer, Doron Ziv, a former director, and Isaac Galazan, a former director of Smoke Anywhere, purchased 4 ,000, 8 ,000, 4 ,000, 4 ,000 and 3,433you shares of our common stock respectively,acquired pursuant to the rights offering if, in our opinion, you are required to obtain prior clearance or approval from any state or federal regulatory authorities to own or control such shares and if, at $ 15 .00 per sharethe time the rights offering expires, you have not obtained such clearance or approval.


We reserve the absolute right to reject any subscriptions not properly submitted or the acceptance of which would be unlawful. We are not soliciting, selling or accepting any offers to participate in our rights offering in any jurisdictions where such actions are prohibited. No offers to purchase any shares of our common stock are made to Subscription Rights holders who are residents of such jurisdictions, and we will not sell or accept offers for the purchase of our common stock from such Subscription Rights holders.


38

Payment for Securities

Participating rights holders may choose between the following methods of payment:

(1)
A participating rights holder may send to the subscription agent (1) payment of the subscription price for shares acquired in the basic right and any additional shares subscribed for pursuant to the over-subscription privilege and (2) a properly completed and duly executed subscription certificate, which must be received by the subscription agent at the subscription agent’s offices set forth above (see “—Subscription Agent”), at or prior to 5:00 p.m. (Eastern Time) on the Expiration Date. A properly completed and duly executed subscription certificate and full payment for the shares must be received by the subscription agent at or prior to 5:00 p.m. (Eastern Time) on                          , 2021, unless this offering is extended by us.
(2)
A participating rights holder may request an Eligible Guarantor Institution as that term is defined in Rule 17Ad-15 under the Exchange Act to send a notice of guaranteed delivery or otherwise guaranteeing delivery of (1) payment of the full subscription price for the shares subscribed for in the basic right and any additional shares subscribed for pursuant to the over-subscription privilege, and (2) a properly completed and duly executed subscription certificate. The subscription agent will not honor a notice of guaranteed delivery unless a properly completed and duly executed subscription certificate and full payment for the shares is received by the subscription agent at or prior to 5:00 p.m. (Eastern Time) on                          , 2021, unless this offering is extended by us.

All payments by a private placementparticipating rights holder must be in U.S. dollars by money order or check or bank draft drawn on terms identicala bank or branch located in the United States and payable to the order of “Broadridge Corporate Issuer Solutions, Inc., as Subscription Agent for Healthier Choices Management Corp.”  Payment also may be made by wire transfer to the account maintained by Broadridge Corporate Issuer Solutions, Inc., as subscription agent, for purposes of accepting subscriptions in this offering at             , ABA #             , Account #              , with reference to the rights holder’s name. The subscription agent will deposit all funds received by it prior to the final payment date into a segregated account pending pro-ration and distribution of the shares.

The method of delivery of subscription certificates and payment of the subscription price to us will be at the election and risk of the participating rights holders, but if sent by mail it is recommended that such certificates and payments be sent by registered mail, properly insured, with return receipt requested, and that a sufficient number of days be allowed to ensure delivery to the subscription agent and clearance of payment prior to 5:00 p.m. (Eastern Time) on the Expiration Date or the date guaranteed payments are due under a notice of guaranteed delivery (as applicable). Because uncertified personal checks may take at least five business days to clear, you are strongly urged to pay, or arrange for payment, by means of wire transfer certified or cashier’s check or money order.

Whichever of the two methods described above is used, Subscription Rights will not be successfully exercised unless the subscription agent actually receives checks and actual payment. If a participating rights holder who subscribes for shares as part of the basic right or over-subscription privilege does not make payment of any amounts due by the Expiration Date, the date guaranteed payments are due under a notice of guaranteed delivery or as promptly as practicable of the confirmation date, as applicable, the subscription agent reserves the right to take any or all of the following actions: (i) reallocate the shares to other investors.

In March 2014, Mr. Kavanaugh, a former director, was elected to our Boardparticipating rights holders in accordance with a Consulting Agreement between the Companyover‑subscription privilege; (ii) apply any payment actually received by it from the participating rights holder toward the purchase of the greatest whole number of shares that could be acquired by such participating rights holder upon exercise of the basic right and/or the over-subscription privilege; and/or (iii) exercise any and Knight Global Services, LLC (“Knight Global”), of which Mr. Kavanaugh was the principal, pursuantall other rights or remedies to which Knight Global was retainedit may be entitled, including the right to assistset off against payments actually received by it with respect to such subscribed for shares.


All questions concerning the Company with increasing awarenesstimeliness, validity, form and eligibility of its electronic cigarette brandsany exercise of Subscription Rights will be determined by us, whose determinations will be final and binding. We may waive any defect or irregularity, or permit a defect or irregularity to be corrected within such time as wellwe may determine, or reject the purported exercise of any right. Subscriptions will not be deemed to have been received or accepted until all irregularities have been waived or cured within such time as assisting the Companywe determine. The subscription agent will not be under any duty to expand and diversify its relationships with large retailers and national chains. Ingive notification of any defect or irregularity in connection with the Consulting Agreement, Mr. Kavanaugh was issued 40 ,000submission of subscription certificates or incur any liability for failure to give such notification.

39

Escrow Arrangements; Return of Funds

The subscription agent will hold funds received in payment for shares of common stock. The Consulting Agreement with Knight Global has been terminated.

On September 23, 2014, the Company and Smoke entered intoin a $1,000,000 term loan (the “Term Loan”) with Entrepreneur Growth Capital, LLC (the “Lender”) and the Lender was issued a secured promissory note (the “Secured Note”). The Secured Note bears interest at 14% per annum and is secured by a security interest in substantially allsegregated account pending completion of the Company’s assets. The principal amount of the Term Loan is payable in 12 successive monthly installments of $83,333 with the last payment due in September 2015. As of the date of this prospectus, the Company had $211,268 of borrowings outstanding under the Term Loan. In connection with the Term Loan, Jeffrey Holman, the Company’s Chief Executive Officer and Harlan Press, the Company’s former Chief Financial Officer have personally guaranteed performance of certain of the Company’s obligations under the Term Loan.

As of June 22, 2015, Mr. Michael Brauser, the father of our President, loaned the Company $380,000, through a company he jointly manages, on identical terms as other investors in therights offering. The Debentures: (i) mature December 22, 2015, (ii) accruesubscription agent will hold this money in escrow until the rights offering is completed or is terminated. If the rights offering is terminated for any reason, all subscription payments received by the subscription agent will be returned, without interest at 10% per year, (iii)or penalty, as soon as practicable.


Delivery of Securities

Stockholders whose shares are convertible into common stock at $2.50 per share and (iv) are securedheld of record by a second lienCede & Co. or by any other depository or nominee on substantially all of the Company’s assets. The principal and accrued interest on the Debentures are payable in three approximately equal installments on September 22, 2015, October 22, 2015 and December 22, 2015, at the election of the holders of the Debentures, (i) in cash for an additional 25% premium,their behalf or (ii) in common stock at $2.50 per share.

In November 2014 and March 2015, the Company had engaged in two private placements each of which precluded the Company from using capital or otherwise issuingtheir broker-dealers’ behalf will have any shares of common stock comprising shares that they acquire credited to the account of Cede & Co. or the other depository or nominee. With respect to all other stockholders, certificates for all common stock equivalents below $10.00 and $5.10, respectively. In orderacquired will be mailed after payment for all the shares subscribed for has cleared, which may take up to raise further capital in15 business days from the June 2015 private placement, the Company was required to enter into agreements with prior investors (including Mr. Michael Brauser and Alpha Capital Anstalt, a 5% holder) modifying these covenants. In connection with these modifications, Mr. Brauser received 62,582 of common stock and 73,689 warrants, a company which Mr. Brauser jointly manages received 5,570 shares and 6,558 warrants and another Alpha Capital Anstalt, which acted as the lead investor in the November 2014 and March 2015 private placements, received 262,954Expiration Date. If you purchase shares of common stock and 142,420 warrants. Seethrough the section titled “Private Placement” on page 23.

PRINCIPAL SHAREHOLDERS

The following table sets forth certain information regardingrights offering, we will issue those shares to you in book-entry, or uncertificated, form as soon as practicable after the beneficial ownershipcompletion of the rights offering. Stock certificates will not be issued for shares of our common stock purchased in the rights offering.


Conditions and Termination

We reserve the right to terminate the rights offering before its expiration for any reason. In particular, we may terminate the rights offering, in whole or in part, if at any time before completion of the rights offering there is any judgment, order, decree, injunction, statute, law or regulation entered, enacted, amended or held to be applicable to the rights offering that in the sole judgment of the board would or might make the rights offering or its completion, whether in whole or in part, illegal or otherwise restrict or prohibit completion of the rights offering. We may choose to proceed with the rights offering even if one or more of these events occur. If we terminate the rights offering in whole or in part, we will issue a press release notifying the stockholders of such event, all affected Subscription Rights will expire without value, and all excess subscription payments received by the subscription agent will be returned, without interest or penalty, as soon as practicable following such termination.

Termination

If this offering is terminated by our board of directors, all rights will expire without value and we will promptly arrange for the refund, without interest or deduction, of all funds received from rights holders. All monies received by the subscription agent in connection with this offering will be held in escrow by the subscription agent, on our behalf, in a segregated account. Any interest earned on such account shall be payable to us even if we determine to terminate this offering and return your subscription payment.

No Recommendation to Stockholders

Our board of directors has not made, nor will it make, any recommendation to stockholders regarding the exercise of Subscription Rights under this offering. We cannot predict the price at which shares of our outstanding common stock will trade after this offering. You should consult with your legal, tax and financial advisors prior to making your independent investment decision about whether or not to exercise your Subscription Rights.

Holders who exercise Subscription Rights risk investment loss on new money invested. We cannot assure you that the market price for common stock will ever be above the subscription price, or that anyone purchasing shares will be able to sell those shares in the future at the same price or a higher price. If you do not exercise your Subscription Rights, you will lose any value represented by your Subscription Rights, and if you do not exercise your basic rights in full, your percentage ownership interest in our company will be diluted. For more information on the risks of participating in this offering, see “Risk Factors.”


40

Effect of the Rights Offering on Existing Stockholders; Interests of Certain Stockholders, Directors and Officers

Based on shares outstanding as of                    July 8 , 2015, on an actual basis and as adjusted to reflect the sale of our common stock offered by this prospectus, by:

our Named Executive Officers ;
each of our directors;
all of our current directors and executive officers as a group; and
each shareholder known by us to own beneficially more than five percent of our common stock.

Except as indicated in footnotes2021, after giving effect to this table,offering (assuming that it is fully subscribed), we believe that the shareholders named in this tablewould have sole voting and investment power with respect to allapproximately            shares of common stock shownoutstanding, representing an increase in outstanding shares of approximately        %. If you fully exercise the basic rights that we distribute to you, your proportional interest in our company will remain the same. If you do not exercise any Subscription Rights, or you exercise less than all of your basic rights, your interest in our company will be diluted, as you will own a smaller proportional interest in our company compared to your interest prior to this offering.


The number of shares of common stock outstanding listed in each case above assumes that (1) all of the other shares of common stock issued and outstanding on the record date will remain issued and outstanding and owned by the same persons as of the closing of this offering, and (2) we will not issue any shares of common stock in the period between the record date and the closing of the offering.

Material U.S. Federal Income Tax Treatment of Rights Distribution

The receipt and exercise of Subscription Rights by stockholders should generally not be taxable for U.S. federal income tax purposes. You should seek specific tax advice from your tax advisor in light of your particular circumstances and as to the applicability and effect of any other tax laws. See “Material U.S. Federal Income Tax Consequences.”

Distribution Arrangements

Maxim is the dealer-manager for this offering. The dealer-manager will provide marketing assistance and advice to us in connection with this offering. The dealer-manager is not underwriting, soliciting or placing any of the rights or the shares of common stock to be beneficially ownedissued in this offering and does not make any recommendation with respect to such Subscription Rights (including with respect to the exercise or expiration of such Subscription Rights) or shares. We have agreed to pay the dealer-manager certain fees and to reimburse the dealer-manager for certain expenses in connection with this offering. See “Plan of Distribution.”

Fees and Expenses

We will pay all fees charged by them, based onthe subscription agent, the information providedagent, and Maxim acting as dealer-manager for this offering. You are responsible for paying any commissions, fees, taxes or other expenses incurred in connection with the exercise of your Subscription Rights.

Other Matters

We are not making this offering in any state or other jurisdiction in which it is unlawful to usdo so, nor are we distributing or accepting any offers to purchase any shares of common stock from rights holders who are residents of those states or other jurisdictions or who are otherwise prohibited by such shareholders. Unlessfederal or state laws or regulations to accept or exercise the Subscription Rights. We may delay the commencement of this offering in those states or other jurisdictions, or change the terms of the offering, in whole or in part, in order to comply with the securities laws or other legal requirements of those states or other jurisdictions. Subject to state securities laws and regulations, we also have the discretion to delay allocation and distribution of any shares you may elect to purchase by exercise of your Subscription Rights in order to comply with state securities laws. We may decline to make modifications to the terms of this offering requested by those states or other jurisdictions, in which case, if you are a resident in those states or jurisdictions or if you are otherwise indicated,prohibited by federal or state laws or regulations from accepting or exercising the address for each director and executive officer listed is: c/o Vapor Corp., 3001 Griffin Road, Dania Beach, Florida 33312.

  Number of Common Share Equivalents  Percentage of Common Share Equivalents Beneficially Owned 
Name of Beneficial Owner Beneficially Owned (1)  Before Offering  After Offering 
Named Executive Officers and Directors:          
           
Jeffrey Holman (2)  256,222 3.4%  3.4% 
           
Kevin Frija (3)  266,672 3.6%  3.6% 
           
Harlan Press (4)  31,400 *  * 
           
Christopher Santi (5)  6,556 *  * 
           
Gregory Brauser (6)  

162,057

 2.2%  2.2% 
           

William Conway III (7)

  0 0%  0% 
           
Daniel MacLachlan ( 8 )  0 0 %  0% 
           

Nikhil Raman (9)

  0  0%  0% 
           
All Executive Officers and Directors as a Group( 7 Persons) ( 10 )  

466,374

 6.2%  6.2% 
           
Other Five Percent Shareholder :          
           
Alpha Capital Anstalt ( 11 )  468,174  6.3%  6.3% 

*Represents less than 1% of the outstanding shares of common stock
(1)

Applicable percentages are based on 7,600,657 shares outstanding as of July 9 , 2015, adjusted as required by rules of the SEC. The percentage of beneficial ownership after the completion of this offering is also based on 7,600,657 shares of common stock outstanding immediately after the closing of this offering. Beneficial ownership is determined under the rules of the SEC and generally includes voting or investment power with respect to securities. Shares of common stock underlying options, warrants and convertible notes currently exercisable or convertible, or exercisable or convertible within 60 days are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person.

(2)Jeffrey Holman: A director and executive officer. Includes 24 ,000 vested options.
(3)Kevin Frija: Former chief executive officer. Because Mr. Frija served as a Chief Executive Officer during fiscal 2014, he is a Named Executive Officer under the SEC’s rules and regulations. Includes 36 ,000 vested options and 895 shares underlying warrants.
(4)Harlan Press: A former executive officer. Includes 8 ,000 vested options and 620 shares underlying warrants.
(5)Christopher Santi:An executive officer. Represents vested options.
(6)Gregory Brauser: A director and executive officer.
(7)William Conway III:A director.
(8)

Daniel MacLachlan: A director.

(9)

Nikhil Raman: A director.

( 10 )Total D&O: Includes securities beneficially owned by executives who are not a Named Executive Officer.
( 11 )Alpha Capital Anstalt: Does not include additional shares underlying warrants and convertible notes that cannot be exercised within 60 days due to a 4.99% blocker. Address is Lettstrasse 32, P.O. Box 1212, FL 9490, Vaduz Furstentum Liechtenstein c/o LH Financial Services Corp., 510 Madison Avenue, Ste. 1400, New York, New York 10022.

Subscription Rights, you will not be eligible to participate in the offering. However, we are not currently aware of any states or jurisdictions that would preclude participation in this offering.

41


DESCRIPTION OF CAPITAL STOCK

Authorized Capital

SECURITIES


We are issuing non-transferable Subscription Rights, at no charge, to each holder of common stock as of a record date of 5:00 p.m. (Eastern Time) on           , 2021, whom we refer to as a holder or you. For each share of common stock you hold as of the record date, we will issue to you (1) one basic right entitling you to purchase one share at a subscription price of $       and (2) an over-subscription privilege which will entitle you to purchase additional shares for which other rights holders do not subscribe, subject to you exercising your basic right in full and other limitations.

The following is a description of the material terms of our charter, by-laws, and the Delaware Business Corporation Law, or the DGCL. This description of our charter and by-laws does not purport to be complete and is qualified in its entirety by the provisions of our charter and bylaws, copies of which have been filed with the SEC and are incorporated by reference as exhibits to the registration statement of which this prospectus is a part.

General

Our authorized to issue 150 ,000,000capital stock consists of 750,000,000,000 shares of common stock, par value $0.001$0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.001 per share. 

Common Stock

We are authorizedshare, the rights and preferences of which may be established from time to issue 150 ,000,000time by our board of directors. As of ___________, 2021, _______________ shares of common stock par value $0.001 per share. The holderswere outstanding and were held by approximately _____ holders. With respect to preferred stock, ____ shares of Series D Preferred Stock were issued and outstanding as of _______________, 2021.


Common Stock

Each share of common stock areis entitled to one vote per share on all matters submitted torequiring a vote of shareholders, includingstockholders and, subject to the electionrights of directors. Therethe holders of any outstanding shares of preference stock, each stockholder is no cumulative votingentitled to receive any dividends, in cash, stock, or otherwise, as our board of directors may declare. Delaware law prohibits the payment of dividends or the repurchase of our shares if we are insolvent or unable to pay our debts as they become due in the electionusual course of directors.business, or if we would become so as a result of the dividend or repurchase. In the event of our liquidation, dissolution or dissolution,winding up, either voluntarily or involuntarily, subject to the rights of the holders of any outstanding shares of preference stock, holders of common stock are entitled to share ratablypro-rata in all of our remaining assets remainingavailable for distribution after paymentproviding for claims of liabilities andcreditors as required by the liquidation preferences of any outstanding shares of preferred stock. DGCL.

Holders of common stock have no preemptive or conversion rights and have no right to convert their common stock into anyor other securitiesSubscription Rights, and there are no redemption or sinking fund provisions applicable to ourthe common stock.

The outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preference stock that we may designate and issue in the future.


Under the DGCL, cumulative voting applies to the election of directors by holders of common stock (and holders of any series of preference stock that is entitled to any dividends that may be declared byvote in the Board outelection of funds legally available for payment of dividends subject to the prior rights of holders of preferred stock and any contractual restrictions we have against the payment of dividends on common stock. For so long as our Senior Convertible Notes, due November 14, 2015, remain outstanding, we are prohibited from paying cash dividends on our common stock and other equity securities without the approval of holders of at least 51% in principal amount of the then outstanding notes.

directors).


Preferred Stock


We are authorized to issue 1,000,000 shares of “blank check” preferred stock with designations, rights and preferences as may be determined from time to time by our Board. We presently have noonly Series D convertible preferred stock issued and outstanding. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control or other corporate action. We have no current plan to issue any additional shares of preferred stock, except pursuant to this prospectus. For a descriptionstock.

The number of how issuance of our preferred stock could affect the rights of our shareholders, see “Certain Provisions of Delaware Law and of Our Charter and Bylaws - Issuance of “Blank Check” Preferred Stock,” below.

Warrants

As of the date of this prospectus, warrants for the issuance of 1,331,305 shares of our common stock were outstanding, exercisable at a weighted average exercise price of $6.46 per share, exercisable through various dates expiring through December 20 20 .

Description of Securities We Are Offering

Units

We are offering Units, consisting of one-fourth of a share ofdesignated as Series A ConvertibleD Preferred Stock and ten Series A Warrants. Each one-fourth share of Series A Convertible Preferred Stock will be convertible into five shares of common stock as described in the following section. Each Series A Warrant is exercisable for one share of common stock at an initial exercise price of $[_______] per share. The Series A Warrants are exercisable upon separation of the Units, provided that upon a Cash Warrant Exercise Trigger the Series A Convertible Preferred Stock will not be convertible until six-months after the date of this prospectus (unless an Early Separation occurs due to a Trading Separation Trigger or Delisting Trigger). The Series A Warrants will expire on the fifth anniversary of the date of this prospectus. This prospectus also covers the securities issuable upon exercise of the unit purchase option to be issued to the underwriters.

Preferred Stock Included in the Units Offered Hereby

In connection with this offering, we will issue as part of the Units shares of Series A Convertible Preferred Stock pursuant to a Certificate of Designation approved by our Board. Each one-fourth share of Series A Convertible Preferred Stock will separate from the warrants5,000 and be convertible into five shares of common stock upon the separation of the Units, provided that upon a Cash Warrant Exercise Trigger the Series A Convertible Preferred Stock will not be convertible until six-months after the date of this prospectus (unless an Early Separation occurs due to a Trading Separation Trigger or Delisting Trigger). The shares of Series A Convertible Preferred Stock and the Series A Warrants will automatically separate six months after the date of this prospectus. However, the shares of Series A Convertible Preferred Stock and the Series A Warrants will separate prior to the expiration of the six-month period at any time after 30 days from the date of this prospectus if (i) there is a Trading Separation Trigger, (ii) there is a Cash Warrant Exercise Trigger, which means the Series A Warrants are exercised for cash (in which case the separation will occur solely with respect to the Units that included the exercised Series A Warrants) or (iii) there is a Delisting Trigger. The Units will become separable: (i) 15 days after the Trading Separation Trigger date, (ii) immediately after the Cash Warrant Exercise Trigger (solely with respect to the Units that included the exercised Series A Warrants) or (iii) immediately upon a Delisting Trigger. In the event of a Trading Separation Trigger or a Delisting Trigger, the Preferred Stock will be convertible into common stock immediately upon Early Separation. In the event of a Cash Warrant Exercise Trigger, the Preferred Stock will not be convertible until six-months after the date of this prospectus (unless an Early Separation occurs due to a Trading Separation Trigger or Delisting Trigger).

The Series A Convertible Preferred Stock will not be convertible by the holder of such preferred stock to the extent (and only to the extent) that the holder or any of its Affiliates would beneficially own in excess of 4.99% of the common stock of the Company. For purposes of the limitation described in this paragraph, beneficial ownership and all determinations and calculations are determined in accordance with Section 13(d) of the Exchange Act and the rule and regulations promulgated thereunder.

Pursuant to the Certificate of Designation for the Series A Convertible Preferred Stock, if the Company or any of its subsidiaries enter into a “Fundamental Transaction”, each share of Series A Convertible Preferred Stock shall be automatically converted into shares of common stock of the Company, subject to the beneficial ownership limitation discussed in the previous paragraph. A “Fundamental Transaction” includes, but is not limited to, (1) a consolidation, merger stock or share purchase or other business combination in which the shareholders of the Company immediately prior to such consolidation or merger hold less than 50% of the outstanding voting stock after such consolidation or merger, (2) sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its respective properties or assets, or (3) allowing any person to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding voting stock of the Company, or any person or group becomes a beneficial owner of 50% of the aggregate ordinary voting power represented by the issued and outstanding voting stock of the corporation.

The Series A ConvertibleD Preferred Stock has a stated value equal to $1,000. Except as set forth below or as otherwise required by law, the Series D Preferred Stock have no voting rights, except that the holdersrights. However, as long as any shares of 100% of the Series A ConvertibleD Preferred Stock will be able to effect or validate any amendment, alteration or repeal of any ofare outstanding, the provisions of the Certificate of Designation that materially and adversely affects the powers, preferences or special rights of the Series A Convertible Preferred Stock, whether by merger or consolidation or otherwise;provided,however, that in the event of an amendment to the terms of the Series A Convertible Preferred Stock, including by merger or consolidation, so long as the Series A Convertible Preferred Stock remains outstanding with the terms thereof materially unchanged, or the Series A Convertible Preferred Stock is converted into, preference securities of the surviving entity, or its ultimate parent, with such powers, preferences or special rights, taken as a whole, not materially less favorable to the holders of the Series A Convertible Preferred Stock than the powers, preferences or special rights of the Series A Convertible Preferred Stock, taken as a whole, the occurrence of such event will not be deemed to materially and adversely affect such powers, preferences or special rights of the Series A Convertible Preferred Stock, and in such case such holdersCompany shall not, have any voting rights with respect towithout the occurrence of such events. An amendment to the terms of the Series A Convertible Preferred Stock only requires theaffirmative vote of the holders of a majority of the then outstanding shares of the Series A ConvertibleD Stock, (a) alter or change adversely the powers, preferences or rights given to the Series D Preferred Stock.

WithStock or alter or amend the Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series D Stock, (c) increase the number of authorized shares of Series D Stock, or (d) enter into any agreement with respect to paymentany of dividends and distribution of assets uponthe foregoing. Upon any liquidation, or dissolution or winding upwinding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation of the Series AD Preferred Stock), the holders of Series D Preferred Stock shall rankbe entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to $1,000 per share of Series D Preferred Stock. The conversion price for the common stockSeries D Preferred Stock shall initially equal $0.0024. Going forward, the conversion price will be lesser of $0.0024 and either (1) 85% of the Company. No sinking fund has been established for the retirement or redemptionaverage of the Convertible Preferred Stock. As such,volume weighted average price (VWAP) during the 10 trading days immediately following the effective date and public announcement of the next reverse stock split of HCMC and (2) 80% of the lowest daily VWAP during the 5 trading days immediately preceding the date the conversion shares are either registered for resale or may be sold pursuant to Rule 144. The rights of the Series A ConvertibleD Preferred Stock is not subject to any restriction on the repurchase or redemption of shares by the Company due to an arrearage in the payment of dividends or sinking fund installments.

The Series A Convertible Preferred Stock also has no liquidation rights or preemption rights, and there are no special classifications of our Board related to the Series A Convertible Preferred Stock.

Warrants Included in the Units Offered Hereby

In connection with this offering, we will issue as part of the Units shares of Series A Warrants to purchase shares of our common stock. The Series A Warrants will separate from the preferred stock and be exercisable upon the separation of the Units , provided that the Series A Warrants may be exercised for cash at any time after 30 days from the date of this prospectus, which exercise shall cause a Cash Warrant Exercise Trigger. The Series A Warrants will terminate on the fifth anniversary of the date of this prospectus and have an exercise price of $[_______] per share. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustmentinclude certain protections in the event of stock dividends, stock splits, reorganizations or similar events affectingdilutive equity issuances.


42

Effect of Certain Provisions of our common stockCertificate of Incorporation and Bylaws and the exercise price.

Delaware Anti-Takeover Statute


Some provisions of Delaware law and our certificate of incorporation and bylaws contain provisions that could make the following transactions more difficult:

acquisition of us by means of a tender offer;
acquisition of us by means of a proxy contest or otherwise; or
removal of our incumbent officers and directors.

Those provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids and to promote stability in our management. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors.

Certificate of Incorporation and Bylaws

Our certificate of incorporation and our bylaws provide for the following:

Undesignated Preferred Stock

There is no established public trading market. The ability to authorize undesignated preferred stock makes it possible for our Series A Warrants,board of directors to issue one or more series of preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company. These and we do not expectother provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.

Stockholder Meetings. Our bylaws provide that in general a market to develop. We do not intend to apply to list Series A Warrants onspecial meeting of stockholders may be called only by our board of directors, the chairman of our board of directors, any securities exchange. Without an active market, the liquidityof our officers, or any stockholder holding at least fifteen percent (15%) of the Series A Warrants will be limited.

Cashless Exercise Provision. Holders may exercise Series A Warrants by paying the exercise price in cash or, in lieu of paymentvoting power of the exercise price in cashcapital stock issued and outstanding and entitled to vote.

Requirements for Advance Notification of Stockholder Nominations and Proposals. Our bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by electing to receiveor at the direction of our board of directors or a cash payment from us (subject to certain conditions not being met by the Company) equal to the Black Scholes Value (as defined below)committee of the numberboard of sharesdirectors.
Limits on Ability of Stockholders to Act by Written Consent. We have provided in our bylaws that our stockholders may not act by written consent. This limit on the holder elects to exercise, which we refer to as the Black Scholes Payment; provided, that we have discretion as to whether to deliver the Black Scholes Payment or, subject to meeting certain conditions, to deliver a number of sharesability of our common stock determined accordingstockholders to act by written consent may lengthen the following formula, referredamount of time required to as the Cashless Exercise.

Total Shares = (A x B) / C

Where:

Total Shares is the number of shares of common stock to be issued upon a Cashless Exercise
A is the total number of shares with respect to which the Series A Warrant is then being exercised.
B is the Black Scholes Value (as defined below).
C is the closing bid price of our common stock as of two trading days prior to the time of such exercise.

take stockholder actions. As defined in the Series A Warrants, “Black Scholes Value” means the Black Scholes value of an option for one sharea result, a holder controlling a majority of our commoncapital stock at the datewould not be able to amend our bylaws or remove directors without holding a meeting of the applicable Black Scholes Payment or Cashless Exercise, as such Black Scholes value is determined, calculated using the Black Scholes Option Pricing Model obtained from the “OV” function on Bloomberg utilizing (i) an underlying price per share equal to the closing bid price of the Common Stock as of the date of this prospectus, (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of the Series A Warrant as of the applicable Black Scholes Payment or Cashless Exercise, (iii) a strike price equal to the exercise price in effect at the time of the applicable Black Scholes Payment or Cashless Exercise, (iv) an expected volatility equal to 135% and (v) a remaining term of such option equal to five years (regardless of the actual remaining term of the Series A Warrant).

The shares of common stock issuable on exercise or exchange of the Series A Warrants will be duly and validly authorized and will be, when issued, delivered and paid forour stockholders called in accordance with our bylaws.


Amendment of Certificate of Incorporation and Bylaws. The amendment of the Series A Warrants, issuedabove provisions of our certificate of incorporation and fully paid and non-assessable. We will authorize and reservebylaws requires approval by holders of at least that numbertwo-thirds of shares of commonour outstanding capital stock equalentitled to the number of shares of common stock issuable upon exercise or exchange of all outstanding Series A Warrants.

The Series A Warrants will not be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its Affiliates would beneficially own in excess of 4.99% of the common stock of the Company. For purposes of the limitation described in this paragraph, beneficial ownership and all determinations and calculations are determined in accordance with Section 13(d) of the Exchange Act and the rule and regulations promulgated thereunder.

If, at any time a Series A Warrant is outstanding, we consummate any fundamental transaction, as describedvote generally in the Series A Warrants and generally including any consolidation or merger into another corporation, or the saleelection of all or substantially all of our assets, or other transaction in which our common stock is converted into or exchanged for other securities or other consideration, the holder of any Series A Warrants will thereafter receive, the securities or other consideration to which a holder of the number of shares of common stock then deliverable upon the exercise or exchange of such Series A Warrants would have been entitled upon such consolidation or merger or other transaction. Notwithstanding the foregoing, in connection with a fundamental transaction, at the request of a holder of Series A Warrants we will be required to purchase the Series A Warrant from the holder by paying to the holder cash in an amount equal to the Black Scholes Value of the Series A Warrant, as described in such Series A Warrant.

The Series A Warrants will be issued in book-entry form under a warrant agent agreement between Equity Stock Transfer as warrant agent, and us, and shall initially be represented by one or more book-entry certificates deposited with Equity Stock Transfer.

THE HOLDER OF A WARRANT WILL NOT POSSESS ANY RIGHTS AS A SHAREHOLDER UNDER THAT WARRANT UNTIL THE HOLDER EXERCISES THE WARRANT.

directors.


Representative’s Unit Purchase Option43

We agreed to issue to the representative of the underwriters’ in this offering a Unit Purchase Option to purchase a number of our Units equal to an aggregate of 5% of the Units sold in this offering. The representative’s Unit Purchase Option will have an exercise price equal to 125% of the public offering price of the Units set forth on the cover of this prospectus (or $[_______] per Unit) and may be exercised on a cashless basis. The representative’s Unit Purchase Option is not redeemable by us. This prospectus also covers the sale of the representative’s Unit Purchase Option and the Units, Series A Convertible Preferred Stock and Series A Warrants issuable upon the exercise of the representative’s Unit Purchase Option, as well as the common stock underlying Series A Convertible Preferred Stock and Series A Warrants. The material terms and provisions of the representative’s Unit Purchase Option are described under the heading “Underwriting—Representative’s Unit Purchase Option”.


Delaware Anti-Takeover Law and Charter and Bylaws Provisions

Statute


We are subject to the provisions of Section 203 of the Delaware General Corporation Law. Subject to exceptions,Law regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a “business combination”business combination with an “interested stockholder”interested stockholder for a period of three years fromfollowing the date of the transaction in which the person became an interested stockholder unlessunless:

prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder attained this status with the approvalowned at least 85% of the Boardvoting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not for determining the outstanding voting stock owned by the interested stockholder, (i) shares owned by persons who are directors and also officers, and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or unlessexchange offer; or
at or subsequent to the date of the transaction, the business combination is approved inby the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder.

Generally, a prescribed manner. A “business combination”business combination includes mergers,a merger, asset sales andor stock sale, or other transactionstransaction resulting in a financial benefit to the interested stockholder. Subject to exceptions, an “interested stockholder”An interested stockholder is a person who, together with affiliates and associates, owns 15% or within three years did own,more of a corporation’s outstanding voting stock or is an affiliate or associate of a corporation and was the owner of 15% or more of the corporation’s outstanding voting stock. This statute could prohibit or delaystock within three years prior to the accomplishmentdetermination of mergers or other takeover or change in control attemptsinterested stockholder status.

MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS

The following discussion is a summary of the material U.S. federal income tax considerations with respect to usthe receipt and accordingly,exercise (or expiration) of the Subscription Rights acquired through this offering, the ownership and disposition of shares of common stock received upon exercise of the Subscription Rights, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or IRS, in each case in effect as of the date hereof. These authorities may discourage attemptschange or be subject to acquire us.differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a holder of the Subscription Rights or shares of common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the receipt of Subscription Rights acquired through this offering by persons holding shares of common stock or, the exercise (or expiration) of the Subscription Rights.


44

This discussion is limited to stockholders that hold the Subscription Rights and shares of common stock, in each case, as a “capital asset” within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a rights holder’s particular circumstances, including the impact of the alternative minimum tax or the unearned income Medicare contribution tax. In addition, it does not address consequences relevant to rights holders subject to particular rules, including:

U.S. expatriates and former citizens or long-term residents of the United States;
persons holding the Subscription Rights or shares of common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment;
banks, insurance companies, and other financial institutions;
brokers, dealers or traders in securities;
“controlled foreign corporations,” “passive foreign investment companies,” and corporations that accumulate earnings to avoid U.S. federal income tax;
entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
tax-exempt organizations or governmental organizations;
persons deemed to sell shares of common stock under the constructive sale provisions of the Code;
persons subject to special tax accounting rules as a result of any item of gross income with respect to the Subscription Rights or shares of common stock being considered in an “applicable financial statement” (as defined in the Code);
persons for whom our Certificatecapital stock constitutes “qualified small business stock” within the meaning of IncorporationSection 1202 of the Code;
persons who hold or receive the Subscription Rights or shares of common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and Bylaws
tax-qualified retirement plans.

If an entity treated as a partnership for U.S. federal income tax purposes holds Subscription Rights, shares of common stock acquired upon exercise of Subscription Rights, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.

THIS DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE RECEIPT, OWNERSHIP AND EXERCISE OF SUBSCRIPTION RIGHTS AND THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF SHARES OF COMMON STOCK ACQUIRED UPON EXERCISE OF SUBSCRIPTION RIGHTS ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON‑U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.


45

Tax Considerations Applicable to U.S. Holders

Definition of a U.S. Holder

For purposes of this discussion, a “U.S. holder” is any beneficial owner of Subscription Rights, shares of common stock acquired upon exercise of Subscription Rights or shares of common stock acquired, as the case may make it more difficultbe, that, for U.S. federal income tax purposes, is:

an individual who is a citizen or resident of the United States;
a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state thereof, or the District of Columbia;
an estate, the income of which is subject to acquireU.S. federal income tax regardless of its source; or
a trust that (1) is subject to the primary supervision of a U.S. court and the control of us. These provisions could deprive shareholdersone or more United States persons (within the meaning of Section 7701(a)(30) of the opportunityCode), or (2) has made a valid election under applicable Treasury Regulations to realizecontinue to be treated as a premiumUnited States person.

Receipt of Subscription Rights

Section 305(a) of the Code states that a stockholder’s taxable income does not include in-kind stock dividends. The general non-recognition rule in Section 305(a) of the Code is, however, subject to exceptions described in Section 305(b) of the Code, which include “disproportionate distributions” and certain distributions with respect to certain preferred stock. A disproportionate distribution is a distribution or a series of distributions, including deemed distributions, that has the effect of the receipt of cash or other property by some stockholders or holders of debt instruments convertible into stock and an increase in the proportionate interest of other stockholders in a corporation’s assets or earnings and profits.

Although the authorities governing transactions such as this offering are complex and do not speak directly to the consequences of certain aspects of the offering, including the effects of the over-subscription privilege, we do not believe a U.S. holder’s receipt of Subscription Rights pursuant to the offering should be treated as a taxable distribution with respect to their existing shares of common stock for U.S. federal income tax purposes. Our position regarding the tax-free treatment of the receipt of Subscription Rights with respect to existing shares of common stock is not binding on the IRS or the courts. If this position were finally determined by the IRS or a court to be incorrect, whether on the basis that the issuance of the Subscription Rights is a “disproportionate distribution” or otherwise, the fair market value of the Subscription Rights would be taxable to U.S. rights in the manner described under “—Tax Consequences Applicable to U.S. Holders- Distributions on Common Stock” below. If our position were incorrect, the U.S. federal income tax consequences applicable to the rights holders may also be materially different than as described below.

The following discussion is based upon the treatment of the subscription right issuance as a non-taxable distribution with respect to a U.S. holder’s existing shares of common stock for U.S. federal income tax purposes.

Tax Basis and Holding Period in the Subscription Rights

If the fair market value of the Subscription Rights a U.S. holder receives with respect to existing shares of common stock is less than 15% of the fair market value of the U.S. holder’s existing shares of common stock (with respect to which the Subscription Rights are distributed) on the date the U.S. holder receives the Subscription Rights, the Subscription Rights will be allocated a zero tax basis for U.S. federal income tax purposes, unless the U.S. holder elects to allocate its tax basis in its existing shares of common stock between its existing shares of common stock and the Subscription Rights in proportion to the relative fair market values of the existing shares of common stock and the Subscription Rights determined on the date of receipt of the Subscription Rights. If a U.S. holder chooses to allocate tax basis between its existing shares of common stock and the Subscription Rights, the U.S. holder must make this election on a statement included with its timely filed tax return (including extensions) for the taxable year in which the U.S. holder receives the Subscription Rights. Such an election is irrevocable. If the fair market value of the Subscription Rights a U.S. holder receives is 15% or more of the fair market value of their existing shares of common stock on the date the U.S. holder receives the Subscription Rights, however, then the U.S. holder must allocate its tax basis in its existing shares of common stock between those shares and the Subscription Rights the U.S. holder receives in proportion to their fair market values determined on the date the U.S. holder receives the Subscription Rights. The holding period of Subscription Rights received will include a holder’s holding period in shares of common stock with respect to which the Subscription Rights were distributed. Please refer to discussion below regarding the U.S. tax treatment of a U.S. holder that, at the time of the receipt of the subscription right, no longer holds the common stock with respect to which the subscription right was distributed.

46

The fair market value of the Subscription Rights on the date that the Subscription Rights are distributed is uncertain, and we have not obtained, and do not intend to obtain, an appraisal of the fair market value of the Subscription Rights on that date. In determining the fair market value of the Subscription Rights, U.S. holders should consider all relevant facts and circumstances, including any difference between the subscription price of the Subscription Rights and the trading price of common stock on the date that the Subscription Rights are distributed, the length of the period during which the Subscription Rights may be exercised and the fact that the Subscription Rights are non-transferable.

Exercise of Subscription Rights

Generally, a U.S. holder will not recognize gain or loss upon the exercise of a subscription right received in this offering. A U.S. holder’s adjusted tax basis, if any, in the subscription right plus the subscription price should be allocated between the new shares of common stock acquired upon exercise of the subscription right in proportion to their relative fair market values on the exercise date. This allocation will establish the U.S. holder’s initial tax basis for U.S. federal income tax purposes in the new shares of common stock received upon exercise. The holding period of a share of common stock or a warrant acquired upon exercise of a subscription right in this offering will begin on the date of exercise.

If, at the time of the receipt or exercise of the subscription right, the U.S. holder no longer holds the common stock with respect to which the subscription right was distributed, then certain aspects of the tax treatment of the receipt and exercise of the subscription right are unclear, including (1) the allocation of the tax basis between the shares of common stock owned by thempreviously sold and may adversely affect the prevailing market pricesubscription right, (2) the impact of oursuch allocation on the amount and timing of gain or loss recognized with respect to the shares of common stock previously sold, and (3) the impact of such allocation on the tax basis of the shares of common stock acquired upon exercise of the subscription right. If a U.S. holder exercises a subscription right received in this offering after disposing of shares of common stock with respect to which the subscription right is received, the U.S. holder should consult its tax advisor.

Expiration of Subscription Rights

If a U.S. holder that receives Subscription Rights with respect to their common stock allows such Subscription Rights received in this offering to expire, the U.S. holder should not recognize any gain or loss for U.S. federal income tax purposes, and the U.S. holder should re-allocate any portion of the tax basis in its existing shares of common stock previously allocated to the Subscription Rights that have expired to the existing shares of common stock.

Sale, Exchange or Other Disposition of Common Stock

Upon a sale, exchange, or other disposition of common stock, a U.S. holder generally will recognize capital gain or loss equal to the difference between the amount realized (not including any amount attributable to declared and unpaid dividends, which will be taxable as described above to U.S. holders of record who have not previously included such dividends in income) and the U.S. holder’s adjusted tax basis in common stock. These provisionsA U.S. holder’s adjusted tax basis in common stock generally will equal its initial tax basis in common stock reduced by the amount of any cash distributions treated as a return of capital as described above. Such capital gain or loss generally will be long-term capital gain or loss if the U.S. holder’s holding period for common stock exceeded one year at the time of disposition). Long-term capital gains recognized by certain non-corporate U.S. holders, including individuals, generally are intended to:

enhance the likelihood of continuity and stability in the composition of the Board and in the policies formulated by the Board;
discourage transactions that may involve an actual or threatened change in control of us;
discourage tactics that may be used in proxy fights;
encourage persons seeking to acquire control of us to consult first with our Board to negotiate the terms of any
proposed business combination or offer; and
reduce our vulnerability to an unsolicited proposal for a takeover that does not contemplate the acquisition of all of our outstanding shares or that is otherwise unfair to our shareholders.

58
subject to reduced rates of taxation. The deductibility of capital losses is subject to limitations.


47

Shareholder Action


Information Reporting and Backup Withholding

A U.S. holder may be subject to information reporting and backup withholding when such holder receives dividend payments or receives proceeds from the sale or other taxable disposition of the shares of common stock acquired. Certain U.S. holders are exempt from backup withholding, including corporations and certain tax-exempt organizations. A U.S. holder will be subject to backup withholding if such holder is not otherwise exempt and such U.S. holder:

fails to furnish such U.S. holder’s taxpayer identification number;
furnishes an incorrect taxpayer identification number;
is notified by Written Consent. Our Bylaws providethe IRS that such U.S. holder previously failed to properly report payments of interest or dividends; or
fails to certify under penalties of perjury that such U.S. holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that such U.S. holder is subject to backup withholding.
Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a U.S. holder’s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. holders should consult their tax advisors regarding their qualification for action byan exemption from backup withholding and the procedures for obtaining such an exemption.

Tax Considerations Applicable to Non-U.S. Holders

For purposes of this discussion, a “non-U.S. holder” is any beneficial owner of Subscription Rights, shares of common stock acquired upon exercise of Subscription Rights, or shares of common stock acquired, as the case may be, that is neither a U.S. holder nor an entity treated as a partnership for U.S. federal income tax purposes.

Receipt, Exercise and Expiration of the Subscription Rights

The discussion assumes that the receipt of Subscription Rights with respect to existing shares of common stock will be treated as a nontaxable distribution. See “—Tax Consequences Applicable to U.S. Holders—Receipt of Subscription Rights” above. Non-U.S. holders that receive Subscription Rights with respect to existing shares of common stock will generally not be subject to U.S. federal income tax (or any withholding thereof) on the receipt,

Distributions on Common Stock

If we make distributions of cash or property on common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our shareholders withoutcurrent or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a meetingreturn of capital and first be applied against and reduce a non-U.S. holder’s adjusted tax basis in its common stock, as the case may be, but not below zero. Any excess will be treated as capital gain and will be treated as described below in the section relating to the sale or disposition of common stock. Because we may not know the extent to which a distribution is a dividend for U.S. federal income tax purposes at the time it is made, for purposes of the withholding rules discussed below we or the applicable withholding agent may treat the entire distribution as a dividend.

Subject to the discussion below on backup withholding and foreign accounts, dividends paid to a non- U.S. holder of common stock that are not effectively connected with the written consentnon-U.S. holder’s conduct of shareholders holdinga trade or business within the number of shares necessaryUnited States will be subject to approve such action if it were takenU.S. federal withholding tax at a meetingrate of shareholders.

Special Shareholder Meetings.Under our Bylaws, the Chairperson of our Board, our Chief Executive Officer and a majority30% of the numbergross amount of total authorized directors (without regardthe dividends (or such lower rate specified by an applicable income tax treaty).


Non-U.S. holders will be entitled to vacancies)a reduction in or an exemption from withholding on dividends as a result of either (1) an applicable income tax treaty or (2) the non-U.S. holder holding common stock in connection with the conduct of a trade or business within the United States and dividends being effectively connected with that trade or business. To claim such a reduction in or exemption from withholding, the non-U.S. holder must provide the applicable withholding agent with a properly executed (1) IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) claiming an exemption from or reduction of the withholding tax under the benefit of an income tax treaty between the United States and the country in which the non-U.S. holder resides or is established, or (2) IRS Form W-8ECI stating that the dividends are not subject to withholding tax because they are effectively connected with the conduct by the non-U.S. holder of a trade or business within the United States, as may callbe applicable. These certifications must be provided to the applicable withholding agent prior to the payment of dividends and must be updated periodically. Non-U.S. holders that do not timely provide the applicable withholding agent with the required certification, but that qualify for a special meetingreduced rate under an applicable income tax treaty, may obtain a refund of shareholders.any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.

If dividends paid to a non-U.S. holder are effectively connected with the non-U.S. holder’s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the non-U.S. holder maintains a permanent establishment in the United States to which such dividends are attributable), then, although exempt from U.S. federal withholding tax (provided the non-U.S. holder provides appropriate certification, as described above), the non-U.S. holder will be subject to U.S. federal income tax on such dividends on a net income basis at the regular graduated U.S. federal income tax rates. In addition, a special meetingnon-U.S. holder that is a corporation may be calledsubject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits for the shareholderstaxable year that are attributable to such dividends, as adjusted for certain items. Non-U.S. holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty.

48

Sale or Other Disposition of Common Stock

Subject to the discussions below on backup withholding and foreign accounts, a non-U.S. holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of common stock unless:

the gain is effectively connected with the non-U.S. holder’s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the non-U.S. holder maintains a permanent establishment in the United States to which such gain is attributable);
the non-U.S. holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the Companydisposition and certain other requirements are met; or
common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property holding corporation, or USRPHC, for U.S. federal income tax purposes.

Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at least one-fourth of all shares entitledthe regular graduated rates. A Non-U.S. holder that is a corporation also may be subject to votea branch profits tax at a meetingrate of shareholders. Our Bylaws establish that no business30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items.

Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on any gain derived from the disposition, which may be transacted atoffset by U.S. source capital losses of the non-U.S. holder (even though the individual is not considered a special meeting otherwise than as specifiedresident of the United States), provided the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses.

With respect to the third bullet point above, we believe we are not currently and do not anticipate becoming a USRPHC. Because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair market value of our other business assets and our non- U.S. real property interests, however, there can be no assurance we are not a USRPHC or will not become one in the notice of meeting provided in advance to shareholders, which must be delivered to shareholders between 10future.

Non-U.S. holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.

49

Information Reporting and 60 days priorBackup Withholding

Subject to the special meeting.

Any aspectdiscussion below on foreign accounts, a non-U.S. holder will not be subject to backup withholding with respect to distributions on common stock we make to the non-U.S. holder, provided the applicable withholding agent does not have actual knowledge or reason to know such non-U.S. holder is a United States person and such non-U.S. holder certifies its non-U.S. status, such as by providing a valid IRS Form W-8BEN, W-8BEN-E or W-8ECI, or other applicable certification. Information returns generally will be filed with the IRS, however, in connection with any distributions (including deemed distributions) made on common stock to the non-U.S. holder, regardless of whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of a specific treaty or agreement to the tax authorities of the foregoing, alonecountry in which the non-U.S. holder resides or together, could delayis established.


Information reporting and backup withholding may apply to the proceeds of a sale or prevent unsolicited takeovers and changes in control or changes in our management.

Transfer Agent, Registrar, Warrant Agent and Preferred Stock Agent

We have appointed Equity Stock Transfer, as our transfer and warrant agent. Their contact information is: 237 West 37th Street, Suite 601, New York, New York 10018, phone number (917) 746-4595, facsimile (347) 584-3644.

Stock Market Listing

Ourother taxable disposition of common stock tradeswithin the United States, and information reporting may (although backup withholding generally will not) apply to the proceeds of a sale or other taxable disposition of common stock outside the United States conducted through certain U.S.-related financial intermediaries, in each case, unless the beneficial owner certifies under penalty of perjury that it is a non-U.S. holder on IRS Form W‑8BEN or W-8BEN-E, or other applicable form (and the Nasdaq Capital Marketpayor does not have actual knowledge or reason to know that the beneficial owner is a U.S. person) or such owner otherwise establishes an exemption. Proceeds of a disposition of common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information reporting.


Backup withholding is not an additional tax. Any amounts withheld under the symbol “VPCO”. We have appliedbackup withholding rules may be allowed as a refund or a credit against a non-U.S. holder’s U.S. federal income tax liability, provided the required information is timely furnished to list the UnitsIRS.

Additional Withholding Tax on the Nasdaq Capital MarketPayments Made to Foreign Accounts

Withholding taxes may be imposed under the symbol “VPCOU”. No assurance canForeign Account Tax Compliance Act, or FATCA, on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be givenimposed on dividends (including deemed dividends) or gross proceeds from the sale or other disposition of common stock paid to a “foreign financial institution” or a “non-financial foreign entity” (each as defined in the Code), unless (1) the foreign financial institution undertakes certain diligence and reporting obligations, (2) the non-financial foreign entity either certifies it does not have any “substantial United States owners” (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3) the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1) above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain “specified United States persons” or “United States-owned foreign entities” (each as defined in the Code), annually report certain information about such listingaccounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.

Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends (including deemed dividends), and will be approved.

apply to payments of gross proceeds from the sale or other disposition of common stock on or after January 1, 2019. Because we may not know the extent to which a distribution is a dividend for U.S. federal income tax purposes at the time it is made, for purposes of these withholding rules we or the applicable withholding agent may treat the entire distribution as a dividend. Prospective investors should consult their tax advisors regarding the potential application of these withholding provisions. 

50


SHARES ELIGIBLE FOR FUTURE SALE

Future salesPLAN OF DISTRIBUTION


Promptly following the effective date of substantial amountsthe registration statement of which this prospectus form is a part, we will distribute the Subscription Rights, Rights Certificates and copies of this prospectus to the holders of our common stock and Series D Preferred Stock on the Record Date. Subscription Rights holders who wish to exercise their Subscription Rights and purchase our common stock must complete the Subscription Rights Certificate and return it with payment for the shares to the Subscription Agent at the following address:

 By mail:
Broadridge Corporate Issuer Solutions, Inc.
Attn: BCIS re-Organization Dept.
P.O. Box 1317
Brentwood, NY 11717-0718
By hand or overnight courier:
Broadridge Corporate Issuer Solutions, Inc.
Attn: BCIS IWS
51 Mercedes Way
Edgewood, NY 11717

If you have any questions, you should contact our Subscription Agent for the rights offering, Broadridge Corporate Issuer Solutions, Inc., toll free at (855) 793-5068 or by email at shareholder@broadridge.com.

Other than as described in this prospectus, we do not know of any existing agreements between any stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the underlying securities.

Maxim Group LLC will act as dealer-manager for the rights offering. In such capacity, the dealer-manager will provide marketing assistance and financial advice (including determining the Subscription Price and the structure of the rights offering) to us in connection with this offering. The dealer-manager will provide us with updated investor feedback and recommendations on pricing and structure through to the end of the subscription period. The dealer- manager is not underwriting, soliciting or placing any of the Subscription Rights or common stock being issued in this offering and does not make any recommendation with respect to such Subscription Rights (including with respect to the exercise or expiration of such Subscription Rights), or shares.

In connection with this rights offering, we have agreed to pay fees to Maxim Group LLC as dealer-manager an aggregate cash fee equal to 7.0% of the gross proceeds received by us directly from exercises of the Subscription Rights. We advanced $15,000 to Maxim Group LLC as an advance against such non-accountable expense allowance upon their engagement as dealer-manager, or the Advance, and agreed to reimburse the reasonable fees and expenses of the dealer-manager up to $65,000 (including the Advance). Any portion of the Advance not used for Maxim’s actual out-of-pocket expenses shall be promptly reimbursed to the Company.

For a period of nine months from the from the commencement of this rights offering, the Company will grant Maxim Group LLC the right of first refusal to act as a lead placement agent or underwriter for any and all future public and private equity, equity-linked, debt offerings, or other capital raising activity. Upon the successful completion of the rights offering for gross proceeds of at least $20,000,000, such period will be increased to eighteen months.

We have also agreed to indemnify the dealer-manager and their respective affiliates against certain liabilities arising under the Securities Act. The dealer-manager participation in this offering is subject to customary conditions contained in the public market, ordealer-manager agreement, including the anticipationreceipt by the dealer-manager of these sales, could materiallyan opinion of our counsel. The dealer-manager and adversely affect market prices prevailingtheir affiliates may provide to us from time to time in the future in the ordinary course of their business certain financial advisory, investment banking and could impair our abilityother services for which they will be entitled to raise capital through salesreceive fees.

Subject to certain exceptions, we have agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of equity or equity-related securities.

A certainotherwise dispose of any common shares or other securities convertible into or exercisable or exchangeable for common shares for a period of 90 days after the expiration of this rights offering.

51


SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

The following table sets forth the number of shares of our common stock will notbeneficially owned as of ______, 2021, by (i) those persons known by us to be available for sale in the public market for a periodowners of 120 days after completion of this offering due to contractual and legal restrictions on resale described below. Nevertheless, sales of a substantial number of sharesmore than 5% of our common stock, in the public market after such restrictions lapse, or the perception that those sales may occur, could materially(ii) each director, (iii) our Named Executive Officers and adversely affect the prevailing market price(iv) all of our common stock.

59

Conversionexecutive officers and Exercise Restrictions

Each one-fourth sharedirectors of Series A Convertible Preferred Stock will be convertible at the option of the holder into five shares of our common stock upon the separation of the Units, provided that uponas a Cash Warrant Exercise Trigger the Series A Convertible Preferred Stock will not be convertible until six-months after the date of this prospectus (unless an Early Separation occurs due to a Trading Separation Trigger or Delisting Trigger). Accordingly, the shares of our common stock issuable upon the conversion of the Series A Convertible Preferred Stock will not be available for sale in the open market until the earlier of (i) six months after the date of this prospectus, or (ii) 15 days after a Trading Separation Trigger or (iii) immediately upon a Delisting Trigger.

Each Series A Warrant is exercisable for one share of common stock. The Series A Warrants are exercisable upon separation of the Units, provided that the Series A Warrants may be exercised for cash at any time after 30 days from the date of this prospectus, which exercise shall cause a Cash Warrant Exercise Trigger.group. Unless there is a Trading Separation Trigger or a Delisting Trigger, the Series A Warrants are not exercisable until the earlier of (i) six months after the date of this prospectus, or (ii) if exercised for cash. 

The Series A Convertible Preferred Stock and the Series A Warrants will not be convertible, or exercisable or exchangeable, as the case may be, by the holder of such securities to the extent (and only to the extent) that the holder or any of its Affiliates would beneficially own in excess of 4. 99 % of the common stock of the Company. For purposes of the limitation described in this paragraph, beneficial ownership and all determinations and calculations are determined in accordance with Section 13(d) of the Exchange Act and the rule and regulations promulgated thereunder.

UNDERWRITING

We have entered into an underwriting agreement with Dawson James Securities, Inc., as representative of the underwriter(s), with respect to the Units subject to this offering. Subject to certain conditions, we have agreed to sell, and the underwriter(s) have/has severally agreed to offer and sell on a best efforts basis, the number of Units provided below.

UnderwritersNumber of
Units
Dawson James Securities, Inc.
Total

This offering is being completed on a “best efforts” basis and the underwriters have no obligation to buy any Units from us or to arrange for the purchase or sale of any specific number or dollar amount of Units. The obligations of the underwriters may be terminated upon the occurrence of certain eventsotherwise specified in the underwriting agreement. Furthermore, pursuantnotes to this table, the underwriting agreement, the underwriters’ obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers’ certificates and legal opinions.

Commissions and Expenses

The underwriters have advised us that they propose to offer the Units to the public at the public offering price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $[_______] per Unit. The commission or reallowance to dealers may be changed by the underwriters. No such change shall change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. The underwriters have informed us that they do not intend to confirm sales to any accounts over which they exercise discretionary authority.

The following table shows the underwriting commissions payable to the underwriters by us in connection with this offering.

address for each person is: c/o Healthier Choices Management Corp., 3800 North 28th Way, Hollywood, Florida 33020.

Title of Class Per
Unit
Public offering priceBeneficial Owner 
Underwriting commissions
Amount and Nature of Beneficial Owner (1)
 
Percent of Class (1)
Proceeds, before expenses, to us

We estimate that expenses payable by us in connection with this offering, other than the underwriting commissions referred to above, will be approximately $[_______]. We have advanced the underwriters $25,000 against “blue sky” expenses to be incurred in the offering. Any portion of the advance payment will be returned to us in the event the foregoing expenses actually incurred are less than such advance.

Underwriters’ Unit Purchase Option

We have also agreed to issue to the representative of the underwriters’ a Unit Purchase Option to purchase a number of our Units equal to an aggregate of 5% of the Units sold in this offering. The representative’s Unit Purchase Option will have an exercise price equal to 125% of the public offering price of the Units set forth on the cover of this prospectus (or $[_______] per Unit) and may be exercised on a cashless basis. The representative’s Unit Purchase Option is not redeemable by us. This prospectus also covers the sale of the representative’s Unit Purchase Option and the shares of Series A Convertible Preferred Stock and Series A Warrants issuable upon the exercise of the representative’s Unit Purchase Option, as well as the shares underlying such Series A Convertible Preferred Stock and Series A Warrants. The representative’s Unit Purchase Option and the underlying securities have been deemed compensation by FINRA, and are therefore subject to FINRA Rule 5110(g)(1). In accordance with FINRA Rule 5110(g)(1), neither the representative’s Unit Purchase Option nor any securities issued upon exercise of the representative’s Unit Purchase Option may be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such securities by any person for a period of 180 days immediately following the date of effectiveness or commencement of sales of the offering pursuant to which the representative’s Unit Purchase Option are being issued, except the transfer of any security:

by operation of law or by reason of reorganization of our company;
to any FINRA member firm participating in this offeringDirectors and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction described above for the remainder of the time period;
if the aggregate amount of our securities held by either an underwriter or a related person do not exceed 1% of the securities being offered;
that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund; or

the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction set forth above for the remainder of the time period.

In addition, in accordance with FINRA Rule 5110(f)(2)(G), the representative’s Unit Purchase Option may not contain certain anti-dilution terms.

Indemnification

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933, or the Securities Act, and liabilities arising from breaches of representations and warranties contained in the underwriting agreement, or to contribute to payments that the underwriters may be required to make in respect of those liabilities.

Lock-Up Agreements

We and each of our directors and executive officers have agreed that, without the prior written consent of Dawson James Securities, Inc. on behalf of the underwriters, we and they will not, subject to limited exceptions, during the period ending 120 days after the date of this prospectus, subject to extension in specified circumstances:

offer, pledge, sell or contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock whether such transaction is to be settled by delivery of shares of our common stock or such other securities, in cash or otherwise;
enter into any swap option, future, forward, or other agreement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock or any securities convertible into or exchangeable or exercisable for shares of our common stock, whether such transaction is to be settled by delivery of shares of our common stock or such other securities, in cash or otherwise;
make any demand for or exercise any right with respect to the registration of any shares of our common stock or any securities convertible into or exchangeable or exercisable for shares of our common stock; or
publicly announce an intention to do any of the foregoing.

Price Stabilization, Short Positions and Penalty Bids

In connection with the offering, the underwriters may engage in stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Regulation M under the Exchange Act:

Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.
Syndicate covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of securities to close out the short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market. A naked short position, the position can only be closed out by buying securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the securities in the open market after pricing that could adversely affect investors who purchase in the offering.

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our Units or preventing or retarding a decline in the market price of our Units. As a result, the price of our Units may be higher than the price that might otherwise exist in the open market. Neither we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of the Units. In addition, neither we nor the underwriters make any representations that the underwriters will engage in these stabilizing transactions or that any transaction, once commenced, will not be discontinued without notice.

Electronic Distribution

This prospectus in electronic format may be made available on websites or through other online services maintained by one or more of the underwriters, or by their affiliates. Other than this prospectus in electronic format, the information on any underwriter’s website and any information contained in any other website maintained by an underwriter is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.

Other

From time to time, certain of the underwriters and/or their affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees. Except for services provided in connection with this offering, no underwriter has provided any investment banking or other financial services during the 180-day period preceding the date of this prospectus and we do not expect to retain any underwriter to perform any investment banking or other financial services for at least 90 days after the date of this prospectus.

NASDAQ Listing

We have applied for listing of the Units on the Nasdaq Capital Market under the trading symbol “VPCOU”.

Offer Restrictions Outside of the United States

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

LEGAL MATTERS

The validity of the issuance of the securities offered by us in this offering will be passed upon for us by Nason Yeager Gerson White & Lioce, P.A., West Palm Beach, Florida. Schiff Hardin LLP, Washington, DC, is acting as counsel for the underwriters in connection with certain legal matters in connection with this offering.

EXPERTS

The audited financial statements of Vapor as of and for the years ended December 31, 2014 and 2013 included in this prospectus have been so included in reliance on the report, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, of Marcum LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

The audited financial statements of Vaporin as of and for the years ended December 31, 2014 and 2013 included in this prospectus have been so included in reliance on the report, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, of RBSM, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the Securities and Exchange Commission, which we refer to as the “SEC”, a registration statement on Form S-1 under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which is part of the registration statement, omits certain information, exhibits, schedules and undertakings set forth in the registration statement. For further information pertaining to us and our securities, reference is made to the registration statement and the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents or provisions of any documents referred to in this prospectus are not necessarily complete, and in each instance where a copy of the document has been filed as an exhibit to the registration statement, reference is made to the exhibit for a more complete description of the matters involved.

You may read and copy all or any portion of the registration statement without charge at the public reference room of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Copies of the registration statement may be obtained from the SEC at prescribed rates from the public reference room of the SEC at such address. You may obtain information regarding the operation of the public reference room by calling 1-800-SEC-0330. In addition, registration statements and certain other filings made with the SEC electronically are publicly available through the SEC’s website at http://www.sec.gov. The registration statement, including all exhibits and amendments to the registration statement, has been filed electronically with the SEC. You may also read all or any portion of the registration statement on our website atwww.vapor-corp.com.

We are subject to the information and periodic reporting requirements of the Exchange Act and, accordingly, are required to file annual reports containing financial statements audited by an independent public accounting firm, quarterly reports containing unaudited financial data, current reports, proxy statements and other information with the SEC. You will be able to inspect and copy such periodic reports, proxy statements and other information at the SEC’s public reference room, the website of the SEC referred to above, and our website referred to above.

Index to Consolidated Financial Statements

Page
Condensed Consolidated Balance Sheets as of March 31, 2015 (unaudited) and December 31, 2014F-2
Condensed Consolidated Statements of Operations for the three months ended March 31, 2015 and 2014 (unaudited)F-3
Condensed Consolidated Statement of Changes in Stockholders’ Equity for the three months ended March 31, 2015 (unaudited)F-4
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2015 and 2014 (unaudited)F-5
Notes to Condensed Consolidated Financial Statements (unaudited)F-6
Reports of Independent Registered Public Accounting FirmF-21
Consolidated Balance Sheets as of December 31, 2014 and 2013F-22
Consolidated Statements of Operations for the years ended December 31, 2014 and 2013F-23
Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2014 and 2013F-24
Consolidated Statements of Cash Flows for the years ended December 31, 2014 and 2013F-25
Notes to Consolidated Financial StatementsF-26

Vaporin, Inc. Financial Statements

F-53

Pro Forma Financials

F-72

VAPOR CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

  March 31, 2015  December 31, 2014 
  (Unaudited)    
ASSETS        
CURRENT ASSETS:        
Cash $1,911,199  $471,194 
Due from merchant credit card processor, net of reserve for chargebacks of $41,355 and $2,500,  respectively  348,192   111,968 
Accounts receivable, net of allowance of $228,856 and $369,731, respectively  203,793   239,652 
Inventories  2,536,149   2,048,883 
Prepaid expenses and vendor deposits  527,207   664,103 
Loans receivable, net  -   467,095 
Deferred financing costs, net  87,292   122,209 
TOTAL CURRENT ASSETS  5,613,832   4,125,104 
         
Property and equipment, net of accumulated depreciation of $158,238 and $84,314, respectively  633,705   712,019 
Intangible assets, net of accumulated amortization of $22,177 and $0, respectively  2,058,423   - 
Goodwill  15,654,484   - 
Other assets  92,131   91,360 
         
TOTAL ASSETS $24,052,575  $4,928,483 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
         
CURRENT LIABILITIES:        
Accounts payable $2,303,051  $1,920,135 
Accrued expenses  1,419,241   975,112 
Senior convertible notes payable – related parties, net of debt discount of $781,250 and $1,093,750, respectively  468,750   156,250 
Convertible notes, net of debt discount of $49,421 and $0 , respectively  517,579   - 
Notes payable – related party  1,000,000   - 
Current portion of capital lease  52,015   52,015 
Term loan  523,727   750,000 
Customer deposits  50,744   140,626 
Income taxes payable  3,092   3,092 
Derivative liabilities  87,603   - 
TOTAL CURRENT LIABILITIES  6,425,802   3,997,230 
         
Capital Lease, net of current portion  107,195   119,443 
TOTAL LIABILITIES  6,532,997   4,116,673 
         

COMMITMENTS AND CONTINGENCIES

        
         
STOCKHOLDERS’ EQUITY:        
         
Preferred stock, $.001 par value, 1,000,000 shares authorized, none issued  -   - 
Common stock, $.001 par value, 50,000,000 shares authorized, 6,727,152 and 3,352,382 shares issued and outstanding, respectively  6,727   3,352 
Additional paid-in capital  36,725,950   16,040,361 
Accumulated deficit  (19,213,099)  (15,231,903)
TOTAL STOCKHOLDERS’ EQUITY  17,519,578   811,810 
         
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $24,052,575  $4,928,483 

See notes to unaudited condensed consolidated financial statements

VAPOR CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

  For The Three Months
Ended March 31,
 
  2015  2014 
       
SALES, NET $1,468,621  $4,792,544 
Cost of goods sold  1,651,110   3,831,928 

GROSS (LOSS) PROFIT

  (182,489)  960,616 
         
EXPENSES:        
Selling, general and administrative  3,243,189   2,769,726 
Advertising  105,177   367,615 
Total operating expenses  3,348,366   3,137,341 
Operating loss  (3,530,855)  (2,176,725)
Other (expense) income:        
Amortization of deferred financing costs  (34,917)  - 
Change in fair value of derivative liabilities  (37,965)  - 
Interest expense  (378,775)  (28,434)
Interest income  1,316   - 
Total other expense  (450,341)  (28,434)
LOSS BEFORE INCOME TAX (BENEFIT) EXPENSE  (3,981,196)  (2,205,159)

Income tax benefit

  -   752,400 
NET LOSS $(3,981,196) $(1,452,759)
         
LOSS PER COMMON SHARE – BASIC AND DILUTED $(0. 89) $(0. 45)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC AND DILUTED  

4,494,855

   

3,253,550

 

See notes to unaudited condensed consolidated financial statements

VAPOR CORP.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED MARCH 31, 2015

(UNAUDITED)

  Common Stock  Additional Paid-In  Accumulated    
  Shares  Amount  Capital  Deficit  Total 
Balance – January 1, 2015  3,352,382  $3,352  $16,040,361  $(15,231,903) $811,810 
                     
Issuance of common stock in connection with the Merger (See Note 4)  2,718,307   2,718   17,025,681      17,028,399 
Issuance of common stock and warrants in connection with private placement  686,463   687   2,941,273      2,941,960 
Contribution of note and interest payable to Vaporin to capital in connection with the Merger        354,029      354,029 
Cancellation of common stock as a result of early termination of consulting agreement  ( 30,000)  ( 30)  30       
Stock-based compensation expense        364,576      364,576 
Net loss           (3,981,196)  (3,981,196)
Balance – March 31, 2015  6,727,152  $6,727  $36,725,950  $(19,213,099) $17,519,578 

See notes to condensed consolidated financial statements

F-4

VAPOR CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

  For The Three Months
Ended March 31,
 
  2015  2014 
OPERATING ACTIVITIES:        
Net loss $(3,981,196) $(1,452,759)
Adjustments to reconcile net loss to net cash used in operating activities:        
Change in allowances  -   (86,314)
Depreciation and amortization  85,013   3,888 
Loss on disposal of assets  289,638   - 
Amortization of deferred debt discount  317,702   - 
Amortization of deferred financing cost  34,917   - 
Write-down of obsolete and slow moving inventory  70,657   - 
Stock-based compensation expense  364,576   610,414 
Deferred income tax benefit  -   (754,249)
Change in fair value of derivative liabilities  37,965   - 
Changes in operating assets and liabilities:        
Due from merchant credit card processors  (35,083)  85,694 
Accounts receivable  117,115   22,443 
Inventories  423,635   (924,169)
Prepaid expenses and vendor deposits  164,917   (40,945)
Other assets  (771)  (25,000)
Accounts payable  (140,092)  293,700 
Accrued expenses  191,384   131,280 
Customer deposits  (89,882)  (27,396)
Income taxes  -   (1,701)
NET CASH USED IN OPERATING ACTIVITIES  (2,149,505)  (2,165,114)
         
INVESTING ACTIVITIES:        
Cash received in connection with the Merger  136,468   - 
Collection of loans receivable  467,095   - 
Purchases of property and equipment  (67,492)  (4,795)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES:  536,071   (4,795)
         
FINANCING ACTIVITIES        
Proceeds from private placement of common stock and warrants, net of offering costs  2,941,960   (109,104)
Principal payments on term loan payable  (226,273)  (181,731)
Principal payments of capital lease obligations  (12,248)  - 
Proceeds from loan payable to Vaporin, Inc.  350,000   - 
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES  3,043,439   (290,835)
         

NET INCREASE (DECREASE) IN CASH

  1,440,005   (2,460,744)
         
CASH — BEGINNING OF PERIOD  471,194   6,570,215 
         
CASH — END OF PERIOD $1,911,199  $4,109,471 
         
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION        
Cash paid for interest $30,351  $29,077 
Cash paid for income taxes $2,791  $3,550 
         
NON-CASH INVESTING AND FINANCING ACTIVITIES        
Purchase Price Allocation in connection with the Merger:        
Cash $136,468   - 
Accounts receivable  81,256   - 
Merchant credit card processor receivable  201,141   - 
Prepaid expense and other current assets  28,021   - 
Inventory  981,558   - 
Property and equipment  206,668   - 
Accounts payable and accrued expenses  (779,782)  - 
Derivative liabilities  (49,638)  - 
Notes payable, net of debt discount of 54,623  (512,377)  - 
Notes payable – related party  (1,000,000)  - 
Net assets acquired $(706,685)    
         
Consideration:        
Value of common stock issued  17,028,399   - 
Excess liabilities over assets assumed  706,685     
Total consideration $17,735,084     
         
Total excess consideration over net assets acquired $17,735,084     
Amount allocated to goodwill  15,654,484   - 
Amount allocated to identifiable intangible assets  2,080,600   - 
Remaining unallocated consideration $-   - 

See notes to unaudited condensed consolidated financial statements

F-5

VAPOR CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1.ORGANIZATION, GOING CONCERN AND MANAGEMENT PLANS, AND BASIS OF PRESENTATION

Organization

Vapor Corp. (the “Company” or “Vapor”) is the holding company for its wholly owned subsidiaries The Vape Store, Inc. (“Vape Store”), Smoke Anywhere U.S.A., Inc. (“Smoke”), Emagine the Vape Store, LLC (“Emagine”) and IVGI Acquisition, Inc. The company operates 10-Florida based vape stores and a website where it sells vaporizers, liquids for vaporizers and electronic cigarettes. The Company designs, markets and distributes vaporizers, e-liquids, electronic cigarettes and accessories under the Vaporin, emagine vapor™, Krave®, VaporX®, Hookah Stix®, Fifty-One® (also known as Smoke 51) and Alternacig® EZ Smoker®, Green Puffer®, Americig®, Vaporin, FumaréTM, and Smoke Star® brands. “Vaporizers”, “Electronic cigarettes” or “e-cigarettes,” are battery-powered products that enable users to inhale nicotine vapor without smoke, tar, ash, or carbon monoxide.

Going Concern and Management Plans

The Company’s condensed consolidated financial statements for the quarter ended March 31, 2015 indicate there is substantial doubt about its ability to continue as a going concern as the Company requires additional equity and/or debt financing to continue its operations. The Company must ultimately generate sufficient cash flow to meet its obligations on a timely basis, attain profitability in its business operations, and be able to fund its long term business development and growth plans. The Company’s business will require significant amounts of capital to sustain operations and make the investments it needs to execute its longer-term business plan. The Company’s liquidity and capital resources have decreased as a result of the $3.98 million net loss that it incurred during the quarter ended March 31, 2015. At March 31, 2015, the Company’s accumulated deficit amounted to $19.21 million. At March 31, 2015, the Company had a working capital deficiency of $811,970 compared to a positive working capital of $127,874 at December 31, 2014, a decrease of $939,844.

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures, working capital deficiency and other financing requirements for the foreseeable future. The Company believes it will need to raise additional debt or equity financing to maintain and expand the business. Any equity financing or the issuance of equity equivalents could be dilutive to its shareholders. If either such additional capital is not available on terms acceptable to the Company or at all then the Company may need to curtail its operations and/or take additional measures to conserve and manage its liquidity and capital resources, any of which would have a material adverse effect on our business, results of operations and financial condition.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required for audited annual financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the condensed consolidated financial statements not misleading have been included. The condensed consolidated balance sheet at December 31, 2014 has been derived from the Company’s audited consolidated financial statements as of that date.

These unaudited condensed consolidated financial statements for the three months ended March 31, 2015 and 2014 should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2014 included elsewhere herein this filing. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2015.

Merger with Vaporin, Inc.

As fully-disclosed in Note 3 to these condensed consolidated financial statements, on December 17, 2014, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Vaporin, Inc., a Delaware corporation (“Vaporin”) pursuant to which Vaporin was to merge with and into the Company with the Company being the surviving entity. On the same date, the Company also entered into a joint venture with Vaporin (the “Joint Venture”) through the execution of an operating agreement (the “Operating Agreement”) of Emagine, pursuant to which the Company and Vaporin were 50% members of Emagine.

On March 4, 2015, the acquisition of Vaporin by the Company (the “Merger”) was completed pursuant to the terms of the Merger Agreement. In connection with the Merger, Vape Store and Emagine became wholly-owned subsidiaries of the Company.

Note 2.SUMMARY OF CERTAIN SIGNIFICANT ACCOUNTING POLICIES

Principles of consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated.

Use of estimates in the preparation of the financial statements

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include allowances, reserves and write-downs of receivables and inventory, valuing equity securities and hybrid instruments, share-based payment arrangements, deferred taxes and related valuation allowances, and the preliminary valuation of the net assets acquired in the Merger. Certain of our estimates could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary.

Revenue recognition

The Company recognizes revenue from product sales or services rendered when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.

Product sales and shipping revenues, net of promotional discounts, rebates, and return allowances, are recorded when the products are shipped, title passes to customers and collection is reasonably assured. Retail sales to customers are made pursuant to a sales contract that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier. Return allowances, which reduce product revenue, are estimated using historical experience. Revenue from product sales and services rendered is recorded net of sales and consumption taxes.

The Company periodically provides incentive offers to its customers to encourage purchases. Such offers include current discount offers, such as percentage discounts off current purchases, inducement offers, such as offers for future discounts subject to a minimum current purchase, and other similar offers. Current discount offers, when accepted by the Company’s customers, are treated as a reduction to the purchase price of the related transaction, while inducement offers, when accepted by its customers, are treated as a reduction to the purchase price of the related transaction based on estimated future redemption rates. Redemption rates are estimated using the Company’s historical experience for similar inducement offers. The Company reports sales, net of current discount offers and inducement offers on its condensed consolidated statements of operations.

Accounts Receivable

Accounts receivable, net is stated at the amount the Company expects to collect. The Company provides a provision for allowances that includes returns, allowances and doubtful accounts equal to the estimated uncollectible amounts. The Company estimates its provision for allowances based on historical collection experience and a review of the current status of trade accounts receivable. It is reasonably possible that the Company’s estimate of the provision for allowances will change.

At March 31, 2015 accounts receivable balances included a concentration fromone customer of an amount greater than 10% of the total net accounts receivable balance. The amount was $54,993. At December 31, 2014 accounts receivable balances included concentrations from seven customers that had balances of an amount greater than 10%. The amounts ranged from $27,729 to $177,200. As to revenues, no customers accounted for revenues in excess of 10% of the net sales for the three-month periods ended March 31, 2015 and 2014.

Identifiable Intangible Assets and Goodwill

Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain identifiable intangible assets are amortized over 5 and 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. No impairment existed at March 31, 2015.

Indefinite-lived intangible assets, such as goodwill are not amortized. The Company tests the carrying amounts of goodwill for recoverability on an annual basis at December 31st or when events or changes in circumstances indicate evidence of potential impairment exists, using a fair value based test.

Inventories

Inventories are stated at the lower of cost (determined by the first-in, first-out method) or market. If the cost of the inventories exceeds their market value, provisions are recorded to write down excess inventory to its net realizable value. The Company’s inventories consist primarily of merchandise available for resale.

Warranty liability

The Company’s limited lifetime warranty policy generally allows its end users and retailers to return defective purchased rechargeable products in exchange for new products. The Company estimates a reserve for warranty liability and records that reserve amount as a reduction of revenues and as an accrued expense on the accompanying condensed consolidated balance sheets. The warranty claims and expense was not deemed material for the years ended December 31, 2014 and three months ended March 31, 2015.

Fair value measurements

The Company applies the provisions of Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements” (“ASC 820”). The Company’s short term financial instruments include cash, due from merchant credit card processors, accounts receivable, accounts payable and accrued expenses, each of which approximate their fair values based upon their short term nature. The Company’s other financial instruments include notes payable obligations. The carrying value of these instruments approximate fair value, as they bear terms and conditions comparable to market, for obligations with similar terms and maturities.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities; Level 2 – quoted prices for similar assets and liabilities in active market or inputs that are observable; and Level 3 – inputs that are unobservable.

Stock-Based Compensation

The Company accounts for stock-based compensation under ASC Topic No. 718, “Compensation-Stock Compensation” (“ASC 718”). These standards define a fair value based method of accounting for stock-based compensation. In accordance with ASC 718, the cost of stock-based compensation is measured at the grant date based on the value of the award and is recognized over the vesting period. The value of the stock-based award is determined using the Black-Scholes-Merton valuation model, whereby compensation cost is the fair value of the award as determined by the valuation model at the grant date or other measurement date. The resulting amount is charged to expense on the straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.

Derivative Instruments

The Company accounts for free-standing derivative instruments and hybrid instruments that contain embedded derivative features in accordance with ASC Topic No. 815, “Derivative Instruments and Hedging Activities,” (“ASC 815”) as well as related interpretations of this topic. In accordance with this topic, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair values with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument.

The Company estimates fair values of derivative instruments and hybrid instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective of measuring fair values. In selecting the appropriate technique, the Company considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex instruments, such as free-standing warrants, the Company generally uses the Black-Scholes-Merton valuation model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as the Black-Scholes-Merton valuation model) are highly volatile and sensitive to changes in the trading market price of the Company’s common stock. Since derivative financial instruments are initially and subsequently carried at fair values, the Company’s income (loss) going forward will reflect the volatility in these estimates and assumption changes. Under ASC 815, increases in the trading price of the Company’s common stock and increases in fair value during a given financial quarter result in the application of non-cash derivative expense. Conversely, decreases in the trading price of the Company’s common stock and decreases in trading fair value during a given financial quarter result in the application of non-cash derivative income.

Convertible Debt Instruments

The Company accounts for convertible debt instruments when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with ASC 470-20 “Debt with Conversion and Other Options”. The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. The Company amortizes the respective debt discount over the term of the notes, using the straight-line method, which approximates the effective interest method. The Company records, when necessary, induced conversion expense, at the time of conversion for the difference between the reduced conversion price per share and the original conversion price per share.

Lease Accounting

The Company evaluates each lease for classification as either a capital lease or an operating lease. If substantially all of the benefits and risks of ownership have been transferred to the Company as lessee, the Company records the lease as a capital lease at its inception. The Company performs this evaluation at the inception of the lease and when a modification is made to a lease. If the lease agreement calls for a scheduled rent increase during the lease term, the Company recognizes the lease expense on a straight-line basis over the lease term. The Company determines the straight-line rent impact of an operating lease upon inception of the lease.

Note 3. MERGER WITH VAPORIN, INC.

Merger with Vaporin, Inc.

On December 17, 2014, the Company entered into the Merger Agreement with Vaporin pursuant to which Vaporin was to merge with and into the Company with Vapor being the surviving and controlling entity (as a result of the current stockholders of the Company maintaining more than 50% ownership in the Company’s outstanding shares of common stock and the current Vapor directors comprising the majority of the board). The Merger closed on March 4, 2015 and the purchase price consideration paid by the Company consisted of the following:

1.

100% of the issued and outstanding shares of Vaporin common stock (including shares of common stock issued upon conversion of Vaporin preferred stock immediately prior to the consummation of the merger in accordance with the Merger Agreement) were converted into, and became 2,718,307 shares of the Company’s common stock such that the former Vaporin stockholders collectively hold approximately 45% of the issued and outstanding shares of the Company’s common stock following consummation of the Merger. The aggregate value of these shares issued was $14,949,328, or approximately $5.50 per share, and was based on the closing price of the Company’s common stock on March 4, 2015.

2.

100% of the issued shares of Vaporin restricted stock units were converted into the right to receive 378,047 shares of the Company’s common stock. The restricted stock units became fully-vested in connection with the Merger and as a result, were included as a part of the Company’s purchase price as no further services from the holders is required to be provided to the Company. The 378,047 restricted stock units remain outstanding as of March 31, 2015. The aggregate value of these shares issued was $2,079,071, or approximately $5.50 per share, and was based on the closing price of the Company’s common stock on March 4, 2015. Based on the terms of the Merger Agreement, the Company has agreed to issue these in twelve equal monthly installments, with the first delivery date being the date of the closing of the Merger, however, all shares of common stock to be delivered on March 15, 2016 to the extent they are not previously delivered.

The Merger Agreement contained customary conditions that were satisfied prior to the closing of the merger, including the requirement for the Company to receive gross proceeds from a $3.5 million equity offering (See Note 5).

Additionally, as required by the Merger Agreement the Company received non-binding commitments from certain third parties for financing of up to $25 million to be used for the construction of retail stores and which is contingent on the achievement of certain performance metrics by the Company.

The fair value of the purchase consideration issued to the sellers of Vaporin was allocated to fair value of the net tangible assets acquired, with the resulting excess allocated to separately identifiable intangibles, and the remainder recorded as goodwill.  Goodwill recognized from the transactions mainly represented the expected operational synergies upon acquisition of the combined entity and intangibles not qualifying for separate recognition. Goodwill is not expected to be deductible for income tax purposes in the tax jurisdiction of the acquired business. The purchase price allocation was based, in part, on management’s knowledge of Vaporin’s business and the results of a preliminary third party appraisal commissioned by management. The fair value was based on a preliminary valuation.

Purchase Consideration    
Value of consideration paid: $17,735,084 
     
Tangible assets acquired and liabilities assumed at fair value    
Cash $136,468 
Due from merchant credit card processor  201,141 
Accounts receivable  81,256 
Inventories  981,558 
Property and Equipment  206,668 
Other Assets  28,021 
Notes payable, net of debt discount of $54,623  (512,377)
Notes payable – related party  (1,000,000)
Accounts Payable and accrued expenses  (775,753)
Derivative Liabilities  (49,638)
Excess liabilities over assets assumed $(706,685)
     
Consideration:    
Value of common stock issued  17,028,399 
Excess liabilities over assets assumed  706,685 
Total purchase price $17,735,084 
     
Identifiable intangible assets    
Trade names and technology  1,500,000 
Customer relationships  488,274 
Assembled workforce  92,326 
Total Identifiable Intangible Assets  2,080,600 
Goodwill  15,654,484 
Total allocation to identifiable intangible assets and goodwill $17,735,084 

In addition, in connection with the Merger, an aggregate $354,029 of a note and interest payable by the Company to Vaporin was forgiven.

In connection with the Merger Agreement, the Company also issued 49,592 warrants to purchase the Company’s common stock to certain warrant holders of Vaporin as replacement for warrants issued in connection with previous Vaporin note payable issuances. In addition, the Company also issued 3,947 options to purchase common stock to certain holders of Vaporin as replacement for options issued for services. The Company determined that based on the remaining term of the warrants and options as well as the nature of the remaining services to be provided by the holders that the value of the warrants and options at the date of the Merger was not material.

The Company was unable to report the financial results of Vaporin for the period from the date the Merger closed on March 4, 2015 through March 31, 2015. The accounting and reporting operations of Vaporin were fully integrated into the Company at Merger and it is impracticable to separate. The following presents the unaudited pro-forma combined results of operations of the Company with Vaporin as if the acquisition occurred on January 1, 2014.

  For the three months Ended 
  March 31, 
  2015  2014 
       
Revenues $2,584,884  $4,975,337 
Net Loss $(5,378,927) $(2,590,724)
Net Loss per share $(0. 86) $(0. 42)
Weighted Average number of shares outstanding  6,252,037   6,153,204 

The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the acquisition been completed as of January 1, 2014 or to project potential operating results as of any future date or for any future periods.

In connection with the acquisition of Vaporin, the Company acquired net deferred tax assets consisting of net operating loss carryforwards offset by the difference between the book and tax basis of intangible assets acquired. At the acquisition date, this net deferred tax asset has been completely offset by a valuation allowance.

The Joint Venture

On December 17, 2014, the Company and Vaporin agreed to enter into the Joint Venture through Emagine, a Delaware limited liability company of which the Company and Vaporin are 50% members. The Operating Agreement provides that Vaporin will serve as the initial manager of Emagine and will manage the day-to-day operations of Emagine, subject to certain customary limitations on managerial actions that require the unanimous consent of the Company and Vaporin, including but not limited to making or guaranteeing loans, distributing cash or other property to the members of Emagine, entering into affiliate transactions, amending or modifying limited liability company organizational documents, and redeeming or repurchasing membership interests from any of the members. The results of operations of Emagine from January 1, 2015 through the date of the Merger were not material.

In connection with the completion of the Merger on March 4, 2015, Emagine became a wholly-owned subsidiary of the Company.

Note 4. Accrued Expenses

Accrued expenses are comprised of the following:

  March 31,2015  December 31,2014 
       
Commissions payable $179,000  $179,000 
Retirement plan contributions  101,000   80,000 
Accrued severance  160,000   82,000 
Accrued customer returns  648,000   360,000 
Other accrued liabilities  331,241   274,112 
Total $1,419,241  $975,112 

Note 5.Notes Payable and Receivable

$567,000 Convertible Notes Payable

Between January 20, 2015 and January 23, 2015, Vaporin entered into a Securities Purchase Agreement with certain accredited investors providing for the sale of $567,000 of Vaporin’s Convertible Notes (the “Vaporin Notes”) and calculated a debt discount on the date of the Merger at $54,623.  The Vaporin Notes accrue interest on the outstanding principal at an annual rate of 10%. The principal and accrued interest on the Notes is due and payable between January 20, 2016 and January 23, 2016.  The Notes are convertible into the Company common stock at the lower of (i) $ 5.40 or (ii) a 15% discount to a 20-trading day VWAP following the closing of the merger, which was calculated at $ 4.75 . Investors were provided with standard piggyback registration rights which were conditioned on the March 4, 2015 merger closing.

$350,000 Convertible Notes Payable

On January 29, 2015, the Company issued a $350,000 convertible promissory note (the “Note”) to Vaporin in consideration for a loan of $350,000 made by Vaporin to the Company. The Note accrued interest on the outstanding principal at an annual rate of 12%. In connection with the completion of the Merger on March 4, 2015, the $350,000 Note along with accrued interest of $4,029 was extinguished.

$1,000,000 Notes Payable Related Party

On December 8, 2014, Emagine entered into a Secured Line of Credit Agreement (the “Agreement”), effective as of December 1, 2014, with one affiliated shareholder of the Company and two unaffiliated investors (the “Lenders”). Under the Agreement, the Lenders agreed to advance up to $3,000,000 in three equal tranches in exchange for secured promissory notes which mature on March 31, 2016, bear interest at 12% per annum, and are secured by a first lien on the assets of Emagine. The Company drew on a first tranche of funding under the Agreement was on December 1, 2014.

The funds were used to purchase and/or open vape stores similar to those operated by the Company. In connection with the completion of the Merger on March 4, 2015, Emagine became a wholly-owned subsidiary of the Company, and the debt was assumed by the Company.

$467,095 Notes Receivable

On January 12, 2015, the Company entered into an agreement with International Vapor Group, Inc. (“IVG”) whereby the Company agreed to reduce the $500,000 principal amount of the loan receivable by $50,000 if IVG were to remit payment of all principal and interest accrued on the loan receivable within one day. The Company included the write-down of the loan receivable in selling, general and administrative expenses on the consolidated statement of operations for the year ended December 31, 2014. On January 13, 2015, IVG paid the Company in full.

Note 6.STOCKHOLDERS’ EQUITY

Issuance of Common Stock

On February 3, 2014, the Company entered into a consulting agreement (the “Consulting Agreement”) with Knight Global Services, LLC (“Knight Global”) pursuant to which the Company retained Knight Global to assist the Company with increasing awareness of its electronic cigarette brands as well as assisting the Company to expand and diversify its relationships with large retailers and national chains. Knight Global is a wholly owned subsidiary of Knight Global, LLC of which Ryan Kavanaugh is an investor and principal. Effective March 5, 2014, the Board of Directors of the Company elected Mr. Kavanaugh as a member of the Board of Directors in accordance with the Consulting Agreement. Knight Global serves as the family office for Mr. Kavanaugh.

Under the terms of the Consulting Agreement, the Company issued to Mr. Kavanaugh 80 ,000 shares of its common stock, of which 10 ,000 shares vested immediately while the remaining 70 ,000 shares vest in installments of 10 ,000 shares per quarterly period beginning on the 90th day following February 3, 2014 and each ensuing quarterly period thereafter so long as the Consulting Agreement has not been terminated and during each quarterly period Knight Global has presented the Company with a minimum of six (6) bona fide opportunities for activities specified in the Consulting Agreement that are intended to increase awareness of the Company’s electronic cigarettes. In addition, during the term of the Consulting Agreement, which is 2 years, and during an 18-month post-termination period, the Company has agreed to pay Knight Global commissions payable in cash equal to 6% of “net sales” (as defined in the Consulting Agreement) of its products to retailers introduced by Knight Global and to retailers with which the Company has existing relationships and with which Knight Global is able, based on its verifiable efforts, to increase net sales of the Company’s products.

The grant date fair value of the common shares issued on February 3, 2014 was $3,080,000 based on closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, on February 3, 2014. On January 24, 2015, the Company and Knight Global mutually agreed to terminate the Consulting Agreement as it was in the best interests of both parties to do so. As a result of such termination, the Company issued 10 ,000 shares of its common stock to Knight Global pursuant to the early termination provisions of the Consulting Agreement. The Company cancelled 30 ,000 shares that were not vested that had been previously issued to Mr. Kavanaugh. In addition, on January 24, 2015, the Company received notice from Ryan Kavanaugh, a director of the Company that he had resigned from the Company’s board of directors, effective immediately.

During the three months ended March 31, 2015 and 2014, the Company recognized stock-based compensation expense, for the Consulting Agreement, in the amount of $322,067 and $592,300, which is included as part of selling, general and administrative expense in the accompanying condensed consolidated statements of operations.

Private Placement of Common Stock

In connection with the Merger, on March 3, 2015, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors providing for the sale of $3,500,960 in shares of the Company’s Common Stock, par value $0.001 per share, at a price of $ 5.10 per share. The Company also issued Warrants to purchasers of the shares to acquire an aggregate of 547,026 shares of the Company’s Common Stock with an exercise price of $ 6.40 per share. The shares and Warrants were issued and sold through an exempt private securities offering to certain accredited investors. The Company incurred aggregate offering costs of $559,000 in connection with the private placement, of which $350,000 was paid to Palladium Capital Advisors, the Company’s placement agent.

Under the Purchase Agreement, the Company made certain customary representations and warranties to the purchasers concerning the Company and its operations. The Company has also agreed to register the Common Stock and the Warrants for resale pursuant to an effective registration statement which must be filed within 45 days of March 3, 2015 and must be effective by the later of (i) the 90thday following March 3, 2015 (if no SEC review) or (ii) the 120th day following March 3, 2015 (if subject to SEC review). If the Form S-3 Registration Statement is not effective for resales for more than 10 consecutive days or more than 15 days in any 12 month period during the registration period (i.e., the earlier of the date on which the shares have been sold or are eligible for sale under SEC Rule 144 without restriction), the Company is required to pay the investors (other than its participating officers and directors) liquidated damages in cash equal to 1.5% of the aggregate purchase price paid by the investors for the shares for every 30 days or portion thereof until the default is cured. Such cash payments could be as much as $52,500 for every 30 days. The initial Form S-3 was filed on April 17, 2015.

F-14

Warrants

A summary of warrant activity for the three months ended March 31, 2015 is presented below:

  

Number of

Warrants

  

Weighted-

Average

Exercise Price

  

Weighted-

Average

Contractual Term

  

Aggregate

Intrinsic

Value

 
Outstanding at January 1, 2015  243,218  $10.05         
Warrants granted  598,763   8.20         
Warrants exercised              
Warrants forfeited or expired              
                 
Outstanding at March 31, 2015  841,981  $8.75   5.0  $- 
                 
Exercisable at March 31, 2015  603,345  $8.25   5.0  $- 

Stock-based Compensation

During the three months ended March 31, 2015 and 2014, the Company recognized stock-based compensation expense in connection with the amortization of stock option expense of $364,576 and $18,106, respectively, which is included as part of selling, general and administrative expense in the accompanying condensed consolidated statements of operations. No employee stock options were granted during the first quarter of 2015, with the exception of the 19,734 options granted in connection with the Merger, for which the grant date fair value was determined to be immaterial.

Stock option activity

Options outstanding at March 31, 2015 under the various plans are as follows:

PlanTotal
Number of OptionsOutstanding
under Plans
Equity compensation plans not approved by security holders180,000
Equity Incentive Plan68,567
248,567

A summary of activity under all option Plans at March 31, 2015 and changes during the three months ended March 31, 2015:

  Number of
Shares
  Weighted-
Average
Exercise Price
  Weighted-
Average
Contractual Term
  Aggregate
Intrinsic
Value
 
Outstanding at January 1, 2015  268,860  $15.4   6.53  $- 
Options granted  3,947   28.05   -   - 
Options exercised  -   -   -   - 
Options forfeited or expired  ( 24,240)  36.60   -   - 
Outstanding at March 31, 2015  248,567  $13.55   6.17  $- 
Exercisable at March 31, 2015  209,847  $11.30   6.52  $- 
Options available for grant at March 31, 2015  281,773             

At March 31, 2015 the amount of unamortized stock-based compensation expense on unvested stock options granted to employees and consultants was $338,105 and will vest over 1.6 years.

Loss per share

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method) and the conversion of the Company’s convertible debt and warrants (using the if-converted method). Diluted loss per share excludes the shares issuable upon the exercise of stock options from the calculation of net loss per share, as their effect is antidilutive. The following table summarizes the Company’s securities that have been excluded from the calculation of basic and dilutive loss per share as their effect would be anti-dilutive:

  March 31, 
  2015  2014 
       
Convertible debt  358,862   - 
Stock options  244,620   234,900 
Warrants  841,981   43,176 
Total  1,445,463   278,076 

Note 7. FAIR VALUE MEASUREMENTS

The fair value framework under the Financial Accounting Standards Board’s guidance requires the categorization of assets and liabilities into three levels based upon the assumptions used to measure the assets or liabilities.  Level 1 provides the most reliable measure of fair value, whereas Level 3, if applicable, would generally require significant management judgment.  The three levels for categorizing assets and liabilities under the fair value measurement requirements are as follows:

Level 1:  Fair value measurement of the asset or liability using observable inputs such as quoted prices in active markets for identical assets or liabilities;

Level 2:  Fair value measurement of the asset or liability using inputs other than quoted prices that are observable for the applicable asset or liability, either directly or indirectly, such as quoted prices for similar (as opposed to identical) assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and

Level 3:  Fair value measurement of the asset or liability using unobservable inputs that reflect the Company’s own assumptions regarding the applicable asset or liability.

The following table summarizes the liabilities measured at fair value on a recurring basis as of March 31, 2015:

  Level 1  Level 2  Level 3  Total 
LIABILITIES:                
Warrant liability  -   -  $87,603  $87,603 
Total derivative liabilities $-  $-  $87,603  $87,603 

The following table summarizes the liabilities measured at fair value on a recurring basis as of December 31, 2014:

Level 1Level 2Level 3Total
LIABILITIES:Executive Officers:       
Common Stock
Jeffrey E. Holman (2)
Common Stock
Christopher Santi (3)
Common Stock
John Ollet (4)
Common Stock
Dr. Anthony Panariello (5)
Common Stock
Clifford J. Friedman (6)
All directors and officers as a group (5 persons) (7)
         
Warrant liability$-5% Stockholders:  $-  $-
None  $-
Total derivative liability$-  $-
Total:  $-  $- 


(1)

Level 3 liabilitiesBeneficial Ownership. Applicable percentages are valued using unobservable inputs tobased on _________________ shares of common stock outstanding as of _________, 2021. Beneficial ownership is determined under the valuation methodology that are significant to the measurementrules of the fair valueSEC and generally includes voting or investment power with respect to securities. Shares of common stock subject to options, warrants, convertible notes and preferred stock currently exercisable or convertible or exercisable or convertible within 60 days are deemed outstanding for computing the percentage of the liabilities. For fair value measurements categorized within Level 3person holding such securities but are not deemed outstanding for computing the percentage of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures.any other person. The development and determinationtable includes shares of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.

Level 3 Valuation Techniques

Level 3 financial liabilities consist of the derivative liabilities for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.

The Company deems financial instruments which do not have fixed settlement provisions to be derivative instruments. The common stock, purchaseoptions, warrants, reissued by the Company in connection with the Merger do not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future. In accordance with Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity, the fair value of these warrants is classified as a liability on the Company’s Condensed Consolidated Balance Sheets because, according to the terms of the warrants, a fundamental transaction could give rise to an obligation of the Company to pay cash to its warrant holders.  Corresponding changes in the fair value of the derivative liabilities are recognized in earnings on the Company’s Condensed Consolidated Statement of Operations in each subsequent period.

The Company’s warrant liabilities are carried at fair value and were classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs. Although the Company determined the warrants include an implied downside protection feature, it performed a Monte-Carlo simulation and concluded that the value of the feature is de minimus and the use of the Black-Scholes valuation model is considered to be a reasonable method to value the warrants.

The following table summarizes the values of certain assumptions used by the Company’s custom model to estimate the fair value of the warrant liabilities as of March 31, 2015:

  March 31,2015 
  (Unaudited) 
Stock price $

5.20

 
Weighted average strike price $1.20 
Remaining contractual term (years)  3.70 
Volatility  124.0%
Risk-free rate  1.37%
Dividend yield  0.0%

The following table sets forth a summary of the changes in the fair value of our Level 3 financial liabilities that are measured at fair value on a recurring basis:

  For the three
months ended
March 31,2015
 
Beginning balance $ 
Fair value of warrant liabilities reissued in connection with the Merger  49,638 
Change in fair value of derivative liabilities  37,965 
Ending balance $87,603 

Note 8. COMMITMENTS AND CONTINGENCIES

Lease Commitments

The Company leases its Florida office and warehouse facilities under a twenty-four month lease agreement with an initial term through April 30, 2013 that the Company extended in March 2015 when it exercised the second of three successive one-year renewal options. The lease provides for annual rental payments of $144,000 per annum (including 45 days of total rent abatement) during the initial twenty-four month term and annual rental payments of $151,200, $158,760 and $174,636 during each of the three one-year renewal options. In October 2013, the Company amended the master lease to include an additional approximately 2,200 square feet for an additional annual rental payment of $18,000 subject to the same renewal options and other terms and conditions set forth in the master lease. During the year ended December 31, 2014, the Company entered into nine (9) real estate leases for eight (8) new retail kiosks and one (1) new retail store. The kiosks opened during the fourth quarter of 2014 and the store is scheduled to open during 2015. The kiosks are located in malls in Florida, Maryland, New Jersey and Texas. The retail store is located in Ft. Lauderdale, FL. Under these leases, the initial lease terms range from one to five years, the Company is required to pay base and percentage rents and the Company is required to pay for common area and maintenance charges and utilities. In addition through the merger which occurred on March 4, 2015 the Company acquired additional lease commitments which included one (1) Florida office space and ten (10) new retail stores. Future minimum lease payments under non-cancelable operating that have initialpreferred stock exercisable or remaining terms in excess of one year at March 31, 2015 are due as follows:

The remaining minimum annual rents for the years ending December 31 are:

2015  $630,256 
2016   539,990 
2017   429,628 
2018   201,853 
2019   153,386 
2020   18,961 
Total  $1,974,074 

Rent expense for the three months ended March 31, 2015 and 2014 was $215,087 and $44,838, respectively, and is included in selling, general and administrative expenses in the accompanying condensed consolidated statement of operations.

Resignation of Chief Financial Officer

On March 27, 2015, Harlan Press notified the Company of his intention to resign from the Company, effective April 10, 2015. Mr. Press previously served as Chief Financial Officer of the Company. In connection with the Company’s previously disclosed merger with Vaporin, Inc. in March 2015, Mr. Press was appointed Vice-President of Finance of the Company. Mr. Press received severance compensation and accrued vacation in accordance with his employment agreement in the total amount of $159,810, which is divided into equal weekly payments that end on January 29, 2016 and has been included in accrued liabilities as of March 31, 2015.

Legal Proceedings

From time to time the Company may be involved in various claims and legal actions arising in the ordinary course of our business. There were no pending material claims or legal matters as of the date of this report other than two of the three following matters.

On June 22, 2012, Ruyan Investment (Holdings) Limited (“Ruyan”) filed a lawsuit against the Company alleging infringement of U.S. Patent No. 8,156,944 (the ‘944 Patent). Ruyan also filed separate cases for patent infringement against nine other defendants asserting infringement of the 944 Patent. Ruyan’s lawsuit against the Company known as Ruyan Investment (Holdings) Limited vs. Vapor Corp. CV-12-5466 is pending in the United States District Court for the Central District of California. All of these lawsuits have been consolidated for discovery and pre-trial purposes. The Company intends to vigorously defend against this lawsuit.

On February 25, 2013, Ruyan’s second patent infringement lawsuit against the Company as well as all of the other consolidated lawsuits were stayed as a result of the Court granting a stay in one of the consolidated lawsuits. The Court granted the motion to stay Ruyan’s separate lawsuits against the Company and the other defendants based on the filing of a request for inter partes reexamination of the ‘944 Patent at the United States Patent and Trademark Office.

All reexamination proceedings of the ‘944 Patent have been stayed by the United States Patent and Trademark Office Patent Trial and Appeal Board pending its approval of one or more of them.

On March 5, 2014, Fontem Ventures, B.V. and Fontem Holdings 1 B.V. (the successors to Ruyan) filed a complaint against the Company alleging infringement of U.S. Patent No. 8,365,742, entitled “Aerosol Electronic Cigarette”, U.S. Patent No. 8,375,957, entitled “Electronic Cigarette”, U.S. Patent No. 8,393,331, entitled “Aerosol Electronic Cigarette” and U.S. Patent No. 8,490,628, entitled “Electronic Atomization Cigarette. On April 8, 2014, plaintiffs amended their complaint to add U.S. Patent No. 8,689,805, entitled “Electronic Cigarette.” The products accused of infringement by the plaintiff are various Krave, Fifty-one and Hookah Stix products and parts. Eight other companies were also sued in separate lawsuits alleging infringement of one or more of the patents listed above. The Company filed its Answer and Counterclaims on May 1, 2014. The Company intends to vigorously defend against this lawsuit.

On October 21, 2014, Fontem Ventures B.V. and Fontem Holdings 1 B.V. filed a complaint against the Company in the U.S. District Court for the Central District of California, captioned Fontem Ventures B.V., et al. v. Vapor Corp., No. 14-cv-8155. The complaint alleges infringement of United States Patent No. 8,863,752, entitled “Electronic Cigarette”. The products accused of infringement by plaintiffs are various Krave and Fifty-One products and parts On January 15, 2015, the Company filed its Answer and Counterclaims. The Company will vigorously defend itself against such allegations.

On December 2, 2014, Fontem Ventures B.V. and Fontem Holdings 1 B.V. filed a complaint against the Company in the U.S. District Court for the Central District of California, captioned Fontem Ventures B.V., et al. v. Vapor Corp., No. 14-cv-09267. The Complaint alleges infringement by the plaintiffs against the Company relating to various Krave, Vapor X and Fifty-One products and parts. Fontem amended its compliant on December 16, 2014, to allege infringement of United States Patent No. 8,910,641, entitled “Electronic Cigarette” against the same products. On January 15, 2015, the Company filed its Answer and Counterclaims. The Company will vigorously defend itself against such allegations.

All of the above referenced cases filed by Fontem have been consolidated and are currently scheduled for trial in November 2015. The parties are currently in active fact discovery and claim construction.

On June 22, 2015, the Center for Environment Health, as plaintiff, filed suit against a number of defendants including Vapor Corp., its wholly-owned subsidiary, the Vape Store, Inc., Vaporin and another wholly-owned subsidiary, Vaporin Florida, Inc. The lawsuit was filed in the Superior Court of the State of California, County of Alameda. The suit seeks relief under California Proposition 65 which makes it unlawful for businesses to knowingly and intentionally expose individuals in California to chemicals known to cause birth defects or other harm without providing clear and reasonable warnings. All of the defendants are alleged to have sold products containing significant quantities of nicotine in violation of Proposition 65. The plaintiff is seeking a civil penalty against these defendants in the amount of $2,500 per day for each violation of Proposition 65, together with attorneys’ fees and costs. The Company and its subsidiaries are in the process of hiring counsel and intend to defend the allegations. The Company believes that all of the products sold by Vapor Corp. have always contained an appropriate warning. The Vape Store, Inc., operates vape stores located only in the State of Florida and has not, to the best of its knowledge, sold any products into the State of California.

Purchase Commitments

At March 31, 2015 and December 31, 2014, the Company has vendor deposits of $298,320 and $319,563, respectively, and vendor deposits are included as a component of prepaid expenses and vendor deposits on the condensed consolidated balance sheets included herewith.

NOTE 9.SUBSEQUENT EVENTS

The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the accompanying condensed consolidated financial statements, except for the following:

During March and April 2015 the Company closed seven of their retail Kiosk locations. This comprised of three in Maryland, two in Texas one in New Jersey and one in Florida. In addition, the Company decided not to proceed with opening the retail store located in Ft, Lauderdale Florida. This was primarily due to the Company’s refocus of resources on management and expansion of the acquired Vape Store brand retail locations. The Company is negotiating early terminations of the lease commitments.

Effective as of May 7, 2015, the Company entered an Engagement Agreement with Dawson James Securities (“Dawson”). In accordance with the Engagement Agreement, Dawson has agreed to act as the lead or managing underwriter on a best-efforts basis in connection with a proposed offering of approximately $24 million of the Company’s equity securities. The Engagement Agreement provides for an underwriting discount of 8% and a $25,000 advance fee which has been paid to Dawson. The actual size of the offering and the offering price will be subject to negotiation and the Company can provide no assurance that any such offering will be successful.

On May 19, 2015, the Company received a deficiency letter from the Nasdaq Listing Qualifications department (the “Staff”) notifying the Company that for the last 30 consecutive business days the Company’s common stock had closed below the minimum $1.00 per share bid price requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 16, 2015, to regain compliance with the bid price requirement. If, at any time before November 16, 2015, the closing bid price for the Company’s common stock is $1.00 or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the bid price requirement. If the Company does not regain compliance with the bid price requirement by November 16, 2015, the Company may be eligible for an additional 180 calendar day compliance period provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and provides the Staff with written notice of its intention to cure the deficiency. If the Company does not regain compliance by November 16, 2015 or the termination of any subsequent compliance period, if applicable, the Staff will provide written notification to the Company that its common stock may be delisted. In anticipation of receiving the Staff’s notice, on May 12, 2015, the Company filed a preliminary proxy statement on Schedule 14A with the Securities and Exchange Commission, followed by a definitive proxy statement filed May 22, 2015, in connection with the Company’s 2015 Annual Meeting of shareholders that included a proposal to approve an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split. The Company’s Annual Meeting is scheduled for July 7, 2015. There can be no assurance that the Company’s shareholders will approve the amendment, or that a reverse stock split will prevent the Company’s stock price from falling below the bid price requirement in the future.

On June 25, 2015, the Company closed on a Securities Purchase Agreement, dated as of June 22, 2015, with certain purchasers pursuant to which the Company sold, at a 5% original issue discount, a total of $1,750,000 convertible debentures (the “Debentures”). Net proceeds to the Company from sale of the Debentures, after payment of commissions and legal fees of the lead investor, were $1,466,250. The Debentures mature December 22, 2015, and accrue interest at 10% per year. Amounts of principal and accrued interest under the Debentures are convertible into common stock of the Company at a price per share of $2.50. Principal and accrued interest on the Debentures are payable in three approximately equal installments on September 22, 2015, October 22, 2015 and December 22, 2015, at the election of the holders of the Debentures, (i) in cash for an additional 25% premium,vested or (ii) in common stock of the Company at a price per share of $2.50. As lead investor under the Securities Purchase Agreement, Redwood Management, LLC received a right of first refusal to purchase up to 100% of the securities offered by the Company in future private placement offerings through December 22, 2015.

The Company’s obligations under the Debentures can be acceleratedvesting within 60 days. Unless otherwise indicated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company’s obligations, the Company would be requiredfootnotes to pay 130% of amounts of principal and interest then outstanding under the Debentures. The Company’s obligations under the Debentures are secured under a Security Agreement, under which Redwood Management, LLC acts as Collateral Agent, by a second lien on substantially all of the Company’s assets, including all of the Company’s interests in its consolidated subsidiaries.

For acting as placement agent in the offering of the Debentures, the Company paid Chardan Capital Management, LLC (the “Placement Agent”) a fee equal to 10% of the gross proceeds from the sale of the Debentures, and issued the Placement Agent 70,000 five-year warrants exercisable at $2.50 per share. In addition, the Company agreed to reduce the exercise price of 143,072 warrants held by the Placement Agent to $2.50 from their original exercise prices ranging from $2.01 to $2.41.

On June 19, 2015, the Company entered into agreements (the “Waivers”), with certain investors in each of its private placement offerings under the Securities Purchase Agreement dated March 3, 2015 (the “2015 Agreement”) and the Securities Purchase Agreement dated November 14, 2014 (the “2014 Agreement,” and with the 2015 Agreement, the “Agreements”). Under the terms of the Waivers, the signatories thereto (the “Prior Investors”) agreed to amend the Agreements and waive or modify certain terms thereunder, including certain price protection provisions and participation rights in subsequent securities offerings. In exchange, the Company agreed to issue the Prior Investors a total of 647,901 shares of common stock (including 142,000 shares issued to the lead investor underthis table, we believe that each of the Agreements in its capacity as lead investor) and 595,685 five-year warrants exercisable at $2.525 per share. In the event that, prior to November 14, 2015, the Company issues shares of common stock, or securities convertible into common stock, at an effective price per share of less than $2.70, the Prior Investors will be entitled to the issuance of additional shares (the “Additional Shares”), the exact amount of which will depend on the effective price per share of such subsequent issuance, but which will not exceed a total of 2,328,598 shares. The Company will not issue any shares of common stock requiring shareholder approval under the Rules of the Nasdaq Stock Market without receipt of such approval. The Company will not issue any of the Additional Shares unless the 647,901 shares of common stock, the shares issuable upon conversion of the Debentures and the Additional Shares are either within the 19.9% Nasdaq limitation or the issuance is approved by shareholders. The Company agreed to file a registration statement with the Securities and Exchange Commission registering the shares and warrant shares issued to the Prior Investors under the Waivers.

On June 16, 2015, the Company issued a total of 292,191 shares of common stock upon the vesting of restricted stock units assumed by the Company in connection with its merger with Vaporin, Inc. effective March 4, 2015. Recipients of the shares issued upon vesting of the restricted stock units included Gregory Brauser, the Company’s president and a member of the board of directors. On May 27, 2015, the Company issued a total of 27,500 shares of common stock to consultants of the Company for consulting services.

On July 7, 2015, the Company filed an amendment to its Certificate of Incorporation to effectuate a one-for-five reverse stock split to its common stock and to increase its authorized common stock to 150,000,000 shares. The amendments were effective on July 8, 2015 at 11:59 pm. All warrant, option, common stock shares and per share information included herein gives effect to the 1 for 5 reverse split of the Company’s common stock effectuated on July 8, 2015.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Audit Committee of the

Board of Directors and Stockholders

of Vapor Corp.

We have audited the accompanying consolidated balance sheets of Vapor Corp. (the “Company”) as of December 31, 2014 and 2013, and the related consolidated statements of operations, changes in stockholders’ equity and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriatestockholders named in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amountstable has sole voting and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Vapor Corp. as of December 31, 2014 and 2013, and the consolidated results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully discussed in Note 2, the Company has incurred net losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Marcum LLP
Marcum LLP
New York, NY
March 31, 2015 , except for Note 14, as to which the date is July 10, 2015

F-21

VAPOR CORP.

CONSOLIDATED BALANCE SHEETS

  DECEMBER 31, 
  2014  2013 
ASSETS        
CURRENT ASSETS:        
Cash $471,194  $6,570,215 
Due from merchant credit card processors, net of reserve for charge-backs of $2,500 and $2,500, respectively  111,968   205,974 
Accounts receivable, net of allowance of $369,731 and $256,833, respectively  239,652   1,802,781 
Inventories  2,048,883   3,321,898 
Prepaid expenses and vendor deposits  664,103   1,201,040 
Loans receivable, net  467,095   - 
Deferred financing costs, net  122,209   - 
Deferred tax asset, net  -   766,498 
TOTAL CURRENT ASSETS  4,125,104   13,868,406 
Property and equipment, net of accumulated depreciation of $84,314 and $27,879, respectively  712,019   28,685 
Other assets  91,360   65,284 
TOTAL ASSETS $4,928,483  $13,962,375 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
CURRENT LIABILITIES:        
Accounts payable $1,920,135  $1,123,508 
Accrued expenses  975,112   420,363 
Senior convertible notes payable – related parties, net of debt discount of $1,093,750 and $0, respectively  156,250   - 
Current portion of capital lease  52,015   - 
Term loan  750,000   478,847 
Customer deposits  140,626   182,266 
Income taxes payable  3,092   5,807 
TOTAL CURRENT LIABILITIES  3,997,230   2,210,791 
         
Capital lease, net of current portion  119,443   - 
TOTAL LIABILITIES  4,116,673   2,210,791 
         
COMMITMENTS AND CONTINGENCIES        
STOCKHOLDERS’ EQUITY:        
Preferred stock, $.001 par value, 1,000,000 shares authorized, none issued or outstanding  -   - 

Common stock, $.001 par value, 50,000,000 shares authorized 3,352,382 and 3,242,906 shares issued and 3,352,382 and 3,242,906 shares outstanding, respectively

  3,352   3,243 
Additional paid-in capital  16,040,361   13,127,995 
Accumulated deficit  (15,231,903)  (1,379,654)
TOTAL STOCKHOLDERS’ EQUITY  811,810   11,751,584 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $4,928,483  $13,962,375 

See notes to consolidated financial statements

F-22

Vapor Corp.

CONSOLIDATED STATEMENTS OF OPERATIONS

  FOR THE YEARS ENDED DECEMBER 31, 
  2014  2013 
SALES NET $15,279,859  $25,990,228 
Cost of goods sold  14,497,254   16,300,333 
Gross Profit  782,605   9,689,895 
         
EXPENSES:        
Selling, general and administrative  11,126,759   6,464,969 
Advertising  2,374,329   2,264,807 
Total operating expenses  13,501,088   8,729,776 
Operating (loss) income  (12,718,483)  960,119 
         
Other expense:        
Induced conversion expense  -   299,577 
Amortization of deferred financing costs  17,458   - 
Interest expense  348,975   383,981 
Total other expenses  366,433   683,558 
         
(LOSS) INCOME BEFORE INCOME TAX (EXPENSE) BENEFIT  (13,084,916)  276,561 
Income tax (expense) benefit  (767,333)  524,791 
         
NET (LOSS) INCOME $(13,852,249) $801,352 
         
BASIC (LOSS) EARNINGS PER COMMON SHARE $( 4.22) $0. 31 
         
DILUTED (LOSS) EARNINGS PER COMMON SHARE $( 4.22) $0. 30 
         
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC  3,283,030   2,563,697 
         
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – DILUTED  3,283,030   2,637,273 

See notes to consolidated financial statements

F-23

VAPOR CORP.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2014 AND 2013

        Additional       
  Common Stock  Paid-In  Accumulated    
  Shares  Amount  Capital  Deficit  Total 
                
Balance – January 1, 2013  2,407,633  $2,407  $1,695,155  $(2,181,006) $(483,444)
Issuance of common stock  for services  4,000   4   86 ,996      87,000 
Issuance of common stock in connection with exercise of stock options  8,660   9   70 ,291      70,300 
Discount on convertible notes to related parties        98,970      98,970 
Stock-based compensation expense        48,239      48,239 
Issuance of common stock for cash, net of offering costs  666,668   667   9,124,436      9,125,103 
Issuance of common stock upon conversion of debt  155,945   156   1, 704,331      1,704,487 
Induced conversion expense        299,577      299,577 
Net income           801,352   801,352 
Balance – December 31, 2013  3,242,906   3,243   13,127,995   (1,379,654)  11,751,584 
Offering costs incurred in 2014 pertaining to December 2013 offering        (109,104)     (109,104)
Issuance of common stock  for services  80,000   80   1,602,853      1,602,933 
Issuance of common stock in connection with exercise of stock options  1,000   1   4,999      5,000 
Issuance of common stock in connection with cashless exercise of warrants  28,477   28   ( 28)      
Discount on senior convertible notes        1,250,000      1,250,000 
Stock-based compensation expense        163,646      163,646 
Net loss           (13,852,249)  (13,852,249)
Balance – December 31, 2014  3,352,382  $3,352  $16,040,361  $(15,231,903) $811,810 

See notes to consolidated financial statements

VAPOR CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

  FOR THE YEARS ENDED DECEMBER 31, 
  2014  2013 
OPERATING ACTIVITIES:        
Net (loss) income $(13,852,249) $801,352 
Adjustments to reconcile net (loss) income to net cash used in operating activities:        
Provision for doubtful accounts  112,898   183,333 
Depreciation  56,435   11,284 
Amortization of deferred debt discount  156,250   102,500 
Amortization of deferred financing costs  17,458   - 
Induced conversion expense  -   299,577 
Write down of loan receivable to realizable value  50,000   - 
Write down of obsolete and slow moving inventory  1,834,619   - 
Stock-based compensation  1,766,579   135,239 
Utilization of net operating loss carryforward  -   (346,783)
Deferred tax  766,498   (197,585)
Changes in operating assets and liabilities:        
Due from merchant credit card processors  94,006   838,002 
Accounts receivable  1,450,231   (1,250,034)
Prepaid expenses and vendor deposits  536,937   (735,180)
Inventories  (561,604)  (1,651,891)
Other assets  (26,076)  (53,284)
Accounts payable  796,627   (2,085,087)
Accrued expenses  554,749   70,212 
Customer deposits  (41,640)  (295,429)
Income taxes  (2,715)  53,622 
NET CASH USED IN OPERATING ACTIVITIES  (6,290,997)  (4,120,152)
         
INVESTING ACTIVITIES:        
Loans receivable  (517,095)  - 
Purchases of property and equipment  (560,410)  (14,779)
NET CASH USED IN INVESTING ACTIVITIES  (1,077,505)  (14,779)
         
FINANCING ACTIVITIES        
Proceeds from sale of common stock, net of offering costs  (109,104)  9,125,103 
Proceeds from senior convertible notes payable to related parties  1,250,000   425,000 
Proceeds from senior convertible notes payable  -   500,000 
Deferred financing costs  (139,667)  - 
Principal repayments of senior note payable to stockholder  -   (70,513)
Proceeds from term loans payable  1,000,000   750,000 
Principal repayments of term loans payable  (728,847)  (271,153)
Principal repayments of capital lease obligations  (7,901)  - 
Proceeds from factoring facility  -   407,888 
Principal repayments of factoring facility  -   (407,888)
Proceeds from exercise of stock options  5,000   70,300 
NET CASH PROVIDED BY FINANCING ACTIVITIES  1,269,481   10,528,737 
INCREASE (DECREASE) IN CASH  (6,009,021)  6,393,806 
CASH — BEGINNING OF YEAR  6,570,215   176,409 
CASH — END OF YEAR $471,194  $6,570,215 
         
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION        
Cash paid for interest $103,068  $297,508 
         
Cash paid for income taxes $3,550  $13,770 
         
Noncash financing activities:        
Issuance of common stock in connection with conversion of notes payable $-  $1,704,487 
Cashless exercise of common stock purchase warrants $143  $- 
Recognition of deferred debt discount on convertible notes payable $1,250,000  $98,970 
Purchase of equipment through capital lease obligation $179,359  $- 

See notes to consolidated financial statements

F-25

VAPOR COrp.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1. ORGANIZATION, BASIS OF PRESENTATION AND RECENT DEVELOPMENTS

Organization

Vapor Corp. (the “Company”) is the holding company for its wholly owned subsidiaries Smoke Anywhere U.S.A., Inc. (“Smoke”) and IVGI Acquisition, Inc. The Company designs, markets and distributes vaporizers, e-liquids, electronic cigarettes and accessories under the emagine vapor™, Krave®, VaporX®, Hookah Stix®, Fifty-One®(also known as Smoke 51) and Alternacig® brands. “Vaporizers”, “Electronic cigarettes” or “e-cigarettes,” are battery-powered products that enable users to inhale nicotine vapor without smoke, tar, ash, or carbon monoxide.

The Company was originally incorporated as Consolidated Mining International, Inc. in 1985 as a Nevada corporation, and the Company changed its name in 1987 to Miller Diversified Corporation whereupon the Company operated in the commercial cattle feeding business until October 31, 2003 when the Company sold substantially all of its assets and became a discontinued operation. On November 5, 2009, the Company acquired Smoke Anywhere USA, Inc., a distributor of electronic cigarettes, in a reverse triangular merger. As a result of the merger, Smoke Anywhere USA, Inc. became the sole operating business. On January 7, 2010, the Company changed its name to Vapor Corp. The Company reincorporated to the State of Delaware from the State of Nevada effective on December 31, 2013.

Basis of Presentation and Reverse Stock Split

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).

Effective on December 27, 2013, the Company effected a reverse stock split of its common stock at a ratio of 1-for-5. No fractional shares of common stock were issued, and no cash or other consideration were paid as a result of the reverse stock split. Instead, the Company issued one whole share of post-reverse stock split common stock in lieu of each fractional share of common stock. As a result of the reverse stock split, the Company’s share capital was reduced to 51,000,000 shares from 251,000,000 shares, of which 50,000,000 shares are common stock and 1,000,000 shares are “blank check” preferred stock.

All references in these notes and in the related consolidated financial statements to number of shares, price per share and weighted average number of shares outstanding of common stock prior to the reverse stock split (including the share capital decrease) have been adjusted to reflect the reverse stock split (including the share capital decrease) on a retroactive basis, unless otherwise noted.

Merger with Vaporin, Inc.

As fully-disclosed in Note 4 to these consolidated financial statements, on December 17, 2014, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Vaporin, Inc., a Delaware corporation (“Vaporin”) pursuant to which Vaporin was to merge with and into the Company with the Company being the surviving entity. On the same date, the Company also entered into a joint venture with Vaporin (the “Joint Venture”) through the execution of an operating agreement (the “Operating Agreement”) of Emagine the Vape Store, LLC, a Delaware limited liability company (“Emagine”), pursuant to which the Company and Vaporin were 50% members of Emagine.

On March 4, 2015, the acquisition of Vaporin by the Company (the “Merger”) was completed pursuant to the terms of the Merger Agreement. In connection with the Merger, Emagine became a wholly-owned subsidiary of the Company.

Note 2. GOING CONCERN AND MANAGEMENT PLANS

The Company’s financial statements for the year ended December 31, 2014 indicate there is substantial doubt about its ability to continue as a going concern as the Company requires additional equity and/or debt financing to continue its operations. The Company must ultimately generate sufficient cash flow to met its obligations on a timely basis, attain profitability in its business operations, and be able to fund its long term business development and growth plans. The Company’s business will require significant amounts of capital to sustain operations and make the investments it needs to execute its longer-term business plan. The Company’s liquidity and capital resources have decreased as a result of the net loss of $13,852,249 that it incurred during the year ended December 31, 2014. At December 31, 2014, the Company’s accumulated deficit amounted to $15,231,903. At December 31, 2014, the Company had working capital of $127,874 compared to $11,657,615 at December 31, 2013, a decrease of $11,529,741. As described in Note 13 (Subsequent Events), on March 3, 2015, the Company and institutional and individual accredited investors entered in a securities purchase agreement pursuant to which the Company issued and sold, in a $3.5 million private placement ($2.9 million in net proceeds), 686,463 shares of common stock and warrants to purchase up to 547,026 shares of the Company’s common stock. The Company will use the net proceeds from the private placement for working capital. In addition, the Merger with Vaporin also provides an additional financing transaction to occur subsequent to the closing of the Merger for up to $25 million in exchange for common stock and warrants of the Company subject to the Company complying with certain financial covenants and performance-based metrics still to be negotiated.

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures, working capital and other financing requirements for the foreseeable future. We believe we will need to raise additional debt or equity financing to maintain and expand the business. Any equity financing or the issuance of equity equivalents including convertible debt could be dilutive to our shareholders. If either such additional capital is not available on terms acceptable to the Company or at all then the Company may need to curtail its operations and/or take additional measures to conserve and manage its liquidity and capital resources, any of which would have a material adverse effect on our business, results of operations and financial condition.

Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of consolidation

The accompanying consolidated financial statements include the accounts of the Company, its wholly owned subsidiary, Smoke Anywhere USA, Inc., and its 50% joint venture interest in Emagine the Vape Store, LLC. All significant intercompany transactions and balances were eliminated.

Use of estimates in the preparation of financial statements

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include allowances, reserves and write-downs of receivables and inventory, valuing equity securities and hybrid instruments, share-based payment arrangements, deferred taxes and related valuation allowances, and the preliminary valuation of the net assets acquired subsequent to December 31, 2014 in the Merger. Certain of our estimates could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary.

Revenue recognition

The Company recognizes revenue from product sales or services rendered when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.

Product sales and shipping revenues, net of promotional discounts, rebates, and return allowances, are recorded when the products are shipped, title passes to customers and collection is reasonably assured. Retail sales to customers are made pursuant to a sales contract that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier. Return allowances, which reduce product revenue, are estimated using historical experience. Revenue from product sales and services rendered is recorded net of sales and consumption taxes.

The Company periodically provides incentive offers to its customers to encourage purchases. Such offers include current discount offers, such as percentage discounts off current purchases, inducement offers, such as offers for future discounts subject to a minimum current purchase, and other similar offers. Current discount offers, when accepted by the Company’s customers, are treated as a reduction to the purchase price of the related transaction, while inducement offers, when accepted by its customers, are treated as a reduction to the purchase price of the related transaction based on estimated future redemption rates. Redemption rates are estimated using the Company’s historical experience for similar inducement offers. The Company reports sales, net of current discount offers and inducement offers on its consolidated statements of operations.

Shipping and Handling Costs

The Company policy is to provide free standard shipping and handling for most orders shipped during the year. Shipping and handling costs incurred are recognized in selling, general and administrative expenses. Such amounts aggregated $661,583 and $658,586 for the years ended December 31, 2014 and 2013 respectively.

In certain circumstances, shipping and handling costs are charged to the customer and recognized in sales, net. The amounts recognized for the years ended December 31, 2014 and 2013 were $71,225 and $129,761, respectively.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. For financial statement purposes, investments in money market funds are considered a cash equivalent and are included in cash and cash equivalents. The Company maintains its cash and cash equivalents at high credit quality federally insured financial institutions, with balances, at times, in excess of the Federal Deposit Insurance Corporation’s insurance coverage limit of $250,000 per federally insured financial institution. Management believes that the financial institutions that hold the Company’s deposits are financially sound and, therefore, pose a minimum credit risk. The Company has not experienced any losses in such accounts. At December 31, 2014 and 2013, the Company did not hold cash equivalents.

Accounts Receivable

Accounts receivable, net is stated at the amount the Company expects to collect. The Company provides a provision for allowances that includes returns, allowances and doubtful accounts equal to the estimated uncollectible amounts. The Company estimates its provision for allowances based on historical collection experience and a review of the current status of trade accounts receivable. It is reasonably possible that the Company’s estimate of the provision for allowances will change.

Due From Merchant Credit Card Processor

Due from merchant credit card processor represents monies held by the Company’s credit card processors. The funds are being held by the merchant credit card processors pending satisfaction of their hold requirements and expiration of charge backs/refunds from customers.

Inventories

Inventories are stated at the lower of cost (determined by the first-in, first-out method) or market. If the cost of the inventories exceeds their market value, provisions are recorded to write down excess inventory to its net realizable value. The Company’s inventories consist primarily of merchandise available for resale.

Property and equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the respective asset, after the asset is placed in service. The Company generally uses the following depreciable lives for its major classifications of property and equipment:

Description

Useful Lives

Warehouse fixtures2 years
Warehouse equipment5 years
Furniture and fixtures5 years
Computer hardware3 years

Impairment of Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. In connection with this review, the Company also reevaluates the depreciable lives for these assets. The Company assesses recoverability by determining whether the net book value of the related asset will be recovered through the projected undiscounted future cash flows of the asset. If the Company determines that the carrying value of the asset may not be recoverable, it measures any impairment based on the projected future discounted cash flows as compared to the asset’s carrying value. Through December 31, 2014, the Company has not recorded any impairment charges on its long-lived assets.

Advertising

The Company expenses advertising cost as incurred.

Warranty liability

The Company’s limited lifetime warranty policy generally allows its end users and retailers to return defective purchased rechargeable products in exchange for new products. The Company estimates a reserve for warranty liability and records that reserve amount as a reduction of revenues and as an accrued expense on the accompanying consolidated balance sheets. The warranty claims and expense was not deemed material for the years ended December 31, 2014 and 2013.

Income taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740.”) Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Product Development

The Company includes product development expenses relating to the commercialization of new products which are expensed as incurred as part of operating expenses. Product development expenses for the years ended December 31, 2014 and 2013 were approximately $312,000 and $174,000, respectively.

Fair value measurements

The Company applies the provisions of Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” (“ASC 820”). The Company’s short term financial instruments include cash, due from merchant credit card processors, accounts receivable, accounts payable and accrued expenses, each of which approximate their fair values based upon their short term nature. The Company’s other financial instruments include notes payable obligations. The carrying value of these instruments approximate fair value, as they bear terms and conditions comparable to market, for obligations with similar terms and maturities.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities; Level 2 – quoted prices for similar assets and liabilities in active market or inputs that are observable; and Level 3 – inputs that are unobservable.

Stock-Based Compensation

The Company accounts for stock-based compensation under ASC 718, “Compensation-Stock Compensation” (“ASC 718”). These standards define a fair value based method of accounting for stock-based compensation. In accordance with ASC Topic 718, the cost of stock-based compensation is measured at the grant date based on the value of the award and is recognized over the vesting period. The value of the stock-based award is determined using the Black-Scholes-Merton valuation model, whereby compensation cost is the fair value of the award as determined by the valuation model at the grant date or other measurement date. The resulting amount is charged to expense on the straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.

Derivative Instruments

The Company accounts for free-standing derivative instruments and hybrid instruments that contain embedded derivative features in accordance with ASC Topic No. 815, “Accounting for Derivative Instruments and Hedging Activities,” (“ASC 815”) as well as related interpretations of this topic. In accordance with this topic, derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair values with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument.

The Company estimates fair values of derivative instruments and hybrid instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective of measuring fair values. In selecting the appropriate technique, the Company considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex instruments, such as free-standing warrants, the Company generally uses the Black-Scholes-Merton valuation model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as the Black-Scholes-Merton valuation model) are highly volatile and sensitive to changes in the trading market price of the Company’s common stock. Since derivative financial instruments are initially and subsequently carried at fair values, the Company’s income (loss) going forward will reflect the volatility in these estimates and assumption changes. Under ASC 815, increases in the trading price of the Company’s common stock and increases in fair value during a given financial quarter result in the application of non-cash derivative expense. Conversely, decreases in the trading price of the Company’s common stock and decreases in trading fair value during a given financial quarter result in the application of non-cash derivative income.

Convertible Debt Instruments

The Company accounts for convertible debt instruments when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with ASC 470-20 “Debt with Conversion and Other Options”. The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. The Company amortizes the respective debt discount over the term of the notes, using the straight-line method, which approximates the effective interest method. The Company records, when necessary, induced conversion expense, at the time of conversion for the difference between the reduced conversion price per share and the original conversion price per share.

Lease Accounting

The Company evaluates each lease for classification as either a capital lease or an operating lease. If substantially all of the benefits and risks of ownership have been transferred to the Company as lessee, the Company records the lease as a capital lease at its inception. The Company performs this evaluation at the inception of the lease and when a modification is made to a lease. If the lease agreement calls for a scheduled rent increase during the lease term, the Company recognizes the lease expense on a straight-line basis over the lease term. The Company determines the straight-line rent impact of an operating lease upon inception of the lease.

Recent Accounting Pronouncements

The Financial Accounting Standards Board (“FASB”) has issued Accounting Standards Update (“ASU”) No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position and results of operations.

The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The Company is currently evaluating the potential impact, if any, the adoption of this standard will have on the Company’s consolidated financial position and results of operations.

The FASB has issued ASU No. 2014-15,Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The guidance, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company has elected to early adopt the provisions of ASU 2014-15 in connection with the issuance of these consolidated financial statements. Information regarding the substantial doubt relating to the Company’s ability to continue as a going concern has been disclosed in Note 2.

Note 4. MERGER WITH VAPORIN, INC.

Merger with Vaporin, Inc.

On December 17, 2014, the Company entered into the Merger Agreement with Vaporin pursuant to which Vaporin was to merge with and into the Company with Vapor being the surviving entity. The Merger closed on March 4, 2015 whereby 100% of the issued and outstanding shares of Vaporin common stock (including shares of common stock issued upon conversion of Vaporin preferred stock immediately prior to the consummation of the merger in accordance with the Merger Agreement) were converted into, and became 2,718,307 shares of the Company’s common stock such that the former Vaporin stockholders collectively hold approximately 45% of the issued and outstanding shares of the Company’s common stock following consummation of the Merger. The options and warrants to acquire Vaporin common stock that were issued and outstanding as of the effective time of the Merger, as well as 182 ,000 restricted stock units which were exchangeable for Vaporin common stock, were assumed by the Company in the merger and the number of shares issued under such securities were adjusted to give effect to the Per Share Merger Consideration (as defined in the Merger Agreement).

Pursuant to the terms of the Merger Agreement, the Company completed actions to cause its board of directors immediately following the consummation of the merger to be comprised of (x) three directors chosen by the Company’s Board of Directors (at least two of whom shall be independent for purposes of the Nasdaq listing rules) and (y) two directors chosen by the Vaporin Board or Directors (at least one of whom shall be independent for purposes of the Nasdaq listing rules), each to serve for a term expiring on the earlier of his or her death, resignation, removal or the Company’s next annual meeting of stockholders and, despite the expiration of his or her term, until his or her successor has been elected and qualified or there is a decrease in the size of the Company’s Board of Directors. If at any time prior to the effective time of the merger, any such board designee becomes unable or unwilling to serve as a director of the Company following consummation of the merger, then the party that designated such individual shall designate another individual to serve in such individual’s place.

The Merger Agreement contained customary representations and warranties of the Company and Vaporin relating to their respective businesses. The Company and Vaporin have agreed to use commercially reasonable efforts to preserve intact its business organization and that of its significant subsidiaries, as well as maintain its rights, franchises and existing relations with customers, suppliers and employees. The Merger Agreement also contains covenants by each party to furnish current information to the other party.

The Company has also agreed that, for a period of six years following the closing date of the merger, it will indemnify, defend and hold harmless each officer and director of Vaporin and its subsidiaries against losses arising from such person’s status as an officer or director of Vaporin or any of its subsidiaries prior to the effective time of the merger. The Company has also agreed to cover such directors and officers with its existing directors’ and officers’ insurance policy or obtain a six-year “tail” policy, in each case with coverages not less advantageous as Vaporin’s existing policy, provided, however, that the Company will not be required to pay more than 200% of Vaporin’s current premium for such insurance.

The Merger Agreement contained customary conditions that were satisfied prior to the closing of the merger, including the requirement for the Company to receive gross proceeds from a $3.5 million equity offering disclosed in Note 13. Additionally, the Company must have received commitments from certain third parties for financing of up to $25 million to be used for the construction of retail stores and which is contingent on the achievement of certain performance metrics by the Company.

The fair value of the purchase consideration issued to the sellers of Vaporin was allocated to fair value of the net tangible assets acquired, with the resulting excess allocated to separately identifiable intangibles, and the remainder recorded as goodwill. Goodwill recognized from the transactions mainly represented the expected operational synergies upon acquisition of the combined entity and intangibles not qualifying for separate recognition. Goodwill is not expected to be deductible for income tax purposes in the tax jurisdiction of the acquired business.

The Company has not completed its evaluation of the purchase price allocation as it is currently conducting a thorough analysis to identify the intangible assets acquired, including whether or not any goodwill is to be recorded, in the Merger and determine the proper allocation of the fair value of such assets with the assistance of a third-party appraiser.

The following table presents the unaudited pro-forma financial results, as if the acquisition of Vaporin had been completed as of January 1, 2013 and 2014:

  For the Years Ended
December 31,
 
  2014  2013 
Revenues $20,253,052  $28,259,309 
Net (loss) income $(19,595,702) $415,316 
Loss per share - basic and diluted $( 2.95) $0. 05 

The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the acquisition been completed as of January 1, 2013 or to project potential operating results as of any future date or for any future periods.

The Joint Venture

On December 17, 2014, the Company and Vaporin agreed to enter into the Joint Venture through Emagine, a Delaware limited liability company of which the Company and Vaporin are 50% members. The Operating Agreement provides that Vaporin will serve as the initial manager of Emagine and will manage the day-to-day operations of Emagine, subject to certain customary limitations on managerial actions that require the unanimous consent of the Company and Vaporin, including but not limited to making or guaranteeing loans, distributing cash or other property to the members of Emagine, entering into affiliate transactions, amending or modifying limited liability company organizational documents, and redeeming or repurchasing membership interests from any of the members.

The purpose of the Joint Venture was to obtain and build-out retail stores for the sale of the Company and Vaporin’s products under the “Emagine Vapor” name or “The Vape Store, Inc.” name or other brands of the respective parties. The parties originally planned to finance the retail stores through third party loan financing secured by a blanket lien on the assets of Emagine. In connection with the Joint Venture, Emagine entered into a Secured Line of Credit Agreement, pursuant to which certain third parties have agreed to provide debt financing of up to $3 million to Emagine to finance the Joint Venture. The Company has accounted for the joint venture under the equity method of accounting for investments. For the year ended December 31, 2014, the operations of the joint-venture were immaterial.

In connection with the completion of the Merger on March 4, 2015, Emagine became a wholly-owned subsidiary of the Company.

Note 5. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

  December 31, 
  2014  2013 
Computer hardware $389,373  $12,471 
Furniture and fixtures  347,612   19,821 
Warehouse fixtures  7,564   7,564 
Warehouse equipment  16,708   16,708 
Leasehold improvements  35,076   - 
   796,333   56,564 
Less: accumulated depreciation and amortization  (84,314)  (27,879)
  $712,019  $28,685 

During the year ended December 31, 2014 and 2013, the Company incurred $56,435 and $11,284, respectively, of depreciation expense.

Note 6. NOTES PAYABLE

$1,250,000 Senior Convertible Notes Payable to Related Parties

On November 14, 2014, the Company entered into securities purchase agreements with certain accredited investors who are also stockholders of Vaporin providing for the sale of $1,250,000 in aggregate principal amount of the Company’s senior convertible notes (the “$1,250,000 Senior Convertible Notes”) and common stock purchase warrants to purchase up to an aggregate of 227,273 shares of the Company’s common stock, $0.001 par value per share with an exercise price of $ 10 .00 per share. The $1,250,000 Senior Convertible Notes accrue interest on the outstanding principal at an annual rate of 7% per annum. The principal and accrued interest on the Notes are due and payable on November 14, 2015, the maturity date of the Notes. The terms of the $1,250,000 Senior Convertible Notes included customary anti-dilution protection and also included “piggy-back” registration rightsinvestment power with respect to the shares of common stock underlyingindicated as beneficially owned by them. The table does not include unvested options that do not vest within 60 days of the $1,250,000 Senior Convertible Notesdate listed above in this footnote.

(2)Holman. Chairman and warrants. Chief Executive Officer. Includes 39,000,000,000 vested options and 10,587,500,000 shares of unvested restricted Common Stock. This restricted stock vests in 1,512,500,000 increments on the last day of each calendar quarter commencing June 30, 2021.
(3)Santi. President and Chief Operation Officer. Includes 17,000,000,000 vested options and 7,700,000,000 shares of unvested restricted Common Stock. This restricted stock vests in 1,100,000,000 increments on the last day of each calendar quarter commencing June 30, 2021.
(4)Ollet. Chief Financial Officer. Includes 5,000,000,000 vested options. He also holds 2,875,500,000 shares of unvested restricted Common Stock. This restricted stock vests in 412,500,000 increments on the last day of each calendar quarter commencing June 30, 2021.
(5)Panariello. A director. Includes 1,000,000,000 vested options. He also holds 481,250,000 shares of unvested restricted Common Stock. This restricted stock vests in 68,750,000 increments on the last day of each calendar quarter commencing June 30, 2021.
(6)Friedman. A director. Includes 990,000,000 vested options and 510,000,000 shares of common stock.
(7)Directors and Executive Officers. Includes executive officers who are not Named Executive Officers under the SEC’s rules and regulations.




52

LEGAL MATTERS

The validity of the securities offered hereby will be passed upon for us by Cozen O’Connor P.C., Miami, Florida. The dealer-manager is being represented by Ellenoff Grossman & Schole, LLP, New York, New York.

EXPERTS

The financial statements as of December 31, 2020 and 2019 and for each of the two years in the period ended December 31, 2020, and the related financial statement schedule, incorporated in this prospectus by reference from the 2020 Form 10-K, have been audited by Marcum LLP, an independent registered public accounting firm, as stated in their reports, which are incorporated herein by reference. Such financial statements and financial statement schedules have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We make periodic filings and other filings required to be filed by us as a reporting company under Sections 13 and 15(d) of the Exchange Act. The SEC maintains a website at http://www.sec.gov that contains the reports, proxy and information statements, and other information that issuers, such as us, file electronically with the SEC. Our website address is https://healthiercmc.com. Information contained on our website, however, is not, and should not be deemed to be, incorporated into this prospectus and you should not consider information contained on our website to be part of this prospectus. We have included our website address as an inactive textual reference only.

This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the documents establishing the terms of the Notes provide thatoffered securities are or may be filed as exhibits to the Company may prepayregistration statement or documents incorporated by reference in the outstanding principal amountregistration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the Notes,relevant matters. You may inspect a copy of the registration statement through the SEC’s website, as provided above.

INCORPORATION BY REFERENCE

The SEC’s rules allow us to “incorporate by reference” information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus. Any statement contained in wholethis prospectus or in part,a previously filed document incorporated by payingreference will be deemed to be modified or superseded for purposes of this prospectus to the holders thereof an amountextent that a statement contained in cash equalthis prospectus modifies or replaces that statement:

our Current Reports on Form 8-K filed with the SEC on March 29, 2021.

In addition to 115%the filings listed above, any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the principal amount to be redeemed, together with accrued but unpaid interest thereon and any and all other sums due, accruedSecurities Exchange Act of 1934, as amended, or payable to such holders throughthe Exchange Act, after (i) the date of such redemption payment. In connection withthis registration statement and prior to effectiveness of this registration statement and (ii) the date of this prospectus and before the completion of the securities purchase agreement for the $1,250,000 Senior Convertible Notes, the Company incurred financing costs of $139,667, which are being amortized on a straight-line basis, which approximates the interest rate method, over the one-year maturity periodoffering of the $1,250,000 Senior Convertible Notes. The Company incurred $17,458securities included in amortization expense of the deferred financing costs during the year ended December 31, 2014.

The Notes are convertible into shares of the Company’s Common Stock at any time, in whole or in part, at the option of the holder thereof at a conversion price of $ 5.50 per share (the “Conversion Price”). The Conversion Price is subject to customary adjustment upon the occurrence of certain events, including but not limited to stock dividends, stock splits, subsequent rights offerings of the Company, pro rata distributions of the Company, and in connection with a “Fundamental Transaction” (as such term is defined in the securities purchase agreement, which includes, without limitation, mergers, consolidations, a sale of all or substantially all of the assets of the Company, transactions effecting a change in control of the Company and other similar transactions).

In connection with the sale and issuance of the $1,250,000 Senior Convertible Notes, the Company also issued warrants to acquire an aggregate of 227,273 shares of the Company’s common stock. The Warrants are exercisable after 180 days from the date of issuance, or May 14, 2015, until the fifth anniversary of such date of issuance at an exercise price of $ 10 .00 per share (subject to certain customary adjustments upon the occurrence of certain events, including but not limited to stock dividends, stock splits, subsequent rights offerings of the Company, pro rata distributions of the Company, and in connection with a Fundamental Transaction. Palladium Capital Advisors, LLC acted as the exclusive placement agent for the $1,250,000 Senior Convertible Notes and, as compensation therefor, the Company paid Palladium Capital Advisors, LLC a placement agent fee of $62,500, included as part of financing fees described above, and issued to them a common stock warrant to purchase up to 11,364 shares of our common stock at an initial exercise price of $ 10 .00 per share. The warrant is immediately exercisable and expires on November 14, 2019. The exercise price and number of shares of common stock issuable under the warrant are subject to customary anti-dilutive adjustments for stock splits, stock dividends, recapitalizations and similar transactions. At any time the warrant may be exercised by means of a “cashless exercise” and the Companythis prospectus, however, we will not receiveincorporate by reference any proceeds at such time.

On the date of the issuance of the $1,250,000 Senior Convertible Notes, the Company recorded a debt discount of $1,250,000, of which $701,250 was allocated on a relative fair value basis to the warrants issued and the remaining $548,750 was allocated on a relative fair value basis to the conversion feature embedded within the $1,250,000 Senior Convertible Notes. The debt discount will be amortized using the effective interest method over the life of the $1,250,000 Senior Convertible Note, as applicable,document or until such time that the $1,250,000 Senior Convertible Notes are converted, in full or in part, into shares of common stock of the Company with any unamortized debt discount continuing to be amortized in the event of any partial conversionportions thereof and any unamortized debt discount being expensed at such time of full conversion thereof. During the year ended December 31, 2014, the Company recorded an aggregate $156,250 in non-cash interest expense related to the amortization of the debt discount, which is included in interest expense in the accompanying consolidated statement of operations.

$300,000 Senior Convertible Notes Payable to Related Parties

On June 19, 2012, the Company entered into securities purchase agreements with Kevin Frija, its former Chief Executive Officer, Harlan Press, its former Chief Financial Officer, and Doron Ziv, a then greater than 10% stockholder of the Company, pursuant to which Messrs. Frija, Press and Ziv purchased from the Company (i) $300,000 aggregate principal amount of the Company’s senior convertible notes (the “$300,000 Senior Convertible Notes”) and (ii) common stock purchase warrants to purchase up to an aggregate of 1,861 shares of the Company’s common stock.

The Company incurred interest expense of $48,674 during 2013 on the $300,000 Senior Convertible Notes until they were converted in full into 56,338 shares of the Company’s common stock and fully extinguished in conjunction with completion of the Private Placement (as defined in Note 9), on October 29, 2013.

$50,000 Senior Convertible Notes Payable to Related Parties

On September 28, 2012, the Company entered into a securities purchase agreement with Kevin Frija, its former Chief Executive Officer, pursuant to which Mr. Frija purchased from the Company (i) a $50,000 principal amount senior convertible note of the Company (the “$50,000 Senior Convertible Note”) and (ii) common stock purchase warrants to purchase up to an aggregate of 275 shares of the Company’s common stock.

The Company incurred interest expense of $8,113 during 2013 on the $50,000 Senior Convertible Notes until they were converted in full into 8,333 shares of the Company’s common stock and fully extinguished in conjunction with completion of the Private Placement (as defined in Note 9), on October 29, 2013. During the year ended December 31, 2013, the Company recorded $3,530 in amortization expense related to the debt discount, which is included in interest expense in the accompanying consolidated statements of operations.

$350,000 Senior Convertible Notes Payable to Related Parties

On July 9, 2013, the Company entered into securities purchase agreements with Ralph Frija, the father of the Company’s former Chief Executive Officer Kevin Frija and a less than 5% stockholder of the Company, Philip Holman, the father of the Company’s Chief Executive Officer Jeffrey Holman and a less than 5% stockholder of the Company, and Angela Vaccaro, the Company’s Controller, pursuant to which Messrs. Frija and Holman and Ms. Vaccaro (each, a “Purchaser”) purchased from the Company (i) $350,000 aggregate principal amount of the Company’s senior convertible notes (the “$350,000 Senior Convertible Notes”) and (ii) common stock purchase warrants to purchase up to an aggregate of 675 shares of the Company’s common stock (the “Warrants”) allocable among such Purchasers as follows:

● Ralph Frija purchased a Convertible Note in the principal amount of $200,000 and a Warrant to purchase up to 385 shares of the Company’s common stock (which number of shares represents the quotient obtained by dividing (x) $10,000 (5% of the $200,000 principal amount of the Convertible Note) by (y) $5.19 (the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding July 9, 2013));
Philip Holman purchased a Convertible Note in the principal amount of $100,000 and a Warrant to purchase up to 964 shares of the Company’s common stock (which number of shares represents the quotient obtained by dividing (x) $5,000 (5% of the $100,000 principal amount of the Convertible Note) by (y) $5.19 (the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding July 9, 2013)); and
Ms. Vaccaro purchased a Convertible Note in the principal amount of $50,000 and a Warrant to purchase up to 482 shares of the Company’s common stock (which number of shares represents the quotient obtained by dividing (x) $2,500 (5% of the $50,000 principal amount of the Convertible Note) by (y) $ 25.95 (the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding July 9, 2013)).

The Convertible Notes issued on July 9, 2013 bear interest at 18% per annum, provide for cash interest payments on a monthly basis, mature on July 8, 2016, are redeemable at the option of the holders at any time after July 8, 2014, subject to certain limitations, are convertible into shares of the Company’s common stock at the option of the holders at an initial conversion price of $ 28.55 per share (which represents 110% of the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding July, 9, 2013) subject to certain anti-dilution protection and are senior unsecured obligations of the Company.

The Company incurred interest expense of $16,126 during 2013 on the $350,000 Senior Convertible Notes. In conjunction with completion of the Private Placement (as defined in Note 9), on October 29, 2013, the conversion price was reduced to $ 15 .00 per share inducing the holders of $350,000 Senior Convertible Notes to fully convert all of these senior convertible notes into 23,334 shares of our common stock, whereupon all of these senior convertible notes were fully extinguished and cease to be outstanding. During the year ended December 31, 2013, the Company recorded $246,375 in induced conversion expense related to the reduction in the conversion price for the $350,000 Senior Convertible Notes. The induced conversion expense is included in other expense in the accompanying consolidated statements of operations.

The Company recorded $4,550 as debt discount on the principal amount of the $350,000 Senior Convertible Notes issued on July 9, 2013 due to the valuation of the Warrants issued in conjunction therewith. Additionally, as a result of issuing the Warrants with the $350,000 Senior Convertible Notes, a beneficial conversion option was recorded as a debt discount reflecting the incremental conversion option intrinsic value benefit of $3,937, at the time of issuance provided to the holders of the Notes. The debt discounts applicable to the $350,000 Senior Convertible Notes was amortized, using the straight-line method, over the life of the $350,000 Senior Convertible Notes, until October 29, 2013 when the $350,000 Senior Convertible Notes were converted in full into shares of common stock of the Company. The remaining unamortized debt discounts was expensed at the time of the conversion. During the year ended December 31, 2013, the Company recorded $4,550 and $3,937 in amortization expense related to the debt discounts and the beneficial conversion option, respectively. The amortization expense related to the debt discounts and the beneficial conversion option is included in interest expense in the accompanying consolidated statements of operations.

The Warrants issued on July 9, 2013 are exercisable at initial exercise prices of $ 28.55 per share (which represents 110% of the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding July 9, 2013) subject to certain anti-dilution protection and may be exercised at the option of the holders for cash or on a cashless basis until July 8, 2018.

$75,000 Senior Convertible Notes Payable to Related Parties

On July 11, 2013, the Company and Ms. Vaccaro entered into another Securities Purchase Agreement pursuant to which she purchased (i) a Convertible Note in the principal amount of $75,000 (the “$75,000 Senior Convertible Note”) and (ii) a Warrant to purchase up to 144 shares of the Company’s common stock (which number of shares represents the quotient obtained by dividing (x) $3,750 (5% of the $75,000 principal amount of the Convertible Note) by (y) $ 26.135 (the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding July 11, 2013)).

The Convertible Note issued on July 11, 2013 is the same as the Convertible Notes issued on July 9, 2013 except that it matures on July 10, 2016, it is redeemable on July 10, 2014 and its initial conversion price is $ 28.75 per share. The Warrant issued on July 11, 2013 is the same as the Warrants issued on July 9, 2013 except that its initial exercise price is $ 28 .75 per share and it is exercisable until July 10, 2018.

The Company incurred interest expense of $3,957 during 2013 on the $75,000 Senior Convertible Notes. In conjunction with completion of the Private Placement (as defined in Note 9), on October 29, 2013, the conversion price was reduced to $ 15 .00 per share inducing the holder of the $75,000 Senior Convertible Note to fully convert all of these senior convertible notes into 5,000 shares of our common stock, whereupon all of these senior convertible notes were fully extinguished and cease to be outstanding. During the year ended December 31, 2013, the Company recorded $53,202 in induced conversion expense related to the reduction in the conversion price for the $75,000 Senior Convertible Note. The induced conversion expense is included in other expense in the accompanying consolidated statements of operations.

The Company recorded $825 as debt discount on the principal amount of the $75,000 Senior Convertible Note issued on July 11, 2013 due to the valuation of the Warrant issued in conjunction therewith. The debt discount applicable to the $75,000 Senior Convertible Note was amortized, using the straight-line method, over the life of the $75,000 Senior Convertible Note, until October 29, 2013 when the $75,000 Senior Convertible Note was converted in full into shares of common stock of the Company. The remaining unamortized debt discounts was expensed at the time of the conversion. During the year ended December 31, 2013, the Company recorded $825 in amortization expense related to the debt discount, and is included in interest expense in the accompanying consolidated statements of operations.

The $300,000 Senior Convertible Notes, as amended, the $50,000 Senior Convertible Note, as amended, the $350,000 Senior Convertible Notes, and the $75,000 Senior Convertible Note did not restrict the Company’s ability to incur future indebtedness.

$500,000 Senior Convertible Note Payable to Stockholder

On July 9, 2012, the Company borrowed $500,000 from Ralph Frija, the father of the Company’s former Chief Executive Officer Kevin Frija and a less than 5% stockholder of the Company, pursuant to a senior note (the “Senior Note”). The Senior Note, as amended (as described below), bears interest at 24% per annum, provides for cash principal and interest payments on a monthly basis, is a senior unsecured obligation of the Company, matures on April 22, 2016, is convertible into shares of the Company’s common stock at the option of the holder at an initial conversion price of $ 12.885 per share (which represents 110% of the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding April 30, 2013) subject to certain anti-dilution protection and is a senior unsecured obligation of the Company.

Initially, this Senior Note provided for only cash interest payments on a monthly basis, matured at the discretion of the Company on the earlier of (x) the date on which the Company consummated a single or series of related financings from which it received net proceeds in excess of 125% of the initial principal amount of the Senior Note or (y) January 8, 2013 and was not convertible at the option of the holder into shares of the Company’s common stock. On November 13, 2012, the Company and the above named holder of the $500,000 Senior Note amended the Note to extend its maturity date for payment from January 8, 2013 to January 8, 2014. On April 30, 2013, the Company and the above named holder of the Senior Note further amended the Note to provide for cash principal and interest payments on a weekly basis, extend the maturity date for payment to April 22, 2016 and make the Note convertible into shares of the Company’s common stock at the option of the holder at an initial conversion price of $ 12.885 per share (which represents 110% of the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding April 30, 2013) subject to certain anti-dilution protection.

The Company incurred interest expense of $93,267 during 2013 on the $50,000 Senior Convertible Notes until they were converted in full into 33,332 shares of the Company’s common stock and fully extinguished in conjunction with completion of the Private Placement (as defined in Note 9), on October 29, 2013.

$500,000 Senior Convertible Note Payable

On January 29, 2013, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Robert John Sali, pursuant to which Mr. Sali purchased from the Company (i) a $500,000 principal amount senior convertible note of the Company (the “2013 Convertible Note”) and (ii) common stock purchase warrants to purchase up to an aggregate of 1,628 shares of the Company’s common stock (the “Warrant”) (which number of shares represents the quotient obtained by dividing (x) $25,000 (5% of the $500,000 principal amount of the 2013 Convertible Note) by (y) $ 15.35 (the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding January 29, 2013)). The Company generated aggregate proceeds of $500,000 from the sale of these securities pursuant to the Securities Purchase Agreement.

The 2013 Convertible Note bears interest at 18% per annum, provides for cash interest payments on a monthly basis, matures on January 28, 2016, is redeemable at the option of the holder at any time after January 28, 2014 subject to certain limitations, is convertible into shares of the Company’s common stock at the option of the holder at an initial conversion price of $ 16.888 per share (which represents 110% of the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding January 29, 2013) subject to certain anti-dilution protection and is a senior unsecured obligation of the Company. The 2013 Convertible Note does not restrict the Company’s ability to incur future indebtedness.

The Company incurred interest expense of $66,329 during 2013 on the $50,000 Senior Convertible Notes until they were converted in full into 148,039 shares of the Company’s common stock and fully extinguished in conjunction with completion of the Private Placement (as defined in Note 9), on October 29, 2013.

The Warrant is exercisable at initial exercise price of $ 16.888 per share (which represents 110% of the 30-day weighted average closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, preceding January 29, 2013) subject to certain anti-dilution protection and may be exercised at the option of the holder for cash or on a cashless basis until January 28, 2018.

The Company recorded $10,131 as debt discount on the principal amount of the 2013 Senior Convertible Note issued on January 29, 2013 due to the valuation of the Warrant issued in conjunction therewith. Additionally, as a result of issuing the Warrant with the 2013 Senior Convertible Note, a beneficial conversion option was recorded as a debt discount reflecting the incremental conversion option intrinsic value benefit of $79,527, at the time of issuance provided to the holder of the Note. The debt discounts applicable to the 2013 Convertible Note was amortized, using the straight-line method, over the life of the 2013 Convertible Note, until October 29, 2013 when the 2013 Convertible Note was converted in full into shares of common stock of the Company. The remaining unamortized debt discounts was expensed at the time of the conversion. During the year ended December 31, 2013, the Company recorded $10,131 and $79,527 in amortization expense related to the debt discounts and the beneficial conversion option, respectively. The amortization expense related to the debt discounts and the beneficial conversion option is included in interest expense in the accompanying consolidated statements of operations.

Note 7. FACTORING FACILITY AND TERM LOAN PAYABLE

Factoring Facility

On August 8, 2013, the Company and Smoke entered into an accounts receivable factoring facility (the “Factoring Facility”) with Entrepreneur Growth Capital, LLC (the “Lender”) pursuant to an Invoice Purchase and Sale Agreement, dated August 8, 2013, by and among them (the “Factoring Agreement”).

The Factoring Facility has an initial term of one year and automatically renews from month to month thereafter subject to the Company terminating it earlier upon at least 15 business days’ advance written notice provided that all obligations are paid (including a termination fee, if applicable, as specified in the Factoring Agreement). The Factoring Facility is secured by a security interest in substantially all of the Company’s assets. Under the terms of the Factoring Agreement, the Lender may, at its sole discretion, purchase certain of the Company’s eligible accounts receivable. Upon any acquisition of an account receivable, the Lender will advance to the Company up to 50% of the face amount of the account receivable. Each account receivable purchased by the Lender will be subject to a factoring fee of 1% of the gross face amount of such purchased account for each 30 day period (or part thereof) the purchased account remains unpaid. The Lender will generally have full recourse against the Company in the event of nonpayment of any such purchased account.

The Factoring Agreement contains covenants and provisions relating to events of default that are customary for agreements of this type. The failure to satisfy covenants under the Factoring Agreement or the occurrence of other specified events that constitute an event of default could result in the termination of the Factoring Facility and/or the acceleration of the repayment obligations of the Company.

During the year ended December 31, 2013 gross borrowings under the Factoring Facility were $407,888, all of which were repaid as of September 30, 2013. There were no borrowings during the year ended December 31, 2014.

2013 Term Loan

On August 16, 2013, the Company and Smoke entered into a $750,000 term loan (the “2013 Term Loan”) with the Lender pursuant to a Credit Card Receivables Advance Agreement, dated August 16, 2013, by and among them (the “Term Agreement”).

The Term Loan matured on August 15, 2014, was payable from the Company’s and Smoke’s merchant credit card receivables at the annual rate of 16% subject to the Lender retaining a daily fixed amount of $3,346 from the daily collection of the merchant credit card receivables and is secured by a security interest in substantially all of the Company’s assets. The Company used the proceeds of the Term Loan for general working capital purposes.

At December 31, 2013 the Company had $478,847 of borrowings outstanding under the 2013 Term Loan. During the year ended December 31, 2014 and 2013, the Company recorded $76,617 and $44,769, respectively, in interest expense for the 2013 Term Loan and this amount is included in interest expense in the accompanying consolidated statements of operations. The 2013 Term Loan was repaid in full during the year ended December 31, 2014.

2014 Term Loan

On September 23, 2014, the Company and Smoke entered into a $1,000,000 term loan (the “2014 Term Loan”) with the Lender pursuant to a secured promissory note entered into by the Company and Smoke in favor of the Lender (the “Secured Note”). Under the Secured Note, the 2014 Term Loan bears interest at 14% per annum and is secured by a security interest in substantially all of the Company’s assets. Under the Secured Note, the principal amount of the 2014 Term Loan is payable in twelve (12) successive monthly installments of $83,333 with the last payment due in September 2015. Interest on the 2014 Term Loan is payable in arrears. The Company used the proceeds of the 2014 Term Loan for general working capital purposes.

The Term Agreement contains covenants that are customary for agreements of this type. The failure to satisfy covenants under the Term Agreement or the occurrence of other specified events that constitute an event of default could result in the termination of the Term Agreement (as well as the Factoring Agreement) and/or the acceleration of the repayment of the Term Loan and the other obligations of the Company (including the Factoring Facility). The Term Agreement contains provisions relating to events of default that are customary for agreements of this type.

At December 31, 2014, the Company had $750,000 of borrowings outstanding under the 2014 Term Loan. During the year ended December 31, 2014, the Company recorded $24,086 in interest expense for the 2014 Term Loan and this amount is included in interest expense in the accompanying consolidated statements of operations.

The Company’s Chief Executive Officer and Former Chief Financial Officer have personally guaranteed performance of certain of the Company’s obligations under the Factoring Agreement and the Term Agreement. In consideration of the Company’s Former Chief Financial Officer providing the personal guarantee, the Company has agreed to amend his employment agreement as described in Note 9.

Note 8. CAPITAL LEASE OBLIGATIONS

On October 1, 2014, the Company entered into a capital lease obligation in connection with the acquisition of equipment for its retail locations in the principal amount of $179,359. Annual interest on the capital lease obligation is 15.8% and borrowings are to be repaid over 36 months maturing on October 17, 2017. During the year ended December 31, 2014, the Company incurred interest expense associated with the capital lease obligation of $4,679. Depreciation expense incurred during the year ended December 31, 2014 for equipment held under capital lease obligations was $9,964. The net book value of equipment held under capital lease obligations at December 31, 2014 is $169,395.

Future minimum lease payments under non-cancelable capital leases that have initial or remaining terms in excess of one year at December 31, 2014 are due as follows:

  Capital
Lease
 
2015 $75,485 
2016  75,485 
2017  62,904 
Total  213,874 
Amounts representing interest payments  (42,416)
Present value of future minimum payments  171,458 
Current portion of capital lease obligations  (52,015)
Capital lease obligations, long term $119,443 

Note 9. STOCKHOLDERS’ EQUITY

Preferred Stock

The Company’s amended and restated articles of incorporation authorizes the Company’s Board of Directors to issue up to 1,000,000 shares of “blank check” preferred stock, having a $0.001 par value, in one or more series without stockholder approval. Each such series of preferred stock may have such number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as determined by the Company’s Board of Directors. At December 31, 2014 and 2013, no shares of preferred stock were issued or outstanding.

Common Stock

The Company’s amended and restated articles of incorporation authorizes the Company’s Board of Directors to issue up to 50,000,000 shares of common stock having a par value of $0.001 per share. Each share entitles the holder to one vote.

Common Stock Issued for Services

On March 15 and June 15, 2013, the Company issued a total of 4,000 shares of common stock, pursuant to a consultancy agreement dated March 4, 2013. The Company terminated this consultancy agreement effective June 2013. Prior to termination of the agreement, the Company had agreed to issue on a quarterly basis common stock as compensation for services provided thereunder. The Company determined that the fair value of the common stock issued was more readily determinable than the fair value of the services provided. Accordingly, the Company recorded the fair market value of the stock as compensation expense. The Company valued the shares issued on March 15 and June 15, 2013 shares at $29,500 and $57,500, respectively, based on closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, on March 15 and June 15, 2013, respectively. During the year ended December 31, 2013, the Company recognized stock-based compensation expense in the amount of $87,000, which is included as part of selling, general and administrative expense in the accompanying consolidated statements of operations.

On February 3, 2014, the Company entered into a consulting agreement (the “Consulting Agreement”) with Knight Global Services, LLC (“Knight Global”) pursuant to which the Company retained Knight Global to assist the Company with increasing awareness of its electronic cigarette brands as well as assisting the Company to expand and diversify its relationships with large retailers and national chains. Knight Global is a wholly owned subsidiary of Knight Global, LLC of which Ryan Kavanaugh is an investor and principal. Effective March 5, 2014, the Board of Directors of the Company elected Mr. Kavanaugh as a member of the Board of Directors in accordance with the Consulting Agreement. Knight Global serves as the family office for Mr. Kavanaugh. Mr. Kavanaugh is the Founder and Chief Executive Officer of Relativity, a next-generation media company engaged in multiple aspects of entertainment, including film production; financing and distribution; television; sports management; music publishing; and digital media.

Under the terms of the Consulting Agreement, the Company has issued to Mr. Kavanaugh 80 ,000 shares of its common stock, of which 10 ,000 shares vested immediately upon execution of the Consulting Agreement, 10 ,000 shares vested on May 3, 2014, 10 ,000 shares vested on August 3, 2014, 10 ,000 shares vested on November 3, 2014 and 10 ,000 shares will vest in installments of 10 ,000 shares each quarterly period beginning on the 90th day following November 3, 2014 and each ensuing quarterly period thereafter so long as the Consulting Agreement has not been terminated and during each quarterly period Knight Global has presented the Company with a minimum of six (6) bona fide opportunities for activities specified in the Consulting Agreement that are intended to increase awareness of the Company’s electronic cigarettes. In addition, during the term of the Consulting Agreement, which is 2 years, and during an 18-month post-termination period, the Company has agreed to pay Knight Global commissions payable in cash equal to 6% of “net sales” (as defined in the Consulting Agreement) of its products to retailers introduced by Knight Global and to retailers with which the Company has existing relationships and with which Knight Global is able, based on its verifiable efforts, to increase net sales of the Company’s products. No commissions were paid under the consulting agreement during the year ended December 31, 2014.

The grant date fair value of the common shares issued on February 3, 2014 was $3,080,000 based on closing price per share of the Company’s common stock, as reported on the OTC Bulletin Board, on February 3, 2014. During the year ended December 31, 2014, the Company recognized stock-based compensation expense relating to the Consulting Agreement, in the amount of $1,602,933, which is included as part of selling, general and administrative expense in the accompanying consolidated statements of operations.

On January 24, 2015, the Company and Knight Global mutually agreed to terminate the Consulting Agreement as it was in the best interests of both parties to do so. As a result of such termination, the Company issued 10 ,000 shares of its common stock to Knight Global pursuant to the early termination provisions of the Consulting Agreement. The Company will incur $322,067 in connection with this final issuance during the first quarter of 2015. In addition, on January 24, 2015, the Company received notice from Ryan Kavanaugh, a director of the Company that he had resigned from the Company’s board of directors, effective immediately.

Private Placement of Common Stock

On October 22, 2013, the Company entered into a purchase agreement (the “Purchase Agreement”) with various institutional and individual accredited investors and certain of its officers and directors to raise gross proceeds of $10 million in a private placement of 666,668 shares of its common stock at a per share price of $ 15 .00 (the “Private Placement”). On October 29, 2013, the Company completed the Private Placement. The Company received net proceeds from the Private Placement of approximately $9.0 million, after paying placement agent fees and estimated offering expenses, which the Company used to fund its growth initiatives and for working capital purposes. Of the approximate $1 million in offering costs, approximately $110,000 were incurred during the year ended December 31, 2014.

Pursuant to the Purchase Agreement, concomitantly with completion of the Private Placement, the Company entered into a registration rights agreement with the investors (other than its participating officers and directors), pursuant to which the Company fileddeemed “filed” with the SEC, an initial registration statementor any information furnished pursuant to register for resale the 643,234 sharesItems 2.02 or 7.01 of the Company’s common stock purchasedForm 8-K or related exhibits furnished pursuant to Item 9.01 of Current Reports on Form 8-K.



53

The documents incorporated by the investors (other than the Company’s participating officers and directors). The initial registration statement was declared effective by the SECreference into this prospectus are also available on January 27, 2014. On March 5, 2014, the Company filed a post-effective amendment to the initial registration statement. The post-effective amendment to the initial registration statement was declared effective by the SEC on March 11, 2014. On June 20, 2014, the Company filed a second post-effective amendment to the initial registration statement. The second post-effective amendment to the initial registration statement was declared effective by the SEC on June 27, 2014. If the second post-effective amendment to the initial registration statement after being declared effective by the SEC is not effective for resales for more than 20 consecutive days or more than 45 days in any 12 month period during the registration period (i.e., the earlier of the date on which the shares have been sold or are eligible for sale under SEC Rule 144 without restriction), the Company is required to pay the investors (other than the Company’s participating officers and directors) liquidated damages in cash equal to 1.5% of the aggregate purchase price paid by the investors for the shares for every 30 days or portion thereof until the default is cured. These cash payments could be as much as $81,489 for every 30 days.

Under the terms of the Purchase Agreement, the Company:

Amended its existing equity incentive plan on November 20, 2013 to reduce the number of shares of its common stock reserved and available for issuance under the plan to 360,000 from 1,600,000 .
Effectuated a reverse stock split of its common stockour corporate website at a ratio of 1-for-5, which became effective in the marketplace at the opening of business December 27, 2013 (as disclosed in Note 1 above).
Reincorporated to the State of Delaware effective on December 31, 2013 (as disclosed in Note 1).
Reconstituted its board of directors effective April 25, 2014 so that the board of directors consists of five members, a majority of whom each qualify as an “independent director” as defined in NASDAQ Marketplace Rule 5605(a)(2) and the related NASDAQ interpretative guidance; and
Listed its common stock on The NASDAQ Capital Market effective May 30, 2014.

In conjunction with completion of the Private Placement, on October 29, 2013, the holders of the Company’s approximately $1.7 million of outstanding senior convertible notes, some of whom were officers and directors of the Company, converted in full all of these senior convertible notes into approximately 780,000 shares of the Company’s common stock, whereupon all of these senior convertible notes were fully extinguished and cease to be outstanding. See Note 6.

All of the warrants issued in conjunction with the convertible notes described in Note 6 and the Private Placement were evaluated in accordance with ASC 815 and were determined to be equity instruments. The Company estimated the fair value of these Warrants using the Black-Scholes-Merton valuation model. The significant assumptions which the Company used to measure their respective fair values included stock prices ranging from $ 5 .00 to $ 17 .50 per share, expected terms of 5 years, volatility ranging from 30.3% to 51.4%, risk free interest rates ranging from 0.71% to 0.90%, and a dividend yield of 0.0%.

Warrantshttps://healthiercmc.com

A summary of warrant activity for the years ended December 31, 2014 and 2013 is presented below:

  Number of
Warrants
  Weighted-
Average
Exercise Price
  Weighted-
Average
Contractual
Term
  Aggregate
Intrinsic
Value
 
Outstanding at January 1, 2013  2,135  $5.40         
Warrants granted  41,041   16.70         
Warrants exercised              
Warrants forfeited or expired              
Outstanding at December 31, 2013  43,176  $16.15         
Warrants granted  238,636   10.00         
Warrants exercised  ( 38,594)  16.50         
Warrants forfeited or expired              
Outstanding at December 31, 2014  243,218  $10.05   5.0  $ 
Exercisable at December 31, 2014  43,124  $16.15   5.0  $ 

During the year ended December 31, 2014, 192,970 warrants were exercised in a cashless manner into 28,477 shares of common stock.

Equity Incentive Plan

There are 360,000 shares of common stock reserved for issuance under the Company’s Equity Incentive Plan (after giving effect to the reduction of the number of shares reserved and available for issuance thereunder and the 1-for-5 reverse stock split, each as implemented in accordance with the Purchase Agreement governing the Private Placement), which was duly adopted by the stockholders on November 24, 2009. The Plan provides for the granting of incentive stock options to employees, the granting of non-qualified stock options to employees, non-employee directors and consultants, and the granting of restricted stock to employees, non-employee directors and consultants in connection with their retention and/or continued employment by the Company. Options issued under the Plan generally have a ten-year term and generally become exercisable over a four-year period. Shares subject to awards that expire unexercised or are forfeited or terminatedheading “Investors/SEC Filings.”  Upon request, we will again become available for issuance under the Plan. No participant in the Equity Incentive Plan can receive option grants and/or restricted shares for more than 20% of the total shares subject to the Plan.

Stock-Based Compensation

On March 6, 2014, the Board granted to Ryan Kavanaugh a non-qualified Director’s stock option award under the Company’s Equity Incentive Plan to purchase up to 12,000 shares of the Company’s common stock at an exercise price per share equal to $ 41.50 (the closing share price of the Company’s common stock as reported on the OTC Bulletin Board at the close of trading on the grant date). On April 25, 2014, the Board grantedprovide to each person, including any beneficial owner, to whom this prospectus is delivered, a copy of the three (3) other New Directors a non-qualified stock option award under the Company’s Equity Incentive Plan to purchase up to 12 ,000 shares of the Company’s common stock at an exercise price per share equal to $ 32.40 (the closing share price of the Company’s common stock as reported on the OTC Bulletin Board at the close of trading on the grant date). Each of the New Director’s stock options expire on the fifth anniversary of the grant date, vest in equal annual installments over a three-year period from the grant date subject to he/she serving as a member of the Board on each such vesting date and is to be evidenced by a non-qualified stock option agreement customarily utilized under the Equity Incentive Plan. The weighted average grant date fair value of the March 6 and April 25, 2014 awards were $149,160 and $315,720, respectively.

In addition, during the year ended December 31, 2014, the Company issued non-qualified stock option awards under the Company’s Equity Incentive Plan to purchase up to 2,400 shares of the Company’s common stock at an exercise price equal to $8.30 (the closing share price of the Company’s common stock as reported on the OTC Bulletin Board at the close of trading on the grant date). The options vest in 3 annual installments and had an aggregate grant date fair value of $29,832.

During the year ended December 31, 2013, the Company issued non-qualified stock option awards under the Company’s Equity Incentive Plan to purchase up to 2 ,000 shares of the Company’s common stock at an exercise price equal to $ 21.75 (the closing share price of the Company’s common stock as reported on the OTC Bulletin Board at the close of trading on the grant date) that vest in 3 annual installments and had an aggregate grant date fair value of $25,900 and up to 31,200 shares of the Company’s common stock at an exercise price equal to $ 21.75 (the closing share price of the Company’s common stock as reported on the OTC Bulletin Board at the close of trading on the grant date) that vest in 4 annual installments and had an aggregate grant date fair value of $80,808.

The fair value of employee stock options was estimated using the following weighted-average assumptions:

  For the Years Ended December 31, 
  2014  2013 
Expected term  5 - 7 years   6.3 - 10 years 
Risk Free interest rate  1.57% - 1.72%  2.62%
Dividend yield  0.0%  0.0%
Volatility  27% - 31%  46.3%

Stock option activity

Options outstanding at December 31, 2014 under the various plans are as follows (in thousands):

PlanTotal
Number of
Options
Outstanding
in Plans
Equity compensation plans not approved by security holders180
Equity Incentive Plan89
269

A summary of activity under all option Plans for the years ended December 31, 2014 and 2013 is presented below (in thousands, except per share data):

  Number of
Shares
  Weighted-
Average
Exercise Price
  Weighted-
Average
Contractual Term
  Aggregate
Intrinsic
Value
 
Outstanding at January 1, 2013  226  $10.30         
Options granted  8   21.75         
Options exercised  ( 8)  7.85         
Options forfeited or expired  ( 2)  6.35         
Outstanding at December 31, 2013  224   10.85         
Options granted  50   35 .00         
Options exercised  ( 1)  5 .00         
Options forfeited or expired  ( 4)  7.35         
Outstanding at December 31, 2014  269  $15.40   6.53  $- 
Exercisable at December 31, 2014  203  $10.85   6.45  $- 
Options available for grants at December 31, 2014  260             

For the years ended December 31, 2014 and 2013, the Company’s estimated forfeiture rate utilized ranged from 0.01% to 0.02%.

During the years ended December 31, 2014 and 2013, the Company recognized stock-based compensation expense, for the vesting of stock options, of $163,646 and $48,239, respectively. Stock-based compensation expense is included as part of selling, general and administrative expense in the accompanying consolidated statements of operations.

As of December 31, 2014, 1,012,745 common stock options that were granted had vested and 66,311 common stock options were unvested. At December 31, 2014 and 2013, the amount of unamortized stock-based compensation expense on unvested stock options granted to employees and consultants was and $476,828 and $150,037, respectively. The unamortized amounts will be amortized over the remaining vesting period through September 30, 2016.

The Company accounts for share-based awards exchanged for employee services at the estimated grant date fair value of the award. Compensation expense includes the impact of an estimate for forfeitures for all stock options. The Company estimated the fair value of employee stock options using the Black-Scholes-Merton option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service periods of the respective awards. The expected term of such stock options represents the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach prescribed by SAB 107 for “plain vanilla” options. Through September 30, 2014, the expected stock price volatility for the Company’s stock options was determined by using an average of the historical volatilities of the Company and industry peers. Beginning in the fourth quarter of 2014, the Company began estimating its expected volatility using the weekly trading prices of its own common stock as the Company felt this was a more appropriate measure. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts.

(Loss) Earnings Per Share

The Company utilizes ASC 260, “Earnings per Share,” (“ASC 260”) to calculate earnings or loss per share. Basic earnings or loss per share is computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings or loss per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method) and the conversion of the Company’s convertible debt and warrants (using the if-converted method). Diluted loss per share excludes the shares issuable upon the exercise of stock options, convertible notes and common stock purchase warrants from the calculation of net loss per share, as their effect is antidilutive.

The following table reconciles the numerator and denominator for the calculation:

  For the years ended
December 31,
 
  2014  2013 
Net (loss) income - basic $(13,852,249) $801,352 
Denominator – basic:        
Weighted average number of common shares outstanding  3,283,030   2,563,697 
Basic (loss) earnings per common share $( 4.22) $0. 31 
Net (loss) earnings – diluted $(13,852,249) $801,352 
Denominator – diluted:        
Basic weighted average number of common shares outstanding  3,283,030   2,563,697 
Weighted average effect of dilutive securities:        
Common share equivalents of outstanding stock options  -   69,886 
Common share equivalents of convertible debt  -   - 
Common share equivalents of outstanding warrants  -   3,690 
Diluted weighted average number of common shares outstanding  3,283,030   2,637,273 
Diluted (loss) earnings per common share $( 4.22) $0. 30 
Securities excluded from the weighted outstanding calculation because their inclusion would have been antidilutive:        
Convertible debt  227,273    
Stock options  268,860   1,287 
Warrants  243,218   818 

F-46

Note 10. INCOME TAXES

The income tax provision (benefit) consists of the following:

  For the Years ended
December 31,
 
  2014  2013 
Current:        
Federal $-  $337,016 
State and local  -   29,344 
Utilization of net operating loss carryforward  -   (346,783)
   -   19,577 
Deferred:        
Federal  (4,337,272)  202,531 
State and local  (463,060)  34,178 
   (4,800,332)  236,709 
Change in valuation allowance  5,567,665   (781,077)
   767,333   (544,368)
Income tax provision (benefit) $767,333  $(524,791)

The following is a reconciliation of the expected tax expense (benefit) on the U.S. statutory rate to the actual tax expense (benefit) reflected in the accompanying statement of operations:

  For the Years Ended
December 31,
 
  2014  2013 
U.S. federal statutory rate  (34.00)%  34.00%
State and local taxes, net of federal benefit  (2.98)%  3.63%
Amortization of debt discount     13.95%
Debt conversion inducement     40.76%
Net operating loss tax adjustment     (9.65)%
Other permanent differences  0.29%  3.00%
Alternative minimum tax     6.97%
Change in valuation allowance  42.55%  (282.42)%
Income tax provision (benefit)  5.86%  (189.76)%

As of December 31, 2014 and 2013, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following:

  Years Ended December 31, 
  2014  2013 
Current deferred tax assets:        
Net operating loss carryforwards $4,556,515  $169,404 
Stock-based compensation expense  507,864   442,813 
Alternative minimum tax credit carryforwards  15,336   19,283 
Reserves and allowances  263,609   97,587 
Inventory  269,865   59,320 
Accrued expenses and deferred income  53,442   8,824 
Severance  27,555    
Charitable contributions  1,260   1,317 
Total current deferred tax assets  5,695,446   798,548 
Current deferred tax liabilities:        
Section 481 (a) adjustment     (24,450)
Property and equipment     (7,600)
Total current deferred tax liabilities     (32,050)
Net current deferred tax assets  5,695,446   766,498 
Valuation allowance  (5,695,446)   
         
Net deferred tax assets $  $766,498 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portionany or all of the deferred tax assetsreports or documents that have been incorporated by reference into this prospectus. If you would like a copy of any of these documents, at no cost, please call us at (305) 600-5004 or through an e-mail request to offeringinfo@hcmc1.com. We will be realized. The ultimate realizationprovide, without charge, to each person, including any beneficial owner, to whom a copy of deferred tax assetsthis prospectus is dependentdelivered, upon the generationsuch person’s written or oral request, a copy of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable incomeany and tax planning strategies in making this assessment. After consideration of all of the positive and negative evidence available, management has determined that a valuation allowance of $5,695,446 and $0 are required at December 31, 2014 and 2013, respectively, to reduce the deferred tax assets to amounts that are more likely than not to be realized. Should the factors underlying management’s analysis change, future valuation adjustmentsinformation incorporated by reference in this prospectus. Exhibits to the Company’s net deferred tax assets may be necessary.

At December 31, 2014 the Company had U.S. federal and state net operating loss carryforwards (“NOLS”) of $12,214,479 and $12,812,444, respectively. At December 31, 2013 the Company had U.S. federal and state NOLS of $251,269 and $1,526,482, respectively. These NOLs expire beginning in 2032. Utilization of our NOLS may be subject to an annual limitation under section 382 and similar state provisions of the Internal Revenue Code due to changes of ownership that may have occurred or that could occur in the future, as defined under the regulations.

As required by the provisions of ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized (or amount of NOL or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.

If applicable, interest costs and penalties related to unrecognized tax benefits are required to be calculated and would be classified as interest and penalties in general and administrative expense in the statement of operations. As of December 31, 2014 and 2013, no liability for unrecognized tax benefit was required to be reported. No interest or penalties were recorded during the years ended December 31, 2014 and 2013. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. The Company files U.S. federal and Florida, Maryland, Texas, New Jersey and Wisconsin state income tax returns. As of December 31, 2014, the Company’s U.S. and state tax returns remain subject to examination by tax authorities beginning with the tax year ended December 31, 2011.

Note 11. COMMITMENTS AND CONTINGENCIES

Employment Agreements

On February 19, 2013, the Company entered into an employment agreement with Mr. Jeffrey Holman pursuant to which Mr. Holman will be employed as President of the Company for a term that shall begin on February 19, 2013, and, unless sooner terminated as provided therein, shall end on December 31, 2015; provided that such term of employment shall automatically extend for successive one-year periods unless either party gives at least six months’ advance written notice of its intention not to extend the term of employment. Mr. Holman will receive a base salary of $182,000 for the first two years of the employment agreement. Mr. Holman shall be eligible to participate in the Company’s annual performance based bonus program, as the same may be established from time to time by the Company’s Board of Directors in consultation with Mr. Holman for executive officers of the Company.

Resignation of Chief Executive Officer and Appointment of New Chief Executive Officer

Effective April 25, 2014, Kevin Frija resigned as the Company’s Chief Executive Officer and the Company’s Board of Directors appointed the Company’s President and incumbent member of the Board, Jeffrey Holman, as the Company’s new Chief Executive Officer. In connection with Mr. Frija’s resignation as Chief Executive Officer, the Board approved severance payments to Mr. Frija in an aggregate amount equal to one year of base salary at the rate of $159,000 per annum payable in installments in accordance with the Company’s normal payroll schedule conditioned upon his execution and delivery of a general release to the Company, which has become irrevocable in accordance with its terms and applicable law, and his compliance with the non-solicitation, confidentiality and non-competition covenants of his Employment Agreement dated February 27, 2012 with the Company until April 24, 2015 in certain respects and indefinitely in other respects. During the year ended December 31, 2014 the Company accrued severance expense in the amount of $167,003, which is included as part of the selling, general and administrative expenses in accompanying consolidated statements of operations in connection with Mr. Frija’s resignation. During the year ended December 31, 2014 $89,925 was paid and $77,028 is included in accrued expenses in accompanying consolidated balance sheets.

Termination of Asset Purchase Agreement With International Vapor Group, Inc.

On May 14, 2014, the Company and the Company’s wholly-owned subsidiary IVGI Acquisition, Inc., a Delaware corporation (the “Buyer”) entered into the Asset Purchase Agreement with International Vapor Group, Inc. (“IVG”) pursuant to which the Company was to purchase the business of IVG by acquiring substantially all of the assets and assuming certain of the liabilities of IVG in an asset purchase transaction. On July 25, 2014, the Company, the Buyer and the Owners David Epstein, David Herrera and Nicolas Molina, in their capacities as the representatives of the Sellers and Owners, entered into a First Amendment to Asset Purchase Agreement (the “First Amendment”). In connection with the First Amendment, the Company entered into a Secured Promissory Note whereby it loaned IVG $500,000 for working capital purposes. The secured promissory note accrued interest at a rate of 8% per year and was due at the earlier of (a) six months after the date of the termination of the Asset Purchase Agreement or the date the asset purchase closed. During the year ended December 31, 2014, the Company recognized interest income of $17,095 relating to this loan receivable.

On August 26, 2014, the Company, the Buyer, and the Sellers and David Epstein, David Herrera and Nicolas Molina, in their capacities as the representatives of the Sellers and the owners of International Vapor Group, Inc., entered into a Termination Letter, pursuant to which the parties mutually terminated their previously announced Asset Purchase Agreement entered into on May 14, 2014 and amended on July 25, 2014. The Company and the Sellers mutually terminated the Asset Purchase Agreement because the parties could not agree upon certain operational and financial matters pertaining to the post-closing integration of the Sellers’ business operations. There are no current disputes or disagreements between the Company and the Sellers and neither party is liable for any breakup fees or reimbursement of costs to the other party as a result of the termination of the Asset Purchase Agreement.

On January 12, 2015, the Company entered into an agreement with IVG whereby the Company agreed to reduce the principal amount of the loan receivable by $50,000 if IVG were to remit payment of all principal and interest accrued on the loan receivable within one day. The Company included the write-down of the loan receivable in selling, general and administrative expenses on the consolidated statement of operations for the year ended December 31, 2014. On January 13, 2015, IVG paid the Company in full.

Lease Commitments

The Company leases its Florida office and warehouse facilities under a twenty-four month lease agreement with an initial term through April 30, 2013 that the Company extended in March 2014 when it exercised the second of three successive one-year renewal options. The lease provides for annual rental payments of $144,000 per annum (including 45 days of total rent abatement) during the initial twenty-four month term and annual rental payments of $151,200, $158,760 and $174,636 during each of the three one-year renewal options. In October 2013, the Company amended the master lease to include an additional approximately 2,200 square feet for an additional annual rental payment of $18,000 subject to the same renewal options and other terms and conditions set forth in the master lease.

During the year ended December 31, 2014, the Company entered into nine (9) real estate leases for eight (8) new retail kiosks and one (1) new retail store. The kiosks opened during the fourth quarter of 2014 and the store is scheduled to open during 2015. The kiosks are located in malls in Florida, Maryland, New Jersey and Texas. The retail store is located in Ft. Lauderdale, FL. Under these leases, the initial lease terms range from one to five years, the Company is required to pay base and percentage rents and the Company is required to pay for common area and maintenance charges and utilities.

Future minimum lease payments under non-cancelable operating that have initial or remaining terms in excess of one year at December 31, 2014 are due as follows:

  Operating
Leases
 
2015 $572,798 
2016  307,488 
2017  300,279 
2018  253,841 
2019  203,964 
Total $1,638,370 

Rent expense for the years ended December 31, 2014 and 2013 was $307,110 and $162,498, respectively.

Legal Proceedings

From time to time the Company may be involved in various claims and legal actions arising in the ordinary course of our business.

On May 15, 2011, the Company became aware that Ruyan Investment (Holdings) Limited (“Ruyan”) had named the Company, along with three other sellers of electronic cigarettes in a lawsuit filed in the U.S. District Court for the Central District of California alleging infringement of U.S. Patent No. 7,832,410, entitled “Electronic Atomization Cigarette” against the Company’s Fifty-One Trio products. In that lawsuit, which was initially filed on January 12, 2011, Ruyan was unsuccessful in bringing suit against the Company due to procedural rules of the court. Subsequent thereto, on July 29, 2011, Ruyan filed a new lawsuit in which it named the Company, along with seven other sellers of electronic cigarettes, alleging infringement of the same patent. On March 1, 2013, the Company and Ruyan settled this multi-defendant federal patent infringement lawsuit as to them pursuant to a settlement agreement by and between them. Under the terms of the settlement agreement:

The Company acknowledged the validity of Ruyan’s U.S. Patent No. 7,832,410 for “Electronic Atomization Cigarette” (the “410 Patent”), which had been the subject of Ruyan’s patent infringement claim against the Company;
The Company paid Ruyan a lump sum payment of $12,000 for the Company’s previous sales of electronic cigarettes based on the 410 Patent; and
On March 1, 2013, in conjunction with releasing one another (including their respective predecessors, successors, officers, directors and employees, among others) from claims related to the 410 Patent, the Company and Ruyan filed a Stipulated Judgment and Permanent Injunction with the above Court dismissing with prejudice all claims which have been or could have been asserted by them in the lawsuit.

On June 22, 2012, Ruyan filed a second lawsuit against the Company alleging infringement of U.S. Patent No. 8,156,944, entitled “Aerosol Electronic Cigarette” (the “944 Patent”). Ruyan also filed separate cases for patent infringement against nine other defendants asserting infringement of the ‘944 Patent. Ruyan’s second lawsuit against the Company known as Ruyan Investment (Holdings) Limited v. Vapor Corp., No. 12-cv-5466, is pending in the United States District Court for the Central District of California. All of these lawsuits have been consolidated for discovery and pre-trial purposes. The Company intends to vigorously defend against this lawsuit.

On February 25, 2013, Ruyan’s second patent infringement lawsuit against the Company as well as all of the other consolidated lawsuits were stayed as a result of the Court granting a stay in one of the consolidated lawsuits. The Court granted the motion to stay Ruyan’s separate lawsuits against the Company and the other defendants based on the filing of a request for inter partes reexamination of the 944 Patent at the U.S. Patent and Trademark Office. As a result of the stay, all of the consolidated lawsuits involving the 944 Patent have been stayed until the reexamination is completed. As a condition to granting the stay of all the lawsuits, the Court required any other defendant who desires to seek reexamination of the 944 Patent and potentially seek another stay (or an extension of the existing stay) based on any such reexamination to seek such reexamination no later than July 1, 2013. Two other defendants sought reexamination of the 944 Patent before expiration of such Court-imposed deadline of July 1, 2013. All reexamination proceedings of the 944 Patent have been stayed by the United States Patent and Trademark Office Patent Trial and Appeal Board pending its approval of one or more of them. On December 24, 2014, the Patent Trial and Appeal Board issued its ruling that all of the challenged claims in the reexamination proceedings of the ‘944 patent were invalid except for one claim. To the extent claim 11 is asserted against the Company, the Company will vigorously defend itself against such allegations. Currently, the case remains stayed.

On March 5, 2014, Fontem Ventures, B.V. and Fontem Holdings 1 B.V. (the successors to Ruyan) filed a complaint against the Company in the U.S. District Court for the Central District of California, captioned Fontem Ventures B.V., et al. v. Vapor Corp., No. 14-cv-1650. The complaint alleges infringement of U.S. Patent No. 8,365,742, entitled “Aerosol Electronic Cigarette”, U.S. Patent No. 8,375,957, entitled “Electronic Cigarette” (the “957 Patent”), U.S. Patent No. 8,393,331, entitled “Aerosol Electronic Cigarette” (the “331 Patent”) and U.S. Patent No. 8,490,628, entitled “Electronic Atomization Cigarette” (the “628 Patent”). On April 8, 2014, plaintiffs amended their complaint to add U.S. Patent No. 8,689,805, entitled “Electronic Cigarette” (the “805 Patent”). The products accused of infringement by plaintiffs are various Krave, Fifty-One and Hookah Stix products and parts. Nine other companies were also sued in separate lawsuits alleging infringement of one or more of the patents listed above. The Company filed its Answer and Counterclaims on May 1, 2014 and believes the claims are without merit. Other defendants have filed petitions for inter partes reexamination of the 331, 628 and 805 Patents at the U.S. Patent and Trademark Office, which petitions are pending.

On October 21, 2014, Fontem Ventures B.V. and Fontem Holdings 1 B.V. filed a complaint against the Company in the U.S. District Court for the Central District of California, captioned Fontem Ventures B.V., et al. v. Vapor Corp., No. 14-cv-8155. The complaint alleges infringement of United States Patent No. 8,863,752, entitled “Electronic Cigarette”. The products accused of infringement by plaintiffs are various Krave and Fifty-One products and parts. On January 15, 2015, the Company filed its Answer and Counterclaims. The Company will vigorously defend itself against such allegations.

On December 2, 2014, Fontem Ventures B.V. and Fontem Holdings 1 B.V. filed a complaint against the Company in the U.S. District Court for the Central District of California, captioned Fontem Ventures B.V., et al. v. Vapor Corp., No. 14-cv-09267. The Compliant alleges infringement by plaintiffs are various Krave, Vapor X and Fifty-One products and parts. Fontem amended its compliant on December 16, 2014, to allege infringement of United States Patent No. 8,910,641, entitled “Electronic Cigarette” against the same products. On January 15, 2015, the Company filed its Answer and Counterclaims. The Company will vigorously defend itself against such allegations.

All of the above referenced cases filed by Fontem have been consolidated and are currently scheduled for trail in November 2014. The parties are currently in active fact discovery and claim construction. 

Purchase Commitments

At December 31, 2014 and 2013, the Company has vendor deposits of $319,563 and $782,363, respectively, and vendor deposits are included as a component of prepaid expenses and vendor deposits on the consolidated balance sheets included herewith.

Note 12. CONCENTRATION OF CREDIT RISK

At December 31, 2014 accounts receivable balances included concentrations from seven customers that had balances of an amount greater than 10%. The amounts ranged from $27,729 to $177,200. At December 31 2013, accounts receivable balances included a concentration from one customer in the amount of $268,768, which was an amount greater than 10% of the total net accounts receivable balance.

Beginning the first quarter of 2012, the Company began selling electronic cigarettes in the country of Canada exclusively through a Canadian distributor. For the years ended December 31, 2014 and 2013, the Company had sales in excess of 10% to this Canadian distributor of $2,912,525 and $3,847,310, respectively. For the year ended December 31, 2014 one other customer accounted for sales in excess of 10% with sales of $1,536,050. No other customer accounted for sales of 10% for the year ended December 31, 2013.

Note 13. SUBSEQUENT EVENTS

The Company evaluates events that have occurred after the balance sheet date but before the consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements other disclosed.

The merger closed on March 4, 2015. Prior to the closing of the Merger, Vapor and Vaporin entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) with certain accredited investors providing for the sale of $350,000 of Vaporin’s Convertible Notes (the “Notes”). On January 29, 2015, the Company issued the notes. The Note accrues interest on the outstanding principal at an annual rate of 12%. The principal and accrued interest on the Note is due and payable on January 29, 2016 (the “Maturity Date”) The Notefilings will not be convertible until such time as the Nasdaq Stock Market (“Nasdaq”) approves the listing of the sharessent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any accompanying prospectus supplement.


54

Subscription Rights to be issued upon conversion of the Note. In no event will the number of shares of the Company’s common stock issuable upon conversion of the Note exceed 19.99% of the Company’s issued and outstanding common stock, regardless of the conversion price.

In connection with the Merger, on March 3, 2015, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors providing for the sale Up to                Shares

of $3,500,960 in shares of the Company’s Common Stock par value $0.001 per share at a price of $ 5.10 per share. The Company also issued Warrants to purchasers of the shares to acquire an aggregate of 547,026 shares of the Company’s Common Stock with an exercise price of $ 6.40 per share. The shares and Warrants were issued and sold through an exempt private securities offering to certain accredited investors.

Under the Purchase Agreement, the Company made certain customary representations and warranties to the purchasers concerning the Company and its operations. The Company has also agreed to register the Common Stock and the Warrants for resale pursuant to an effective registration statement which must be filed within 45 days of March 3, 2015 and must be effective by the later of (i) the 90th day following March 3, 2015 (if no SEC review) or (ii) the 120th day following March 3, 2015 (if subject to SEC review). If the Form S-3 Registration Statement is not effective for resales for more than 10 consecutive days or more than 15 days in any 12 month period during the registration period (i.e., the earlier of the date on which the shares have been sold or are eligible for sale under SEC Rule 144 without restriction), we are required to pay the investors (other than our participating officers and directors) liquidated damages in cash equal to 1.5% of the aggregate purchase price paid by the investors for the shares for every 30 days or portion thereof until the default is cured. Such cash payments could be as much as $52,500 for every 30 days.

Note 14. REVERSE STOCK SPLIT

On July 7, 2015, the Company filed an amendment to its Certificate of Incorporation to effectuate a one-for-five reverse stock split to its common stock and to increase its authorized common stock to 150,000,000 shares. The amendments were effective on July 8, 2015 at 11:59 pm. All warrant, option, common stock shares and per share information included herein gives effect to the 1 for 5 reverse split of the Company’s common stock effectuated on July 8, 2015.

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of

Vaporin Inc.

We have audited the accompanying balance sheet of Vaporin Inc. as of December 31, 2014 and the related statement of operations, stockholders’ deficit, and cash flows for the year ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Vaporin, Inc. as of December 31, 2014 and the results of its operations, stockholders’ deficit, and cash flows for the year then ended in conformity accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered losses from operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.


/s/ RBSM LLP
Las Vegas Nevada
May 12, 2015PROSPECTUS

New York, NY, Washington DC, San Francisco, CA, Athens, Greece, Beijing, China, and Mumbai, India

Member of Antea Alliance with affiliated offices worldwide

VAPORIN, Inc.

(FORMERLY VALOR GOLD CORP.)

CONSOLIDATED BALANCE SHEETS

 

 December 31, 2014  December 31, 2013 
ASSETS        
CURRENT ASSETS        
Cash and cash equivalents $865,737  $25,221 
Due from merchant credit card processor, net of reserve  160,216    
Accounts receivable – trade net Allowance for uncollectable accounts  88,614   16,587 
Prepaid expenses and other current assets  42,996   32,522 
Inventory  1,173,124   316,195 
Total Current Assets  2,330,687   390,525 
FIXED ASSETS        
Property and equipment, net  160,620   8,395 
OTHER ASSETS        
Intangible assets, net  1,472   12,276 
Goodwill  3,732,268    
Total Other Assets  3,894,360   12,276 
TOTAL ASSETS $6,225,047  $411,196 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
CURRENT LIABILITIES        
Accounts payable and accrued liabilities $824,104  $31,312 
Accrued interest – related party     804 
Notes payable     75,000 
Notes payable – related party  1,000,000   260,899 
Derivative liabilities  43,944    
Total Current Liabilities  1,868,048   368,015 
STOCKHOLDERS’ EQUITY        
Preferred Stock, $.0001 par value per share, 50,000,000 shares authorized, as of December 31, 2014 and December 31, 2013, respectively.        
Preferred Stock Series A, $0.0001 par value per share, 100,000 shares authorized and 0 shares issued and outstanding, as of December 31, 2014 and December 31, 2013, respectively.      
Preferred Stock Series B, $0.0001 par value per share, 5,000,000 shares authorized, 100,000 and 0 shares issued and outstanding, as of December 31, 2014 and December 31, 2013, respectively.  10    
Preferred Stock Series C, $0.0001 par value per share, 100,000 shares authorized 1,550 and 0 shares issued and outstanding, as December 31, 2014 and December 31, 2013, respectively.      
Preferred Stock Series E, $0.0001 par value per share, 2 shares authorized
0 shares issued and outstanding, as of December 31, 2014 and December 31, 2013.
      
Common Stock, $0.0001 par value per share, 200,000,000 shares authorized, 4,893,254 and 700,000 shares issued and outstanding, as of December 31, 2014 and December 31, 2013, respectively.  489   70 
Additional paid-in capital  10,864,408   349,930 
Accumulated deficit  (6,502,903)  (306,819)
Total Vaporin Stockholders’ Equity  4,362,004   43,181 
Non-Controlling Interest in Subsidiary  (5,005)   
Total Stockholders’ Equity  4,356,999    
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $6,225,047  $411,196 

The accompanying notes are an integral part of these consolidated financial statements.

VAPORIN, Inc.

(FORMERLY VALOR GOLD CORP.)

CONSOLIDATED STATEMENTS OF OPERATIONS

  For the Year Ended
December 31,
 
  2014  2013 
       
Revenues $3,281,838  $23,268 
         
Cost of sales  1,790,098   10,851 
         
Gross margin  1,491,740   12,417 
         
Costs and expenses        
Promotional and marketing  983,507   57,189 
General and administrative  6,131,510   238,999 
Depreciation and amortization  19,987   6,082 
Professional fees  315,086   15,779 
         
Total operating costs and expenses  7,450,090   318,049 
Operating loss  (5,958,350)  (305,632)
         
Other income and (expense)        
Derivative expense  (86,484)   
Change in fair value of derivatives  251,625   (219)
Interest expense – related party  (407,890)  (804)
Total other income and expense  (242,749)  (1,023)
Loss before provision for income tax  (6,201,099)  (306,655)
Provision for income tax      
Net loss $(6,201,099) $(306,655)
Loss attributable to common stockholders and loss per common share:        
Net loss  (6,196,084)  (306,655)
Non-Controlling interest  5,015    
Net loss  (6,201,099)  (306,655)
Weighted average shares outstanding, basic and diluted  3,554,486   700,000 
         
Net loss per basic and diluted share $(1.74) $(0.44)

The accompanying notes are an integral part of these consolidated financial statements.

F-55

Dealer-Manager

VAPORIN, INC.

(FORMERLY VALOR GOLD CORP.)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ (DEFICIT) EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2014 AND DECEMBER 31, 2013

  Preferred Stock        Additional    Non-    
  Series A  Series B  Series C  Series E  Common Stock  Paid in  Accumulated  Controlling    
  Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Deficit  Interest  Total 
                                           
Balance at December 31, 2013                          700,000   70  $349,930  $(306,819)    $43,181 
                                                         
Recapitalization of the company  60,000   6         2,000            1,883,250   188   66,026         66,220 
Issuance of common stock – private placement        100,000   10               820,993   82   4,357,378           4,357,470 
Shares issued for services                          363,250   36   1,294,459         1,294,495 
Shares issued for the conversion of debt                          44,333   5   321,395         321,400 
Series E issued in connection with an acquisition                    2            3,142,854         3,142,854 
Conversion of Series E into common shares                    (2)     571,428   57   (57)          
Reclassification of derivative liability to equity                                90,064         90,064 
Stock based compensation in connection with restricted stock grants                                1,239,130         1,239,130 
Stock based compensation in connection with stock option grants                                3,284         3,284 
Shares issued for conversion of preferred stock  (60,000)  (6)        (450)           510,000   51   (45)         
Non-Controlling interest in subsidiary                                  (10)     10    
Net loss                                   (6,196,084)  (5015)  (6,201,099)
Balance at December 31, 2014     $   100,000   10   1,550            4,893,254  $489  $10,864,408   (6,502,903)  (5,005) $4,356,999 

See accompanying notes to consolidated financial statements.

VAPORIN, Inc.

(FORMERLY VALOR GOLD CORP.)

CONSOLIDATED STATEMENTS OF CASH FLOWS

  Twelve Months Ended
December 31,
 
  2014  2013 
OPERATING ACTIVITIES        
Net loss $(6,201,099) $(306,655)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization  19,987   6,082 
Amortization of debt discount  253,844    
Derivative expense  86,484    
Change in fair value of derivative liabilities  (251,625)   
Interest expense in connection with the grant of warrants  78,869    
Interest expense in connection with conversion of debt  26,400    
Stock based compensation  2,536,909    
Changes in operating assets and liabilities        
Due from merchant credit card processor  (160,216)   
Trade and related party receivable  (72,027)  (16,587)
Inventory  (517,908)  (316,195)
Other current assets  (3,877)  (32,522)
Accounts payable and accrued liabilities  746,312   

31,312

 
Accrued Interest – Related party     804 
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES  (3,457,947)  (633,761)
INVESTING ACTIVITIES        
Acquisition of business, net of cash acquired  (798,000)   
(Increase) decrease in intangible assets     (17,678)
(Increase) decrease in fixed assets  (61,007)  (9,075)
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES  (859,007)  (26,753)
 FINANCING ACTIVITIES        
Payment of notes payable  (100,000)   
Proceeds received from issuance of note payable     75,000 
Proceeds received from issuance of note payable - related party  1,000,000   610,735 
Proceeds received from issuance of note prior to recapitalization  100,000    
Issuance of common stock, net of issuance costs  3,857,470    
Issuance of preferred stock  500,000    
NET CASH PROVIDED BY FINANCING ACTIVITIES  5,157,470   685,735 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS  840,516   25,221 
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD  25,221    
CASH AND CASH EQUIVALENTS AT END OF PERIOD $865,737  $25,221 
Supplemental disclosures:        
Non cash activities:        
Reclassification of derivative liability to equity  90,064    
Note payable converted to common stock  295,000    
Note payable – related party exchanged to preferred stock pursuant to the Share Exchange  285,710    
Issuance of note payable in connection with the acquisition
of business
  200,000    
Purchase of inventory and other assets upon acquisition of
business
  345,618    
Purchase of property and equipment upon acquisition of
business
  100,401    
Assumption of liabilities upon acquisition of business  37,433    
         
Preferred Series A shares issued for conversion of debt     350,000 

The accompanying notes are an integral part of these consolidated financial statements

NOTE 1 – NATURE OF OPERATIONS

Vaporin, Inc. (the “Company”)

Maxim Group LLC

, (formerly Valor Gold Corp.), was incorporated under the laws of the State of Delaware in June 2009. In January 2014, the Company entered into a Share Exchange Agreement (the “Share Exchange”) with Vaporin Florida, Inc., a privately-held Florida corporation (“Vaporin Florida”). Pursuant to the Exchange Agreement, all of the issued and outstanding common stock of Vaporin Florida was exchanged for an aggregate of 35 million shares of the Company’s common stock. The Share Exchange was accounted for as a reverse acquisition and re-capitalization, whereas Vaporin Florida is deemed the accounting acquirer and Vaporin, Inc. the legal acquirer. As a result, the assets and liabilities and the historical operations that are reflected in the Company’s financial statements are those of Vaporin Florida, and the Company’s assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of Vaporin Florida effective January 24, 2014. The Company is a distributor and marketer of vaporizers, e-liquids and related products.

Effective August 29, 2014 (the “Closing”), the Company , Vaporin Acquisitions, Inc., a Florida corporation and wholly-owned subsidiary of the Company (the “Merger Sub”), The Vape Store, Inc., a Florida corporation (“Vape Store”), and Steve and Christy Cantrell, holders of all outstanding Vape Store shares (the “Cantrells”) entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, Vape Store merged with and into Merger Sub (the “Merger”), with Merger Sub continuing as the surviving corporation and a wholly-owned subsidiary of the Company (see Note 7).

On September 8, 2014, the Company filed an amendment to its Certificate of Incorporation with the Secretary of State of Delaware effecting a 1-for-50 reverse stock split of the Company’s common stock (the “Reverse Split”). As a result of the Reverse Split, every 50 shares of the Company’s common stock were combined into one share of common stock. All shares and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split (see Note 10).

On November 6, 2014, the Company executed a binding Term Sheet to merge with and into Vapor Corp., a NASDAQ listed issuer. Shareholders of the Company will receive 45% of the combined company as merger consideration. On December 17, 2014, Vaporin, Inc. (“Vaporin”) and Vapor Corp. (“Vapor”) entered into an Agreement and Plan of Merger (the “Vapor Merger Agreement”) providing for the acquisition of Vaporin by Vapor. The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Vaporin will be merged with and into Vapor (the “Vapor Merger”). Following the Merger, current shareholders of Vaporin common and preferred stock will own 45% of the outstanding shares of common stock of the combined company. On the same date, Vapor also entered into a joint venture with Vaporin (the “Joint Venture”) through the execution of an operating agreement (the “Operating Agreement”) of Emagine the Vape Store, LLC, a Delaware limited liability company (“Emagine”), pursuant to which the Registrant and Vaporin are 50% members of Emagine.

On March 4, 2015, the acquisition of Vaporin by Vapor (the “Vapor Merger”) was completed pursuant to the terms of the Merger Agreement. In connection with the Merger, Emagine became a wholly-owned subsidiary of the Vapor.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and present the consolidated financial statements of the Company and its wholly-owned subsidiary. In the preparation of consolidated financial statements of the Company, all intercompany transactions and balances were eliminated.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.

Risks and Uncertainties

The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.

Cash and cash equivalents

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2014 and December 31, 2013, the Company had no cash equivalents.

Accounts receivable

The Company accounts receivable, represents our estimate of the amount that ultimately will be realized in cash. The Company reviews the adequacy and adjusts its allowance for doubtful accounts on an ongoing basis, using historical payment trends and the age of the receivables and knowledge of its individual customers. However, if the financial condition of our customers were to deteriorate, additional allowances may be required. While estimates are involved, bad debts historically have not been a significant factor given the diversity of its customer base and well established historical payment patterns. As of December 31, 2014 and December 31, 2013, the Company recorded allowance for uncollectable accounts of $61,000 and $0 respectively.

Inventory

Inventories are stated at the lower of cost or market value. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated forecast of product demand, production availability and/or our ability to sell the product(s) concerned. Demand for our products can fluctuate significantly. Factors that could affect demand for our products include unanticipated changes in consumer preferences, general market and economic conditions or other factors that may result in cancellations of advance orders or reductions in the rate of reorders placed by customers and/or continued weakening of economic conditions. Additionally, our estimates of future product demand may be inaccurate, which could result in an understated or overstated provision required for excess and obsolete inventory. Product-related inventories are primarily maintained using the average cost method.

Fixed Assets

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

Equipment3-5 years
Furniture7 years

The Company reviews the carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets.

Intangible assets

ASC 350 requires that goodwill and intangible assets with indefinite useful lives no longer be amortized, but instead tested for impairment at least annually in accordance with the provisions of ASC 350. This standard also requires that intangible assets with definite useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment. The Company did not record any impairment charges on its intangible assets during the twelve months ended December 31, 2014 and 2013.

The Company’s intangible assets consist of the costs of building company’s website. Amortization will be recorded over the estimated useful life of the assets using the straight-line method for financial statement purposes.

Website Development Costs

Costs incurred in the planning stage of a website are expensed, while costs incurred in the development stage are capitalized and amortized over the estimated useful life of the asset.

Revenue recognition

The Company recognizes ecommerce revenues and the related cost of goods sold at the time the products are delivered to customers. Revenue generated through the Company’s brick and mortar locations is recognized at the point of sale. Discounts provided to customers are accounted for as a reduction of sales. The Company records a reserve for estimated product returns in each reporting period. Shipping and handling fees charged to the customer are recognized as revenue at the time the products are delivered to the customer. Revenues are presented net of any taxes collected from customers and remitted to governmental authorities.

Cost of sales

Cost of goods sold includes cost of goods, occupancy expenses and shipping costs. Cost of goods consists of cost of merchandise, inbound freight expenses, freight-to-store expenses and other inventory related costs such as shrinkage, damages and replacements. Occupancy expenses consist of rent, depreciation and other occupancy costs, including common area maintenance, property taxes and utilities. Shipping costs consist of third party delivery services and shipping materials.

Shipping and Handling

Product sold to customers is shipped from our warehouse. Any freight billed to customers is offset against shipping costs and included in cost of goods sold.

Income taxes

The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”) Income Taxes. Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Fair Value of Financial Instruments

We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” (“ASC Topic 820-10”). ASC Topic 820-10 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). ASC Topic 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Level 1 instruments include cash, account receivable, prepaid expenses, inventory and account payable and accrued liabilities. The carrying values are assumed to approximate the fair value due to the short term nature of the instrument. The carrying amount of the notes payable at December 31, 2014 approximate their respective fair value based on the Company’s incremental borrowing rate.

The following table presents a reconciliation of the derivative liability measured at fair value on a recurring basis using significant unobservable input (Level 3) from January 1, 2014 to December 31, 2014:

  Conversion feature derivative liability  Warrant liability 
Balance at January 1, 2014 $41,881  $ 
Recognition of derivative liability  72,064   271,688 
Reclassification of derivative liability to equity  (90,064)   
Change in fair value included in earnings  (23,881)  (227,742)
Balance at December 31, 2014 $-  $43,944 

The three levels of the fair value hierarchy under ASC Topic 820-10 are described below:

Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access. We believe our carrying value of level 1 instruments approximate their fair value at December 30, 2014.
Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms.

Advertising

The Company expenses advertising costs as incurred. The Company’s advertising expenses totaled $983,507 and $0 during the twelve months ended December 31, 2014 and 2013.

Earnings (Loss) Per Share

Net earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.

For the year ended December 31, 2014, diluted net loss per share did not include the effect of a total of 1,680,374 shares of stock represented by 11,000 shares of common stock issuable upon the exercise of outstanding stock options, 119,374 shares of common stock issuable upon the exercise of outstanding warrants, and 1,650,000 shares of common stock issuable on the conversion of the preferred stock as their effect would be anti-dilutive.

Warranty

A return program for defective goods is offered to all of the Company’s online customers. Customers are allowed to return defective goods within a specified period of time (90 days), after shipment. The Company records a liability for its defective goods allowance program at the time of sale for the estimated costs that may be incurred. The liability for defective goods is included in warranty provisions on the Consolidated Balance Sheets.

Changes in the Company’s obligations for return and allowance programs are presented in the following table:

  Year Ended 
  December 31, 2014  December 31, 2013 
Estimated return and allowance liabilities at beginning of period $0  $0 
         
Costs accrued for new estimated returns and allowances $4,500  $0 
         
Return and allowance obligations honored  (0)  (0)
         
Estimated return and allowance liabilities at end of period $4,500  $0 

Concentration of Business and Credit Risk

The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. The Company’s financial instruments that are exposed to concentration of credit risks consist primarily of cash. The Company maintains its cash in bank accounts which, may at times, exceed federally-insured limits. We review a customer’s credit history before extending credit.

The following table shows significant concentrations in our revenues and accounts receivable for the periods indicated.

  Percentage of Revenue during the  Percentage of Accounts Receivable 
  period ended,  period ended, 
  December 31, 2014  December 31, 2013  December 31, 2014  December 31, 2013 
Customer A  17%  51%  26%  71%
Customer B  5%  14%  18%  0%

Recent accounting pronouncements

Accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

Year-end

The Company has adopted December 31 as its fiscal year end.

F-62
2021

NOTE 3 – GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the recoverability of assets and the satisfaction of liabilities in the normal course of business. Since its inception, the Company has been engaged substantially in financing activities and developing its business plan and marketing. As a result, the Company incurred accumulated net losses during the year ended December 31, 2014 of $6,201,099. In addition to raising capital from the sale of equity, the Company’s development activities since inception have been financially sustained through capital contributions from note holders.

The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital from the sale of common stock or through debt financing and, ultimately, the achievement of significant operating revenues. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

NOTE 4 – INVENTORY

Inventories consist of the following:

  December 31, 2014  December 31, 2013 
Finished goods $1,173,124  $316,195 

NOTE 5 – PROPERTY & EQUIPMENT

The following is a summary of property and equipment:

  December 31, 2014  December 31, 2013 
Leasehold Improvements $47,443    
Computer Equipment  8,413  $8,413 
Furniture, Fixtures and Equipment  114,627   662 
Less: accumulated depreciation  (9,863)  (680)
  $160,620  $8,395 

Depreciation for the twelve months ended December 31, 2014 and 2013 was $9,183 and $680, respectively.

NOTE 6 – INTANGIBLE ASSETS

Intangible assets consist of the following:

  December 31, 2014  December 31, 2013 
Website, capitalized $17,678  $17,678 
Less: accumulated amortization  (16,206)  (5,402)
  $1,472  $12,276 

Amortization for the twelve months ended December 31, 2014 and 2013 was $10,804 and $5,402 respectively.

F-63

NOTE 7 – ACQUISITION

Effective August 29, 2014 (the “Closing”), the Company, Vaporin Acquisitions, Inc., a Florida corporation and wholly-owned subsidiary of the Company (the “Merger Sub”), The Vape Store, Inc., a Florida corporation (“Vape Store”), and Steve and Christy Cantrell, holders of all outstanding Vape Store shares (the “Cantrells”) entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, Vape Store merged with and into Merger Sub (the “Merger”), with Merger Sub continuing as the surviving corporation and a wholly-owned subsidiary of the Company.

In connection with the Merger Agreement, the Company paid the Cantrells $800,000 at the Closing and agreed to pay the Cantrells an additional $200,000 within 30 days of the Closing. In addition, the Company issued the Cantrells two shares of the Company’s newly created Series E Convertible Preferred Stock. On September 8, 2014, the Company’s Series E shares were converted to 571,428 shares of the Company’s common stock 10% of the shares of common stock will remain in escrow until completion of an audit of Vape Store’s balance sheet as of Closing. Additionally, the Company agreed to assume certain liabilities and business obligations of Vape Store, with respect to which the Company will indemnify the Cantrells. The Company valued these common shares at the fair market value on the date of grant at $5.50 per share or $3,142,854 based on a recent sale of common stock in a private placement. The total purchase price aggregated to $4,142,854. The transaction resulted in a business combination and caused Vape Store to become a wholly-owned subsidiary of the Company.

Pursuant to the Merger Agreement, the Company has an irrevocable option to repurchase from the Cantrells up to a total of 280,000 shares of the Company’s common stock at a price of $5.00 per share during the first 12 months following the Closing and at a price of $7.50 per share during the second 12 months following the Closing.

In connection with the Merger, the Company entered into an employment agreement, dated as of August 29, 2014 (the “Employment Agreement”) with Steve Cantrell. Under the terms of the Employment Agreement, Mr. Cantrell will serve as Vice President of the Company and receive an annual salary of $200,000. The Employment Agreement has an initial term of two years and is automatically renewable for successive one-year terms unless either party opts not to renew. In the event of termination by the Company other than for Cause or Abandonment, or in the event of termination by Mr. Cantrell for Good Reason (as capitalized terms are defined in the Employment Agreement), Mr. Cantrell will be entitled to severance in an amount equal to $400,000 less all salary previously received under the Employment Agreement. In accordance with the Employment Agreement, on September 5, 2014 the Company appointed Mr. Cantrell to serve as Vice President and as a Director of the Company.

The Company accounted for the acquisition utilizing the purchase method of accounting in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and Vape Store is the acquired company. Accordingly, the Company applied push–down accounting and adjusted to fair value all of the assets and liabilities directly on the financial statements of the subsidiary. The net purchase price paid by the Company was allocated to assets acquired and liabilities assumed on the records of the Company as follows:

Current assets (including cash of $2,000) $341,021 
Other Assets  6,597 
Property and equipment  100,401 
Goodwill  3,732,268 
Liabilities assumed  (37,433)
Net purchase price $4,142,854 

The following table summarizes the unaudited pro forma consolidated results of operations as though the Company and Vape Store acquisition had occurred on January 1, 2014:

  For the twelve months Ended 
  December 31, 2014 
  As Reported  Pro Forma 
       
Net Revenues $3,281,838  $5,056,029 
Loss from operations  (5,958,350)  (5,348,336)
Net Loss  (6,201,099)  (5,534,088)
Loss per common share:        
Basic $(1.74) $(1.56)
Diluted $(1.74) $(1.56)

The unaudited pro forma consolidated income statements are for informational purposes only and should not be considered indicative of actual results that would have been achieved if the Company and Vape Store acquisition had been completed at the beginning of 2014, or results that may be obtained in any future period.

NOTE 8 – MERGER WITH VAPOR CORP.

On December 17, 2014, Vaporin, Inc. (“Vaporin”) and Vapor Corp. (“Vapor”) entered into an Agreement and Plan of Merger (the “Vapor Merger Agreement”) providing for the acquisition of Vaporin by Vapor. The Vapor Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Vapor Merger Agreement, Vaporin will be merged with and into Vapor (the “Vapor Merger”).The merger closed on March 4, 2015 whereby 100% of the issued and outstanding shares of Vaporin common stock (including shares of common stock issued upon conversion of Vaporin preferred stick immediately prior to the consummation of the merger agreement in accordance with the Vapor Merger Agreement) were converted into, and became 13,591,533 shares of Vapor common stock such that the former Vaporin stockholders collectively hold approximately 45% of the issued and outstanding shares of Vapor’s common stock following the consummation of the merger.

The options and warrants to acquire Vaporin common stock that are issued and outstanding as of the effective time of the Merger, as well as 910,000 restricted stock units which are exchangeable for Vaporin common stock, will be assumed by Vapor in the Merger and the number of shares issuable under such securities shall be adjusted to give effect to the Per Share Merger Consideration (as defined in the Merger Agreement).

The Merger Agreement contained customary representations and warranties of the Company and Vapor relating to their respective businesses. The Company and Vapor have agreed to use commercially reasonable efforts to preserve intact its business organization and that of its significant subsidiaries, as well as maintain its rights, franchises and existing relations with customers, suppliers and employees. The Merger Agreement also contains covenants by each party to furnish current information to the other party.

The Merger Agreement contained customary conditions that were satisfied prior to the closing of the merger, including the requirement for the Vapor to receive gross proceeds from a $3.5 million equity offering disclosed in Note 13. Additionally, the Vapor must have received commitments from certain third parties for financing of up to $25 million to be used for the construction of retail stores and which is contingent on the achievement of certain performance metrics.

NOTE 9 – NOTES PAYABLE

Convertible notes payable

On January 24, 2014, following the closing of the Share Exchange, the Company assumed convertible notes payable for a total of $350,000. On January 24, 2014, the debt discount on the convertible notes has a remaining balance of $253,844. These convertible notes payable consisted of the following:

$75,000 10% secured convertible promissory note due in June 2014 with a 5-year warrant to purchase 75,000 shares of the Company’s common stock at an exercise price of $10 per share for gross proceeds to the Company of $75,000. The note was convertible into shares of the Company’s common stock at an initial conversion price of $10 per share. In September 2014, the Company issued 11,000 shares of common stock for the conversion of principal debt of $75,000 including accrued interest of $7,500. The warrants have an exercise price of $0.50 per share, as a result of being reduced from $10 per share pursuant to full-ratchet anti-dilution protection. The Company accounted for the reduction of the conversion price from $10 to a lower price per share and such conversion under ASC 470-20-40 “Debt with Conversion and Other Options” and accordingly recorded an additional interest expense of $9,900 which is equal to the fair value of shares issued in excess of the fair value issuable pursuant to the original conversion terms.

$175,000 10% secured convertible promissory notes due in August 2014 with a 5-year warrant to purchase 30,000 shares of the Company’s common stock at an exercise price of $0.50 per share for gross proceeds to the Company of $175,000. The notes are convertible into shares of the Company’s common stock at an initial conversion price of $10 per share. In February 2014, the Company paid back the principal plus accrued interest owed to one of the investors for a sum total of $52,433. In September 2014, the Company issued 18,333 shares of common stock for the conversion of principal debt of $125,000 including accrued interest of $12,500. The warrants have an exercise price of $0.50 per share, as a result of being reduced from $10 per share pursuant to full-ratchet anti-dilution protection. The Company accounted for the reduction of the conversion price from $10 to a lower price per share and such conversion under ASC 470-20-40 “Debt with Conversion and Other Options” and accordingly recorded an additional interest expense of $16,500 which is equal to the fair value of shares issued in excess of the fair value issuable pursuant to the original conversion terms.

$100,000 of its 10% convertible promissory notes due in January 2015 with warrants to purchase up to an aggregate of 20,000 shares of the Company’s common stock at an exercise price of $5.00 per share for gross proceeds to the Company of $100,000. The notes are convertible into shares of the Company’s common stock at an initial conversion price of $5.00 per share, subject to adjustment. On January 22, 2014, prior to the closing of the Share Exchange, the Company issued 10,000 shares of the Company’s common stock in connection with the conversion of $50,000 of the notes at a conversion price of $5.00 per share. The warrants have an initial exercise price of $5.00 per share.

In accordance with ASC 470-20-25, the convertible notes were considered to have an embedded beneficial conversion feature because the effective conversion price was less than the fair value of the Company’s common stock. These convertible notes were fully convertible at the issuance date thus the value of the beneficial conversion and the warrants were treated as a discount on the convertible notes to be amortized over the term of the convertible notes. The fair value of this warrant was estimated on the date of grant using the Black-Scholes option-pricing model using the following weighted-average assumptions: expected dividend yield of 0%; expected volatility ranging from 120% to 131%; risk-free interest rate ranging from 1.39% to 1.73% and an expected holding period of five years. During the nine months ended December 31, 2014, amortization of debt discount amounted to $253,844 and was included in interest expense.

On January 14, 2014, prior to the closing of the Share Exchange, the Company granted warrants to purchase up to an aggregate of 12,500 shares of the Company’s common stock at an exercise price of $0.50 (collectively the “Additional Warrants”) to a certain note holder in connection with a note that is due in August 2014. The Company issued the Additional Warrants in connection with certain protection clause contained in the note holder’s respective securities purchase agreements as a result of the Company’s subsequent issuance in January 2014 of its warrants related to a convertible note payable at a per share price lower than the per share price paid by the note holder. The fair value of this warrant was estimated on the date of grant using the Black-Scholes option-pricing model using the following weighted-average assumptions: expected dividend yield of 0%; expected volatility of 131%; risk-free interest rate of 1.65% and an expected holding period of five years. During the year ended December 31, 2014, the Company recognized an interest expense of $78,869 and a corresponding derivative liability in connection with the Additional Warrants.

The initial conversion price of the notes above and initial exercise prices of warrants issued above are subject to full-ratchet anti-dilution protection. In accordance with ASC Topic 815 “Derivatives and Hedging”, these convertible notes include a down-round provision under which the conversion price and exercise price could be affected by future equity offerings (see Note 7). Instruments with down-round protection are not considered indexed to a company’s own stock under ASC Topic 815, because neither the occurrence of a sale of common stock by the company at market nor the issuance of another equity-linked instrument with a lower strike price is an input to the fair value of a fixed-for-fixed option on equity shares.

Notes payable

On December 19, 2013, the Company issued a six month 10% note payable of $50,000. The note was scheduled to mature on June 18, 2014. In April 2014, the Company paid off the note including interest in the amount of $51,762.

On December 19, 2013, the Company issued a six month 10% note payable of $25,000. The note was scheduled to mature on June 18, 2014. In February 2014, the Company issued 5,000 shares of the Company’s common stock in connection with the full conversion of this note.

Notes payable – related party

In connection with the Merger Agreement, the Company agreed to pay the Cantrells $200,000 within 30 days of the Closing. The Company subsequently paid the $200,000 in October 2014.

At the closing of the Share Exchange, $285,710 in principal amount plus accrued interest of the notes were cancelled in exchange for the issuance of an aggregate of 100,000 shares of Series C Preferred Stock of the Company.

On December 8, 2014, Emagine the Vape Stores, LLC, a Delaware limited liability company (“Emagine”) managed by Vaporin, Inc., a Delaware corporation (the “Company”), entered into a Secured Line of Credit Agreement (the “Agreement”), effective as of December 1, 2014, with one affiliated shareholder of the Company and two unaffiliated investors (the “Lenders”). Under the Agreement, the Lenders agreed to advance up to $3,000,000 in three equal tranches in exchange for secured promissory notes which mature on March 31, 2016, bear interest at 12% per annum, and are secured by a first lien on the assets of Emagine. The first tranche of funding under the Agreement was provided on December 1, 2014.

The funds will be used to purchase and/or open Vape Stores similar to those operated by the Company. In connection with the completion of the Vapor Merger on March 4, 2015, Emagine became a wholly-owned subsidiary of Vapor.

NOTE 10 – DERIVATIVE LIABILITIES

In connection with the issuance of the 10% convertible notes (see Note 9), the Company determined that the terms of the convertible notes include a down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company. Accordingly, under the provisions of FASB ASC Topic No. 815-40, “Derivatives and Hedging - Contracts in an Entity’s Own Stock”, the convertible instrument was accounted for as a derivative liability at the date of issuance and adjusted to fair value through earnings at each reporting date. The Company has recognized a derivative liability of $43,944 and $0 at December 31, 2014 and December 31, 2013, respectively. The gain resulting from the decrease in fair value of this convertible instrument was $251,625 for year ended December 31, 2014. The derivative expense was $86,484, for year ended December 31, 2014. The Company reclassified $90,064 to paid-in capital due to the payment of convertible notes during the twelve months ended December 31, 2014.

The Company used the following assumptions for determining the fair value of the convertible instruments under the Black-Scholes option pricing model:

December 31, 2014
Dividend rate0%
Term (in years)0.33 - 5 Years
Volatility126% - 131%
Risk-free interest rate0.05% - 1.73%


F-67
PART II

NOTE 11 – STOCKHOLDERS’ EQUITY

The Company is authorized to issue up to 200,000,000 shares of common stock, par value $0.0001 per share, and 50,000,000 shares of blank check preferred stock, par value $0.0001 per share.On September 8, 2014, the Company filed an amendment to its Certificate of Incorporation with the Secretary of State of Delaware effecting the Reverse Split (the “Reverse Split”). As a result of the Reverse Split, every 50 shares of the Company’s common stock were combined into one share of common stock. Immediately after the September 8, 2014 effective date, the Company had approximately 3,826,493 shares of common stock outstanding. The authorized number of shares of the Company’s common stock and the par value remained the same. The Reverse Split did not affect the number of shares of preferred stock and certain derivative securities outstanding; however it did affect the number of shares issuable to holders upon conversion or exercise of such securities. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split.

On May 30, 2014, the Board of Directors of the Company approved an amendment (the “Amendment”) to the 2014 Equity Incentive Plan (the “Plan”) which provides for the grant of incentive stock options, non-qualified stock options, restricted stock, restricted stock units (“RSUs”) and stock appreciation rights to employees, consultants, officers and directors of the Company in order to help the Company attract, retain and incentivize qualified individuals that will contribute to the Company’s success. The Amendment increased the maximum number of shares of the Company’s common stock that may be issued under the Plan from a total of 500,000 shares to a total of 1,000,000 shares.

Series A Preferred Stock

On April 8, 2014, the holders of all shares of the Company’s Series A Preferred Stock converted the shares of Series A Preferred Stock into a total of 60,000 shares of common stock. At December 31, 2014, the Company did not have any shares of Series A Preferred Stock outstanding.

Series B Preferred Stock

The Company has outstanding 100,000 shares of Series B Preferred Stock. Each share has a liquidation preference equal to $0.0001 per share. Shares of Series B Preferred Stock are convertible at any time on a share-for-share basis, subject to a limitation that the holder shall not at any time be a beneficial owner of more than 9.99% of the Company’s common stock outstanding at such time. The Series B votes on an as-converted basis, subject to this limitation. Holders of Series B have no dividend preference.

Series C Preferred Stock

The Company has outstanding 1,550 shares of Series C Preferred Stock. Each share has a liquidation preference equal to $0.0001 per share. Shares of Series C Preferred Stock are convertible at any time on a 1 share of Series C Preferred Stock-for-1,000 shares of common stock basis, subject to a limitation that the holder shall not at any time be a beneficial owner of more than 9.99% of the Company’s common stock outstanding at such time. The Series C votes on an as-converted basis, subject to this limitation. Holders of Series C have no dividend preference.

Series E Preferred Stock

On September 2, 2014, the Company filed a Certificate of Designation creating the Series E Convertible Preferred Stock of the Company. The Series E shares: (i) automatically convert into shares of the Company’s common stock at a rate of 285,714.29 shares of common stock for each share of Series E at such time that the Company has sufficient authorized capital, (ii) are entitled to vote on all matters submitted to shareholders of the Company on an as-converted basis and (iii) have a nominal liquidation preference. The Series E converted into common stock on September 8, 2014.

F-68

(A)Share Exchange
In January 2014, the Company entered into the Share Exchange with Vaporin Florida. Pursuant to the Exchange Agreement, all of the issued and outstanding common stock of Vaporin Florida was exchanged for an aggregate of 700,000 shares of the Company’s common stock. Additionally, the holders of all of Vaporin Florida’s issued and outstanding Series A Preferred Stock and the holders of outstanding notes of Vaporin Florida in the aggregate principal amount of $285,710 (the “Vaporin Florida Notes”) exchanged all of the outstanding shares of Vaporin Florida’s Series A Preferred Stock and converted the Vaporin Florida Notes into an aggregate of 2,000 shares of the Company’s Series C Preferred Stock. This transaction was accounted for as a reverse recapitalization of Vaporin Florida whereby Vaporin Florida is considered the acquirer for accounting purposes. The Company is deemed to have issued 1,883,250 shares of common stock and 60,000 shares of Series A Preferred Stock which represents the outstanding common and preferred stock of the Company just prior to the closing of the transaction.
(B)Private Placement
In January 2014, the Company entered into stock purchase agreements with accredited investors pursuant to which they purchased 115,000 shares of common stock and 100,000 shares of Series B Preferred Stock at a price of $5.00 per share for net proceeds of $1,043,500. The Company paid placement agent fees of $31,500 in connection with the sale of common and preferred stock.
On April 1, 2014, the Company closed on a private placement of 503,993 shares of the Company’s common stock to accredited investors at a price per share of $5.00. Subsequent closings took place on April 7, 2014 and May 6, 2014. The offering generated gross proceeds to the Company of $2,529,965. As compensation, the acting placement agent for the offering received a commission of 10% of the gross proceeds from the shares it sold and a number of five-year warrants equal to 10% of the shares it sold. To date, the Company has paid the placement agent $144,997 and issued the placement agent 28,999 five-year warrants exercisable at $5.00 per share. The net proceeds to the Company, after deducting placement agent fees, legal fees, filing fees and escrow expenses, were $2,290,768.
On August 29, 2014, the Company raised $880,000 in gross proceeds from the sale of 160,000 shares of common stock at a price of $5.50 per share in a private placement offering to four accredited investors. The Company has paid legal fees and escrow expenses related to the private placement of approximately $58,000 which resulted to a net proceeds to the Company of approximately $822,000.
On September 29, 2014, the Company raised $220,000 in gross proceeds from the sale of 40,000 shares of common stock at a price of $5.50 per share in a private placement offering to four accredited investors. The Company has paid legal fees, filing fees and escrow expenses related to the private placement of approximately $18,700 which resulted to a net proceeds to the Company of approximately $201,000.
The securities were not registered under the Securities Act and were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Act and Rule 506(b) promulgated thereunder.
(C)Common stock for services
In March 2014, the Company issued an aggregate of 51,000 shares of the Company’s common stock to two consultants for consulting services rendered. The Company valued these common shares at the fair market value on the date of grant at approximately $5.00 per share or $255,000 based on the sale of commons stock in a private placement at $5.00 per common share. In connection with the issuance of these common shares, the Company recorded stock based consulting for the year ended December 31, 2014 of $255,000.
Between April 2014 and May 2014, the Company issued an aggregate of 102,000 shares of the Company’s common stock to various consultants for consulting and accounting service rendered. The Company valued these common shares at the fair market value on the date of grant at approximately $5.00 per share or $510,000 based on the sale of commons stock in a private placement at $5.00 per common share. In connection with the issuance of these common shares, the Company recorded stock based consulting for the year ended December 31, 2014 of $510,000.

On May 30, 2014, the Board of Directors approved the grant under the Plan of 400,000 restricted stock units (“RSU”) to Marlin Capital Investments, LLC, a consultant to the Company, 200,000 RSU’s to Greg Brauser, the Company’s Chief Operating Officer, and 200,000 RSU’s to Scott Frohman, the Company’s Chief Executive Officer and Director. All the RSU’s will vest quarterly in approximately equal installments over a three-year period from the date of issuance or upon a “change in control” as defined in the Plan, subject to the consultant’s or individual’s continued service to the Company on each applicable vesting date, with delivery of shares taking place on the third anniversary of the date of issuance. In connection with the grant of these RSU’s, the Company recorded stock based compensation and consulting in the year ended December 31, 2014 of $1,239,129.

Between July 2014 and August 2014, the Company issued an aggregate of 34,250 shares of the Company’s common stock to various consultants for consulting service rendered. In connection with the issuance of these common shares, the Company recorded stock based consulting for twelve year ended December 31, 2014 of $124,375.

In July 2014, the Company entered into a one-year employment agreement for a Vice President of Internet Marketing. The Company granted the executive 10,000 restricted shares of common stock and 5,000 stock options exercisable at $4.15 vesting quarterly over a three-year period. The Company valued these common shares at the fair market value on the date of grant at $5.00 per share or a total of $50,000 based on the quoted trading price on the grant date. In connection with the issuance of these common shares, the Company recorded stock based compensation for the year ended December 31, 2014 of $50,000. The 5,000 stock options were valued on the grant date at approximately $17,650 or $3.53 per option using a Black-Scholes option pricing model with the following assumptions: stock price of approximately $4.15 per share, volatility of 127%, expected term of 5 years, and a risk free interest rate of 1.70%.

Between October 2014 and December 2014, the Company issued an aggregate of 196,000 shares of the Company’s common stock to various consultants for consulting service rendered. In connection with the issuance of these common shares, the Company recorded stock based consulting for year ended December 31, 2014 of $355,120.

(D) Stock Options

A summary of the stock options for the twelve months ending December 31, 2014 and for the year ending December 31, 2013 and changes during the period are presented below:

  Number of
Options
  Weighted
Average Exercise
Price
  Weighted
Average
Remaining
Contractual Life
(Years)
 
Recapitalization on January 24, 2014  6,000   20.00   8.69 
Granted  5,000   4.15   5.00 
Exercised  -   -   - 
Forfeited  -   -   - 
Cancelled  -   -   - 
Balance outstanding at December 31, 2014  11,000  $12.80   6.29 
             
Options exercisable at December 31, 2014  4,917  $19.00     
Options expected to vest  4,583         
             
Weighted average fair value of options granted during the twelve months ended December 31, 2014         $3.53 

Stock options outstanding at December 31, 2014 as disclosed in the above table have no intrinsic value at the end of the period. For the twelve months ended December 31, 2014, total stock-based compensation related to the options was $3,284. The value of stock based compensation expense not yet recognized pertaining to unvested options and stock grants was approximately $2,047,883 at December 31, 2014.

(E) Stock Warrants

A summary of the status of the Company’s outstanding stock warrants for the twelve months ending December 31, 2014 and for the year ending December 31, 2013 and changes during the period then ended is as follows:

   Number
of
Warrants
  Weighted
Average
Exercise
Price
  Weighted
Average
Remaining Contractual
Life
(Years)
 
Recapitalization on January 24, 2014   90,375   14.00   4.32 
Granted   28,999   5.00   5.00 
Cancelled   -   -   - 
Forfeited   -   -   - 
Exercised   -   -   - 
Balance at December 31, 2014   119,374  $12.00   3.60 
              
Warrants exercisable at December 31, 2014   119,374  $12.00   3.60 
              
Weighted average fair value of warrants granted during the twelve months ended December 31, 2014      $5.00     

NOTE 12 – RELATED PARTY TRANSACTIONS

The Company purchases most of its products from Direct Source China, LLC. , an entity controlled by Gregory Brauser, our Chief Operating Officer. This entity purchases the products directly from the manufacturers in China and charges the Company an 8% premium. The Company paid Direct Source net of all credits approximately $509,000 for products for the twelve months ended December 31, 2014.

Note Payable – Related Party – See Note 9

During the year ended December 31, 2014, the Company paid total of $24,500 in consulting fees to related parties.

The Company purchases most of its products from Direct Source China, LLC. , an entity controlled by Gregory Brauser, our Chief Operating Officer. This entity purchases the products directly from the manufacturers in China and charges the Company an 8% premium. The Company paid Direct Source net of all credits approximately $509,000 for products for the twelve months ended December 31, 2014.

NOTE 13 – SUBSEQUENT EVENTS

On January 20, 2015, Vaporin, Inc. (the “Company”) and Vapor Corp. (“Vapor”) entered into a Securities Purchase Agreement with certain accredited investors providing for the sale of $350,000 of the Company’s Convertible Notes (the “Notes”). The Notes accrue interest on the outstanding principal at an annual rate of 10%. The principal and accrued interest on the Notes is due and payable on January 20, 2016. Assuming the merger between the Company and Vapor (“Merger”) closes, the Notes will be convertible into Vapor common stock at the lower of (i) $1.08 or (ii) a 15% discount to a 20-trading day VWAP following the closing of the merger (subject to a maximum issuance of 525,000 shares). If the Merger does not close, the Notes will not be convertible into either the Company’s or Vapor’s stock. Investors were provided with standard piggyback registration rights which are conditioned on the Merger closing.

On January 29, 2015, Vaporin, Inc. (the “Company”) was issued a $350,000 note by Vapor Corp. (“Borrower”) in consideration for a loan of $350,000. The note accrues interest on the outstanding principal at an annual rate of 12%. The principal and accrued interest on the note is due and payable on January 29, 2016 (the “Maturity Date”). If the merger between the Company and the Borrower (“Merger”) does not close by May 31, 2015 (the “End Date”), the Maturity Date will accelerate and become due June 1, 2015. Additionally, if the Merger does not close by the End Date or in the event of a default by the Borrower, the note will be convertible into the Borrower’s common stock at 85% of the Borrower’s closing price on May 29, 2015. If the merger closes prior to the End Date, the note shall not be convertible. The note shall not be convertible until such time as the Nasdaq Stock Market (“Nasdaq”) approves the issuance of the shares underlying the note.

On March 4, 2015, the acquisition of Vaporin by Vapor (the “Vapor Merger”) was completed pursuant to the terms of the Merger Agreement. In connection with the Merger, Emagine became a wholly-owned subsidiary of the Vapor.

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Background of the Merger

Vapor completed its acquisition of Vaporin, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated December 17, 2014, by and between the Vapor and Vaporin. In accordance with the Merger Agreement, the Company acquired Vaporin through the merger of Vaporin with and into Vapor with Vapor being the surviving entity and maintaining control (as a result of the current stockholders of Vapor maintaining more than 50% ownership in the Company’s outstanding shares of common stock and the current Vapor directors comprising the majority of the board) (the “Merger”). The assets and liabilities and the historical operations that are reflected in the Company’s financial statements filed with the SEC are those of Vapor, and Vaporin’s assets, liabilities and results of operations are consolidated with the assets, liabilities and results of operations of Vapor effective March 4, 2015.

Basis of Presentation

The accompanying Unaudited Pro Forma Condensed Combined Balance Sheet, or the pro forma balance sheet, as of December 31, 2014 and the Unaudited Pro Forma Condensed Combined Statement of Operations, or the pro forma statements of operations, for the year ended December 31, 2014 combine the historical financial information of Vaporin and Vapor and are adjusted on a pro forma basis to give effect to the Merger as described in the notes to the unaudited pro forma condensed combined financial statements. The pro forma balance sheet reflects the Merger, which was completed on March 4, 2015, as if it had been consummated on December 31, 2014, and the pro forma statement of operations for the year ended December 31, 2014 reflects the Merger as if it had been consummated on January 1, 2014. The pro forma financial statements have been derived from and should be read in conjunction with the historical consolidated financial statements of each of Vaporin and Vapor, which are included herein.

The following unaudited pro forma condensed combined financial statements give effect to the merger under the acquisition method of accounting in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standard Topic 805, Business Combinations (“ASC 805”). The pro forma financial statements are provided for illustrative purposes only and are not intended to represent, and are not necessarily indicative of, what the operating results or financial position of the Company would have been had the Merger been completed on the dates indicated, nor are they necessarily indicative of the Company’s future operating results or financial position. The pro forma financial statements do not reflect the impacts of any potential operational efficiencies, asset dispositions, cost savings or economies of scale that the Company may achieve with respect to the combined operations. Additionally, the pro forma statements of operations do not include non-recurring charges or credits which result directly from the transactions. Differences between estimates used in the purchase price allocation included here within this unaudited pro forma financial information and the final purchase price allocation amounts will occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial statements.

The historical consolidated financial information has been adjusted in the unaudited pro forma condensed combined financial statements to give effect to pro forma events that are (1) directly attributable to the Merger, (2) factually supportable, and (3) expected to have a continuing impact on the combined results of Vapor and Vaporin. These unaudited pro forma condensed combined financial statements do not give effect to anticipated synergies, integration costs or nonrecurring transaction costs which result directly from the merger. The unaudited pro forma condensed combined financial statements also do not contemplate any additional debt that Vapor may elect to incur in the future, which could result in interest expense that is different from what is reflected in these unaudited pro forma condensed combined financial statements. Further, because the tax rate used for these unaudited pro forma condensed combined financial statements is an estimated statutory tax rate, it will likely vary from the actual effective rate in periods subsequent to completion of the transactions, and no adjustment has been made to the unaudited pro forma condensed combined financial information as it relates to limitations on the ability to utilize deferred tax assets, such as those related to net operating losses and tax credit carryforwards, as a result of the transaction.

The unaudited pro forma condensed combined financial statements should be read in conjunction with the accompanying notes to the unaudited pro forma condensed combined financial statements, the audited historical consolidated financial statements and accompanying notes of Vapor and Vaporin.

VAPOR CORP, INC.

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

December 31, 2014

  Historical  Historical  Pro Forma   Pro Forma 
  Vapor Corp.  Vaporin, Inc.  Adjustments   Combined 
CURRENT ASSETS:                 
Cash $471,194  $865,737   2,941,960(b)   4,278,891 
Due from merchant credit card processor, net  111,968   160,216   -    272,184 
Accounts receivable, net  239,652   88,614   -    328,266 
Inventory  2,048,883   1,173,124   -    3,222,007 
Prepaid expenses and vendor deposits  664,103   42,996   -    707,099 
Loan receivable, net  467,095   -   -    467,095 
Deferred financing costs, net  122,209   -   -    122,209 
TOTAL CURRENT ASSETS  4,125,104   2,330,687   2,941,960    9,397,751 
                  
Property and equipment, net  712,019   160,620   -   $872,639 
Intangible assets  -   -   2,080,600(a)  $2,080,600 
Goodwill  -   3,732,268   12,296,819(a)  $16,029,087 
Other assets  91,360   1,472   -   $92,832 
TOTAL ASSETS $4,928,483  $6,225,047  $17,319,379   $28,472,909 
                  
CURRENT LIABILITIES:                 
Accounts payable and accrued expenses $2,895,247  $824,104  $-   $3,719,351 
Current portion of capital lease  52,015            52,015 
Derivative liabilities  -   43,944   -    43,944 
Senior convertible notes payable – related parties, net of debt discount of $1,093,750  156,250   -        156,250 
Term loan  750,000   -   -    750,000 
Customer deposits  140,626   -   -    140,626 
Income taxes payable  3,092   -   -    3,092 
TOTAL CURRENT LIABILITIES  3,997,230   868,048   -    4,865,278 
                  
Capital lease, net of current portion  119,443   -   -    119,443 
Loan payable - related party  -   1,000,000   -    1,000,000 
TOTAL LONG-TERM DEBT  119,443   1,000,000   -    1,119,443 
                  
COMMITMENTS AND CONTINGENCIES                 
STOCKHOLDERS’ EQUITY                 
Preferred stock  -   -   -    - 
Series B preferred stock  -   10   (10(c)   - 
Common stock  

3,352

   489   3,307(c,d)   7,148 
Additional paid-in capital  16,040,361   10,864,408   11,367,174(c,d)   38,271,943 
Accumulated deficit  (15,231,903)  (6,502,903)  5,943,903(b,c)   (15,790,903 
TOTAL STOCKHOLDERS’ EQUITY  811,810   4,362,004   17,314,374    22,488,188 
Non-Controlling Interest in Subsidiary  -   (5,005)  5,005(c)   - 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $4,928,483  $6,225,047  $17,319,379   $28,472,909 

See accompanying notes to the pro forma condensed combined financial statements.

VAPOR CORP, INC.

UNAUDITED PRO FORMA CONDENSED COMBINED

STATEMENT OF OPERATIONS

For the year ended December 31, 2014

     Pro Forma Vaporin       
  Audited  Audited               
  12/31/2014  12/31/2014  Historical    Pro Forma    
  Vapor 
Corp.
  Vaporin, 
Inc.
  Vape 
Store
  Pro Forma
Adjustment
  Vaporin
(e)
 Pro Forma
Adjustments
  Pro Forma
Combined
 
                     
Revenue $15,279,859  $3,281,838  $1,774,191  $-  $5,056,029 $-  $20,335,888 
Cost of goods sold  14,497,254   1,790,098   315,958   -  2,106,056  -   16,603,310 
Gross Profit  782,605   1,491,740   1,458,233   -  2,949,973  -   3,732,578 
                           
Operating expenses                          
Selling, general and administrative  11,126,759   6,466,583   842,830   -  7,309,413  266,120(f)  18,702,291 
Advertising  2,374,329   983,507   28,409   -  1,011,916  -   3,386,245 
Total operating expenses  13,501,088   7,450,090   871,239   -  8,321,329  266,120   22,088,537 
Operating income (loss)  (12,718,483)  (5,958,350)  586,995   -  (5,371,355)  (266,120)  (18,355,958)
                           
Other expenses/income                          
Derivative expense  -   86,484   -   -  86,484  -   86,484 
Change in fair value of derivatives  -   (251,625)  -   -  (251,625)  -   (251,625)
Amortization of deferred financing cost  17,458   -   -   -  -  -   17,458 
Interest expenses  348,975   407,890   -   -  407,890  -   756,865 
Total other expenses  366,433   242,749   -   -  242,749  -   609,182 
                           
Net income (loss) before income taxes  (13,084,916)  (6,201,099)  586,995   -  (5,614,104)  (266,120)  (18,965,140)
                           
Income tax (expense) benefit  (767,333)  -   -   -  -  -   (767,333)
Net income (loss)  (13,852,249) $(6,201,099)  586,995  $-  (5,614,104)  (266,120)  (19,732,473)
                           
Net loss per common share - basic and diluted  (4.22) $(1.74)  -   -         (2.95)
                           
Weighted average common shares outstanding - basic and diluted  3,283,030   

3,554,486

             3,404,773(g)  6,687,803 

See accompanying notes to the pro forma condensed combined financial statements.

F-74

1. Description of Transaction

Merger with Vaporin, Inc.

On December 17, 2014, Vapor Corp, Inc. (the “Company”) entered into the Merger Agreement with Vaporin, Inc. (“Vaporin”) pursuant to which Vaporin was to merge with and into the Company with Vapor being the surviving and controlling entity. The Merger closed on March 4, 2015 and the purchase price consideration paid by the Company consisted of the following:

1.100% of the issued and outstanding shares of Vaporin common stock (including shares of common stock issued upon conversion of Vaporin preferred stock immediately prior to the consummation of the merger in accordance with the Merger Agreement) were converted into, and became 2,718,310 shares of the Company’s common stock such that the former Vaporin stockholders collectively hold approximately 45% of the issued and outstanding shares of the Company’s common stock following consummation of the Merger.
2.100% of the issued shares of Vaporin restricted stock units were converted into the right to receive 1,890,237 shares of the Company’s common stock. The restricted stock units became fully-vested in connection with the Merger and as a result, were included as a part of the Company’s purchase price as no further services from the holders is required to be provided to the Company. The 1,890,237 restricted stock units remain outstanding as of March 31, 2015. Based on the terms of the Merger Agreement, the Company has agreed to issue these in twelve equal monthly instalments, with the first delivery date being the date of the closing of the Merger, however, all shares of common stock to be delivered on March 15, 2016 to the extent they are not previously delivered.

The Merger Agreement contained customary conditions that were satisfied prior to the closing of the Merger, including the requirement for the Company to receive gross proceeds from a $3.5 million equity offering. Additionally, as required by the Merger Agreement the Company received non-binding commitments from certain third parties for financing of up to $25 million to be used for the construction of retail stores and which is contingent on the achievement of certain performance metrics by the Company. In addition, in connection with the Merger, an aggregate $354,029 of a note and interest payable by the Company to Vaporin was forgiven.

Vaporin, Inc. merger with The Vape Store, Inc.

On August 29, 2014, Vaporin, Vaporin Acquisitions, Inc., Vaporin Acquisitions, Inc., a Florida corporation and wholly-owned subsidiary of Vaporin (the “Merger Sub”), The Vape Store, Inc., a Florida corporation (“Vape Store”), and Steve and Christy Cantrell, holders of all outstanding Vape Store shares entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, Vape Store merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation and a wholly-owned subsidiary of the Vaporin.

The pro forma statement of operations for Vaporin was prepared as if the merger of The Vape Store, Inc. had occurred on January 1, 2014.

2. Purchase Consideration and Preliminary Purchase Price Allocation

Assuming the merger was completed on December 31, 2014, each share of Vaporin’s common stock and each share of Vaporin’s preferred stock outstanding immediately prior to closing would have been exchanged for approximately .42 shares of Vapor common stock. An estimate of the merger consideration paid to Vaporin stockholders assuming the merger was completed on December 31, 2014 is presented below:

Vaporin common shares outstanding  4,893,254 
Restricted stock units  910,000 
Issuable common shares upon conversion:    
Series B preferred stock  100,000 
Series C preferred stock  1,550,000 
Total Vaporin common and preferred shares eligible for exchange  7,453,254 
Exchange ratio  

0.42

 
Vapor common shares to be issued  

3,096,082

 
Vapor price per common share at December 31, 2014 $

6.05

 
Fair value of total consideration transferred $18,732,947 

The fair value of the purchase consideration issued to the sellers of Vaporin was based on a preliminary valuation analysis and was allocated to fair value of the net tangible assets acquired, with the resulting excess allocated to separately identifiable intangibles, and the remainder recorded as goodwill. Goodwill recognized from the transactions mainly represented the expected operational synergies upon acquisition of the combined entity and intangibles not qualifying for separate recognition. Goodwill is not expected to be deductible for income tax purposes in the tax jurisdiction of the acquired business.

Purchase Consideration   
    
Value of consideration paid: $18,732,947 
     
Tangible assets acquired and liabilities assumed at fair value    
Cash $865,737 
Due from merchant credit card processor  160,216 
Accounts receivable  88,614 
Inventories  1,173,124 
Property and Equipment  160,620 
Other Assets  42,996 
Notes payable – related party  (1,000,000)
Accounts Payable and accrued expenses  (824,103)
Derivative Liabilities  (43,944)
Net tangible assets acquired $623,260 
     
Consideration:    
Value of common stock issued  18,732,947 
Net tangible assets acquired  623,260 
Excess purchase price over net tangible assets acquired $18,109,687 
     
Identifiable intangible assets    
Trade names and technology  1,500,000 
Customer relationships  488,274 
Assembled workforce  92,326 
Total Identifiable Intangible Assets  2,080,600 
Goodwill  16,029,087 
Total allocation to identifiable intangible assets and goodwill $18,109,687 

As of December 31, 2014, Vaporin’s consolidated balance sheet included goodwill of $3,732,286 resulting from the acquisition of Vape Store. Such amount was not considered as a component of the net tangible assets acquired of Vaporin for purposes of the allocation of the purchase by Vapor and was based on its preliminary valuation.

3. Pro Forma Adjustments

Pro forma adjustments reflect those matters that are direct result of the Merger Agreement with Vaporin, which are factually supportable and, for pro forma adjustments to the unaudited pro forma statements of operations, are expected to have continuing impact. The pro forma adjustments are based on preliminary estimates that may change as additional information is obtained.

Unaudited Pro Forma Condensed Combined Balance Sheet

a)To adjust the amount of goodwill to $15,983,039 as a result of the merger and to record identifiable intangible assets of $1,500,000 of trade names and technology, $488,274 of customer relationships and $92,326 for assembled workforce based on a preliminary valuation analysis.
b)Represents (a) cash received by Vapor of $3.5 million in exchange for 686,463 shares of common stock in connection with the required financing transaction per the terms of the merger offset by (b) $559,000 of estimated costs incurred by Vapor in connection with the acquisition of Vaporin and assumes such expenses were incurred on December 31, 2014 in connection with the closing of the merger.
c)Reflects an adjustment to remove the historical equity balances of Vaporin and account for the $3.5 million required financing as disclosed in “b” above.
d)Reflects the issuance of 2,718,310 shares of $0.001 par value Vapor common stock as merger consideration. Such number of shares issued was calculated based on the number of outstanding shares of Vapor common stock. The value of the consideration transferred was based on the closing stock price of the Vapor common stock at December 31, 2014.

Unaudited Pro Forma Condensed Combined Statements of Operations

e)As discussed above, Vaporin completed its acquisition of Vape Store on August 29, 2014. For purposes of this pro forma, Vaporin has included adjustments to reflect the results of operations of Vape Store as of the acquisition had occurred on January 1, 2014. The pro forma adjustments represent the combined results of Vaporin and The Vape Store for the respective period presented.
f)Reflects the incremental depreciation and amortization expense based on the preliminary fair values of the tangible and identifiable intangible assets acquired as follows:

  Pro Forma Amortization 
  Intangible
Assets
  Estimated Useful
Lives (years)
  For the
Year Ended
December 31, 2014
 
Trade Names and Technology $1,500,000   10  $150,000 
Customer Relationships  488,274   5  $97,655 
Assembled Workforce  92,326   5   18,465 
  $2,080,600      $​ 266,120 ​ 

g)Reflects the issuance of  (a) 2,718,310 shares of  $0.001 par value Vapor common stock as merger consideration, as described in the Basis of the Pro Forma Presentation note above (b) 1,890,237 shares of common stock to be issued by Vapor in connection with restricted stock units as part of the merger consideration and (c) the 3,462,314 shares of common stock to be issued by Vapor in connection with the $3.5 million financing.

PART II—INFORMATION NOT REQUIRED IN THE PROSPECTUS


Item 13. Other Expenses of Issuance and Distribution

Distribution.


The following table sets forth allthe expenses other than the underwriting commissions, payable by the registrantus in connection with the saleoffering of the common stock being registered.securities described in this registration statement. All the amounts shown are estimates, except for the SEC registration fee and the FINRA filing fee.

We will bear all expenses shown below.

Amount
to be paid
SEC registration fee
$

8,819.50

10,910
FINRA filing fee $11,885
NASDAQ listing fees $

5,000

Blue sky qualification
Subscription agent fees and expenses
 $10,000*
Transfer
Information agent fees and registrar feesexpenses 
 $5,000*
Printing and engraving expenses 
*
Legal fees and expenses 
*
Accounting fees and expenses
 $30,000*
Legal
Miscellaneous fees and expenses
  $

120,000

*
Printing and engraving expenses
Total 
 $5,000
Miscellaneous $

9,295.50

Total $

205,000

*

_______
*To be provided by amendment.

Item 14. Indemnification of Directors and Officers

Officers.


Under Section 145(a)145 of the Delaware General Corporation Law, Registrant has broad powers to indemnify its directors and officers against liabilities they may incur in such capacities, including liabilities under the Securities Act of 1933, as amended (the “DGCL”“Securities Act”), which Vapor is subject to, provides. Registrant’s Bylaws (the “Bylaws”) provide that a corporation mayRegistrant shall indemnify any person who wasits directors and officers if such officer or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted (i) in good faith, and(ii) in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation,Registrant, and (iii) with respect to any criminal action or proceeding, had no reasonable cause to believe the person’ssuch conduct was unlawful. Section 145(b) of the DGCL providesRegistrant believes that a corporation may indemnify any person who was or is a party or is threatenedindemnification under its Bylaws covers at least negligence and gross negligence, and requires Registrant to be made a party to any threatened, pending or completed action or suit by oradvance litigation expenses in the rightcase of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, truststockholder derivative actions or other enterpriseactions, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. To the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 145(a) and (b) of the DGCL, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith.

II-1

Any indemnification under Section 145(a) and (b) of the DGCL (unless ordered by a court) shall be made by Vapor only as authorized in the specific case upon a determination that indemnification of the present or director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in Section 145(a) and (b). Such determination shall be made, with respect to a person who is a director or officer at the time of such determination, (1) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (2) by a committee of such directors designated by majority vote of such directors, even though less than a quorum, or (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion, or (4) by the shareholders. Expenses (including attorneys’ fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officerthe directors and officers to repay such amountadvances if it shallis ultimately be determined that such personthe director is not entitled to be indemnified by the corporation as authorized in this section. Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents may be so paid uponindemnification. The Bylaws further provide that rights conferred under such terms and conditions, if any, as the corporation deems appropriate. The indemnification and advancement of expenses provided by, or granted pursuant to, Section 145Bylaws shall not be deemed to be exclusive of any other rights to which those seeking indemnificationright such persons may have or advancement of expenses may be entitledacquire under any bylaw, agreement, vote of shareholdersstockholders or disinterested directors, or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office.

Section 145 of the DGCL also empowers a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section 145.

Article 10 of the Vapor’sotherwise.


In addition, Registrant’s Certificate of Incorporation and Article 7(the “Certificate of Vapor’s Bylaws provideIncorporation”) provides that, pursuant to Delaware law, none of its directors officers, employees and agents shall be indemnifiedliable for monetary damages for breach of his or her fiduciary duty of care to Registrant and its stockholders to the fullest extent permitted by the DGCL.

Vapor carriesDelaware General Corporation Law as it presently exists or may hereafter be amended from time to time. This provision in the Certificate of Incorporation does not eliminate the duty of care, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware law. In addition, each director will continue to be subject to liability for breach of the director’s duty of loyalty to Registrant for acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that are in willful or negligent violation of applicable Delaware law. The provision also does not affect a director’s responsibilities under any other law, such as the federal securities laws or state or federal environmental laws. The Certificate of Incorporation further provides that Registrant shall indemnify its directors and officers liability coverages designed to insure its officers and directors and those of its subsidiaries against certain liabilities incurred by them in the performance of their duties, and also providing for reimbursement in certain cases to Vapor and its subsidiaries for sums paid to directors and officers as indemnification for similar liability. Vapor has entered into Indemnification Agreements with its executive officers and directors providing for advancement of expenses and indemnification to the fullest extent permissiblepermitted by law and requires Registrant to advance litigation expenses in the case of stockholder derivative actions or other actions, against an undertaking by the director to repay such advances if it is ultimately determined that the director is not entitled to indemnification. The Certificate of Incorporation also provides that rights conferred under DGCL.

Insofar as indemnificationsuch Certificate of Incorporation shall not be deemed to be exclusive of any other right such persons may have or acquire under any statute, the Certificate of Incorporation, the Bylaws, agreement, vote of stockholders or disinterested directors, or otherwise.


II-1

Registrant has obtained liability insurance policies for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuantdirectors that, subject to certain limitations, terms and conditions, will insure them against losses arising from wrongful acts (as defined by the policy) in their capacity as directors or officers.

In addition, Registrant has entered into agreements to indemnify its directors and certain of its officers in addition to the foregoing provisions, or otherwise, Vapor has been advised thatindemnification provided for in the opinionCertificate of the CommissionIncorporation and Bylaws. These agreements, among other things, indemnify Registrant’s directors and certain of its officers for certain expenses (including attorney’s fees), judgments, fines and settlement amounts incurred by such indemnification is against public policy as expressedperson in any action or proceeding, including any action by or in the Securities Act and is, therefore, unenforceable.

II-2
right of Registrant, on account of services as a director or officer of Registrant or as a director or officer of any subsidiary of Registrant, or as a director or officer of any other company or enterprise that the person provides services to at the request of Registrant.

Item 15.Recent Sales of Unregistered Securities

Securities.


On June 25, 2015,August 13, 2018, the Compensation Committee of the Board of Directors of the Company closedapproved a modification of share-based payment awards to Jeffrey Holman, the Chief Executive Officer, Christopher Santi, the President and Chief Operating Officer of the Company. As part of the share modification, Mr. Holman and Mr. Santi were granted 11 billion and 8 billion shares of restricted common stock, respectively, on the condition that the same number of shares from their options to purchase the Company’s common stock are forfeited.

On August 13, 2018, the Compensation Committee of the Board of Directors of the Company approved an issuance of 3 billion shares of restricted common stock to the John Ollet, Chief Financial Officer of the Company.

On January 14, 2021, the Compensation Committee of the Board of Directors of the Company approved an issuance of restricted stock to the Chief Executive Officer, Chief Operating Officer, Chief Financial Officer and Anthony Panierello, a director of the Company, in consideration for agreeing to a new vesting schedule for the existing awarded restricted stock. Each Officer of the Company was granted a 10% increase from the original award agreement.

On January 14, 2021, the Compensation Committee of the Board of Directors of the Company approved an issuance of restricted stock to Anthony Panierello a Director of the Company, in consideration for agreeing to a new vesting schedule for the existing awarded restricted stock. The Director of the Company was granted a 10% increase from the original award agreement for a total of 50 million shares of restricted common stock, which will vest on December 31, 2022, provided that the grantee remains an employee of the Company through the vesting date.

On March 29, 2021, Healthier Choices Management Corp. (the “Company”) entered into agreements (each an “Exchange Agreement”) with certain holders (the “Holders”) of the Company’s indebtedness (the “Notes”) in an aggregate amount of $1,290,260.64 to exchange the Notes for 1,172,964,218 shares of the Company’s common stock at a price per share of $0.0011 (the “Exchange”), the closing bid price of the Company’s common stock on March, 26 2021. The Notes were issued pursuant to that Loan and Security Agreement (the “Credit Agreement”), dated as of August 18, 2020, among The Vape Store, Inc., the Company, Healthy Choice Markets, Inc., Sabby Healthcare Master Fund, Ltd., and Sabby Volatility Warrant Master Fund, Ltd. In connection with the Exchange, the Credit Agreement and all related loan documents were terminated and the Holder’s liens on the assets of the Company and its subsidiaries were cancelled.


II-2

Series B Convertible Preferred Stock

On August 16, 2018, the Company entered into agreements with certain holders of its Series A Warrants. The Company issued Series B Convertible Preferred Stock (the “Series B Stock”) in exchange for certain Series A Warrants. A total of 20,722 shares of Series B Stock were exchanged for 46,048,318 of Series A Warrants (including those warrants issuable pursuant to a unit purchase option). Each share of Series B Stock has a stated value equal to $1,000 and is convertible into Common Stock on a fixed basis at a conversion price of $0.00 per share.

Series C Convertible Preferred Stock

On November 17, 2020, the Company finalized the closing of the stock exchange with certain holders of its Series B Stock to exchange all the Series B Stock for 20,150 shares of Series C Convertible Preferred Stock (the “Series C Stock”). Each share of Series C Stock has a stated value equal to $1,000 and is convertible into Common Stock on a fixed basis at a conversion price of $0.0001 per share. As of March 5, 2021, the Series C Stock have been 100% been converted into 201.5 billion shares of Company common stock.

Series D Convertible Preferred Stock

On February 7, 2021, Healthier Choices Management Corp. (the “Company”) entered into a Securities Purchase Agreement, dated as of June 22, 2015, with certain purchasers pursuant to which the Company sold at a 5% original issue discount, a totaland issued 5,000 shares of $1,750,000 convertible debenturesits Series D Convertible Preferred Stock (the “Debentures”“Preferred Stock”). Net proceeds to the Company from saleinstitutional investors for $1,000 per share or an aggregate subscription of the Debentures, after payment of commissions and legal fees of the lead investor, were $1,466,250.$5,000,000. The Debentures mature December 22, 2015, and accrue interest at 10% per year. Amounts of principal and accrued interest under the Debentures arePreferred Stock is currently convertible into common stock of the Company at a price per share of $2.50. Principal and accrued interest on the Debentures are payable in three approximately equal installments on September 22, 2015, October 22, 2015 and December 22, 2015, at the election of the holders of the Debentures, (i) in cash for an additional 25% premium, or (ii) in common stock of the Company at a price per share of $2.50. As lead investor under the Securities Purchase Agreement, Redwood Management, LLC received a right of first refusal to purchase up to 100% of the securities offered by the Company in future private placement offerings through December 22, 2015.

The Company’s obligations under the Debentures can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration2,083,333,333 shares of the Company’s obligations, the Company would be requiredCommon Stock at a conversion price of $0.0024 per share, with such conversion price subject to pay 130% of amounts of principal and interest then outstanding under the Debentures. The Company’s obligations under the Debentures are secured under a Security Agreement, under which Redwood Management, LLC actsadjustment as Collateral Agent, by a second lien on substantially all of the Company’s assets, including all of the Company’s interests in its consolidated subsidiaries.

For acting as placement agentdescribed in the offeringCertificate of the Debentures, the Company paid Chardan Capital Management, LLC (the “Placement Agent”) a fee equal to 10% of the gross proceeds from the sale of the Debentures,Designation.

II-3

Item 16. Exhibits and issued the Placement Agent 70,000 five-year warrants exercisable at $2.50 per share. In addition, the Company agreed to reduce the exercise price of 28,614 warrants held by the Placement Agent to $2.50 from their original exercise prices ranging from $10.05 to $12.05.

On June 19, 2015, the Company entered into agreements (the “Waivers”), with certain investors in each of its private placement offerings under the Securities Purchase Agreement dated March 3, 2015 (the “2015 Agreement”) and the Securities Purchase Agreement dated November 14, 2014 (the “2014 Agreement,” and with the 2015 Agreement, the “Agreements”). Under the terms of the Waivers, the signatories thereto (the “Prior Investors”) agreed to amend the Agreements and waive or modify certain terms thereunder, including certain price protection provisions and participation rights in subsequent securities offerings. In exchange, the Company agreed to issue the Prior Investors a total of 647,901 shares of common stock (including 142,000 shares issued to the lead investor under each of the Agreements in its capacity as lead investor) and 595,685 five-year warrants exercisable at $2.525 per share. In the event that, prior to November 14, 2015, the Company issues shares of common stock, or securities convertible into common stock, at an effective price per share of less than $2.70, the Prior Investors will be entitled to the issuance of additional shares (the “Additional Shares”), the exact amount of which will depend on the effective price per share of such subsequent issuance, but which will not exceed a total of 2,328,598 shares. The Company will not issue any shares of common stock requiring shareholder approval under the Rules of the Nasdaq Stock Market without receipt of such approval. The Company will not issue any of the Additional Shares unless the 647,901 shares of common stock, the shares issuable upon conversion of the Debentures and the Additional Shares are either within the 19.9% Nasdaq limitation or the issuance is approved by shareholders. The Company agreed to file a registration statement with the Securities and Exchange Commission registering the shares and warrant shares issued to the Prior Investors under the Waivers.

On June 16, 2015, the Company issued a total of 292,191 shares of common stock upon the vesting of restricted stock units assumed by the Company in connection with its merger with Vaporin, Inc. effective March 4, 2015. Recipients of the shares issued upon vesting of the restricted stock units included Gregory Brauser, the Company’s President and a member of the Board. On May 27, 2015, the Company issued a total of 27,500 shares of common stock to consultants of the Company for consulting services.

The shares and warrants issued under the Waivers, the shares issued upon vesting of the restricted stock units, and the shares issued to consultants, were issued without registration under the Securities Act of 1933 in reliance upon the exemption provided in Section 4(a)(2).

Consolidated Financial Statement Schedules.


Exhibit   Incorporated by Reference Filed or Furnished
No. Exhibit Description Form Date Number Herewith
1.1*
 
Form of Dealer Manager Agreement
        
2.1(a)
  8-K 5/23/16 2.1  
2.1(b)
  8-K 8/3/16 1.1  
2.1(c)
  8-K 11/21/18 2.1  
2.1(d)
  8-K 12/26/18 2.2  
3.1
  10-Q 11/16/15 3.1  
3.1(a)
  8-K 3/03/17 3.1  
3.1(b)
  S-1 7/10/15 3.2  
3.1(c)
  S-4 12/11/15 3.2  
3.1(d)
  8-K 2/2/16 3.1  
3.1(e)
  8-K 3/9/16 3.1  
3.1(f)
  8-K 6/1/16 3.1  
3.1(g)
  8-K 8/5/16 3.1  
3.1(h)
  S-1 7/10/15 3.4  
3.1(i)
  8-A12B 7/27/15 3.5  
3.1(j)
  8-K 8/21/18 3.1  
3.1(k)
  8-K 9/25/20 3.1  
3.1(l)
  8-K 2/8/21 3.1  
3.2
  8-K 12/31/13 3.4  
10.1
  S-1 6/01/15 10.28  
10.2
  8-K 1/7/19 10.1  
10.3
  8-K 1/7/19 10.2  
10.4+
  S-8 2/8/17 4.2  
10.5+
  8-K 8/20/18 10.4  
10.6+
  8-K 3/5/21 10.1  
10.7+
  10-K 3/8/21 10.12  
10.8+
  10-K 3/8/21 10.13  
10.9+
  10-K 3/8/21 10.14  
10.10+
  10-K 3/8/21 10.5  
10.11+
  8-K 8/20/18 10.2  
10.12+
  8-K 8/20/18 10.3  
10.13+
  8-K 3/29/2021    
10.14+
  8-K 2/8/21    
23.1
        X
23.2*
 
Consent of Cozen O’Connor P.C. (included in Exhibit 5.1 and Exhibit 8.1)
        
24.1
 
Power of Attorney (set forth on the signature page of this Registration Statement)
       X
99.1*
 
Form of Instructions as to Use of Non-Transferable Subscription Rights Certificates
        
99.2*
 
Form of Letter to Stockholders who are Record Holders
        
99.3*
 
Form of Letter to Brokers and Other Nominee Holders
        
99.4*
 
Form of Broker Letter to Clients Who are Beneficial Holders
        
99.5*
 
Form of Beneficial Owner Election Form
        
99.6*
 
Form of Nominee Holder Certification
        
99.7*
 
Form of Notice of Guaranteed Delivery
        
99.8*
 
Form of Notice of Important Tax Information
        
#Previously filed.
*To be filed by amendment.
+Indicates management contract or compensatory plan.

Item 16.II-4Exhibits and

(b) Consolidated Financial Statement Schedules

(a)Exhibits

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this registration statement on Form S-1, which Exhibit Index is incorporated herein by reference.

(b)Financial Statement


Schedules

Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.


Item 17.Undertakings

Undertakings.


(a) The undersigned registrant hereby undertakes:


(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:


(i)to
To include any prospectus required by sectionSection 10(a)(3) of the Securities Act of 1933;Act;


(ii)to
To reflect in the prospectus any facts or events arising after the effective date of thethis registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high endand of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20%20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii)to
To include any material information with respect to the plan of distribution not previously disclosed in thethis registration statement or any material change to such information in thethis registration statement.statement;


provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the registration statement is on Form S-1 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

II-5

(2)
That, for the purpose of determining any liability under the Securities Act, of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initialbona fide offering thereof.

(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.


II-3

(4)
That, for the purpose of determining liability under the Securities Act to any purchaser:

(i)
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and
(ii)
Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

(5)
That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:


(i)Any
any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii)Any
any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
(iii)

The

the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv)Any
any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions described under Item 14 above, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes that:


II-6

(b)(1)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c)
Insofar as indemnification for liabilities arising under the Securities Act, as amended, may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act (“Act”) in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Act.

(d)
The undersigned registrant hereby undertakes that:

(i)
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1)(I) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.effective; and
(ii)
(2)
For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-4

II-7


SIGNATURES

In accordance with


Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Dania Beach,Hollywood, State of Florida, on July 10, 2015.

April 19, 2021.

VaporHealthier Choices Management Corp.
  
By:
/s/ Jeffrey E. Holman
 By:
/s/
Jeffrey E. Holman
 
Jeffrey Holman
Chief Executive Officer

In accordance with


Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons on April 19, 2021 in the capacities indicated. Each person whose signature appears below, hereby makes, constitutes and on the dates indicated.

appoints Jeffrey E. Holman, and Christopher Santi, or any of them, as their respective true and lawful attorney, with full power to sign for such person and in such person’s name and capacity indicated below, and with full power of substitution, any and all amendments, including post-effective amendments, to this registration statement, hereby ratifying and confirming such person’s signature as it may be signed by said attorney to any and all amendments.

Signature
Title
Title
Date
/s/ Jeffrey E. Holman
Jeffrey E. Holman
Principal
Chief Executive Officer and Director
(Principal Executive Officer)
July 10 , 2015April 19, 2021
Jeffrey Holman
/s/ James MartinJohn Ollet
John Ollet
Chief Financial Officer, (Principal(Principal Financial Officer and Principal Accounting Officer) and
July 10 , 2015April 19, 2021
James Martin
/s/ Christopher Santi
Christopher Santi
Chief Operating Officer and President

Chief Accounting Officer (Principal Accounting Officer)

April 19, 2021
/s/ Clifford Friedman
Clifford Friedman
Director
April 19, 2021
/s/ Gregory BrauserAnthony Panariello
Anthony Panariello
Director
DirectorJuly 10 , 2015
Gregory Brauser

/s/ William Conway III

DirectorJuly 10 , 2015

William Conway III

/s/ Daniel MacLachlan

DirectorJuly 10 , 2015
Daniel MacLachlan
/s/ Nikhil RamanDirectorJuly 10 , 2015
Nikhil RamanApril 19, 2021

II-5


EXHIBIT INDEX

Exhibit

Number

Description of Exhibit
1.1 *Form of Underwriting Agreement
2.1Smoke Anywhere USA, Inc. Acquisition Agreement and Plan of Merger dated as of September 1, 2009 (1)
2.2††Vaporin, Inc. Agreement and Plan of Merger, dated as of December 17, 2014 (19)
3.1Certificate of Incorporation (3)
3.2*Certificate of Amendment to the Certificate of Incorporation
3.3Bylaws (3)
3.4*Certificate of Designation for Series A Convertible Preferred Stock
4.1Specimen Common Stock Certificate (3)
4.2 *Form of Series A Warrant to be issued in connection with this Offering
4.3*Form of Unit Purchase Option to be issued in connection with this Offering

4. 4 **

Form of Unit Certificate

5.1 *Opinion Regarding Legality
10.1†2009 Equity Incentive Plan (2)
10.2Lease Agreement dated March 21, 2011 - 3001 Griffin Partners, LLC (5)
10.3†Kevin Frija Employment Agreement, dated February 27, 2012 (6)
10.4†Harlan Press Employment Agreement, dated February 27, 2012 (6)
10.5†Christopher Santi Employment Agreement, dated December 12, 2012 (7)
10.6†Jeffrey Holman Employment Agreement, dated February 19, 2013 (8)
10.7Spike Marks Inc./Casa CubanaPrivate Label Production and Supply Agreement (9)
10.8Form of Warrant, dated as of June 19, 2012 (10)
10.9Entrepreneur Growth Capital, LLC Invoice Purchase and Sale Agreement made as of August 8, 2013 (11)
10.10†Form of Letter Amendment to Harlan Press Employment Agreement (11)
10.11Entrepreneur Growth Capital, LLC Credit Card Receivables Advance Agreement dated as of August 16, 2013 (12)

II-6
II-8

10.12Entrepreneur Growth Capital LLC Secured Promissory Note dated September 23, 2014 (13)
10.13Purchase Agreement, dated as of October 22, 2013 (4)
10.14Registration Rights Agreement, dated as of October 29, 2013 (4)
10.15Form of Warrant issued to Roth Capital Partners, LLC (16)  
10.16Securities Purchase Agreement, dated as of November 14, 2014 (18)
10. 17Form of Convertible Note Due November 14, 2015 (18)
10. 18Form of Warrant, dated as of November 14, 2014 (18)
10. 19 †Form of 2009 Equity Incentive Plan Stock Option Agreement (14)
10. 20 †Form of Non-Equity Incentive Plan Stock Option Agreement (14)
10. 21 †Amendment to 2009 Equity Incentive Plan (15)
10. 22Knight Global Services Consulting Agreement dated as of February 3, 2014 (17)
10. 23Operating Agreement of Emagine the Vape Store, LLC (19)
10. 24Convertible Promissory Note, dated January 29, 2015 (20)
10. 25Securities Purchase Agreement, dated as of January 20, 2015 (21)
10. 26Form of Note, dated as of January 20, 2015 (21)

10. 27Ω†

2015 Equity Incentive Plan
10. 28Securities Purchase Agreement, dated as of March 3, 2015 (22)
10. 29Form of Warrant, dated as of March 3, 2015 (22)
10.30

Form of Waiver Agreement relating to November 14, 2014 Securities Purchase Agreement (23)

10.31

Form of Waiver Agreement relating to March 3, 2015 Securities Purchase Agreement (23)

10.32

Form of Warrant, dated as of June 19, 2015 (23)

10.33

Form of Registration Rights Agreement, dated as of June 16, 2015 (23)

10.34

Form of Securities Purchase Agreement, dated as of June 22, 2015 (23)

10.35

Form of Senior Secured Convertible Debenture, due December 22, 2015 (23)

10.36

Form of Security Agreement dated as of June 22, 2015 (23)

21. 1Ω

Subsidiaries
23.1*Consent of Marcum LLP

23.2*

Consent of RBSM LLP

23. 3Consent of Nason, Yeager, Gerson, White & Lioce, P.A. (contained in Exhibit 5.1)
101.INS*XBRL Instance Document^
101.SCH*XBRL Taxonomy Extension Schema Document^
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document^
101.LAB*XBRL Taxonomy Extension Label Linkbase Document^
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document^
101.DEF*XBRL Taxonomy Definition Linkbase Document^

* Filed herewith.

^ XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 , is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

Ω Previously filed.

II-7

† Represents management contract or compensatory plan.

†† A schedule to the agreement has been omitted pursuant to Item 601(b)(2) of Regulation S-K; a copy of the schedule will be furnished supplementary to the SEC upon request.

(1)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated November 11, 2009, as filed with the Securities and Exchange Commission (“SEC”) on November 13, 2009.
(2)Incorporated by reference to the Registrant’s Definitive Information Statement on Schedule 14C dated November 24, 2009, as filed with the SEC on December 10, 2009.
(3)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated December 31, 2013, as filed with the SEC on December 31, 2013.
(4)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated October 22, 2013, as filed with the SEC on October 23, 2013.
(5)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated March 21, 2011, as filed with the SEC on April 7, 2011.
(6)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated February 27, 2012, as filed with the SEC on February 28, 2012.
(7)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated December 12, 2012, as filed with the SEC on December 13, 2012.

II-8

(8)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated February 19, 2013, as filed with the SEC on February 26, 2013.
(9)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated December 6, 2011, as filed with the SEC on April 25, 2012.
(10)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated June 19, 2012, as filed with the SEC on June 22, 2012.
(11)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated August 8, 2013, as filed with the SEC on August 13, 2013.
(12)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated August 16, 2013, as filed with the SEC on August 19, 2013.
(13)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated August 16, 2013, as filed with the SEC on September 23, 2014.
(14)Incorporated by reference to the Registrant’s Form S-8 Registration Statement (No. 333-188888), as filed with the SEC on May 28, 2013.
(15)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated November 20, 2013, as filed with the SEC on November 20, 2013.
(16)Incorporated by reference to the Registrant’s Form S-1 Registration Statement (No. 333-192391), as filed with the SEC on November 18, 2013 and declared effective on January 27, 2014.
(17)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated February 3, 2014, as filed with the SEC on February 6, 2014.
(18)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated November 14, 2014, as filed with the SEC on November 17, 2014
(19)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated December 17, 2014, as filed with the SEC on December 18, 2014.
(20)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated January 29, 2015, as filed with the SEC on February 3, 2015.
(21)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated January 20, 2015, as filed with the SEC on January 26, 2015.
(22)Incorporated by reference to the Registrant’s Current Report on Form 8-K dated March 3, 2015, as filed with the SEC on March 5, 2015.
(23)

Incorporated by reference to the Registrant’s Current Report on Form 8-K dated June 19, 2015, as filed with the SEC on June 25, 2015.

II-9